64698871-20AC-EF11-835E-0EB8EE3DFFC7,2024-11-26 13:01:22.543,"NCI-2022-01791,NCI-2023-05813,NCI-2021-12361,NCI-2023-06649,NCI-2024-06647,NCI-2023-10904,NCI-2023-08892,NCI-2022-05160,NCI-2023-04004,NCI-2023-10529,NCI-2019-07941,NCI-2017-01017,NCI-2022-05419,NCI-2022-05617,NCI-2020-04069,NCI-2022-04465,NCI-2022-10316,NCI-2023-00566,NCI-2022-10927,NCI-2012-01187,NCI-2017-01648,NCI-2019-07825,NCI-2024-02778,NCI-2024-06506,NCI-2023-10662,NCI-2024-05975,NCI-2024-04302,NCI-2021-11191,NCI-2021-04226,NCI-2024-06705,NCI-2023-04100,NCI-2023-05201,NCI-2024-08353,NCI-2024-06804,NCI-2021-12558,NCI-2024-03901,NCI-2024-08286,NCI-2022-08320,NCI-2021-12550,NCI-2021-11329,NCI-2023-07070,NCI-2020-04956,NCI-2023-04725,NCI-2023-00135,NCI-2022-11032,NCI-2021-05915,NCI-2018-02725,NCI-2023-08689,NCI-2021-01360,NCI-2020-08392,NCI-2022-04431,NCI-2019-08392,NCI-2023-00183,NCI-2022-04657,NCI-2024-08200,NCI-2024-02584,NCI-2020-14193,NCI-2024-08760,NCI-2023-02455,NCI-2024-07038,NCI-2021-02560,NCI-2019-03377","[{""Label"":""Primary Cancer Type/Condition"",""Value"":""Non-Small Cell Lung Cancer""},{""Label"":""Subtype"",""Value"":""Advanced Lung Non-Small Cell Carcinoma, Advanced Non-Small Cell Squamous Lung Cancer, Advanced Lung Adenocarcinoma, Advanced Non-Squamous Non-Small Cell Lung Cancer, EGFR-Positive Lung Non-Small Cell Carcinoma, Lung Adenocarcinoma, Metastatic Lung Adenocarcinoma, Metastatic Lung Adenosquamous Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Squamous Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Adenosquamous Lung Cancer, Non-Small Cell Squamous Lung Cancer, Non-Squamous Non-Small Cell Lung Cancer, Unresectable Lung Adenocarcinoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Lung Non-Small Cell Squamous Carcinoma, Unresectable Lung Non-Squamous Non-Small Cell Carcinoma""},{""Label"":""Drug/Drug Family"",""Value"":""Tyrosine Kinase Inhibitor, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, VEGFR Tyrosine Kinase Inhibitor, EGFR Exon 20 Inhibitor, Tyrosine Kinase Inhibitor TL-895, Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981, Osimertinib, Gefitinib, Erlotinib, Amivantamab, Lazertinib, Afatinib, Erlotinib Hydrochloride, Afatinib Dimaleate""}]"," <!DOCTYPE html> <html lang=""en""> <head> 	 <meta name=""robots"" content=""noindex""> 	 <title>Clinical Trial Search Results</title> 	 <script src=""//assets.adobedtm.com/f1bfa9f7170c81b1a9a9ecdcc6c5215ee0b03c84/satelliteLib-5b3dcf1f2676c378b518a1583ef5355acd83cd3d.js""></script> 	 <script src=""https://ajax.googleapis.com/ajax/libs/jquery/3.1.1/jquery.min.js""></script> 	 <script src=""/CTS.Print-js/BasicCTSPrintPage.js"" type=""text/javascript""></script>  	 <link rel=""stylesheet"" id=""gFonts"" href=""https://fonts.googleapis.com/css?family=Noto+Sans:400,400i,700,700i"" /> 	 <link href=""/CTS.Print-styles/nvcg.css"" rel=""stylesheet"" /> 	 <link href=""/CTS.Print-styles/BasicCTSPrintPage.css"" rel=""stylesheet"" /> 	 <meta name=""dcterms.subject"" content=""Clinical Trials Print Results Page"" />      <meta name=""Generator"" content=""CTS.Print"" /> </head> <body> 	<div class=""wa-data-element hide"" data-prop3=""/"" data-prop6=""Comprehensive Cancer Information"" data-prop16=""Comprehensive Cancer Information"" data-prop25=""01/01/1980"" data-prop44=""Clinical Trials"" data-prop62=""Clinical Trials: Print Results Page"" data-evar44=""Clinical Trials"" data-evar62=""Clinical Trials: Print Results Page"" ></div> 	<div id=""cgovContainer""> 		<div id=""CT-results-print-banner""><img id=""NCILogo"" src=""https://www.cancer.gov/profiles/custom/cgov_site/themes/custom/cgov/static/images/design-elements/logos/nci-logo-full.svg"" alt=""NCI Logo""/></div> 		<div id=""cgvBody""> 			<div id=""bodyHeading""> 				<div id=""headingWrapper""> 					<h1 id=""ctPrintBodyHeading"">Your Clinical Trials Search Results</h1> 					<div id=""bodyHeadingLinks""> 						<a id=""printPage"" href=""javascript:window.print();"">Print</a> | 						<a id=""ctl10_EmailResults"" href=""${generatePrintURL}"" target=""_blank"">E-Mail These Results</a> | 						<a id=""newSearch"" href=""/research/participate/clinical-trials-search/advanced"">New Search</a> 					</div> 				</div> 			</div> 				<div id=""clinical-trials-print"">  					 	        								     <a href=""#"" class=""ctscb"" id=""ctscb"">Show Search Criteria</a>     <div class=""search-criteria-box"" aria-expanded=""false"" aria-labelledby=""ctscb"">       <div class=""clinicaltrials-results-criteria-display"">         <h3>Your Search Criteria</h3>         <table class=""table no-auto-enlarge"" style=""width: 100%;"">             <thead>                 <tr>                   <th class=""hdrlft"" scope=""col""><h3>Category</h3></th>                   <th class=""hdrrt"" scope=""col""><h3>Your Selection</h3></th>                 </tr>             </thead>             <tbody>                                                     <tr>                         <td class=""hdrlft""><strong>Primary Cancer Type/Condition:</strong></td>                         <td>Non-Small Cell Lung Cancer</td>                     </tr>                                                     <tr>                         <td class=""hdrlft""><strong>Subtype:</strong></td>                         <td>Advanced Lung Non-Small Cell Carcinoma, Advanced Non-Small Cell Squamous Lung Cancer, Advanced Lung Adenocarcinoma, Advanced Non-Squamous Non-Small Cell Lung Cancer, EGFR-Positive Lung Non-Small Cell Carcinoma, Lung Adenocarcinoma, Metastatic Lung Adenocarcinoma, Metastatic Lung Adenosquamous Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Squamous Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Adenosquamous Lung Cancer, Non-Small Cell Squamous Lung Cancer, Non-Squamous Non-Small Cell Lung Cancer, Unresectable Lung Adenocarcinoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Lung Non-Small Cell Squamous Carcinoma, Unresectable Lung Non-Squamous Non-Small Cell Carcinoma</td>                     </tr>                                                     <tr>                         <td class=""hdrlft""><strong>Drug/Drug Family:</strong></td>                         <td>Tyrosine Kinase Inhibitor, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, VEGFR Tyrosine Kinase Inhibitor, EGFR Exon 20 Inhibitor, Tyrosine Kinase Inhibitor TL-895, Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981, Osimertinib, Gefitinib, Erlotinib, Amivantamab, Lazertinib, Afatinib, Erlotinib Hydrochloride, Afatinib Dimaleate</td>                     </tr>                             </tbody>         </table>       </div>     </div> 					                     <p class=""printIntroText"">Here are the trials you selected from your search on 11/26/2024.</p> 					<p class=""printIntroText"">You will be able to access this page for approximately 90 days. Since trial information is updated regularly, you should check for updates to see the most current information on any of the trials below.</p>   				<div> 								<div class=""trialContainer""> 			<h2 class=""hangingIndent"">1. Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC</h2> 						<a class=""hangingIndent print-check-for-updates"" href=""/research/participate/clinical-trials-search/v?d=C1967&d=C2167&d=C93259&d=C199379&d=C172809&d=C82379&d=C116377&d=C1855&d=C65530&d=C124993&d=C148147&d=C66940&d=C2693&d=C97273&loc=0&pn=7&rl=2&st=C162158&st=C153201&st=C176727&st=C147924&st=C202131&st=C3512&st=C155908&st=C156093&st=C156094&st=C157364&st=C128798&st=C9133&st=C133254&st=C135017&st=C174510&st=C155901&st=C171612&st=C162642&t=C2926&id=NCI-2022-01791""><span>Check for Updates</span></a> 			<table class=""trialDataTable""> 				<tr class=""trialDataHeaderRow""> 					<td>Phase</td> 					<td>Type</td> 					<td>Status</td> 					<td>Age</td> 					<td>Trial IDs</td> 				</tr> 				<tr> 					<td>Phase II</td> 					<td>Treatment</td> 					<td>Active</td> 					<td>18 													and over 						 						</td> 					<td class=""trialIDCell""> 						<span class = ""dataTableIDLabel"">Primary ID</span> AB-106-G208<br> 						<span class = ""dataTableIDLabel"">Secondary IDs</span> NCI-2022-01791<br> 						<span class = ""dataTableIDLabel"">Clinicaltrials.gov ID</span> <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT04919811"" target=""_blank"">NCT04919811</a><br> 					</td> 			</table>  			<h3>Description</h3> 			<div>The main purpose of the study is to evaluate safety and efficacy of taletrectinib (also known as AB-106 or DS-6051b) monotherapy in the treatment of advanced NSCLC.</div>  			<h3 class=""printHeading"">Eligibility Criteria</h3>  																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																		<h4>Inclusion Criteria</h4> 										<div> 							<ul> 															<li>Age ≥18 years (or ≥20 years as required by local regulations).</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Histologically or cytologically confirmed diagnosis of locally advanced (including inoperable Stage IIIA or IIIB NSCLC) or metastatic NSCLC or other solid tumors.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Evidence of ROS1 fusion by a validated assay.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patients with central nervous system (CNS) involvement, including leptomeningeal carcinomatosis, must be stable, either asymptomatic or previously treated and controlled within 14 days of first dose.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>The patient can be either ROS1 TKI treatment na&#239;ve or treated with prior ROS1 TKI(s).</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>The patient must have at least 1 measurable disease per RECIST 1.1 as assessed by the investigator.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Eastern Cooperative Oncology Group Performance Status: 0 or 1.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patient with a life expectancy ≥12 weeks based on the judgement of investigator.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patients with adequate organ function meeting the following criteria:</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Aspartate aminotransferase (AST) and alanine aminotransferase (ALT): ≤3.0 &#215; upper limit of normal (ULN) (or ≤5.0 &#215; ULN, for patients with concurrent liver metastases)</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Serum total bilirubin: ≤1.5 &#215; ULN (≤3.0 &#215; ULN for patients with Gilbert syndrome or if liver function abnormalities are due to underlying malignancy)</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Absolute neutrophil count: ≥1,500/μL</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Platelet count: ≥100,000/μL</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Hemoglobin: ≥9.0 g/dL</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Serum creatinine ≤1.5 &#215; ULN</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patients must be able to practice required contraception during the study.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>For males (irrespective of surgical sterilization [vasectomy]): agree to use effective contraception methods during the study intervention period and for at least 90 days after the last dose of investigational drug or agree with complete abstinence.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Females without menses for at least 1 year prior to screening or documented to be surgically sterilized. Women of childbearing potential (WOCBP) must agree to use two concurrent highly effective methods of contraception or agree with complete abstinence from sexual intercourse since the informed consent until 45 days after the last dose of investigational drug. The patient is willing and capable to give written informed consent.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>The patient is willing and capable to comply with the study scheduled visits, treatment plans, laboratory tests and other procedures.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>The patient is willing and capable to comply with study site&#39;s COVID-19 policies.</li> 												</ul> 						</div> 														<h4>Exclusion Criteria</h4> 										<div> 							<ul> 																<li>Treatment with small molecule anticancer therapy including other investigational agents or cytotoxic systemic anticancer therapy within 2 weeks (or 5 half-lives of the compound, whichever is shorter) prior to the first dose of taletrectinib; Treatment with immuno-oncology (IO) including immune checkpoint inhibitors within 4 weeks before the first dose of taletrectinib.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Major surgical procedure, open biopsy, or significant traumatic injury ≤4 weeks before the first dose of taletrectinib. • Placement of vascular access device is not considered major surgery. Other minor surgical procedures, such as catheter placement or minimally invasive biopsy, are allowed.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Radiotherapy within 14 days before study treatment. Stereotactic radiosurgery (SRS), stereotactic radiation therapy (SRT), and palliative radiation outside the chest and brain are allowed but must be completed 1 week before starting study treatment.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Have been diagnosed with another primary malignancy other than NSCLC except for adequately treated non-melanoma skin cancer or cervical cancer in situ; definitively treated non-metastatic prostate cancer; or patients with another primary malignancy who are definitively relapse-free with at least 3 years elapsed since the diagnosis of the other primary malignancy.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Adverse events due to prior therapy are unresolved to ≤ CTCAE Grade 1 or has not returned to baseline, by the first dose of taletrectinib except for AEs not constituting a safety risk to the patient based on the judgment of investigators.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Patients with untreated spinal cord compression caused by tumor and/or cancerous meningitis.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>History or evidence of interstitial fibrosis, interstitial lung disease or drug-induced pneumonitis.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Any gastrointestinal disorders that may affect absorption of oral medications.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Active and clinically significant bacterial, fungal, or viral infection including hepatitis B virus (HBV), hepatitis C virus (HCV), or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Clinically significant cardiovascular diseases within 3 months prior to the first dose of taletrectinib: myocardial infarction, severe/unstable angina, coronary/peripheral endovascular treatment, heart failure or cerebrovascular disorder including transient ischemic attack.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Ongoing cardiac dysrhythmias of ≥ CTCAE Grade 2, uncontrolled atrial fibrillation of any grade, or QT interval corrected for heart rate by Fredericia&#39;s formula (QTcF) &gt;470 milliseconds, or symptomatic bradycardia &lt;45 beats per minute; patient has family or medical history of long QT syndrome.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Pregnancy or lactation/breastfeeding.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Use of food or drugs that are known potent cytochrome P450 3A4/5 (CYP3A4/5) inhibitors or inducers or P-glycoprotein inhibitors or inducers within 14 days prior to the first dose of study treatment and while on treatment.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Administration of agents with potential QT interval prolonging effect within 14 days prior to first dose of study treatment and while on treatment.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Patients with other severe medical or mental diseases in whom the risk is increased by the participation to the study or treatment with study treatment in the opinion of the investigator.</li> 												</ul> 						</div> 							 							<h3 class=""printHeading"">Trial Objectives and Outlines</h3> 				<div id=""trialObjectives""><p class='ctrp'>This is a global Phase 2, multicenter, single-arm, open label study of taletrectinib in</p><p class='ctrp'>patients of NSCLC harboring with ROS1 fusion gene.</p><p class='ctrp'></p><p class='ctrp'>About 224 patients will be enrolled and divided into 6 cohorts, depending on past history</p><p class='ctrp'>of ROS1 TKI treatment.</p><p class='ctrp'></p><p class='ctrp'>In the cohorts open to enrollment, taletrectinib will be administered either 400mg or</p><p class='ctrp'>600mg once daily in 21-day cycles. In one cohort, this will be in combination with</p><p class='ctrp'>carboplatin and pemetrexed both administered by IV infusion in 21-day cycles for 4</p><p class='ctrp'>cycles. Patients will continue with the treatment on taletrectinib until progression of</p><p class='ctrp'>disease as determined by the investigator.</p><p class='ctrp'></p><p class='ctrp'>The tumor response evaluation will be conducted on a regular basis until progression of</p><p class='ctrp'>disease. Long-term survival follow up will be conducted as well.</p></div> 			 							<h3 class=""printHeading"">Lead Organization</h3> 									<div>Nuvation Bio Inc.</div> 														<h3 class=""printHeading"">Locations & Contacts</h3> 			<div class=""locationNoteBlock""> 				<span>Note:</span> Information about participating sites on pharmaceutical industry trials may be incomplete, so please look up the <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT04919811"" target=""_blank"">NCT number</a> on ClinicalTrials.gov 			</div> 			<div> 								           <h3 class=""locationCountryLabel"">U.S.A.</h3>               <h4>California</h4>                           <h5 class=""locationCity"">Los Angeles</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Los Angeles General Medical Center</strong>     <br>Contact: Sandy Tran <br>Phone: 626-688-7013 <br>Email: <a href=""mailto:sandy.tran@med.usc.edu"">sandy.tran@med.usc.edu</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">USC / Norris Comprehensive Cancer Center</strong>     <br>Contact: Sandy Tran <br>Phone: 626-688-7013 <br>Email: <a href=""mailto:sandy.tran@med.usc.edu"">sandy.tran@med.usc.edu</a>   </span> </div>                                       <h5 class=""locationCity"">Orange</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">UC Irvine Health/Chao Family Comprehensive Cancer Center</strong>     <br>Contact: Mason Michael Huynh <br>Phone: 714-509-2979 <br>Email: <a href=""mailto:masonmh@hs.uci.edu"">masonmh@hs.uci.edu</a>   </span> </div>                                       <h5 class=""locationCity"">San Diego</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">UC San Diego Medical Center - Hillcrest</strong>     <br>Name Not Available   </span> </div>                                   <h4>Minnesota</h4>                           <h5 class=""locationCity"">Rochester</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Mayo Clinic in Rochester</strong>     <br>Name Not Available   </span> </div>                                   <h4>Ohio</h4>                           <h5 class=""locationCity"">Cleveland</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Case Comprehensive Cancer Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>Texas</h4>                           <h5 class=""locationCity"">Houston</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">M D Anderson Cancer Center</strong>     <br>Name Not Available   </span> </div>                           			</div> 		</div> 			<div class=""trialContainer""> 			<h2 class=""hangingIndent"">2. A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)</h2> 						<a class=""hangingIndent print-check-for-updates"" href=""/research/participate/clinical-trials-search/v?d=C1967&d=C2167&d=C93259&d=C199379&d=C172809&d=C82379&d=C116377&d=C1855&d=C65530&d=C124993&d=C148147&d=C66940&d=C2693&d=C97273&loc=0&pn=7&rl=2&st=C162158&st=C153201&st=C176727&st=C147924&st=C202131&st=C3512&st=C155908&st=C156093&st=C156094&st=C157364&st=C128798&st=C9133&st=C133254&st=C135017&st=C174510&st=C155901&st=C171612&st=C162642&t=C2926&id=NCI-2023-05813""><span>Check for Updates</span></a> 			<table class=""trialDataTable""> 				<tr class=""trialDataHeaderRow""> 					<td>Phase</td> 					<td>Type</td> 					<td>Status</td> 					<td>Age</td> 					<td>Trial IDs</td> 				</tr> 				<tr> 					<td>Phase III</td> 					<td>Treatment</td> 					<td>Active</td> 					<td>18 													and over 						 						</td> 					<td class=""trialIDCell""> 						<span class = ""dataTableIDLabel"">Primary ID</span> DZ2022E0005<br> 						<span class = ""dataTableIDLabel"">Secondary IDs</span> NCI-2023-05813<br> 						<span class = ""dataTableIDLabel"">Clinicaltrials.gov ID</span> <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT05668988"" target=""_blank"">NCT05668988</a><br> 					</td> 			</table>  			<h3>Description</h3> 			<div>This is a phase 3, open-label, randomized, multi-center study assessing the efficacy and safety of DZD9008 versus platinum-based doublet chemotherapy in participants with locally advanced or metastatic NSCLC with EGFR Exon20ins mutation, who are newly diagnosed or have not received prior systemic therapy in advanced stage.  Primary objective of this study is to assess the efficacy of DZD9008 versus platinum-based doublet chemotherapy using by BICR-assessed PFS per RECIST 1.1 as primary endpoint. Approximately 320 participants are estimated to be randomized into the study. Participants enrolled will be randomized to DZD9008 or platinum-based doublet chemotherapy in a 1:1 manner, stratified by baseline brain metastasis (with/without).</div>  			<h3 class=""printHeading"">Eligibility Criteria</h3>  																																																																																																																																																																																																																																																																																																											<h4>Inclusion Criteria</h4> 										<div> 							<ul> 															<li>Aged at least 18 years old (or per local regulatory/IRB requirement).</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Histologically or cytologically confirmed diagnosis of non-squamous NSCLC, locally advanced (Stage IIIB and IIIC according to the 8th edition of the AJCC TNM staging criteria) or metastatic (Stage IV), not suitable for curative therapy.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Adequate tumor tissue available, for central laboratory confirmation of EGFR exon 20 insertion mutation</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>At least 1 measurable lesion per RECIST Version 1.1</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Life expectancy ≥ 12 weeks</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Adequate organ and hematologic function</li> 												</ul> 						</div> 														<h4>Exclusion Criteria</h4> 										<div> 							<ul> 																<li>Prior treatment with any systemic anti-cancer therapy for locally advanced or metastatic NSCLC.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Spinal cord compression or leptomeningeal metastasis.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Concurrent EGFR mutations: exon 19 deletion, L858R, T790M, G719X, S768I, or L861Q.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>History of stroke or intracranial hemorrhage within 6 months before randomization.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>As judged by the investigator, any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses (i.e., hemophilia and Von Willebrand disease).</li> 												</ul> 						</div> 							 			 							<h3 class=""printHeading"">Lead Organization</h3> 									<div>Dizal Pharmaceuticals</div> 														<h3 class=""printHeading"">Locations & Contacts</h3> 			<div class=""locationNoteBlock""> 				<span>Note:</span> Information about participating sites on pharmaceutical industry trials may be incomplete, so please look up the <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT05668988"" target=""_blank"">NCT number</a> on ClinicalTrials.gov 			</div> 			<div> 								           <h3 class=""locationCountryLabel"">U.S.A.</h3>               <h4>Colorado</h4>                           <h5 class=""locationCity"">Aurora</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">UCHealth University of Colorado Hospital</strong>     <br>Contact: Stephanie Biller <br>Phone: 720-848-0729 <br>Email: <a href=""mailto:stephanie.biller@cuanschutz.edu"">stephanie.biller@cuanschutz.edu</a>   </span> </div>                                   <h4>New York</h4>                           <h5 class=""locationCity"">New York</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Laura and Isaac Perlmutter Cancer Center at NYU Langone</strong>     <br>Name Not Available   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>Ohio</h4>                           <h5 class=""locationCity"">Columbus</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Ohio State University Comprehensive Cancer Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>Texas</h4>                           <h5 class=""locationCity"">Houston</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">M D Anderson Cancer Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>Virginia</h4>                           <h5 class=""locationCity"">Charlottesville</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">University of Virginia Cancer Center</strong>     <br>Name Not Available   </span> </div>                           			</div> 		</div> 			<div class=""trialContainer""> 			<h2 class=""hangingIndent"">3. First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)</h2> 						<a class=""hangingIndent print-check-for-updates"" href=""/research/participate/clinical-trials-search/v?d=C1967&d=C2167&d=C93259&d=C199379&d=C172809&d=C82379&d=C116377&d=C1855&d=C65530&d=C124993&d=C148147&d=C66940&d=C2693&d=C97273&loc=0&pn=7&rl=2&st=C162158&st=C153201&st=C176727&st=C147924&st=C202131&st=C3512&st=C155908&st=C156093&st=C156094&st=C157364&st=C128798&st=C9133&st=C133254&st=C135017&st=C174510&st=C155901&st=C171612&st=C162642&t=C2926&id=NCI-2021-12361""><span>Check for Updates</span></a> 			<table class=""trialDataTable""> 				<tr class=""trialDataHeaderRow""> 					<td>Phase</td> 					<td>Type</td> 					<td>Status</td> 					<td>Age</td> 					<td>Trial IDs</td> 				</tr> 				<tr> 					<td>Phase I/II</td> 					<td>Treatment</td> 					<td>Active</td> 					<td>18 													and over 						 						</td> 					<td class=""trialIDCell""> 						<span class = ""dataTableIDLabel"">Primary ID</span> 21607<br> 						<span class = ""dataTableIDLabel"">Secondary IDs</span> NCI-2021-12361, 2021-003022-77, 2023-503795-24-00<br> 						<span class = ""dataTableIDLabel"">Clinicaltrials.gov ID</span> <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT05099172"" target=""_blank"">NCT05099172</a><br> 					</td> 			</table>  			<h3>Description</h3> 			<div>Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC), a group of lung cancers that have spread to nearby tissues or to other parts of the body.  Epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) are proteins that help cells to grow and divide. A damage (also called mutation) to the building plans (genes) for these proteins in cancer cells leads to a production of abnormal EGFR and/or HER2. These abnormal proteins drive the growth and the spread of the cancer. Several EGFR and/or HER2 mutations exist in the cancer cells. The study treatment, BAY2927088, is expected to block the mutated EGFR and HER2 proteins which may stop the spread of NSCLC.  The main purpose of this study is to learn:  Escalation, Backfill, and Expansion Part:    -  How safe is BAY2927088 for the participants?    -  What is the highest dose of BAY2927088 that can be tolerated (maximum tolerated      dose) by or given to (maximum administered dose) the participants?    -  How does BAY2927088 move into, through, and out of the bodies of the participants?  For this, the researchers will measure the followings:    -  The number of participants with medical problems, also called adverse events and      serious adverse events, and their severity    -  The number of participants who discontinue study treatment due to an adverse event.    -  The highest dose of BAY2927088 that the participants can take without having adverse      events (maximum tolerated dose (MTD)) or the maximum dose that is tested and found      to be safe for the participants in case MTD cannot be found out (maximum      administered dose (MAD)) of BAY2927088    -  Number of participants experiencing adverse events that prevent an increase in the      dose of BAY2927088 (dose-limiting toxicities (DLTs)) at each dose level    -  The (average) total level of BAY2927088 in the blood (also called AUC) after      receiving single or multiple doses of BAY2927088    -  The (average) highest level of BAY2927088 in the blood (also called Cmax) after      receiving a single or multiple doses of BAY2927088 Extension Part    -  How well does BAY2927088 work in participants?  For this, the researchers will measure the following:  • Percentage of participants whose cancer completely disappears (complete response) or reduces by at least 30% (partial response) after taking the treatment (also known as objective response rate (ORR)). This will be assessed by doctors other than the study doctor.  This study has 4 parts:    -  The escalation part aims to find the maximum daily amount (dose) of BAY2927088 that      participants can receive.    -  The backfill part aims to test the doses of BAY2927088 that are considered safe in      the escalation part by giving it to more participants. This will help find optimal      doses of BAY2927088 that work well and are safe to be tested in the next part.    -  The expansion part aims to determine the dose of BAY2927088 to be tested in further      studies.    -  The extension part aims to determine whether the selected dose of BAY2927088 from      the expansion part works well.  The participants in this study will take the study treatment BAY2927088 in 3-week periods called &quot;cycles&quot;. They will in general take BAY2927088 once or twice daily as a liquid/tablet by mouth until their cancer gets worse, they have medical problems, they leave the study, or the study is terminated. Participants will have no more than 5 visits per cycle.  During the study, the study team will:    -  take blood and urine samples,    -  check the status of the cancer by doing computed tomography (CT) or magnetic      resonance imaging (MRI) scans,    -  check the participants&#39; overall health and heart health,    -  ask the participants questions about how they are feeling and what adverse events      they are having.  An adverse event is considered &quot;serious&quot; when it leads to death, puts the participant&#39;s life at risk, requires hospitalization, causes disability, causes a baby being born with medical problems, or is medically important.</div>  			<h3 class=""printHeading"">Eligibility Criteria</h3>  																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																							<h4>Inclusion Criteria</h4> 										<div> 							<ul> 															<li>Documented histologically or cytologically confirmed locally advanced NSCLC, not suitable for definitive therapy or recurrent or metastatic NSCLC at screening (small cell or mixed histologies are excluded).</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Documented disease progression after treatment with at least one prior systemic therapy for advanced disease. Participants who do not have standard of care access due to any reason, are intolerant to, or are not eligible for standard treatments, may also be eligible. Note: Except for participants eligible for one of the groups (Expansion or Extension) who should have received no prior systemic treatment for locally advanced or metastatic disease.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Adequate archival tumor tissue (ideally taken after last targeted treatment and not older than 6 months) has to be available, either from primary or metastatic sites. If archival material is not available, a fresh tumor biopsy should be performed if feasible and if the procedure poses no significant risk for the participant.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Measurable disease by RECIST v1.1 with at least one lesion not chosen for biopsy during the screening period (if a biopsy is taken during screening) that can be accurately measured at baseline with computed tomography (CT) or magnetic resonance imaging (MRI) and that is suitable for accurate repeated measurements. A biopsied lesion should not be used as a target lesion for RECIST 1.1 tumor assessments (or, for participants in Expansion Group G, for RANO-BM tumor assessments). Previously irradiated lesions must have shown progression to be considered measurable.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Documented activating EGFR and/or HER2 mutation assessed by a Clinical Laboratory Improvement Amendments (CLIA)-certified (United States [US] sites) or an equally accredited (outside of the US) local laboratory</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Minimum life expectancy of 12 weeks.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Adequate bone marrow function as assessed by the following laboratory tests to be conducted within 7 days before the first dose of study treatment:</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Hemoglobin ≥ 9.0 g/dL. Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion within 2 weeks prior to testing.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Platelets ≥ 100 &#215; 10^9 cells/L.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Absolute neutrophil count ≥ 1.5 &#215;10^9 cells/L. Criteria must be met without the use of hematopoietic growth factors (e.g., G-CSF) within 2 weeks prior to testing.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Adequate kidney function as assessed by following laboratory test to be conducted within 7 days before the first dose of study treatment: a. Estimated glomerular filtration rate (eGFR) &gt; 50 mL/min per 1.73 m^2 according to the Modification of Diet in renal Disease Study Group (MDRD) formula.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Adequate liver function as assessed by following laboratory tests to be conducted within 7 days before the first dose of study treatment:</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Total bilirubin ≤ 1.5 &#215; ULN (or ≤ 3 X ULN for participants with documented Gilbert-Meulengracht Syndrome, or for participants with hyperbilirubinemia considered due to liver metastasis).</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Aspartate transaminase and alanine transaminase ≤ 2.5 &#215; ULN (or ≤ 5 &#215; ULN if due to liver involvement by tumor).</li> 												</ul> 						</div> 														<h4>Exclusion Criteria</h4> 										<div> 							<ul> 																<li>Treatment with an EGFR tyrosine kinase inhibitor (TKI) ≤ 8 days or 5x the terminal phase, elimination half-lives, whichever is shorter, prior to the first dose of study drug.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Treatment with a systemic anti-cancer treatment (excluding EGFR TKIs as described above) ≤ 14 days prior to the first dose of study drug.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Radiation therapy, stereotactic radiosurgery (SRS) and palliative radiation ≤ 14 days prior to the first dose of study drug.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Treatment with immunotherapy ≤ 28 days prior to the first dose of study drug.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Have any unresolved toxicity of Grade ≥ 2 from previous anti-cancer treatment, except for alopecia and skin pigmentation. Participants with chronic, but stable Grade 2 toxicities may be allowed to enroll after agreement between the Investigator and Sponsor.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Any history of primary brain or leptomeningeal disease (symptomatic or asymptomatic), presence of symptomatic central nervous system (CNS) metastases, or CNS metastases that require local treatment (such as radiotherapy or surgery).</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>History of spinal cord compression or brain metastases with the following exceptions:</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Participants with treated brain metastases that are asymptomatic at screening and who are off or receiving low-dose corticosteroids (≤10 mg prednisone or equivalent) for at least 7 days prior to first dose of BAY 2927088 are eligible to enroll in Dose Escalation and Backfill.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Participants with treated brain metastases that are asymptomatic at screening are eligible in Dose Expansion/Extension (with the exception of Group G) if all of the following criteria are met:</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>there is no evidence of progression (new or enlarging brain metastases) for at least 4 weeks after CNS-directed treatment, as ascertained by clinical examination and brain imaging (MRI or CT) during the screening period.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Participants must be off or receiving low-dose corticosteroids (≤10 mg prednisone or equivalent) for 7 days prior to first dose of BAY2927088.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Participants with history of spinal cord compression &gt;3 months from definitive therapy and stable by imaging (MRI or CT) during the screening period and clinically asymptomatic.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Expansion Group G only: Participants with active (new or progressing) clinically stable brain metastases who do not require immediate CNS-directed treatment as per Investigator&#39;s judgement and who are off or receiving low-dose corticosteroids (≤10 mg prednisone or equivalent such as ≤ 1.5 mg/day dexamethasone) in the 7 days prior to first dose of BAY2927088 are eligible.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>History of congestive heart failure (CHF) Class &gt;II according to the New York Heart Association (NYHA) Functional Classification or serious cardiac arrhythmias requiring treatment (e.g. ventricular arrhythmias, atrial fibrillation) or any clinically important abnormalities in rhythm, conduction or morphology or resting ECG (e.g., complete left bundle branch block, third degree heart block, second degree heart block, PR interval &gt;250 msec)</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Participants with:</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Known human immunodeficiency virus (HIV), except as noted below: Participants with history of HIV infection are eligible at the Investigator&#39;s discretion provided that: • CD4+ T-cell (CD4+) counts are ≥ 350 cells/uL • The participant has been on established antiretroviral therapy (ART) for at least 4 weeks prior to the start of study drug and has an HIV viral load less than 400 copies/mL prior to start of the study treatment • The ART being used does not contain strong inducers or inhibitors of CYP3A4, and is not anticipated to cause overlapping toxicities with study drug • The participant has not had an opportunistic infection within the past 12 months</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Active Hepatitis B infection (positive for Hepatitis B surface antigen [HbsAg]) and Hepatitis B virus [HBV] DNA).</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Active Hepatitis C infection (positive anti-HCV Antibody and quantitative HCV RNA results greater than the lower limits of detection of the assay). NOTE: Participants with history of chronic HBV or HCV infection are eligible at the Investigator&#39;s discretion provided that the disease is stable and sufficiently controlled under treatment.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Use of strong CYP3A4 inhibitors and inducers from 14 days prior to first administration of study drug. Strong CYP3A4 inhibitors and inducers are prohibited during the study and until Safety FU (follow up) visit.</li> 												</ul> 						</div> 							 			 							<h3 class=""printHeading"">Lead Organization</h3> 									<div>Bayer Corporation</div> 														<h3 class=""printHeading"">Locations & Contacts</h3> 			<div class=""locationNoteBlock""> 				<span>Note:</span> Information about participating sites on pharmaceutical industry trials may be incomplete, so please look up the <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT05099172"" target=""_blank"">NCT number</a> on ClinicalTrials.gov 			</div> 			<div> 								           <h3 class=""locationCountryLabel"">U.S.A.</h3>               <h4>California</h4>                           <h5 class=""locationCity"">Duarte</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">City of Hope Comprehensive Cancer Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>Georgia</h4>                           <h5 class=""locationCity"">Atlanta</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Emory University Hospital/Winship Cancer Institute</strong>     <br>Name Not Available   </span> </div>                                   <h4>Massachusetts</h4>                           <h5 class=""locationCity"">Boston</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Brigham and Women's Hospital</strong>     <br>Name Not Available   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Dana-Farber Cancer Institute</strong>     <br>Name Not Available   </span> </div>                                   <h4>Minnesota</h4>                           <h5 class=""locationCity"">Minneapolis</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">University of Minnesota/Masonic Cancer Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>Texas</h4>                           <h5 class=""locationCity"">Houston</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">M D Anderson Cancer Center</strong>     <br>Name Not Available   </span> </div>                           			</div> 		</div> 			<div class=""trialContainer""> 			<h2 class=""hangingIndent"">4. A Study of DB-1310 in Advanced/Metastatic Solid Tumors</h2> 						<a class=""hangingIndent print-check-for-updates"" href=""/research/participate/clinical-trials-search/v?d=C1967&d=C2167&d=C93259&d=C199379&d=C172809&d=C82379&d=C116377&d=C1855&d=C65530&d=C124993&d=C148147&d=C66940&d=C2693&d=C97273&loc=0&pn=7&rl=2&st=C162158&st=C153201&st=C176727&st=C147924&st=C202131&st=C3512&st=C155908&st=C156093&st=C156094&st=C157364&st=C128798&st=C9133&st=C133254&st=C135017&st=C174510&st=C155901&st=C171612&st=C162642&t=C2926&id=NCI-2023-06649""><span>Check for Updates</span></a> 			<table class=""trialDataTable""> 				<tr class=""trialDataHeaderRow""> 					<td>Phase</td> 					<td>Type</td> 					<td>Status</td> 					<td>Age</td> 					<td>Trial IDs</td> 				</tr> 				<tr> 					<td>Phase I/II</td> 					<td>Treatment</td> 					<td>Active</td> 					<td>18 													and over 						 						</td> 					<td class=""trialIDCell""> 						<span class = ""dataTableIDLabel"">Primary ID</span> DB-1310-O-1001<br> 						<span class = ""dataTableIDLabel"">Secondary IDs</span> NCI-2023-06649, CTR20231736<br> 						<span class = ""dataTableIDLabel"">Clinicaltrials.gov ID</span> <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT05785741"" target=""_blank"">NCT05785741</a><br> 					</td> 			</table>  			<h3>Description</h3> 			<div>This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors.</div>  			<h3 class=""printHeading"">Eligibility Criteria</h3>  																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																											<h4>Inclusion Criteria</h4> 										<div> 							<ul> 															<li>Male or female adults (defined as ≥ 18 years of age or acceptable age according to local regulations at the time of voluntarily signing of informed consent).</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Have relapsed or progressed on or after standard systemic treatments, or intolerable with standard treatment, or for which no standard treatment is available. Documented radiological disease progression during/after most recent treatment regimen for advanced/unresectable, or metastatic disease.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>At least one measurable lesion as assessed by the investigator according to response evaluation criteria in solid tumors (RECIST) version 1.1 criteria. Subjects with nonmeasurable disease only are allowed in Cohort 2c of Phase 2a.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Has a life expectancy of ≥ 3 months.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Has an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Has LVEF ≥ 50% by either echocardiography (ECHO) or multiple-gated acquisition (MUGA) within 28 days before enrollment.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Has adequate organ functions within 7 days prior to Day 1 of Cycle 1.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Has adequate treatment washout period prior to Day 1 of Cycle 1.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Is willing to provide pre-existing resected tumor samples or undergo fresh tumor biopsy for the measurement of HER3 level and other biomarkers if no contraindication.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Is capable of comprehending study procedures and risks outlined in the informed consent and able to provide written consent and agree to comply with the requirements of the study and the schedule of assessments.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Male and female subjects of reproductive/childbearing potential must agree to use adequate contraceptive methods (e.g., double barrier or intrauterine contraceptive) during the study and for at least 4 months and 7 months after the last dose of study drug, respectively.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Male subjects must not freeze or donate sperm starting at screening and throughout the study period, and at least 4 months after the final study drug administration.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Female subjects must not donate, or retrieve for their own use, ova from the time of screening and throughout the study treatment period, and for at least 7 months after the final study drug administration.</li> 												</ul> 						</div> 														<h4>Exclusion Criteria</h4> 										<div> 							<ul> 																<li>Prior treatment with HER3 targeted therapy.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Prior treatment with antibody drug conjugate with topoisomerase I inhibitor (exclusive of trastuzumab deruxtecan for Cohort 2e of Phase 2a).</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Has a medical history of symptomatic congestive heart failure (CHF) (New York Heart Association [NYHA] classes II-IV) or serious cardiac arrhythmia requiring treatment.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Has a medical history of myocardial infarction or unstable angina within 6 months before enrollment.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Has any clinically important abnormalities in rhythm, conduction or morphology of resting electrocardiogram (ECG), e.g., complete left bundle branch block, third-degree heart block, second-degree heart block, or PR interval &gt; 250 milliseconds (ms).</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Has an average of Fredericia&#39;s formula-QT corrected interval (QTcF) prolongation to &gt; 470 millisecond (ms) in males and females based on a 12-lead electrocardiogram (ECG) in triplicate.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Unable or unwilling to discontinue concomitant drugs that are known to prolong the QT interval.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Has a medical history of interstitial lung diseases (e.g., non-infectious interstitial pneumonia, pneumonitis, pulmonary fibrosis, and severe radiation pneumonitis) or current interstitial lung diseases or who are suspected to have these diseases by imaging at screening.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Has an uncontrolled infection requiring intravenous injection of antibiotics, antivirals, or antifungals.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Has clinically significant corneal disease.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Know human immunodeficiency virus (HIV) infection.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Subjects have active viral (any etiology) hepatitis are excluded. However, subjects with positive hepatitis B surface antigen (HBsAg) who have the HBV DNA (viral load) below the lower limit quantification or HBV DNA titer &lt; 1000 cps/mL or 200 IU/mL per local testing and are not currently on viral suppressive therapy may be eligible and should be discussed with the Sponsor&#39;s Medical Monitor. However, subjects with a history of hepatitis C virus (HCV) infection who have completed curative antiviral treatment and have the HCV RNA below the lower limit of quantification per local testing are eligible for study entry.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Is a lactating mother (women who are willing to temporarily interrupt breastfeeding will also be excluded), or pregnant as confirmed by serum pregnancy tests performed within 7 days prior to Cycle 1 Day 1.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Has clinically active brain metastases, defined as untreated and symptomatic, or requiring therapy with steroids or anticonvulsants to control associated symptoms. However, subjects with asymptomatic central nervous system (CNS) metastases who are radiologically and neurologically stable for at least 4 weeks following CNS-directed therapy, and who are on stable or decreasing doses of corticosteroids equivalent to ≤10 mg/day prednisone are eligible for study entry. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.</li> 												</ul> 						</div> 							 							<h3 class=""printHeading"">Trial Objectives and Outlines</h3> 				<div id=""trialObjectives""><p class='ctrp'>This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a study. Phase 1 adopts</p><p class='ctrp'>the standard &quot;3+3&quot; design to identify: the MTD and/or RP2D of DB-1310 as monotherapy, the</p><p class='ctrp'>RCD_A of DB-1310 in combination with trastuzumab and the RCD_B of DB-1310 in combination</p><p class='ctrp'>with Osimertinib; Phase 2a is a dose expansion phase to confirm the safety, tolerability</p><p class='ctrp'>and explore efficacy in selected malignant solid tumors treated with DB-1310 as</p><p class='ctrp'>monotherapy or in combination with trastuzumab or in combination with Osimertinib.</p></div> 			 							<h3 class=""printHeading"">Lead Organization</h3> 									<div>DualityBio Inc.</div> 													<div>Principal Investigator: Raymond Zhao</div> 										<h3 class=""printHeading"">Locations & Contacts</h3> 			<div class=""locationNoteBlock""> 				<span>Note:</span> Information about participating sites on pharmaceutical industry trials may be incomplete, so please look up the <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT05785741"" target=""_blank"">NCT number</a> on ClinicalTrials.gov 			</div> 			<div> 								           <h3 class=""locationCountryLabel"">U.S.A.</h3>               <h4>California</h4>                           <h5 class=""locationCity"">Los Angeles</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">UCLA / Jonsson Comprehensive Cancer Center</strong>     <br>Contact: Heather Horowitz <br>Phone: 310-633-8400 <br>Email: <a href=""mailto:Hhorowitz@mednet.ucla.edu"">Hhorowitz@mednet.ucla.edu</a>   </span> </div>                                       <h5 class=""locationCity"">Sacramento</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">University of California Davis Comprehensive Cancer Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>Florida</h4>                           <h5 class=""locationCity"">Miami</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">University of Miami Miller School of Medicine-Sylvester Cancer Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>Georgia</h4>                           <h5 class=""locationCity"">Atlanta</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Emory University Hospital/Winship Cancer Institute</strong>     <br>Name Not Available   </span> </div>                                   <h4>Massachusetts</h4>                           <h5 class=""locationCity"">Boston</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Brigham and Women's Hospital</strong>     <br>Name Not Available   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Dana-Farber Cancer Institute</strong>     <br>Name Not Available   </span> </div>                           			</div> 		</div> 			<div class=""trialContainer""> 			<h2 class=""hangingIndent"">5. A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)</h2> 						<a class=""hangingIndent print-check-for-updates"" href=""/research/participate/clinical-trials-search/v?d=C1967&d=C2167&d=C93259&d=C199379&d=C172809&d=C82379&d=C116377&d=C1855&d=C65530&d=C124993&d=C148147&d=C66940&d=C2693&d=C97273&loc=0&pn=7&rl=2&st=C162158&st=C153201&st=C176727&st=C147924&st=C202131&st=C3512&st=C155908&st=C156093&st=C156094&st=C157364&st=C128798&st=C9133&st=C133254&st=C135017&st=C174510&st=C155901&st=C171612&st=C162642&t=C2926&id=NCI-2024-06647""><span>Check for Updates</span></a> 			<table class=""trialDataTable""> 				<tr class=""trialDataHeaderRow""> 					<td>Phase</td> 					<td>Type</td> 					<td>Status</td> 					<td>Age</td> 					<td>Trial IDs</td> 				</tr> 				<tr> 					<td>Phase I</td> 					<td>Treatment</td> 					<td>Active</td> 					<td>18 													and over 						 						</td> 					<td class=""trialIDCell""> 						<span class = ""dataTableIDLabel"">Primary ID</span> NVL-330-01<br> 						<span class = ""dataTableIDLabel"">Secondary IDs</span> NCI-2024-06647<br> 						<span class = ""dataTableIDLabel"">Clinicaltrials.gov ID</span> <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT06521554"" target=""_blank"">NCT06521554</a><br> 					</td> 			</table>  			<h3>Description</h3> 			<div>Phase 1a/1b dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-330, determine the recommended Phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced or metastatic HER2-altered NSCLC.  Phase 1a dose escalation is designed to assess the safety and tolerability of NVL-330 and to select the candidate RP2D(s) and, if applicable, the MTD.  Phase 1b expansion is designed to further evaluate the overall safety and tolerability of the candidate RP2D(s) of NVL-330 and to determine the RP2D of NVL 330 in patients with advanced or metastatic HER2 mutant NSCLC.</div>  			<h3 class=""printHeading"">Eligibility Criteria</h3>  																																																																																																																																																																																																																																																																																																																																																									<h4>Inclusion Criteria</h4> 										<div> 							<ul> 															<li>Age ≥ 18 years</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Histologically or cytologically confirmed locally advanced or metastatic NSCLC</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Documented HER2 status as follows:</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Phase 1a: Documented oncogenic HER2 mutation such as HER2 exon20 insertion mutations or single nucleotide variants or HER2 amplification.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Phase 1b: Documented oncogenic HER2 mutation.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Identification of lesions as follows:</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Phase 1a: Must have evaluable disease (target or nontarget) according to RECIST 1.1.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Phase 1b: Must have measurable disease, defined as ≥ 1 radiologically measurable target lesion according to RECIST 1.1.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Adequate organ function and bone marrow reserve</li> 												</ul> 						</div> 														<h4>Exclusion Criteria</h4> 										<div> 							<ul> 																<li>Patient&#39;s cancer has known oncogenic driver alteration other than HER2</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Known allergy/hypersensitivity to excipients of NVL-330</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Major surgery within 4 weeks of the first dose of study drug</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Ongoing or recent anticancer therapy</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Actively receiving systemic treatment or direct medical intervention on another therapeutic clinical study</li> 												</ul> 						</div> 							 							<h3 class=""printHeading"">Trial Objectives and Outlines</h3> 				<div id=""trialObjectives""><p class='ctrp'>The planned Phase 1a/1b first-in-human study is designed as a two-part clinical trial to</p><p class='ctrp'>investigate NVL-330 in pre-treated patients with advanced or metastatic HER2-altered</p><p class='ctrp'>NSCLC. The dose escalation phase of the trial is designed to enroll a set number of</p><p class='ctrp'>patients per cohort at protocol defined dose levels. After the initial patients are</p><p class='ctrp'>treated at a given dose level and monitored for at least 28 days, available data will be</p><p class='ctrp'>reviewed, and initiation of the next dosing group will proceed with consideration given</p><p class='ctrp'>to the overall safety profile.</p><p class='ctrp'></p><p class='ctrp'>The expansion phase of the trial is designed to further evaluate safety and activity and</p><p class='ctrp'>to confirm the RP2D(s).</p></div> 			 							<h3 class=""printHeading"">Lead Organization</h3> 									<div>Nuvalent Inc.</div> 													<div>Principal Investigator: Vivek Upadhyay</div> 										<h3 class=""printHeading"">Locations & Contacts</h3> 			<div class=""locationNoteBlock""> 				<span>Note:</span> Information about participating sites on pharmaceutical industry trials may be incomplete, so please look up the <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT06521554"" target=""_blank"">NCT number</a> on ClinicalTrials.gov 			</div> 			<div> 								           <h3 class=""locationCountryLabel"">U.S.A.</h3>               <h4>Massachusetts</h4>                           <h5 class=""locationCity"">Boston</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Massachusetts General Hospital Cancer Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>Missouri</h4>                           <h5 class=""locationCity"">Saint Louis</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Siteman Cancer Center at Washington University</strong>     <br>Name Not Available   </span> </div>                                   <h4>New York</h4>                           <h5 class=""locationCity"">New York</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Memorial Sloan Kettering Cancer Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>Texas</h4>                           <h5 class=""locationCity"">Houston</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">M D Anderson Cancer Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>Washington</h4>                           <h5 class=""locationCity"">Seattle</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Fred Hutch/University of Washington/Seattle Children's Cancer Consortium</strong>     <br>Name Not Available   </span> </div>                           			</div> 		</div> 			<div class=""trialContainer""> 			<h2 class=""hangingIndent"">6. A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.</h2> 						<a class=""hangingIndent print-check-for-updates"" href=""/research/participate/clinical-trials-search/v?d=C1967&d=C2167&d=C93259&d=C199379&d=C172809&d=C82379&d=C116377&d=C1855&d=C65530&d=C124993&d=C148147&d=C66940&d=C2693&d=C97273&loc=0&pn=7&rl=2&st=C162158&st=C153201&st=C176727&st=C147924&st=C202131&st=C3512&st=C155908&st=C156093&st=C156094&st=C157364&st=C128798&st=C9133&st=C133254&st=C135017&st=C174510&st=C155901&st=C171612&st=C162642&t=C2926&id=NCI-2023-10904""><span>Check for Updates</span></a> 			<table class=""trialDataTable""> 				<tr class=""trialDataHeaderRow""> 					<td>Phase</td> 					<td>Type</td> 					<td>Status</td> 					<td>Age</td> 					<td>Trial IDs</td> 				</tr> 				<tr> 					<td>Phase II</td> 					<td>Treatment</td> 					<td>Active</td> 					<td>18 													and over 						 						</td> 					<td class=""trialIDCell""> 						<span class = ""dataTableIDLabel"">Primary ID</span> TAS6417-201<br> 						<span class = ""dataTableIDLabel"">Secondary IDs</span> NCI-2023-10904, 2023-503865-48<br> 						<span class = ""dataTableIDLabel"">Clinicaltrials.gov ID</span> <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT05967689"" target=""_blank"">NCT05967689</a><br> 					</td> 			</table>  			<h3>Description</h3> 			<div>The purpose of this study is to evaluate the safety and efficacy of zipalertinib in patients with locally advanced or metastatic NSCLC harboring EGFR ex20ins mutations and other mutations.</div>  			<h3 class=""printHeading"">Eligibility Criteria</h3>  																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																		<h4>Inclusion Criteria</h4> 										<div> 							<ul> 															<li>Written informed consent</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>≥18 years of age (or meets the country&#39;s regulatory definition of legal adult age, whichever is greater</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Pathologically confirmed, locally advanced or metastatic NSCLC meeting all the following criteria: Cohort A patients:</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Documented EGFR ex20ins mutation status, as determined by local testing performed at a CLIA certified (US) or locally certified laboratory (outside the US).</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Progressed on or after systemic therapy with an agent targeting ex20ins, either alone or in combination with standard platinum-based chemotherapy for the treatment of advanced disease. Patients who discontinued previous treatment due to unacceptable toxicity are eligible.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patients with brain metastasis must be neurologically stable. Patients must have received CNS-directed therapy and have no evidence of progression for at least 4 weeks after CNS-directed treatment, as ascertained by clinical examination and brain imaging (MRI or CT scan) during the screening period, and they must be on a stable or decreasing dose of corticosteroids and/or anti-convulsant medications for at least 2 weeks prior to the first dose of study treatment. Patients with history of uncontrolled seizures or leptomeningeal disease are not eligible. Cohort B patients:</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Documented EGFR ex20ins mutation status, as determined by local testing performed at a CLIA certified (US) or locally certified laboratory (outside the US).</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Not received prior systemic therapy for locally advanced or metastatic disease. Prior adjuvant/neoadjuvant treatment for early-stage disease must have been completed &gt;6 months prior to the first dose of study treatment.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patients with brain metastasis must be neurologically stable. Patients must have received CNS-directed therapy and have no evidence of progression for at least 4 weeks after CNS-directed treatment, as ascertained by clinical examination and brain imaging (MRI or CT scan) during the screening period, and they must be on a stable or decreasing dose of corticosteroids and/or anti-convulsant medications for at least 2 weeks prior to the first dose of study treatment. Patients with history of uncontrolled seizures or leptomeningeal disease are not eligible. Cohort C patients:</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Documented EGFR ex20ins mutation status, as determined by local testing performed at a CLIA certified (US) or locally certified laboratory (outside the US).</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Presence of brain metastasis(es), which may be measurable or nonmeasurable by RANO-BM criteria, characterized as one of the following:</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Newly diagnosed and/or progressive brain metastasis (es) not subjected to CNS-directed therapy, OR</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Leptomeningeal disease (LMD) confirmed by a positive cerebrospinal fluid cytology, or unequivocal radiographic and/or clinical determination. Cohort D patients:</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Documented other non-ex20ins uncommon single or compound EGFRmt status, as determined by local testing performed at a CLIA certified (US) or locally certified laboratory (outside the US). A list of eligible mutations will be provided in a separate manual.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patients with brain metastasis must be neurologically stable. Patients must have received CNS-directed therapy and have no evidence of progression for at least 4 weeks after CNS-directed treatment, as ascertained by clinical examination and brain imaging (MRI or CT scan) during the screening period, and they must be on a stable or decreasing dose of corticosteroids and/or anti-convulsant medications for at least 2 weeks prior to the first dose of study treatment. Patients with history of uncontrolled seizures or leptomeningeal disease are not eligible.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Measurable disease per RECIST 1.1.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Archival tumor tissue available for submission, with minimum quantity sufficient to evaluate EGFRmt status and, where possible, other biomarkers (details provided in a laboratory manual). Patients with insufficient tissue may be eligible following discussion with the sponsor.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 17. Adequate organ function, as defined by the hematologic, renal and hepatic laboratory values</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Women of childbearing potential (WOCBP) must have a negative serum pregnancy test prior to administration of the first dose of study treatment. Female patients are not considered to be of childbearing potential if they are post-menopausal (no menses for 12 months without an alternative medical cause) or permanently sterile (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy).</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Both males and females of reproductive potential must agree to use effective birth control during the study prior to the first dose of study drug and for 6 months after the last dose of study treatment.</li> 												</ul> 						</div> 														<h4>Exclusion Criteria</h4> 										<div> 							<ul> 																<li>Patient is currently receiving an investigational drug in a clinical trial or participating in any other type of medical research judged to be scientifically or medically incompatible with this study.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Has received any of the following within the specific time frame specified:</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Patient has received Zipalertinib (TAS6417/CLN081) at any time</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Thoracic radiotherapy ≤28 days or palliative radiation ≤14 days prior to the first dose of study treatment</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Anticancer immunotherapy ≤28 days prior to the first dose of study treatment</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Major surgery (excluding placement of vascular access) ≤28 days prior to the first dose of study treatment.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Have any unresolved toxicity of Grade ≥2 from previous anticancer treatment, except for Grade 2 alopecia or skin pigmentation. Patients with other chronic but stable Grade 2 toxicities may be allowed to enroll after agreement between the investigator and Sponsor.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Past medical history of interstitial lung disease, treatment-related pneumonitis (any grade), or evidence of clinically active interstitial lung disease.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Impaired cardiac function or clinically significant cardiac disease including any of the following:</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>History of congestive heart failure (CHF) Class III/IV according to the New York Heart Association (NYHA) Functional Classification (Appendix A)</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Serious cardiac arrhythmias requiring treatment.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Resting corrected QT interval (QTc) &gt;470 msec using Fridericia&#39;s formula (QTcF).</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Is unable to swallow tablets/capsules or has any disease or condition that may significantly affect gastrointestinal absorption of zipalertinib (eg, inflammatory bowel disease, malabsorption syndrome, or prior gastric/bowel resection).</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>History of another primary malignancy ≤2 years prior to the date of first dose of study treatment unless at least one of the following criteria are met:</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Adequately treated basal or squamous cell carcinoma of the skin</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Cancer of the breast or cervix in situ</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Patients with previously treated malignancy if all treatment for that malignancy was completed at least 2 years prior to first dose and no evidence of disease</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Patients with concurrent malignancy clinically stable and not requiring tumor-directed treatment</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Known history of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) that is not controlled with treatment.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>History of COVID-19 infection within 4 weeks prior to enrolment and/or has persistent clinically significant pulmonary symptoms related to prior COVID-19 infection.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Active bleeding disorders.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Known hypersensitivity to the ingredients in zipalertinib or any drugs similar in structure or class.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Is pregnant or lactating.</li> 												</ul> 						</div> 							 							<h3 class=""printHeading"">Trial Objectives and Outlines</h3> 				<div id=""trialObjectives""><p class='ctrp'>This study will evaluate the safety and efficacy of zipalertinib in patients with locally</p><p class='ctrp'>advanced or metastatic NSCLC harboring EGFR ex20ins mutations or other uncommon/single or</p><p class='ctrp'>compound EGFRmt.</p><p class='ctrp'></p><p class='ctrp'>Patients will be enrolled into 1 of the 4 following cohorts:</p><p class='ctrp'></p><p class='ctrp'>  -  Cohort A (&quot;prior ex20ins treatment&quot;) will include patients harboring EGFR ex20ins</p><p class='ctrp'>     mutations who have progressed on or after initial treatment with standard</p><p class='ctrp'>     platinum-based chemotherapy and prior treatment with an ex20 agent for their</p><p class='ctrp'>     advanced disease (administered together or separately).</p><p class='ctrp'></p><p class='ctrp'>  -  Cohort B (&quot;1st line&quot;) will include patients harboring EGFR ex20ins mutations who</p><p class='ctrp'>     have not received prior treatment for advanced disease.</p><p class='ctrp'></p><p class='ctrp'>  -  Cohort C (&quot;active brain mets&quot;) will include patients harboring EGFR ex20ins or other</p><p class='ctrp'>     uncommon single and compound mutations and active brain metastases. Patients may or</p><p class='ctrp'>     may not have had prior treatment for advanced disease.</p><p class='ctrp'></p><p class='ctrp'>  -  Cohort D (&quot;other uncommon EGFRmt&quot;) will include patients harboring other, non</p><p class='ctrp'>     ex20ins uncommon single or compound EGFRmt who have progressed on or after treatment</p><p class='ctrp'>     with standard systemic anticancer therapy.</p></div> 			 							<h3 class=""printHeading"">Lead Organization</h3> 									<div>Taiho Pharmaceutical Company Limited</div> 														<h3 class=""printHeading"">Locations & Contacts</h3> 			<div class=""locationNoteBlock""> 				<span>Note:</span> Information about participating sites on pharmaceutical industry trials may be incomplete, so please look up the <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT05967689"" target=""_blank"">NCT number</a> on ClinicalTrials.gov 			</div> 			<div> 								           <h3 class=""locationCountryLabel"">U.S.A.</h3>               <h4>California</h4>                           <h5 class=""locationCity"">Duarte</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">City of Hope Comprehensive Cancer Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>Massachusetts</h4>                           <h5 class=""locationCity"">Boston</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Beth Israel Deaconess Medical Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>New York</h4>                           <h5 class=""locationCity"">New York</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Memorial Sloan Kettering Cancer Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>Texas</h4>                           <h5 class=""locationCity"">Houston</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">M D Anderson Cancer Center</strong>     <br>Name Not Available   </span> </div>                           			</div> 		</div> 			<div class=""trialContainer""> 			<h2 class=""hangingIndent"">7. A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors</h2> 						<a class=""hangingIndent print-check-for-updates"" href=""/research/participate/clinical-trials-search/v?d=C1967&d=C2167&d=C93259&d=C199379&d=C172809&d=C82379&d=C116377&d=C1855&d=C65530&d=C124993&d=C148147&d=C66940&d=C2693&d=C97273&loc=0&pn=7&rl=2&st=C162158&st=C153201&st=C176727&st=C147924&st=C202131&st=C3512&st=C155908&st=C156093&st=C156094&st=C157364&st=C128798&st=C9133&st=C133254&st=C135017&st=C174510&st=C155901&st=C171612&st=C162642&t=C2926&id=NCI-2023-08892""><span>Check for Updates</span></a> 			<table class=""trialDataTable""> 				<tr class=""trialDataHeaderRow""> 					<td>Phase</td> 					<td>Type</td> 					<td>Status</td> 					<td>Age</td> 					<td>Trial IDs</td> 				</tr> 				<tr> 					<td>Phase I</td> 					<td>Treatment</td> 					<td>Active</td> 					<td>18 													and over 						 						</td> 					<td class=""trialIDCell""> 						<span class = ""dataTableIDLabel"">Primary ID</span> ST316-101<br> 						<span class = ""dataTableIDLabel"">Secondary IDs</span> NCI-2023-08892<br> 						<span class = ""dataTableIDLabel"">Clinicaltrials.gov ID</span> <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT05848739"" target=""_blank"">NCT05848739</a><br> 					</td> 			</table>  			<h3>Description</h3> 			<div>This is an open-label, two-part, phase 1-2 study designed to determine the safety, tolerability, PK, pharmacodynamics (PD), and proof-of-concept efficacy of ST316 administered IV in subjects with selected advanced solid tumors likely to harbor abnormalities of the WNT/β-catenin signaling pathway. The study consists of two phases: a phase 1 dose escalation/regimen exploration phase and a phase 2 expansion phase.</div>  			<h3 class=""printHeading"">Eligibility Criteria</h3>  																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																<h4>Inclusion Criteria</h4> 										<div> 							<ul> 															<li>Able and willing to sign an informed consent form (ICF) and comply with the protocol and the restrictions and assessments therein.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Male or female ≥18 years of age.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Eastern Cooperative Oncology Group (ECOG) performance status 0-1.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Must have a locally advanced or metastatic inoperable tumor as follows:</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>For the dose-escalation phase: CRC, HCC, TNBC, NSCLC, OC, melanoma, CCA, and SS.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>For the expansion phase: CRC. Note: if additional indications and combinations are added inclusion/exclusion criteria will be updated.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Agrees to provide a newly obtained biopsy of an accessible lesion (if they can be biopsied based on the Investigator&#39;s assessment) prior to the start of study treatment, and to repeat biopsy once during study treatment. Tissue obtained for the biopsy must not be previously irradiated, but a new or progressing lesion in the radiation field is acceptable. Subjects without accessible lesion for biopsy must be able to provide an archival tumor tissue sample for central lab analysis.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>In the Investigator&#39;s opinion, the subject may not derive clinical benefit from, or is ineligible for, a particular form of standard therapy on medical grounds, or the subject failed or did not tolerate one or more of other anticancer therapies: a. For the dose escalation phase: i. Refractory, intolerant, or refused available standard-of-care therapies. ii. Up to three previous lines of systemic anticancer therapies for metastatic disease are allowed (adjuvant or neoadjuvant setting do not count as lines of systemic therapy). iii. Subjects with TNBC or OC with known BRCA mutations must have been previously treated with or intolerant to Food and Drug Administration (FDA) approved treatments prior to enrolling in this study (e.g., iPARP). iv. Subjects with OC must have been treated with, refused, or were ineligible for treatment with bevacizumab to enroll. v. Subjects with CRC tumors that are MSI-H/dMMR must have received, refused or be intolerant to a checkpoint inhibitor (CPI). vi. Subjects with HCC must have confirmed diagnosis of inoperable hepatocellular carcinoma by histology or clinical/radiological criteria. No more than two prior lines of systemic therapy only and Child Pugh Score A or B7. b. For the expansion phase: i. For all cohorts: Subjects with MSI-H/dMMR must have received, refused or be intolerant to a CPI. ii. Cohort 1 ST316 monotherapy: CRC that has progressed after or on treatment with all of the following, alone or in combination, comprising a maximum of four prior lines of therapy for their advanced/metastatic disease: oxaliplatin, irinotecan, fluoropyrimidines, anti-vascular-endothelial growth factor (VEGF), anti-epidermal growth factor receptor (EGFR) targeted agents (as indicated). iii. Cohort 2: Combination with standard of care (SOC) FOLFIRI + bevacizumab: CRC that has progressed after or on treatment with all of the following, alone or in combination, comprising a maximum of one prior line of therapy for their advanced/metastatic disease: oxaliplatin, irinotecan, fluoropyrimidines, anti-VEGF. Subjects with RAS wild-type must have been treated with an anti-EGFR targeted agent during the first line of treatment. iv. Cohort 3: Combination with fruquintinib: CRC that has progressed after or on treatment with all of the following, alone or in combination, comprising a maximum of two prior lines of therapy for their advanced/metastatic disease: oxaliplatin, irinotecan, fluoropyrimidines or anti-VEGF Subjects with RAS wild-type must have been treated with an anti-EGFR targeted agent during the first or second line of treatment. v. Cohort 4: Combination with Lonsurf + beva: CRC that has progressed after or on treatment with all of the following, alone or in combination, comprising a maximum of two prior lines of therapy for their advanced/metastatic disease: oxaliplatin, irinotecan, fluoropyrimidines or anti-VEGF Subjects with RAS wild-type must have been treated with an anti-EGFR targeted agent during the first or second line of treatment.</li> 												</ul> 						</div> 														<h4>Exclusion Criteria</h4> 										<div> 							<ul> 																<li>Known hypersensitivity to ST316 or any of its excipients.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Known hypersensitivity to bevacizumab, 5-FU, leucovorin or irinotecan for Cohort 2, to fruquintinib for Cohort 3 and trifluridine or tipiracil for Cohort 4 in the expansion.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Corrected interval between Q and T wave on electrocardiogram (ECG) (QTc) &gt; 480 msec using Fredericia&#39;s formula.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Symptomatic ascites or pleural effusion. A subject who is clinically stable for 4 weeks following treatment for these conditions (including therapeutic thoraco- or paracentesis) is eligible.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are clinically stable for at least 2 weeks prior to study entry and have no evidence of new or enlarging brain metastases. Subjects with treated brain metastases must also follow the steroid exclusion criterion (#11) listed below.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>For expansion phase only: presence of any other active malignancy requiring systemic therapy other than the disease under study.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>For subjects to be treated with a regimen containing bevacizumab:</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>History of cardiac disease: congestive heart failure (CHF) ≥NYHA Class II; active coronary artery disease, myocardial infarction within 6 months prior to study entry; unevaluated new onset angina within 3 months or unstable angina (angina symptoms at rest) or cardiac arrhythmias requiring anti-arrhythmic therapy (βeta blockers or digoxin are permitted).</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Current uncontrolled hypertension (systolic blood pressure [BP] &gt;150 mmHg or diastolic pressure &gt;90 mmHg despite optimal medical management) as well as prior history of hypertensive crisis or hypertensive encephalopathy.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>History of arterial thrombotic or embolic events (within 6 months prior to study entry).</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Significant vascular disease (e.g., aortic aneurysm, aortic dissection, symptomatic peripheral vascular disease).</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Evidence of bleeding diathesis or clinically significant coagulopathy.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Major surgical procedure (including open biopsy, significant traumatic injury, etc.) within 28 days, or anticipation of the need for major surgical procedure during the course of the study as well as minor surgical procedure (excluding placement of a vascular access device or bone marrow biopsy) within 7 days prior to study enrollment.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Proteinuria at screening as demonstrated by urinalysis with proteinuria ≥2+ (subjects discovered to have ≥2+ proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate ≤1g of protein in 24 hours to be eligible).</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>History of abdominal fistula, gastrointestinal perforation, peptic ulcer, or intraabdominal abscess within 6 months.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Ongoing serious, non-healing wound, ulcer, or bone fracture.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>History of reversible posterior leukoencephalopathy syndrome (RPLS).</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>History of hypersensitivity to Chinese hamster ovary (CHO) cells or other human or humanized recombinant antibodies. -</li> 												</ul> 						</div> 							 			 							<h3 class=""printHeading"">Lead Organization</h3> 									<div>Sapience Therapeutics</div> 													<div>Principal Investigator: Abi Vainstein-Haras</div> 										<h3 class=""printHeading"">Locations & Contacts</h3> 			<div class=""locationNoteBlock""> 				<span>Note:</span> Information about participating sites on pharmaceutical industry trials may be incomplete, so please look up the <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT05848739"" target=""_blank"">NCT number</a> on ClinicalTrials.gov 			</div> 			<div> 								           <h3 class=""locationCountryLabel"">U.S.A.</h3>               <h4>California</h4>                           <h5 class=""locationCity"">Los Angeles</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Los Angeles General Medical Center</strong>     <br>Contact: Xiomara Menendez <br>Phone: 323-865-0212 <br>Email: <a href=""mailto:menendez_x@med.usc.edu"">menendez_x@med.usc.edu</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">USC / Norris Comprehensive Cancer Center</strong>     <br>Contact: Xiomara Menendez <br>Phone: 323-865-0212 <br>Email: <a href=""mailto:menendez_x@med.usc.edu"">menendez_x@med.usc.edu</a>   </span> </div>                                   <h4>North Carolina</h4>                           <h5 class=""locationCity"">Durham</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Duke University Medical Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>Oklahoma</h4>                           <h5 class=""locationCity"">Oklahoma City</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">University of Oklahoma Health Sciences Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>Washington</h4>                           <h5 class=""locationCity"">Seattle</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Fred Hutch/University of Washington/Seattle Children's Cancer Consortium</strong>     <br>Name Not Available   </span> </div>                           			</div> 		</div> 			<div class=""trialContainer""> 			<h2 class=""hangingIndent"">8. Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment</h2> 						<a class=""hangingIndent print-check-for-updates"" href=""/research/participate/clinical-trials-search/v?d=C1967&d=C2167&d=C93259&d=C199379&d=C172809&d=C82379&d=C116377&d=C1855&d=C65530&d=C124993&d=C148147&d=C66940&d=C2693&d=C97273&loc=0&pn=7&rl=2&st=C162158&st=C153201&st=C176727&st=C147924&st=C202131&st=C3512&st=C155908&st=C156093&st=C156094&st=C157364&st=C128798&st=C9133&st=C133254&st=C135017&st=C174510&st=C155901&st=C171612&st=C162642&t=C2926&id=NCI-2022-05160""><span>Check for Updates</span></a> 			<table class=""trialDataTable""> 				<tr class=""trialDataHeaderRow""> 					<td>Phase</td> 					<td>Type</td> 					<td>Status</td> 					<td>Age</td> 					<td>Trial IDs</td> 				</tr> 				<tr> 					<td>Phase III</td> 					<td>Treatment</td> 					<td>Active</td> 					<td>18 													to 130 years 						 						</td> 					<td class=""trialIDCell""> 						<span class = ""dataTableIDLabel"">Primary ID</span> D5087C00001<br> 						<span class = ""dataTableIDLabel"">Secondary IDs</span> NCI-2022-05160, 2021-006374-24, 2024-511169-12-00<br> 						<span class = ""dataTableIDLabel"">Clinicaltrials.gov ID</span> <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT05261399"" target=""_blank"">NCT05261399</a><br> 					</td> 			</table>  			<h3>Description</h3> 			<div>Clinical study to investigate the efficacy and safety of savolitinib in combination with osimertinib versus platinum-based doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on treatment with Osimertinib.</div>  			<h3 class=""printHeading"">Eligibility Criteria</h3>  																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																										<h4>Inclusion Criteria</h4> 										<div> 							<ul> 															<li>Provision of signed and dated written ICF prior to any mandatory and non-mandatory study-specific procedures, sampling and analyses.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Participant must be ≥18 years (≥ 19 years of age in South Korea) at the time of signing the informed consent. All genders are permitted.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Histologically or cytologically confirmed locally advanced or metastatic NSCLC which is not amenable to curative therapy.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Must have at least one documented sensitising EGFR mutation: exon19 deletion, L858R mutation, and/or T790M.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Documented radiologic progression on first- or second-line treatment with osimertinib as the most recent anti-cancer therapy.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Mandatory provision of FFPE tumour tissue.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>MET overexpression and/or amplification in tumour specimen collected following progression on prior osimertinib treatment.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Measurable disease as defined by RECIST 1.1.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Adequate haematological, liver, renal and cardiac functions, and coagulation parameters.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>ECOG performance status of 0 or 1.</li> 												</ul> 						</div> 														<h4>Exclusion Criteria</h4> 										<div> 							<ul> 																<li>Predominant squamous NSCLC, and small cell lung cancer.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Prior or current treatment with a third-generation EGFR-TKI other than Osimertinib.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Prior or current treatment with savolitinib or another MET inhibitors.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Spinal cord compression or brain metastases, unless asymptomatic and are stable.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>History or active leptomeningeal carcinomatosis.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Unresolved toxicities from any prior therapy greater than CTCAE Grade 1 and prior platinum-therapy related Grade 2 neuropathies with the exception of alopecia and haemoglobin ≥ 9.0 g/dL.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Active/unstable cardiac diseases currently or within the last 6 months, clinically significant ECG abnormalities, and/or factors/medications that may affect QTc intervals.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>History of liver cirrhosis of any origin and clinical stage; or history of other serious liver disease or chronic disease with relevant liver involvement.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Known serious active infection including, but not limited to, tuberculosis, or HIV, HBV or HCV or gastrointestinal disease.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Receipt of live attenuated vaccine (including against COVID-19) within 30 days prior to the first dose of study intervention.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Past medical history of ILD, drug-induced ILD, radiation pneumonitis, which required steroid treatment, or any evidence of clinically active ILD.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Participants currently receiving medications or herbal supplements known to be strong inducers of cytochrome P450 (CYP)3A4 or strong inhibitors of CYP1A2.</li> 												</ul> 						</div> 							 							<h3 class=""printHeading"">Trial Objectives and Outlines</h3> 				<div id=""trialObjectives""><p class='ctrp'>This is a multicentre, Phase III, randomised, open-label study to investigate the</p><p class='ctrp'>efficacy and safety of savolitinib administered orally in combination with osimertinib</p><p class='ctrp'>versus platinum-based doublet chemotherapy in participants with EGFR mutated,</p><p class='ctrp'>MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have</p><p class='ctrp'>progressed on first- or second-line treatment with osimertinib as the most recent</p><p class='ctrp'>therapy.</p><p class='ctrp'></p><p class='ctrp'>Approximately 324 participants with EGFR mutated, MET-overexpressed and/or amplified,</p><p class='ctrp'>locally advanced or metastatic NSCLC will be randomly assigned to study intervention with</p><p class='ctrp'>1:1 ratio.</p><p class='ctrp'></p><p class='ctrp'>Patients will be treated until either objective progression of disease (PD) by Response</p><p class='ctrp'>Evaluation Criteria in Solid Tumours 1.1 (RECIST 1.1) is assessed by the investigator,</p><p class='ctrp'>unacceptable toxicity occurs, consent is withdrawn, or another discontinuation criterion</p><p class='ctrp'>is met.</p></div> 			 							<h3 class=""printHeading"">Lead Organization</h3> 									<div>AstraZeneca Pharmaceuticals LP</div> 														<h3 class=""printHeading"">Locations & Contacts</h3> 			<div class=""locationNoteBlock""> 				<span>Note:</span> Information about participating sites on pharmaceutical industry trials may be incomplete, so please look up the <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT05261399"" target=""_blank"">NCT number</a> on ClinicalTrials.gov 			</div> 			<div> 								           <h3 class=""locationCountryLabel"">U.S.A.</h3>               <h4>Massachusetts</h4>                           <h5 class=""locationCity"">Boston</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Massachusetts General Hospital Cancer Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>New Jersey</h4>                           <h5 class=""locationCity"">New Brunswick</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Rutgers Cancer Institute of New Jersey</strong>     <br>Name Not Available   </span> </div>                                   <h4>Tennessee</h4>                           <h5 class=""locationCity"">Nashville</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Vanderbilt University/Ingram Cancer Center</strong>     <br>Name Not Available   </span> </div>                           			</div> 		</div> 			<div class=""trialContainer""> 			<h2 class=""hangingIndent"">9. Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)</h2> 						<a class=""hangingIndent print-check-for-updates"" href=""/research/participate/clinical-trials-search/v?d=C1967&d=C2167&d=C93259&d=C199379&d=C172809&d=C82379&d=C116377&d=C1855&d=C65530&d=C124993&d=C148147&d=C66940&d=C2693&d=C97273&loc=0&pn=7&rl=2&st=C162158&st=C153201&st=C176727&st=C147924&st=C202131&st=C3512&st=C155908&st=C156093&st=C156094&st=C157364&st=C128798&st=C9133&st=C133254&st=C135017&st=C174510&st=C155901&st=C171612&st=C162642&t=C2926&id=NCI-2023-04004""><span>Check for Updates</span></a> 			<table class=""trialDataTable""> 				<tr class=""trialDataHeaderRow""> 					<td>Phase</td> 					<td>Type</td> 					<td>Status</td> 					<td>Age</td> 					<td>Trial IDs</td> 				</tr> 				<tr> 					<td>Phase III</td> 					<td>Treatment</td> 					<td>Active</td> 					<td>18 													and over 						 						</td> 					<td class=""trialIDCell""> 						<span class = ""dataTableIDLabel"">Primary ID</span> FURMO-004<br> 						<span class = ""dataTableIDLabel"">Secondary IDs</span> NCI-2023-04004, 2022-502977-41-00<br> 						<span class = ""dataTableIDLabel"">Clinicaltrials.gov ID</span> <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT05607550"" target=""_blank"">NCT05607550</a><br> 					</td> 			</table>  			<h3>Description</h3> 			<div>Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of furmonertinib (firmonertinib) at 2 dose levels (160 mg once daily [QD] and 240 mg QD) compared to platinum-based chemotherapy in previously untreated patients with locally advanced or metastatic non-squamous Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) exon 20 insertion mutations. A target of approximately 375 patients will be randomized in a 1:1:1 ratio to treatment with furmonertinib 240 mg QD, furmonertinib 160 mg QD, or platinum-based chemotherapy.</div>  			<h3 class=""printHeading"">Eligibility Criteria</h3>  																																													<h4>Inclusion Criteria</h4> 										<div> 							<ul> 															<li>Key Inclusion Criteria:    -  Histologically or cytologically documented, locally advanced or metastatic      non-squamous Non-Small Cell Lung Cancer (NSCLC) not amenable to curative surgery or      radiotherapy.    -  Documented results of the presence of an Epidermal Growth Factor Receptor (EGFR)      exon 20 insertion mutation in tumor tissue or blood from local or central testing.    -  No prior systemic anticancer therapy regimens received for locally advanced or      metastatic Non-Small Cell Lung Cancer (NSCLC) including prior treatment with any      Epidermal Growth Factor Receptor (EGFR)-targeting agents (e.g., previous (EGFR)      TKIs, monoclonal antibodies, or bispecific antibodies).    -  Patients who have received prior neo-adjuvant and/or adjuvant chemotherapy,      immunotherapy, or chemo radiotherapy for non-metastatic disease (excluding      EGFR-TKIs) must have experienced a treatment free interval of at least 12 months.    -  Patients with a history of treated CNS metastases or new asymptomatic CNS metastases      are eligible.</li> 												</ul> 						</div> 										 			 							<h3 class=""printHeading"">Lead Organization</h3> 									<div>ArriVent BioPharma, Inc.</div> 														<h3 class=""printHeading"">Locations & Contacts</h3> 			<div class=""locationNoteBlock""> 				<span>Note:</span> Information about participating sites on pharmaceutical industry trials may be incomplete, so please look up the <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT05607550"" target=""_blank"">NCT number</a> on ClinicalTrials.gov 			</div> 			<div> 								           <h3 class=""locationCountryLabel"">U.S.A.</h3>               <h4>California</h4>                           <h5 class=""locationCity"">Los Angeles</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">UCLA / Jonsson Comprehensive Cancer Center</strong>     <br>Contact: Lia Etheridge <br>Phone: 310-825-7174 <br>Email: <a href=""mailto:LEtheridge@mednet.ucla.edu"">LEtheridge@mednet.ucla.edu</a>   </span> </div>                                       <h5 class=""locationCity"">Sacramento</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">University of California Davis Comprehensive Cancer Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>New York</h4>                           <h5 class=""locationCity"">Bronx</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Montefiore Medical Center-Weiler Hospital</strong>     <br>Name Not Available   </span> </div>                           			</div> 		</div> 			<div class=""trialContainer""> 			<h2 class=""hangingIndent"">10. A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC</h2> 						<a class=""hangingIndent print-check-for-updates"" href=""/research/participate/clinical-trials-search/v?d=C1967&d=C2167&d=C93259&d=C199379&d=C172809&d=C82379&d=C116377&d=C1855&d=C65530&d=C124993&d=C148147&d=C66940&d=C2693&d=C97273&loc=0&pn=7&rl=2&st=C162158&st=C153201&st=C176727&st=C147924&st=C202131&st=C3512&st=C155908&st=C156093&st=C156094&st=C157364&st=C128798&st=C9133&st=C133254&st=C135017&st=C174510&st=C155901&st=C171612&st=C162642&t=C2926&id=NCI-2023-10529""><span>Check for Updates</span></a> 			<table class=""trialDataTable""> 				<tr class=""trialDataHeaderRow""> 					<td>Phase</td> 					<td>Type</td> 					<td>Status</td> 					<td>Age</td> 					<td>Trial IDs</td> 				</tr> 				<tr> 					<td>Phase II</td> 					<td>Treatment</td> 					<td>Active</td> 					<td>18 													to 75 years 						 						</td> 					<td class=""trialIDCell""> 						<span class = ""dataTableIDLabel"">Primary ID</span> TL-EGFR-2201<br> 						<span class = ""dataTableIDLabel"">Secondary IDs</span> NCI-2023-10529<br> 						<span class = ""dataTableIDLabel"">Clinicaltrials.gov ID</span> <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT06010329"" target=""_blank"">NCT06010329</a><br> 					</td> 			</table>  			<h3>Description</h3> 			<div>The main objective of the study will be to evaluate the efficacy of sutetinib maleate capsules in participants with locally advanced or metastatic non-small cell lung cancer NSCLC (uncommon EGFR mutations only).</div>  			<h3 class=""printHeading"">Eligibility Criteria</h3>  																																																																																																																																																																																																																																																																																																																																																																													<h4>Inclusion Criteria</h4> 										<div> 							<ul> 															<li>Age 18-75 years old, male or female</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Histopathological and/or cytopathological confirmation of locally advanced or metastatic NSCLC</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Confirmation that the tumor harbors an uncommon epidermal growth factor receptor (EGFR) mutation (tumor tissue biopsy)</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>At least one measurable lesion</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Eastern Cooperative Oncology Group (ECOG) score of 0, 1, or 2</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>A minimum life expectancy of &gt; 3 months</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Adequate bone marrow reserve, hepatic, renal, and coagulation function Other inclusion criteria apply for participating in the study</li> 												</ul> 						</div> 														<h4>Exclusion Criteria</h4> 										<div> 							<ul> 																<li>Participant ever used the epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) for anti-tumor therapy prior to enrollment (Cohort 1), or second generation EGFR TKI (Cohort 2)</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Any systemic anti-tumor therapy such as chemotherapy and radiation therapy (including curative radiotherapy or spinal radiotherapy portion &gt;30%) used within 3 weeks prior to enrollment; immunotherapy within 4 weeks; any palliative radiotherapy for non-target lesions used to relieve symptoms and traditional Chinese medicines indicated for the tumor within 2 weeks prior to enrollment</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Use or intake of drugs or foods containing potent inhibitors or inducers of cytochrome P450 isozyme 3A4 (CYP3A4) within 14 days or 5 half-lives, whichever is the longer, prior to enrollment</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Surgical operation (excluding aspiration biopsy) of main organs or a significant injury within 4 weeks prior to enrollment</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Any unresolved toxicities from prior therapy greater than Grade 1, at the time of screening except for alopecia</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Inability to swallow the study medication, any seriously chronic gastrointestinal disorder, malabsorption syndrome or any other conditions with influence on gastrointestinal absorption</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Active central nervous system metastases</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Any active infection which has not been controlled at screening. Other exclusion criteria apply for participating in the Study</li> 												</ul> 						</div> 							 							<h3 class=""printHeading"">Trial Objectives and Outlines</h3> 				<div id=""trialObjectives""><p class='ctrp'>Sutetinib is an investigational irreversible EGFR tyrosine kinase inhibitor. EGFR is a</p><p class='ctrp'>gene that makes a protein that is involved in cell growth and cell survival. Mutated</p><p class='ctrp'>(changed) forms of the EGFR gene and protein have been found in some types of cancer,</p><p class='ctrp'>including non-small cell lung cancer. These changes may cause cancer cells to grow and</p><p class='ctrp'>spread in the body. The purpose of this study is to explore how effective Sutetinib</p><p class='ctrp'>maleate capsules are for the treatment of patients with locally advanced or metastatic</p><p class='ctrp'>NSCLC with uncommon EGFR mutations.</p></div> 			 							<h3 class=""printHeading"">Lead Organization</h3> 									<div>Teligene US</div> 														<h3 class=""printHeading"">Locations & Contacts</h3> 			<div class=""locationNoteBlock""> 				<span>Note:</span> Information about participating sites on pharmaceutical industry trials may be incomplete, so please look up the <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT06010329"" target=""_blank"">NCT number</a> on ClinicalTrials.gov 			</div> 			<div> 								           <h3 class=""locationCountryLabel"">U.S.A.</h3>               <h4>California</h4>                           <h5 class=""locationCity"">La Jolla</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">UC San Diego Moores Cancer Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>Florida</h4>                           <h5 class=""locationCity"">Tampa</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Moffitt Cancer Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>New York</h4>                           <h5 class=""locationCity"">New York</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Laura and Isaac Perlmutter Cancer Center at NYU Langone</strong>     <br>Name Not Available   </span> </div>                                   <h4>Texas</h4>                           <h5 class=""locationCity"">Houston</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">M D Anderson Cancer Center</strong>     <br>Name Not Available   </span> </div>                           			</div> 		</div> 			<div class=""trialContainer""> 			<h2 class=""hangingIndent"">11. Osimertinib with or without Bevacizumab as Initial Treatment for Patients with EGFR-Mutant Lung Cancer</h2> 						<a class=""hangingIndent print-check-for-updates"" href=""/research/participate/clinical-trials-search/v?d=C1967&d=C2167&d=C93259&d=C199379&d=C172809&d=C82379&d=C116377&d=C1855&d=C65530&d=C124993&d=C148147&d=C66940&d=C2693&d=C97273&loc=0&pn=7&rl=2&st=C162158&st=C153201&st=C176727&st=C147924&st=C202131&st=C3512&st=C155908&st=C156093&st=C156094&st=C157364&st=C128798&st=C9133&st=C133254&st=C135017&st=C174510&st=C155901&st=C171612&st=C162642&t=C2926&id=NCI-2019-07941""><span>Check for Updates</span></a> 			<table class=""trialDataTable""> 				<tr class=""trialDataHeaderRow""> 					<td>Phase</td> 					<td>Type</td> 					<td>Status</td> 					<td>Age</td> 					<td>Trial IDs</td> 				</tr> 				<tr> 					<td>Phase III</td> 					<td>Treatment</td> 					<td>Active</td> 					<td>18 													and over 						 						</td> 					<td class=""trialIDCell""> 						<span class = ""dataTableIDLabel"">Primary ID</span> EA5182<br> 						<span class = ""dataTableIDLabel"">Secondary IDs</span> NCI-2019-07941<br> 						<span class = ""dataTableIDLabel"">Clinicaltrials.gov ID</span> <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT04181060"" target=""_blank"">NCT04181060</a><br> 					</td> 			</table>  			<h3>Description</h3> 			<div>This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.</div>  			<h3 class=""printHeading"">Eligibility Criteria</h3>  																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																<h4>Inclusion Criteria</h4> 										<div> 							<ul> 															<li>Patient must have a pathologically-confirmed diagnosis of non-squamous, non-small cell lung cancer (NSCLC)</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patient must have advanced disease, defined as - either stage IV disease, stage IIIB disease not amenable to definitive multi-modality therapy, or recurrent disease after a prior diagnosis of stage I-III disease. All staging is via the American Joint Committee on Cancer (AJCC)/International Association for the Study of Lung Cancer (IASLC) 8th edition staging criteria</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patient must have somatic activating sensitizing mutation in EGFR (e.g. but not limited to Exon 19 deletion, L858R, E709X, G719X, exon 19 insertions, L861Q, S768I). Patients with non-sensitizing mutations in EGFR (EGFR exon 20 insertions) are not eligible. Test results originating from a Clinical Laboratory Improvement Act (CLIA)-certified or similarly accredited laboratory are acceptable; no specific assay is mandated. Plasma, cytology, or tumor tissue can be utilized for mutation testing</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patient must not have received any prior treatment with an anti-VEGF agent * NOTE: Prior treatment with an EGFR TKI is not allowed, however if a candidate for this study has already started osimertinib within 21 days prior to randomization, the exact osimertinib start date is known, and the patient had the required study baseline imaging completed prior to the osimertinib start date, the patient will be eligible</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patients that have received prior radiation therapy are eligible. Radiation (limited field stereotactic radiation or conventional radiation) must have been completed at least one week prior to study drug initiation and more extensive field radiation (i.e., whole-brain radiotherapy [WBRT]) must have been completed at least two weeks prior to drug initiation</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patient must not have any risk factors for anti-VEGF administration, specifically, hemoptysis, active cardiovascular disease, uncontrolled hypertension, significant proteinuria (screening urinalysis &gt; 300 mg/dl) and tumor invading major blood vessels</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patient must have measurable disease. Baseline measurements of sites of disease must be obtained within 4 weeks prior to study randomization. If a potential target lesion is previously irradiated without subsequent growth and/or is radiated after the imaging from which baseline measurements are obtained, they cannot be included as target lesions, and additional target lesions are required to meet criteria for measurable disease</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patient must not have had any prior systemic treatment for metastatic disease</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patient must be ≥ 18 years of age</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>All females of childbearing potential must have a blood test or urine study within 14 days prior to randomization to rule out pregnancy</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>A female of childbearing potential is defined as any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patient of childbearing potential and sexually active males must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse for 2 weeks prior to the start of treatment, while on study treatment, and for * 6 weeks after the last dose of protocol treatment for female patients on the osimertinib (AZD9291) alone arm * 4 months after the last dose of protocol treatment for male patients on osimertinib (AZD9291) alone arm * 6 months after the last dose of protocol treatment for all patients on osimertinib (AZD9291) plus bevacizumab combination arm * NOTE: Female patients should also not breastfeed while on treatment and for 6 months after the last dose bevacizumab</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Leukocytes &gt;= 3,000/mcL (obtained =&lt; 14 days prior to randomization)</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Absolute neutrophil count &gt;= 1,500/mcL (obtained =&lt; 14 days prior to randomization)</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Platelets &gt;= 100,000/mcL (obtained =&lt; 14 days prior to randomization)</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Hemoglobin &gt;= 9 g/dL (obtained =&lt; 14 days prior to randomization)</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Total bilirubin and creatinine =&lt; 1.5 x institutional upper limit of normal (ULN) (obtained =&lt; 14 days prior to randomization)</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =&lt; 2.5 x institutional ULN (obtained =&lt; 14 days prior to randomization)</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patients with treated brain metastases are eligible if neurologically stable without glucocorticoid therapy after the stated washout period from radiation therapy (RT) or surgery provided the metastatic lesions are non-hemorrhagic</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patients with untreated brain metastases or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required provided the metastatic lesions are non-hemorrhagic and are neurologically stable without glucocorticoid therapy</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patients with known history or current symptoms of cardiac disease, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patient must have the ability to understand and the willingness to sign a written informed consent document and comply with study requirements</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patient must not have had treatment with any investigational drug within five half-lives or 3 months (whichever is greater), prior to study initiation</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patient must not be currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be strong inducers of CYP3A4. For any patient currently receiving such inducers of CYP3A4, they must discontinue use prior to first dose of study treatment. All patients must try to avoid concomitant use of any medications, herbal supplements and/or ingestion of foods with known inducer effects on CYP3A4</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patient must not have any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) grade 1 at the time of randomization, with the exception of alopecia and grade 2 prior platinum-therapy–related neuropathy</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patient must not have any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the investigator’s opinion makes it challenging for the patient to participate in the study. Screening for chronic conditions is not required</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patient must not have refractory nausea and vomiting, chronic gastrointestinal diseases, the inability to swallow the osimertinib tablets or previous significant bowel resection that would preclude adequate absorption of osimertinib</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patient must not have a medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patient must not have a history of hypersensitivity to active or inactive excipients of osimertinib or drugs with a similar chemical structure or class to osimertinib</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patient must not have mean resting corrected QT interval (QTc) &gt; 470 msec obtained from 3 electrocardiograms (ECGs), using the screening clinic ECG machine derived QTc value (using Bazett’s correction)</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patient must not have any clinically important abnormalities in rhythm, conduction or morphology of resting ECG e.g. complete left bundle branch block, third degree heart block and second-degree heart block</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patient must not have any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, electrolyte abnormalities (including: potassium &lt; lower limit of normal [LLN]; magnesium &lt; LLN; calcium &lt; LLN), congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval and cause torsades de pointes</li> 												</ul> 						</div> 										 							<h3 class=""printHeading"">Trial Objectives and Outlines</h3> 				<div id=""trialObjectives""><p class='ctrp'>PRIMARY OBJECTIVE:</p><p class='ctrp'>I. To evaluate progression-free survival (PFS) of osimertinib (AZD9291) and bevacizumab versus osimertinib (AZD9291) alone as first-line treatment for patients with metastatic EGFR-mutant lung cancers.</p><p class='ctrp'></p><p class='ctrp'>SECONDARY OBJECTIVES:</p><p class='ctrp'>I. To evaluate overall survival (OS).</p><p class='ctrp'>II. To evaluate best objective response rate and duration of objective response.</p><p class='ctrp'>III. To evaluate time to central nervous system (CNS) progression and CNS PFS.</p><p class='ctrp'>IV. To evaluate toxicity of the combination regimen.</p><p class='ctrp'></p><p class='ctrp'>CORRELATIVE OBJECTIVES:</p><p class='ctrp'>I. To characterize mechanisms of resistance to osimertinib (AZD9291) and osimertinib (AZD9291) with bevacizumab first-line therapy through post-progression circulating tumor-derived deoxyribonucleic acid (ctDNA).</p><p class='ctrp'>II. To assess for ctDNA clearance on study treatment and associate ctDNA clearance with clinical outcomes.</p><p class='ctrp'></p><p class='ctrp'>OUTLINE: Patients are randomized to 1 of 2 arms.</p><p class='ctrp'></p><p class='ctrp'>ARM A: Patients receive osimertinib orally (PO) once daily (QD) on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.</p><p class='ctrp'></p><p class='ctrp'>ARM B: Patients receive osimertinib PO QD on days 1-21 and bevacizumab intravenously (IV) over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.</p><p class='ctrp'></p><p class='ctrp'>Patients undergo echocardiography (ECHO), multigated acquisition scan (MUGA), computed tomography (CT) and may undergo magnetic resonance imaging (MRI) and blood and urine sample collection on study. </p><p class='ctrp'></p><p class='ctrp'>After completion of study treatment, patients are followed up every 3 months for 10 years.</p></div> 			 							<h3 class=""printHeading"">Lead Organization</h3> 									<div>ECOG-ACRIN Cancer Research Group</div> 													<div>Principal Investigator: Helena A. Yu</div> 										<h3 class=""printHeading"">Locations & Contacts</h3> 			<div class=""locationNoteBlock""> 				<span>Note:</span> Information about participating sites on pharmaceutical industry trials may be incomplete, so please look up the <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT04181060"" target=""_blank"">NCT number</a> on ClinicalTrials.gov 			</div> 			<div> 								           <h3 class=""locationCountryLabel"">U.S.A.</h3>               <h4>Alaska</h4>                           <h5 class=""locationCity"">Anchorage</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Alaska Breast Care and Surgery LLC</strong>     <br>Contact: Site Public Contact <br>Phone: 907-212-6871 <br>Email: <a href=""mailto:AKPAMC.OncologyResearchSupport@providence.org"">AKPAMC.OncologyResearchSupport@providence.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Alaska Oncology and Hematology LLC</strong>     <br>Contact: Site Public Contact <br>Phone: 907-212-6871 <br>Email: <a href=""mailto:AKPAMC.OncologyResearchSupport@providence.org"">AKPAMC.OncologyResearchSupport@providence.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Alaska Women's Cancer Care</strong>     <br>Contact: Site Public Contact <br>Phone: 907-212-6871 <br>Email: <a href=""mailto:AKPAMC.OncologyResearchSupport@providence.org"">AKPAMC.OncologyResearchSupport@providence.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Anchorage Associates in Radiation Medicine</strong>     <br>Contact: Site Public Contact <br>Phone: 907-212-6871 <br>Email: <a href=""mailto:AKPAMC.OncologyResearchSupport@providence.org"">AKPAMC.OncologyResearchSupport@providence.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Anchorage Oncology Centre</strong>     <br>Contact: Site Public Contact <br>Phone: 907-212-6871 <br>Email: <a href=""mailto:AKPAMC.OncologyResearchSupport@providence.org"">AKPAMC.OncologyResearchSupport@providence.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Anchorage Radiation Therapy Center</strong>     <br>Contact: Site Public Contact <br>Phone: 907-212-6871 <br>Email: <a href=""mailto:AKPAMC.OncologyResearchSupport@providence.org"">AKPAMC.OncologyResearchSupport@providence.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Katmai Oncology Group</strong>     <br>Contact: Site Public Contact <br>Phone: 907-212-6871 <br>Email: <a href=""mailto:AKPAMC.OncologyResearchSupport@providence.org"">AKPAMC.OncologyResearchSupport@providence.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Providence Alaska Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 907-212-6871 <br>Email: <a href=""mailto:AKPAMC.OncologyResearchSupport@providence.org"">AKPAMC.OncologyResearchSupport@providence.org</a>   </span> </div>                                       <h5 class=""locationCity"">Fairbanks</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Fairbanks Memorial Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 907-458-3043 <br>Email: <a href=""mailto:Veronica.Stevenson@foundationhealth.org"">Veronica.Stevenson@foundationhealth.org</a>   </span> </div>                                   <h4>Arizona</h4>                           <h5 class=""locationCity"">Phoenix</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Cancer Center at Saint Joseph's</strong>     <br>Contact: Site Public Contact <br>Phone: 720-874-1881 <br>Email: <a href=""mailto:ResearchInstituteInquiries@CommonSpirit.org"">ResearchInstituteInquiries@CommonSpirit.org</a>   </span> </div>                                   <h4>Arkansas</h4>                           <h5 class=""locationCity"">Ft. Smith</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Mercy Hospital Fort Smith</strong>     <br>Contact: Site Public Contact <br>Phone: 800-378-9373   </span> </div>                                       <h5 class=""locationCity"">Hot Springs</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">CHI Saint Vincent Cancer Center Hot Springs</strong>     <br>Contact: Site Public Contact <br>Phone: 855-313-2409 <br>Email: <a href=""mailto:ResearchInstituteInquiries@CommonSpirit.org"">ResearchInstituteInquiries@CommonSpirit.org</a>   </span> </div>                                       <h5 class=""locationCity"">Jonesboro</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro</strong>     <br>Contact: Site Public Contact <br>Phone: 870-936-7066 <br>Email: <a href=""mailto:Emily.Carvell@bmhcc.org"">Emily.Carvell@bmhcc.org</a>   </span> </div>                                   <h4>California</h4>                           <h5 class=""locationCity"">Antioch</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Kaiser Permanente-Deer Valley Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 877-642-4691 <br>Email: <a href=""mailto:Kpoct@kp.org"">Kpoct@kp.org</a>   </span> </div>                                       <h5 class=""locationCity"">Arroyo Grande</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Mission Hope Medical Oncology - Arroyo Grande</strong>     <br>Contact: Site Public Contact <br>Phone: 720-874-1881 <br>Email: <a href=""mailto:ResearchInstituteInquiries@CommonSpirit.org"">ResearchInstituteInquiries@CommonSpirit.org</a>   </span> </div>                                       <h5 class=""locationCity"">Burbank</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Providence Saint Joseph Medical Center/Disney Family Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 818-847-4793 <br>Email: <a href=""mailto:Najee.Boucher@providence.org"">Najee.Boucher@providence.org</a>   </span> </div>                                       <h5 class=""locationCity"">Dublin</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Kaiser Permanente Dublin</strong>     <br>Contact: Site Public Contact <br>Phone: 877-642-4691   </span> </div>                                       <h5 class=""locationCity"">Fremont</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Kaiser Permanente-Fremont</strong>     <br>Contact: Site Public Contact <br>Phone: 877-642-4691 <br>Email: <a href=""mailto:Kpoct@kp.org"">Kpoct@kp.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Washington Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 510-745-6433   </span> </div>                                       <h5 class=""locationCity"">Fresno</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Kaiser Permanente-Fresno</strong>     <br>Contact: Site Public Contact <br>Phone: 877-642-4691 <br>Email: <a href=""mailto:Kpoct@kp.org"">Kpoct@kp.org</a>   </span> </div>                                       <h5 class=""locationCity"">Modesto</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Kaiser Permanente-Modesto</strong>     <br>Contact: Site Public Contact <br>Phone: 877-642-4691 <br>Email: <a href=""mailto:Kpoct@kp.org"">Kpoct@kp.org</a>   </span> </div>                                       <h5 class=""locationCity"">Oakland</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Kaiser Permanente-Oakland</strong>     <br>Contact: Site Public Contact <br>Phone: 877-642-4691 <br>Email: <a href=""mailto:Kpoct@kp.org"">Kpoct@kp.org</a>   </span> </div>                                       <h5 class=""locationCity"">Palo Alto</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Stanford Cancer Institute Palo Alto</strong>     <br>Contact: Site Public Contact <br>Phone: 650-498-7061 <br>Email: <a href=""mailto:ccto-office@stanford.edu"">ccto-office@stanford.edu</a>   </span> </div>                                       <h5 class=""locationCity"">Richmond</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Kaiser Permanente-Richmond</strong>     <br>Contact: Site Public Contact <br>Phone: 877-642-4691 <br>Email: <a href=""mailto:Kpoct@kp.org"">Kpoct@kp.org</a>   </span> </div>                                       <h5 class=""locationCity"">Roseville</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Kaiser Permanente-Roseville</strong>     <br>Contact: Site Public Contact <br>Phone: 877-642-4691 <br>Email: <a href=""mailto:Kpoct@kp.org"">Kpoct@kp.org</a>   </span> </div>                                       <h5 class=""locationCity"">Sacramento</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Kaiser Permanente Downtown Commons</strong>     <br>Contact: Site Public Contact <br>Phone: 877-642-4691 <br>Email: <a href=""mailto:kpoct@kp.org"">kpoct@kp.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Kaiser Permanente-South Sacramento</strong>     <br>Contact: Site Public Contact <br>Phone: 877-642-4691 <br>Email: <a href=""mailto:Kpoct@kp.org"">Kpoct@kp.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">University of California Davis Comprehensive Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 916-734-3089   </span> </div>                                       <h5 class=""locationCity"">San Francisco</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Kaiser Permanente-San Francisco</strong>     <br>Contact: Site Public Contact <br>Phone: 877-642-4691 <br>Email: <a href=""mailto:Kpoct@kp.org"">Kpoct@kp.org</a>   </span> </div>                                       <h5 class=""locationCity"">San Jose</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Kaiser Permanente-Santa Teresa-San Jose</strong>     <br>Contact: Site Public Contact <br>Phone: 877-642-4691 <br>Email: <a href=""mailto:Kpoct@kp.org"">Kpoct@kp.org</a>   </span> </div>                                       <h5 class=""locationCity"">San Leandro</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Kaiser Permanente San Leandro</strong>     <br>Contact: Site Public Contact <br>Phone: 877-642-4691 <br>Email: <a href=""mailto:Kpoct@kp.org"">Kpoct@kp.org</a>   </span> </div>                                       <h5 class=""locationCity"">San Luis Obispo</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Pacific Central Coast Health Center-San Luis Obispo</strong>     <br>Contact: Site Public Contact <br>Phone: 720-874-1881 <br>Email: <a href=""mailto:ResearchInstituteInquiries@CommonSpirit.org"">ResearchInstituteInquiries@CommonSpirit.org</a>   </span> </div>                                       <h5 class=""locationCity"">San Rafael</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Kaiser San Rafael-Gallinas</strong>     <br>Contact: Site Public Contact <br>Phone: 877-642-4691 <br>Email: <a href=""mailto:Kpoct@kp.org"">Kpoct@kp.org</a>   </span> </div>                                       <h5 class=""locationCity"">Santa Clara</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Kaiser Permanente Medical Center - Santa Clara</strong>     <br>Contact: Site Public Contact <br>Phone: 877-642-4691 <br>Email: <a href=""mailto:Kpoct@kp.org"">Kpoct@kp.org</a>   </span> </div>                                       <h5 class=""locationCity"">Santa Maria</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Mission Hope Medical Oncology - Santa Maria</strong>     <br>Contact: Site Public Contact <br>Phone: 720-874-1881 <br>Email: <a href=""mailto:ResearchInstituteInquiries@CommonSpirit.org"">ResearchInstituteInquiries@CommonSpirit.org</a>   </span> </div>                                       <h5 class=""locationCity"">Santa Rosa</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Kaiser Permanente-Santa Rosa</strong>     <br>Contact: Site Public Contact <br>Phone: 877-642-4691 <br>Email: <a href=""mailto:Kpoct@kp.org"">Kpoct@kp.org</a>   </span> </div>                                       <h5 class=""locationCity"">South San Francisco</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Kaiser Permanente-South San Francisco</strong>     <br>Contact: Site Public Contact <br>Phone: 877-642-4691 <br>Email: <a href=""mailto:Kpoct@kp.org"">Kpoct@kp.org</a>   </span> </div>                                       <h5 class=""locationCity"">Stockton</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Kaiser Permanente-Stockton</strong>     <br>Contact: Site Public Contact <br>Phone: 877-642-4691 <br>Email: <a href=""mailto:Kpoct@kp.org"">Kpoct@kp.org</a>   </span> </div>                                       <h5 class=""locationCity"">Vacaville</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Kaiser Permanente Medical Center-Vacaville</strong>     <br>Contact: Site Public Contact <br>Phone: 877-642-4691 <br>Email: <a href=""mailto:Kpoct@kp.org"">Kpoct@kp.org</a>   </span> </div>                                       <h5 class=""locationCity"">Vallejo</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Kaiser Permanente-Vallejo</strong>     <br>Contact: Site Public Contact <br>Phone: 877-642-4691 <br>Email: <a href=""mailto:Kpoct@kp.org"">Kpoct@kp.org</a>   </span> </div>                                       <h5 class=""locationCity"">Walnut Creek</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Kaiser Permanente-Walnut Creek</strong>     <br>Contact: Site Public Contact <br>Phone: 877-642-4691 <br>Email: <a href=""mailto:Kpoct@kp.org"">Kpoct@kp.org</a>   </span> </div>                                   <h4>Colorado</h4>                           <h5 class=""locationCity"">Aurora</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Rocky Mountain Cancer Centers-Aurora</strong>     <br>Contact: Site Public Contact <br>Phone: 303-777-2663 <br>Email: <a href=""mailto:info@westernstatesncorp.org"">info@westernstatesncorp.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">The Medical Center of Aurora</strong>     <br>Contact: Site Public Contact <br>Phone: 303-777-2663 <br>Email: <a href=""mailto:info@westernstatesncorp.org"">info@westernstatesncorp.org</a>   </span> </div>                                       <h5 class=""locationCity"">Boulder</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Boulder Community Foothills Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 303-777-2663 <br>Email: <a href=""mailto:info@westernstatesncorp.org"">info@westernstatesncorp.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Rocky Mountain Cancer Centers-Boulder</strong>     <br>Contact: Site Public Contact <br>Phone: 303-777-2663 <br>Email: <a href=""mailto:info@westernstatesncorp.org"">info@westernstatesncorp.org</a>   </span> </div>                                       <h5 class=""locationCity"">Centennial</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Rocky Mountain Cancer Centers - Centennial</strong>     <br>Contact: Site Public Contact <br>Phone: 303-777-2663 <br>Email: <a href=""mailto:info@westernstatesncorp.org"">info@westernstatesncorp.org</a>   </span> </div>                                       <h5 class=""locationCity"">Colorado Springs</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Penrose-Saint Francis Healthcare</strong>     <br>Contact: Site Public Contact <br>Phone: 720-874-1881 <br>Email: <a href=""mailto:ResearchInstituteInquiries@CommonSpirit.org"">ResearchInstituteInquiries@CommonSpirit.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Rocky Mountain Cancer Centers-Penrose</strong>     <br>Contact: Site Public Contact <br>Phone: 720-874-1881 <br>Email: <a href=""mailto:ResearchInstituteInquiries@CommonSpirit.org"">ResearchInstituteInquiries@CommonSpirit.org</a>   </span> </div>                                       <h5 class=""locationCity"">Denver</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Colorado Blood Cancer Institute</strong>     <br>Contact: Site Public Contact <br>Phone: 303-777-2663 <br>Email: <a href=""mailto:info@westernstatesncorp.org"">info@westernstatesncorp.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Kaiser Permanente-Franklin</strong>     <br>Contact: Site Public Contact <br>Phone: 303-720-2685 <br>Email: <a href=""mailto:kristi.m.bronkan@kp.org"">kristi.m.bronkan@kp.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Porter Adventist Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 719-776-6550 <br>Email: <a href=""mailto:ResearchTracking@Centura.Org"">ResearchTracking@Centura.Org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Presbyterian - Saint Lukes Medical Center - Health One</strong>     <br>Contact: Site Public Contact <br>Phone: 303-777-2663 <br>Email: <a href=""mailto:info@westernstatesncorp.org"">info@westernstatesncorp.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Rocky Mountain Cancer Centers-Midtown</strong>     <br>Contact: Site Public Contact <br>Phone: 303-777-2663 <br>Email: <a href=""mailto:info@westernstatesncorp.org"">info@westernstatesncorp.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Rocky Mountain Cancer Centers-Rose</strong>     <br>Contact: Site Public Contact <br>Phone: 303-777-2663 <br>Email: <a href=""mailto:info@westernstatesncorp.org"">info@westernstatesncorp.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">The Women's Imaging Center</strong>     <br>Contact: Site Public Contact <br>Phone: 303-777-2663 <br>Email: <a href=""mailto:info@westernstatesncorp.org"">info@westernstatesncorp.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Western Surgical Care</strong>     <br>Contact: Site Public Contact <br>Phone: 303-777-2663   </span> </div>                                       <h5 class=""locationCity"">Durango</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Mercy Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 720-874-1881 <br>Email: <a href=""mailto:ResearchInstituteInquiries@CommonSpirit.org"">ResearchInstituteInquiries@CommonSpirit.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Southwest Oncology PC</strong>     <br>Contact: Site Public Contact <br>Phone: 720-874-1881 <br>Email: <a href=""mailto:ResearchInstituteInquiries@CommonSpirit.org"">ResearchInstituteInquiries@CommonSpirit.org</a>   </span> </div>                                       <h5 class=""locationCity"">Englewood</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Mountain Blue Cancer Care Center - Swedish</strong>     <br>Contact: Site Public Contact <br>Phone: 303-777-2663 <br>Email: <a href=""mailto:info@westernstatesncorp.org"">info@westernstatesncorp.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Rocky Mountain Cancer Centers - Swedish</strong>     <br>Contact: Site Public Contact <br>Phone: 303-777-2663 <br>Email: <a href=""mailto:info@westernstatesncorp.org"">info@westernstatesncorp.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Swedish Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 303-777-2663 <br>Email: <a href=""mailto:info@westernstatesncorp.org"">info@westernstatesncorp.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">The Melanoma and Skin Cancer Institute</strong>     <br>Contact: Site Public Contact <br>Phone: 720-316-8091 <br>Email: <a href=""mailto:ryan.weight@theskincancerinstitute.com"">ryan.weight@theskincancerinstitute.com</a>   </span> </div>                                       <h5 class=""locationCity"">Greeley</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Banner North Colorado Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 970-810-3046 <br>Email: <a href=""mailto:BMDACCResearchCOMailbox@bannerhealth.com"">BMDACCResearchCOMailbox@bannerhealth.com</a>   </span> </div>                                       <h5 class=""locationCity"">Lafayette</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Kaiser Permanente-Rock Creek</strong>     <br>Contact: Site Public Contact <br>Phone: 303-720-2685 <br>Email: <a href=""mailto:kristi.m.bronkan@kp.org"">kristi.m.bronkan@kp.org</a>   </span> </div>                                       <h5 class=""locationCity"">Lakewood</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Rocky Mountain Cancer Centers-Lakewood</strong>     <br>Contact: Site Public Contact <br>Phone: 303-777-2663 <br>Email: <a href=""mailto:info@westernstatesncorp.org"">info@westernstatesncorp.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Anthony Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 720-874-1881 <br>Email: <a href=""mailto:ResearchInstituteInquiries@CommonSpirit.org"">ResearchInstituteInquiries@CommonSpirit.org</a>   </span> </div>                                       <h5 class=""locationCity"">Littleton</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Littleton Adventist Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 719-776-6550 <br>Email: <a href=""mailto:ResearchTracking@Centura.Org"">ResearchTracking@Centura.Org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Rocky Mountain Cancer Centers-Littleton</strong>     <br>Contact: Site Public Contact <br>Phone: 303-777-2663 <br>Email: <a href=""mailto:info@westernstatesncorp.org"">info@westernstatesncorp.org</a>   </span> </div>                                       <h5 class=""locationCity"">Lone Tree</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Kaiser Permanente-Lone Tree</strong>     <br>Contact: Site Public Contact <br>Phone: 303-720-2685 <br>Email: <a href=""mailto:kristi.m.bronkan@kp.org"">kristi.m.bronkan@kp.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Rocky Mountain Cancer Centers-Sky Ridge</strong>     <br>Contact: Site Public Contact <br>Phone: 303-777-2663 <br>Email: <a href=""mailto:info@westernstatesncorp.org"">info@westernstatesncorp.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Sky Ridge Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 303-777-2663 <br>Email: <a href=""mailto:info@westernstatesncorp.org"">info@westernstatesncorp.org</a>   </span> </div>                                       <h5 class=""locationCity"">Longmont</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Longmont United Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 720-874-1881 <br>Email: <a href=""mailto:ResearchInstituteInquiries@CommonSpirit.org"">ResearchInstituteInquiries@CommonSpirit.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Rocky Mountain Cancer Centers-Longmont</strong>     <br>Contact: Site Public Contact <br>Phone: 719-776-6550 <br>Email: <a href=""mailto:ResearchTracking@Centura.Org"">ResearchTracking@Centura.Org</a>   </span> </div>                                       <h5 class=""locationCity"">Loveland</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Banner McKee Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 970-810-3046 <br>Email: <a href=""mailto:BMDACCResearchCOMailbox@bannerhealth.com"">BMDACCResearchCOMailbox@bannerhealth.com</a>   </span> </div>                                       <h5 class=""locationCity"">Parker</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Parker Adventist Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 719-776-6550 <br>Email: <a href=""mailto:ResearchTracking@Centura.Org"">ResearchTracking@Centura.Org</a>   </span> </div>                                       <h5 class=""locationCity"">Pueblo</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Mary Corwin Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 720-874-1881 <br>Email: <a href=""mailto:ResearchInstituteInquiries@CommonSpirit.org"">ResearchInstituteInquiries@CommonSpirit.org</a>   </span> </div>                                       <h5 class=""locationCity"">Thornton</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Rocky Mountain Cancer Centers-Thornton</strong>     <br>Contact: Site Public Contact <br>Phone: 303-777-2663 <br>Email: <a href=""mailto:info@westernstatesncorp.org"">info@westernstatesncorp.org</a>   </span> </div>                                   <h4>Connecticut</h4>                           <h5 class=""locationCity"">Derby</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Smilow Cancer Hospital-Derby Care Center</strong>     <br>Contact: Site Public Contact <br>Phone: 203-785-5702 <br>Email: <a href=""mailto:canceranswers@yale.edu"">canceranswers@yale.edu</a>   </span> </div>                                       <h5 class=""locationCity"">Fairfield</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Smilow Cancer Hospital Care Center-Fairfield</strong>     <br>Contact: Site Public Contact <br>Phone: 203-785-5702 <br>Email: <a href=""mailto:canceranswers@yale.edu"">canceranswers@yale.edu</a>   </span> </div>                                       <h5 class=""locationCity"">Glastonbury</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Smilow Cancer Hospital Care Center at Glastonbury</strong>     <br>Contact: Site Public Contact <br>Phone: 203-785-5702 <br>Email: <a href=""mailto:canceranswers@yale.edu"">canceranswers@yale.edu</a>   </span> </div>                                       <h5 class=""locationCity"">Greenwich</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Smilow Cancer Hospital Care Center at Greenwich</strong>     <br>Contact: Site Public Contact <br>Phone: 203-785-5702 <br>Email: <a href=""mailto:canceranswers@yale.edu"">canceranswers@yale.edu</a>   </span> </div>                                       <h5 class=""locationCity"">Guilford</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Smilow Cancer Hospital Care Center - Guilford</strong>     <br>Contact: Site Public Contact <br>Phone: 203-785-5702 <br>Email: <a href=""mailto:canceranswers@yale.edu"">canceranswers@yale.edu</a>   </span> </div>                                       <h5 class=""locationCity"">Hartford</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Hartford Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 860-545-5363   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Smilow Cancer Hospital Care Center at Saint Francis</strong>     <br>Contact: Site Public Contact <br>Phone: 203-785-5702 <br>Email: <a href=""mailto:canceranswers@yale.edu"">canceranswers@yale.edu</a>   </span> </div>                                       <h5 class=""locationCity"">Meriden</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Midstate Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 866-662-5678   </span> </div>                                       <h5 class=""locationCity"">New Britain</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">The Hospital of Central Connecticut</strong>     <br>Contact: Site Public Contact <br>Phone: 860-224-5660   </span> </div>                                       <h5 class=""locationCity"">New Haven</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Yale University</strong>     <br>Contact: Site Public Contact <br>Phone: 203-785-5702 <br>Email: <a href=""mailto:canceranswers@yale.edu"">canceranswers@yale.edu</a>   </span> </div>                                       <h5 class=""locationCity"">North Haven</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Yale-New Haven Hospital North Haven Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 203-785-5702 <br>Email: <a href=""mailto:canceranswers@yale.edu"">canceranswers@yale.edu</a>   </span> </div>                                       <h5 class=""locationCity"">Orange</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Smilow Cancer Hospital-Orange Care Center</strong>     <br>Contact: Site Public Contact <br>Phone: 203-785-5702 <br>Email: <a href=""mailto:canceranswers@yale.edu"">canceranswers@yale.edu</a>   </span> </div>                                       <h5 class=""locationCity"">Stamford</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Smilow Cancer Hospital Care Center at Long Ridge</strong>     <br>Contact: Site Public Contact <br>Phone: 203-785-5702 <br>Email: <a href=""mailto:canceranswers@yale.edu"">canceranswers@yale.edu</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Stamford Hospital/Bennett Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 203-323-8944   </span> </div>                                       <h5 class=""locationCity"">Torrington</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Smilow Cancer Hospital-Torrington Care Center</strong>     <br>Contact: Site Public Contact <br>Phone: 203-785-5702 <br>Email: <a href=""mailto:canceranswers@yale.edu"">canceranswers@yale.edu</a>   </span> </div>                                       <h5 class=""locationCity"">Trumbull</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Smilow Cancer Hospital Care Center-Trumbull</strong>     <br>Contact: Site Public Contact <br>Phone: 203-785-5702 <br>Email: <a href=""mailto:canceranswers@yale.edu"">canceranswers@yale.edu</a>   </span> </div>                                       <h5 class=""locationCity"">Waterbury</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Smilow Cancer Hospital-Waterbury Care Center</strong>     <br>Contact: Site Public Contact <br>Phone: 203-785-5702 <br>Email: <a href=""mailto:canceranswers@yale.edu"">canceranswers@yale.edu</a>   </span> </div>                                       <h5 class=""locationCity"">Waterford</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Smilow Cancer Hospital Care Center - Waterford</strong>     <br>Contact: Site Public Contact <br>Phone: 203-785-5702 <br>Email: <a href=""mailto:canceranswers@yale.edu"">canceranswers@yale.edu</a>   </span> </div>                                   <h4>Delaware</h4>                           <h5 class=""locationCity"">Seaford</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">TidalHealth Nanticoke / Allen Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 410-543-7019 <br>Email: <a href=""mailto:anna-maria.howard@peninsula.org"">anna-maria.howard@peninsula.org</a>   </span> </div>                                   <h4>Florida</h4>                           <h5 class=""locationCity"">Fort Lauderdale</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Holy Cross Hospital</strong>     <br>Contact: Site Public Contact <br>Email: <a href=""mailto:eileen.georgi@holy-cross.com"">eileen.georgi@holy-cross.com</a>   </span> </div>                                   <h4>Georgia</h4>                           <h5 class=""locationCity"">Atlanta</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Emory University Hospital Midtown</strong>     <br>Contact: Site Public Contact <br>Phone: 888-946-7447   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Emory University Hospital/Winship Cancer Institute</strong>     <br>Contact: Site Public Contact <br>Phone: 404-778-1868   </span> </div>                                       <h5 class=""locationCity"">Savannah</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Lewis Cancer and Research Pavilion at Saint Joseph's/Candler</strong>     <br>Contact: Site Public Contact <br>Phone: 912-819-5704 <br>Email: <a href=""mailto:underberga@sjchs.org"">underberga@sjchs.org</a>   </span> </div>                                   <h4>Hawaii</h4>                           <h5 class=""locationCity"">Honolulu</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Kaiser Permanente Moanalua Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 808-432-5195 <br>Email: <a href=""mailto:shelley.a.clark@kp.org"">shelley.a.clark@kp.org</a>   </span> </div>                                   <h4>Idaho</h4>                           <h5 class=""locationCity"">Boise</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Alphonsus Cancer Care Center-Boise</strong>     <br>Contact: Site Public Contact <br>Phone: 734-712-3671 <br>Email: <a href=""mailto:stephanie.couch@stjoeshealth.org"">stephanie.couch@stjoeshealth.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Luke's Cancer Institute - Boise</strong>     <br>Contact: Site Public Contact <br>Phone: 208-381-2774 <br>Email: <a href=""mailto:eslinget@slhs.org"">eslinget@slhs.org</a>   </span> </div>                                       <h5 class=""locationCity"">Caldwell</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Alphonsus Cancer Care Center-Caldwell</strong>     <br>Contact: Site Public Contact <br>Phone: 734-712-3671 <br>Email: <a href=""mailto:stephanie.couch@stjoeshealth.org"">stephanie.couch@stjoeshealth.org</a>   </span> </div>                                       <h5 class=""locationCity"">Coeur D'Alene</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Kootenai Health - Coeur d'Alene</strong>     <br>Contact: Site Public Contact <br>Phone: 406-969-6060 <br>Email: <a href=""mailto:mccinfo@mtcancer.org"">mccinfo@mtcancer.org</a>   </span> </div>                                       <h5 class=""locationCity"">Emmett</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Walter Knox Memorial Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 734-712-3671 <br>Email: <a href=""mailto:stephanie.couch@stjoeshealth.org"">stephanie.couch@stjoeshealth.org</a>   </span> </div>                                       <h5 class=""locationCity"">Fruitland</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Luke's Cancer Institute - Fruitland</strong>     <br>Contact: Site Public Contact <br>Phone: 208-381-2774 <br>Email: <a href=""mailto:eslinget@slhs.org"">eslinget@slhs.org</a>   </span> </div>                                       <h5 class=""locationCity"">Meridian</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Idaho Urologic Institute-Meridian</strong>     <br>Contact: Site Public Contact <br>Phone: 734-712-3671 <br>Email: <a href=""mailto:stephanie.couch@stjoeshealth.org"">stephanie.couch@stjoeshealth.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Luke's Cancer Institute - Meridian</strong>     <br>Contact: Site Public Contact <br>Phone: 208-381-2774 <br>Email: <a href=""mailto:eslinget@slhs.org"">eslinget@slhs.org</a>   </span> </div>                                       <h5 class=""locationCity"">Nampa</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Alphonsus Cancer Care Center-Nampa</strong>     <br>Contact: Site Public Contact <br>Phone: 406-969-6060 <br>Email: <a href=""mailto:mccinfo@mtcancer.org"">mccinfo@mtcancer.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Luke's Cancer Institute - Nampa</strong>     <br>Contact: Site Public Contact <br>Phone: 208-381-2774 <br>Email: <a href=""mailto:eslinget@slhs.org"">eslinget@slhs.org</a>   </span> </div>                                       <h5 class=""locationCity"">Post Falls</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Kootenai Clinic Cancer Services - Post Falls</strong>     <br>Contact: Site Public Contact <br>Phone: 406-969-6060 <br>Email: <a href=""mailto:mccinfo@mtcancer.org"">mccinfo@mtcancer.org</a>   </span> </div>                                       <h5 class=""locationCity"">Sandpoint</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Kootenai Clinic Cancer Services - Sandpoint</strong>     <br>Contact: Site Public Contact <br>Phone: 406-969-6060 <br>Email: <a href=""mailto:mccinfo@mtcancer.org"">mccinfo@mtcancer.org</a>   </span> </div>                                       <h5 class=""locationCity"">Twin Falls</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Luke's Cancer Institute - Twin Falls</strong>     <br>Contact: Site Public Contact <br>Phone: 208-381-2774 <br>Email: <a href=""mailto:eslinget@slhs.org"">eslinget@slhs.org</a>   </span> </div>                                   <h4>Illinois</h4>                           <h5 class=""locationCity"">Alton</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">OSF Saint Anthony's Health Center</strong>     <br>Contact: Site Public Contact <br>Phone: 618-463-5623   </span> </div>                                       <h5 class=""locationCity"">Aurora</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Rush - Copley Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 630-978-6212 <br>Email: <a href=""mailto:Cancer.Research@rushcopley.com"">Cancer.Research@rushcopley.com</a>   </span> </div>                                       <h5 class=""locationCity"">Bloomington</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Illinois CancerCare-Bloomington</strong>     <br>Contact: Site Public Contact <br>Phone: 309-243-3605 <br>Email: <a href=""mailto:andersonj@illinoiscancercare.com"">andersonj@illinoiscancercare.com</a>   </span> </div>                                       <h5 class=""locationCity"">Canton</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Illinois CancerCare-Canton</strong>     <br>Contact: Site Public Contact <br>Phone: 309-243-3605 <br>Email: <a href=""mailto:andersonj@illinoiscancercare.com"">andersonj@illinoiscancercare.com</a>   </span> </div>                                       <h5 class=""locationCity"">Carbondale</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Memorial Hospital of Carbondale</strong>     <br>Contact: Site Public Contact <br>Phone: 618-457-5200 <br>Email: <a href=""mailto:clinical.research@sih.net"">clinical.research@sih.net</a>   </span> </div>                                       <h5 class=""locationCity"">Carterville</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">SIH Cancer Institute</strong>     <br>Contact: Site Public Contact <br>Phone: 618-985-3333 <br>Email: <a href=""mailto:clinical.research@sih.net"">clinical.research@sih.net</a>   </span> </div>                                       <h5 class=""locationCity"">Carthage</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Illinois CancerCare-Carthage</strong>     <br>Contact: Site Public Contact <br>Phone: 309-243-3605 <br>Email: <a href=""mailto:andersonj@illinoiscancercare.com"">andersonj@illinoiscancercare.com</a>   </span> </div>                                       <h5 class=""locationCity"">Centralia</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Centralia Oncology Clinic</strong>     <br>Contact: Site Public Contact <br>Phone: 217-876-4762 <br>Email: <a href=""mailto:morganthaler.jodi@mhsil.com"">morganthaler.jodi@mhsil.com</a>   </span> </div>                                       <h5 class=""locationCity"">Chicago</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Jesse Brown Veterans Affairs Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 312-469-4304   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Northwestern University</strong>     <br>Contact: Site Public Contact <br>Phone: 312-695-1301 <br>Email: <a href=""mailto:cancer@northwestern.edu"">cancer@northwestern.edu</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Swedish Covenant Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 773-878-8200   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">University of Illinois</strong>     <br>Contact: Site Public Contact <br>Phone: 312-355-3046   </span> </div>                                       <h5 class=""locationCity"">Danville</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Carle at The Riverfront</strong>     <br>Contact: Site Public Contact <br>Phone: 800-446-5532 <br>Email: <a href=""mailto:Research@Carle.com"">Research@Carle.com</a>   </span> </div>                                       <h5 class=""locationCity"">Decatur</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Cancer Care Specialists of Illinois - Decatur</strong>     <br>Contact: Site Public Contact <br>Phone: 217-876-4762 <br>Email: <a href=""mailto:morganthaler.jodi@mhsil.com"">morganthaler.jodi@mhsil.com</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Decatur Memorial Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 217-876-4762 <br>Email: <a href=""mailto:morganthaler.jodi@mhsil.com"">morganthaler.jodi@mhsil.com</a>   </span> </div>                                       <h5 class=""locationCity"">DeKalb</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Northwestern Medicine Cancer Center Kishwaukee</strong>     <br>Contact: Site Public Contact <br>Phone: 630-352-5360 <br>Email: <a href=""mailto:Donald.Smith3@nm.org"">Donald.Smith3@nm.org</a>   </span> </div>                                       <h5 class=""locationCity"">Dixon</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Illinois CancerCare-Dixon</strong>     <br>Contact: Site Public Contact <br>Phone: 815-285-7800   </span> </div>                                       <h5 class=""locationCity"">Effingham</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Carle Physician Group-Effingham</strong>     <br>Contact: Site Public Contact <br>Phone: 800-446-5532 <br>Email: <a href=""mailto:Research@carle.com"">Research@carle.com</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Crossroads Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 217-876-4762 <br>Email: <a href=""mailto:morganthaler.jodi@mhsil.com"">morganthaler.jodi@mhsil.com</a>   </span> </div>                                       <h5 class=""locationCity"">Eureka</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Illinois CancerCare-Eureka</strong>     <br>Contact: Site Public Contact <br>Phone: 309-243-3605 <br>Email: <a href=""mailto:andersonj@illinoiscancercare.com"">andersonj@illinoiscancercare.com</a>   </span> </div>                                       <h5 class=""locationCity"">Galesburg</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Illinois CancerCare-Galesburg</strong>     <br>Contact: Site Public Contact <br>Phone: 309-243-3605 <br>Email: <a href=""mailto:andersonj@illinoiscancercare.com"">andersonj@illinoiscancercare.com</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Western Illinois Cancer Treatment Center</strong>     <br>Contact: Site Public Contact <br>Phone: 309-344-2831   </span> </div>                                       <h5 class=""locationCity"">Geneva</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Northwestern Medicine Cancer Center Delnor</strong>     <br>Contact: Site Public Contact <br>Phone: 630-352-5360 <br>Email: <a href=""mailto:Donald.Smith3@nm.org"">Donald.Smith3@nm.org</a>   </span> </div>                                       <h5 class=""locationCity"">Glenview</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Northwestern Medicine Glenview Outpatient Center</strong>     <br>Contact: Site Public Contact <br>Phone: 312-695-1102   </span> </div>                                       <h5 class=""locationCity"">Grayslake</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Northwestern Medicine Grayslake Outpatient Center</strong>     <br>Contact: Site Public Contact <br>Phone: 312-695-1102   </span> </div>                                       <h5 class=""locationCity"">Harvey</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Ingalls Memorial Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 708-915-4673 <br>Email: <a href=""mailto:clinicaltrials@ingalls.org"">clinicaltrials@ingalls.org</a>   </span> </div>                                       <h5 class=""locationCity"">Kewanee</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Illinois CancerCare-Kewanee Clinic</strong>     <br>Contact: Site Public Contact <br>Phone: 309-243-3605 <br>Email: <a href=""mailto:andersonj@illinoiscancercare.com"">andersonj@illinoiscancercare.com</a>   </span> </div>                                       <h5 class=""locationCity"">Lake Forest</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Northwestern Medicine Lake Forest Hospital</strong>     <br>Contact: Site Public Contact <br>Email: <a href=""mailto:cancertrials@northwestern.edu"">cancertrials@northwestern.edu</a>   </span> </div>                                       <h5 class=""locationCity"">Macomb</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Illinois CancerCare-Macomb</strong>     <br>Contact: Site Public Contact <br>Phone: 309-243-3605 <br>Email: <a href=""mailto:andersonj@illinoiscancercare.com"">andersonj@illinoiscancercare.com</a>   </span> </div>                                       <h5 class=""locationCity"">Mattoon</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Carle Physician Group-Mattoon/Charleston</strong>     <br>Contact: Site Public Contact <br>Phone: 800-446-5532 <br>Email: <a href=""mailto:Research@carle.com"">Research@carle.com</a>   </span> </div>                                       <h5 class=""locationCity"">Mount Vernon</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Good Samaritan Regional Health Center</strong>     <br>Contact: Site Public Contact <br>Phone: 618-242-4600   </span> </div>                                       <h5 class=""locationCity"">O'Fallon</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Cancer Care Center of O'Fallon</strong>     <br>Contact: Site Public Contact <br>Phone: 217-876-4762 <br>Email: <a href=""mailto:morganthaler.jodi@mhsil.com"">morganthaler.jodi@mhsil.com</a>   </span> </div>                                       <h5 class=""locationCity"">Orland Park</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Northwestern Medicine Orland Park</strong>     <br>Contact: Site Public Contact <br>Email: <a href=""mailto:nctnprogram_rhlccc@northwestern.edu"">nctnprogram_rhlccc@northwestern.edu</a>   </span> </div>                                       <h5 class=""locationCity"">Ottawa</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Illinois CancerCare-Ottawa Clinic</strong>     <br>Contact: Site Public Contact <br>Phone: 309-243-3605 <br>Email: <a href=""mailto:andersonj@illinoiscancercare.com"">andersonj@illinoiscancercare.com</a>   </span> </div>                                       <h5 class=""locationCity"">Pekin</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Illinois CancerCare-Pekin</strong>     <br>Contact: Site Public Contact <br>Phone: 309-243-3605 <br>Email: <a href=""mailto:andersonj@illinoiscancercare.com"">andersonj@illinoiscancercare.com</a>   </span> </div>                                       <h5 class=""locationCity"">Peoria</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Illinois CancerCare-Peoria</strong>     <br>Contact: Site Public Contact <br>Phone: 309-243-3605 <br>Email: <a href=""mailto:andersonj@illinoiscancercare.com"">andersonj@illinoiscancercare.com</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Methodist Medical Center of Illinois</strong>     <br>Contact: Site Public Contact <br>Phone: 309-243-3605 <br>Email: <a href=""mailto:andersonj@illinoiscancercare.com"">andersonj@illinoiscancercare.com</a>   </span> </div>                                       <h5 class=""locationCity"">Peru</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Illinois CancerCare-Peru</strong>     <br>Contact: Site Public Contact <br>Phone: 309-243-3605 <br>Email: <a href=""mailto:andersonj@illinoiscancercare.com"">andersonj@illinoiscancercare.com</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Valley Radiation Oncology</strong>     <br>Contact: Site Public Contact <br>Phone: 815-664-4141   </span> </div>                                       <h5 class=""locationCity"">Princeton</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Illinois CancerCare-Princeton</strong>     <br>Contact: Site Public Contact <br>Phone: 309-243-3605 <br>Email: <a href=""mailto:andersonj@illinoiscancercare.com"">andersonj@illinoiscancercare.com</a>   </span> </div>                                       <h5 class=""locationCity"">Springfield</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Southern Illinois University School of Medicine</strong>     <br>Contact: Site Public Contact <br>Phone: 217-545-7929   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Springfield Clinic</strong>     <br>Contact: Site Public Contact <br>Phone: 800-444-7541   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Springfield Memorial Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 217-528-7541 <br>Email: <a href=""mailto:pallante.beth@mhsil.com"">pallante.beth@mhsil.com</a>   </span> </div>                                       <h5 class=""locationCity"">Swansea</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Southwest Illinois Health Services LLP</strong>     <br>Contact: Site Public Contact <br>Phone: 618-236-1000 <br>Email: <a href=""mailto:lynns@thecancercenter.com"">lynns@thecancercenter.com</a>   </span> </div>                                       <h5 class=""locationCity"">Urbana</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Carle Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 800-446-5532 <br>Email: <a href=""mailto:Research@carle.com"">Research@carle.com</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">The Carle Foundation Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 800-446-5532 <br>Email: <a href=""mailto:Research@carle.com"">Research@carle.com</a>   </span> </div>                                       <h5 class=""locationCity"">Warrenville</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Northwestern Medicine Cancer Center Warrenville</strong>     <br>Contact: Site Public Contact <br>Phone: 630-352-5360 <br>Email: <a href=""mailto:Donald.Smith3@nm.org"">Donald.Smith3@nm.org</a>   </span> </div>                                       <h5 class=""locationCity"">Washington</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Illinois CancerCare - Washington</strong>     <br>Contact: Site Public Contact <br>Phone: 309-243-3605 <br>Email: <a href=""mailto:andersonj@illinoiscancercare.com"">andersonj@illinoiscancercare.com</a>   </span> </div>                                       <h5 class=""locationCity"">Yorkville</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Rush-Copley Healthcare Center</strong>     <br>Contact: Site Public Contact <br>Phone: 630-978-6212 <br>Email: <a href=""mailto:Cancer.Research@rushcopley.com"">Cancer.Research@rushcopley.com</a>   </span> </div>                                   <h4>Indiana</h4>                           <h5 class=""locationCity"">Crown Point</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Northwest Cancer Center - Main Campus</strong>     <br>Contact: Site Public Contact <br>Phone: 219-310-2550   </span> </div>                                       <h5 class=""locationCity"">Dyer</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Northwest Oncology LLC</strong>     <br>Contact: Site Public Contact <br>Phone: 219-924-8178   </span> </div>                                       <h5 class=""locationCity"">Hobart</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Northwest Cancer Center - Hobart</strong>     <br>Contact: Site Public Contact <br>Phone: 219-947-1795   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Mary Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 219-836-6875 <br>Email: <a href=""mailto:CancerResearch@COMHS.org"">CancerResearch@COMHS.org</a>   </span> </div>                                       <h5 class=""locationCity"">Indianapolis</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Catherine Hospital</strong>     <br>Contact: Site Public Contact <br>Email: <a href=""mailto:ecog.rss@jimmy.harvard.edu"">ecog.rss@jimmy.harvard.edu</a>   </span> </div>                                       <h5 class=""locationCity"">Munster</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">The Community Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 219-836-3349   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Women's Diagnostic Center - Munster</strong>     <br>Contact: Site Public Contact <br>Phone: 219-934-8869 <br>Email: <a href=""mailto:mnicholson@comhs.org"">mnicholson@comhs.org</a>   </span> </div>                                       <h5 class=""locationCity"">Richmond</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Reid Health</strong>     <br>Contact: Site Public Contact <br>Phone: 937-528-2900 <br>Email: <a href=""mailto:clinical.trials@daytonncorp.org"">clinical.trials@daytonncorp.org</a>   </span> </div>                                       <h5 class=""locationCity"">Valparaiso</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Northwest Cancer Center - Valparaiso</strong>     <br>Contact: Site Public Contact <br>Phone: 219-836-6875 <br>Email: <a href=""mailto:CancerResearch@COMHS.org"">CancerResearch@COMHS.org</a>   </span> </div>                                   <h4>Iowa</h4>                           <h5 class=""locationCity"">Ames</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Mary Greeley Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 515-956-4132   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">McFarland Clinic - Ames</strong>     <br>Contact: Site Public Contact <br>Phone: 515-239-4734 <br>Email: <a href=""mailto:ksoder@mcfarlandclinic.com"">ksoder@mcfarlandclinic.com</a>   </span> </div>                                       <h5 class=""locationCity"">Ankeny</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Mission Cancer and Blood - Ankeny</strong>     <br>Contact: Site Public Contact <br>Phone: 515-282-2921   </span> </div>                                       <h5 class=""locationCity"">Boone</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">McFarland Clinic - Boone</strong>     <br>Contact: Site Public Contact <br>Phone: 515-956-4132   </span> </div>                                       <h5 class=""locationCity"">Carroll</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Anthony Regional Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 515-689-7658 <br>Email: <a href=""mailto:sbenson@iora.org"">sbenson@iora.org</a>   </span> </div>                                       <h5 class=""locationCity"">Clive</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Mercy Cancer Center-West Lakes</strong>     <br>Contact: Site Public Contact <br>Phone: 515-358-6613 <br>Email: <a href=""mailto:cancerresearch@mercydesmoines.org"">cancerresearch@mercydesmoines.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Mission Cancer and Blood - West Des Moines</strong>     <br>Contact: Site Public Contact <br>Phone: 515-241-3305   </span> </div>                                       <h5 class=""locationCity"">Council Bluffs</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Alegent Health Mercy Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 402-717-1510 <br>Email: <a href=""mailto:ResearchInstituteInquiries@CommonSpirit.org"">ResearchInstituteInquiries@CommonSpirit.org</a>   </span> </div>                                       <h5 class=""locationCity"">Creston</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Greater Regional Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 515-358-6613 <br>Email: <a href=""mailto:cancerresearch@mercydesmoines.org"">cancerresearch@mercydesmoines.org</a>   </span> </div>                                       <h5 class=""locationCity"">Des Moines</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Broadlawns Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 515-282-2200   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Iowa Lutheran Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 515-241-8704   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Iowa Methodist Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 515-241-6727   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Mercy Medical Center - Des Moines</strong>     <br>Contact: Site Public Contact <br>Phone: 515-358-6613 <br>Email: <a href=""mailto:cancerresearch@mercydesmoines.org"">cancerresearch@mercydesmoines.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Mission Cancer and Blood - Des Moines</strong>     <br>Contact: Site Public Contact <br>Phone: 515-241-3305   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Mission Cancer and Blood - Laurel</strong>     <br>Contact: Site Public Contact <br>Phone: 515-241-3305   </span> </div>                                       <h5 class=""locationCity"">Fort Dodge</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">McFarland Clinic - Trinity Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 515-956-4132   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Trinity Regional Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 515-574-8302   </span> </div>                                       <h5 class=""locationCity"">Jefferson</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">McFarland Clinic - Jefferson</strong>     <br>Contact: Site Public Contact <br>Phone: 515-956-4132   </span> </div>                                       <h5 class=""locationCity"">Marshalltown</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">McFarland Clinic - Marshalltown</strong>     <br>Contact: Site Public Contact <br>Phone: 515-956-4132   </span> </div>                                       <h5 class=""locationCity"">West Des Moines</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Mercy Medical Center-West Lakes</strong>     <br>Contact: Site Public Contact <br>Phone: 515-358-6613 <br>Email: <a href=""mailto:cancerresearch@mercydesmoines.org"">cancerresearch@mercydesmoines.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Methodist West Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 515-343-1000   </span> </div>                                   <h4>Kansas</h4>                           <h5 class=""locationCity"">Garden City</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Central Care Cancer Center - Garden City</strong>     <br>Contact: Site Public Contact <br>Phone: 913-948-5588 <br>Email: <a href=""mailto:aroland@kccop.org"">aroland@kccop.org</a>   </span> </div>                                       <h5 class=""locationCity"">Great Bend</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Central Care Cancer Center - Great Bend</strong>     <br>Contact: Site Public Contact <br>Phone: 913-948-5588 <br>Email: <a href=""mailto:aroland@kccop.org"">aroland@kccop.org</a>   </span> </div>                                       <h5 class=""locationCity"">Wichita</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Ascension Via Christi Hospitals Wichita</strong>     <br>Contact: Site Public Contact <br>Phone: 316-291-4774 <br>Email: <a href=""mailto:research@viachristi.org"">research@viachristi.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Cancer Center of Kansas - Wichita</strong>     <br>Contact: Site Public Contact <br>Phone: 316-291-4774 <br>Email: <a href=""mailto:research@viachristi.org"">research@viachristi.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Cancer Center of Kansas-Wichita Medical Arts Tower</strong>     <br>Contact: Site Public Contact <br>Phone: 316-291-4774 <br>Email: <a href=""mailto:research@viachristi.org"">research@viachristi.org</a>   </span> </div>                                   <h4>Kentucky</h4>                           <h5 class=""locationCity"">Bardstown</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Flaget Memorial Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 720-874-1881 <br>Email: <a href=""mailto:ResearchInstituteInquiries@CommonSpirit.org"">ResearchInstituteInquiries@CommonSpirit.org</a>   </span> </div>                                       <h5 class=""locationCity"">Corbin</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Commonwealth Cancer Center-Corbin</strong>     <br>Contact: Site Public Contact <br>Phone: 720-874-1881 <br>Email: <a href=""mailto:ResearchInstituteInquiries@CommonSpirit.org"">ResearchInstituteInquiries@CommonSpirit.org</a>   </span> </div>                                       <h5 class=""locationCity"">Lexington</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Joseph Hospital East</strong>     <br>Contact: Site Public Contact <br>Phone: 720-874-1881 <br>Email: <a href=""mailto:ResearchInstituteInquiries@CommonSpirit.org"">ResearchInstituteInquiries@CommonSpirit.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Joseph Radiation Oncology Resource Center</strong>     <br>Contact: Site Public Contact <br>Phone: 720-874-1881 <br>Email: <a href=""mailto:ResearchInstituteInquiries@CommonSpirit.org"">ResearchInstituteInquiries@CommonSpirit.org</a>   </span> </div>                                       <h5 class=""locationCity"">London</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Joseph London</strong>     <br>Contact: Site Public Contact <br>Phone: 720-874-1881 <br>Email: <a href=""mailto:ResearchInstituteInquiries@CommonSpirit.org"">ResearchInstituteInquiries@CommonSpirit.org</a>   </span> </div>                                       <h5 class=""locationCity"">Louisville</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Jewish Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 859-629-7169 <br>Email: <a href=""mailto:ResearchInstituteInquiries@CommonSpirit.org"">ResearchInstituteInquiries@CommonSpirit.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saints Mary and Elizabeth Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 859-629-7169 <br>Email: <a href=""mailto:ResearchInstituteInquiries@CommonSpirit.org"">ResearchInstituteInquiries@CommonSpirit.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">UofL Health Medical Center Northeast</strong>     <br>Contact: Site Public Contact <br>Phone: 502-852-2755 <br>Email: <a href=""mailto:ctoinfo@louisville.edu"">ctoinfo@louisville.edu</a>   </span> </div>                                       <h5 class=""locationCity"">Shepherdsville</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Jewish Hospital Medical Center South</strong>     <br>Contact: Site Public Contact <br>Phone: 859-629-7169 <br>Email: <a href=""mailto:ResearchInstituteInquiries@CommonSpirit.org"">ResearchInstituteInquiries@CommonSpirit.org</a>   </span> </div>                                   <h4>Maryland</h4>                           <h5 class=""locationCity"">Bethesda</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Walter Reed National Military Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 301-319-2100   </span> </div>                                   <h4>Massachusetts</h4>                           <h5 class=""locationCity"">Worcester</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">UMass Memorial Medical Center - University Campus</strong>     <br>Contact: Site Public Contact <br>Phone: 508-856-3216 <br>Email: <a href=""mailto:cancer.research@umassmed.edu"">cancer.research@umassmed.edu</a>   </span> </div>                                   <h4>Michigan</h4>                           <h5 class=""locationCity"">Adrian</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Hickman Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 517-265-0116   </span> </div>                                       <h5 class=""locationCity"">Ann Arbor</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Trinity Health Saint Joseph Mercy Hospital Ann Arbor</strong>     <br>Contact: Site Public Contact <br>Phone: 734-712-7251 <br>Email: <a href=""mailto:MCRCwebsitecontactform@stjoeshealth.org"">MCRCwebsitecontactform@stjoeshealth.org</a>   </span> </div>                                       <h5 class=""locationCity"">Brighton</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Trinity Health  IHA Medical Group Hematology Oncology - Brighton</strong>     <br>Contact: Site Public Contact <br>Phone: 734-712-7251 <br>Email: <a href=""mailto:MCRCwebsitecontactform@stjoeshealth.org"">MCRCwebsitecontactform@stjoeshealth.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Trinity Health Medical Center - Brighton</strong>     <br>Contact: Site Public Contact <br>Phone: 734-712-7251 <br>Email: <a href=""mailto:MCRCwebsitecontactform@stjoeshealth.org"">MCRCwebsitecontactform@stjoeshealth.org</a>   </span> </div>                                       <h5 class=""locationCity"">Canton</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Trinity Health  IHA Medical Group Hematology Oncology - Canton</strong>     <br>Contact: Site Public Contact <br>Phone: 734-712-7251 <br>Email: <a href=""mailto:MCRCwebsitecontactform@stjoeshealth.org"">MCRCwebsitecontactform@stjoeshealth.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Trinity Health Medical Center - Canton</strong>     <br>Contact: Site Public Contact <br>Phone: 734-712-7251 <br>Email: <a href=""mailto:MCRCwebsitecontactform@stjoeshealth.org"">MCRCwebsitecontactform@stjoeshealth.org</a>   </span> </div>                                       <h5 class=""locationCity"">Caro</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Caro Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 989-907-8411 <br>Email: <a href=""mailto:lori.srebinski@ascension.org"">lori.srebinski@ascension.org</a>   </span> </div>                                       <h5 class=""locationCity"">Chelsea</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Chelsea Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 734-712-7251 <br>Email: <a href=""mailto:MCRCwebsitecontactform@stjoeshealth.org"">MCRCwebsitecontactform@stjoeshealth.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Trinity Health  IHA Medical Group Hematology Oncology - Chelsea Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 734-712-7251 <br>Email: <a href=""mailto:MCRCwebsitecontactform@stjoeshealth.org"">MCRCwebsitecontactform@stjoeshealth.org</a>   </span> </div>                                       <h5 class=""locationCity"">Clarkston</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Hematology Oncology Consultants-Clarkston</strong>     <br>Contact: Site Public Contact <br>Phone: 734-712-7251 <br>Email: <a href=""mailto:MCRCwebsitecontactform@stjoeshealth.org"">MCRCwebsitecontactform@stjoeshealth.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Newland Medical Associates-Clarkston</strong>     <br>Contact: Site Public Contact <br>Phone: 734-712-7251 <br>Email: <a href=""mailto:MCRCwebsitecontactform@stjoeshealth.org"">MCRCwebsitecontactform@stjoeshealth.org</a>   </span> </div>                                       <h5 class=""locationCity"">Dearborn</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Corewell Health Dearborn Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 248-551-7695   </span> </div>                                       <h5 class=""locationCity"">Detroit</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Henry Ford Health Saint John Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 313-343-3166 <br>Email: <a href=""mailto:Kkeenan1@hfhs.org"">Kkeenan1@hfhs.org</a>   </span> </div>                                       <h5 class=""locationCity"">East China</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Henry Ford River District Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 313-343-3166 <br>Email: <a href=""mailto:kforman1@hfhs.org"">kforman1@hfhs.org</a>   </span> </div>                                       <h5 class=""locationCity"">Flint</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Genesee Cancer and Blood Disease Treatment Center</strong>     <br>Contact: Site Public Contact <br>Phone: 810-762-8038 <br>Email: <a href=""mailto:wstrong@ghci.org"">wstrong@ghci.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Genesee Hematology Oncology PC</strong>     <br>Contact: Site Public Contact <br>Phone: 810-762-8038 <br>Email: <a href=""mailto:wstrong@ghci.org"">wstrong@ghci.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Genesys Hurley Cancer Institute</strong>     <br>Contact: Site Public Contact <br>Phone: 810-762-8038 <br>Email: <a href=""mailto:wstrong@ghci.org"">wstrong@ghci.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Hurley Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 810-762-8038 <br>Email: <a href=""mailto:wstrong@ghci.org"">wstrong@ghci.org</a>   </span> </div>                                       <h5 class=""locationCity"">Grosse Pointe Woods</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Great Lakes Cancer Management Specialists-Van Elslander Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 313-343-3166 <br>Email: <a href=""mailto:kforman1@hfhs.org"">kforman1@hfhs.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Henry Ford Saint John Hospital - Academic</strong>     <br>Contact: Site Public Contact <br>Phone: 313-343-3166 <br>Email: <a href=""mailto:kforman1@hfhs.org"">kforman1@hfhs.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Henry Ford Saint John Hospital - Breast</strong>     <br>Contact: Site Public Contact <br>Phone: 313-343-3166 <br>Email: <a href=""mailto:karen.forman@ascension.org"">karen.forman@ascension.org</a>   </span> </div>                                       <h5 class=""locationCity"">Lansing</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">University of Michigan Health - Sparrow Lansing</strong>     <br>Contact: Site Public Contact <br>Phone: 517-364-3712 <br>Email: <a href=""mailto:harsha.trivedi@umhsparrow.org"">harsha.trivedi@umhsparrow.org</a>   </span> </div>                                       <h5 class=""locationCity"">Livonia</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Hope Cancer Clinic</strong>     <br>Contact: Site Public Contact <br>Phone: 734-712-3671 <br>Email: <a href=""mailto:stephanie.couch@stjoeshealth.org"">stephanie.couch@stjoeshealth.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Trinity Health Saint Mary Mercy Livonia Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 734-712-7251 <br>Email: <a href=""mailto:MCRCwebsitecontactform@stjoeshealth.org"">MCRCwebsitecontactform@stjoeshealth.org</a>   </span> </div>                                       <h5 class=""locationCity"">Macomb Township</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Henry Ford Saint John Hospital - Macomb Medical</strong>     <br>Contact: Site Public Contact <br>Phone: 313-343-3166 <br>Email: <a href=""mailto:kforman1@hfhs.org"">kforman1@hfhs.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Henry Ford Warren Hospital - Breast Macomb</strong>     <br>Contact: Site Public Contact <br>Phone: 313-343-3166 <br>Email: <a href=""mailto:kforman1@hfhs.org"">kforman1@hfhs.org</a>   </span> </div>                                       <h5 class=""locationCity"">Marlette</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Mary's Oncology/Hematology Associates of Marlette</strong>     <br>Contact: Site Public Contact <br>Phone: 989-907-8411 <br>Email: <a href=""mailto:lori.srebinski@ascension.org"">lori.srebinski@ascension.org</a>   </span> </div>                                       <h5 class=""locationCity"">Monroe</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Toledo Clinic Cancer Centers-Monroe</strong>     <br>Contact: Site Public Contact <br>Phone: 800-444-3561   </span> </div>                                       <h5 class=""locationCity"">Pontiac</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Hope Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 734-712-7251 <br>Email: <a href=""mailto:MCRCwebsitecontactform@stjoeshealth.org"">MCRCwebsitecontactform@stjoeshealth.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Michigan Healthcare Professionals Pontiac</strong>     <br>Contact: Site Public Contact <br>Phone: 248-858-6215 <br>Email: <a href=""mailto:Emily.Crofts@trinity-health.org"">Emily.Crofts@trinity-health.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Newland Medical Associates-Pontiac</strong>     <br>Contact: Site Public Contact <br>Phone: 734-712-7251 <br>Email: <a href=""mailto:MCRCwebsitecontactform@stjoeshealth.org"">MCRCwebsitecontactform@stjoeshealth.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Trinity Health Saint Joseph Mercy Oakland Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 734-712-7251 <br>Email: <a href=""mailto:MCRCwebsitecontactform@stjoeshealth.org"">MCRCwebsitecontactform@stjoeshealth.org</a>   </span> </div>                                       <h5 class=""locationCity"">Rochester Hills</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Great Lakes Cancer Management Specialists-Rochester Hills</strong>     <br>Contact: Site Public Contact <br>Phone: 734-712-3671 <br>Email: <a href=""mailto:stephanie.couch@stjoeshealth.org"">stephanie.couch@stjoeshealth.org</a>   </span> </div>                                       <h5 class=""locationCity"">Royal Oak</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Corewell Health William Beaumont University Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 248-551-7695   </span> </div>                                       <h5 class=""locationCity"">Saginaw</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">MyMichigan Medical Center Saginaw</strong>     <br>Contact: Site Public Contact <br>Phone: 734-712-7251 <br>Email: <a href=""mailto:MCRCwebsitecontactform@stjoeshealth.org"">MCRCwebsitecontactform@stjoeshealth.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Oncology Hematology Associates of Saginaw Valley PC</strong>     <br>Contact: Site Public Contact <br>Phone: 989-907-8411 <br>Email: <a href=""mailto:lori.srebinski@ascension.org"">lori.srebinski@ascension.org</a>   </span> </div>                                       <h5 class=""locationCity"">Sterling Heights</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Bhadresh Nayak MD PC-Sterling Heights</strong>     <br>Contact: Site Public Contact <br>Phone: 313-343-3166 <br>Email: <a href=""mailto:karen.forman@ascension.org"">karen.forman@ascension.org</a>   </span> </div>                                       <h5 class=""locationCity"">Tawas City</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">MyMichigan Medical Center Tawas</strong>     <br>Contact: Site Public Contact <br>Phone: 734-712-7251 <br>Email: <a href=""mailto:MCRCwebsitecontactform@stjoeshealth.org"">MCRCwebsitecontactform@stjoeshealth.org</a>   </span> </div>                                       <h5 class=""locationCity"">Troy</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Corewell Health Beaumont Troy Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 248-551-7695   </span> </div>                                       <h5 class=""locationCity"">Warren</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Advanced Breast Care Center PLLC</strong>     <br>Contact: Site Public Contact <br>Phone: 313-343-3166 <br>Email: <a href=""mailto:karen.forman@ascension.org"">karen.forman@ascension.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Henry Ford Health Warren Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 313-343-3166 <br>Email: <a href=""mailto:kforman1@hfhs.org"">kforman1@hfhs.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Henry Ford Madison Heights Hospital - Breast</strong>     <br>Contact: Site Public Contact <br>Phone: 313-343-3166 <br>Email: <a href=""mailto:kforman1@hfhs.org"">kforman1@hfhs.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Henry Ford Warren Hospital - GLCMS</strong>     <br>Contact: Site Public Contact <br>Phone: 313-343-3166 <br>Email: <a href=""mailto:kforman1@hfhs.org"">kforman1@hfhs.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Macomb Hematology Oncology PC</strong>     <br>Contact: Site Public Contact <br>Phone: 313-343-3166 <br>Email: <a href=""mailto:karen.forman@ascension.org"">karen.forman@ascension.org</a>   </span> </div>                                       <h5 class=""locationCity"">West Branch</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Mary's Oncology/Hematology Associates of West Branch</strong>     <br>Contact: Site Public Contact <br>Phone: 989-907-8411 <br>Email: <a href=""mailto:lori.srebinski@ascension.org"">lori.srebinski@ascension.org</a>   </span> </div>                                       <h5 class=""locationCity"">Ypsilanti</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Huron Gastroenterology PC</strong>     <br>Contact: Site Public Contact <br>Phone: 734-712-7251 <br>Email: <a href=""mailto:MCRCwebsitecontactform@stjoeshealth.org"">MCRCwebsitecontactform@stjoeshealth.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Trinity Health  IHA Medical Group Hematology Oncology  Ann Arbor Campus</strong>     <br>Contact: Site Public Contact <br>Phone: 734-712-7251 <br>Email: <a href=""mailto:MCRCwebsitecontactform@stjoeshealth.org"">MCRCwebsitecontactform@stjoeshealth.org</a>   </span> </div>                                   <h4>Minnesota</h4>                           <h5 class=""locationCity"">Bemidji</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Sanford Joe Lueken Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 218-333-5000 <br>Email: <a href=""mailto:OncologyClinicalTrialsFargo@sanfordhealth.org"">OncologyClinicalTrialsFargo@sanfordhealth.org</a>   </span> </div>                                       <h5 class=""locationCity"">Burnsville</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Fairview Ridges Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 952-993-1517 <br>Email: <a href=""mailto:mmcorc@healthpartners.com"">mmcorc@healthpartners.com</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Minnesota Oncology - Burnsville</strong>     <br>Contact: Site Public Contact <br>Phone: 952-993-1517 <br>Email: <a href=""mailto:mmcorc@healthpartners.com"">mmcorc@healthpartners.com</a>   </span> </div>                                       <h5 class=""locationCity"">Cambridge</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Cambridge Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 952-993-1517 <br>Email: <a href=""mailto:mmcorc@healthpartners.com"">mmcorc@healthpartners.com</a>   </span> </div>                                       <h5 class=""locationCity"">Coon Rapids</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Mercy Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 952-993-1517 <br>Email: <a href=""mailto:mmcorc@healthpartners.com"">mmcorc@healthpartners.com</a>   </span> </div>                                       <h5 class=""locationCity"">Edina</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Fairview Southdale Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 952-993-1517 <br>Email: <a href=""mailto:mmcorc@healthpartners.com"">mmcorc@healthpartners.com</a>   </span> </div>                                       <h5 class=""locationCity"">Maple Grove</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Fairview Clinics and Surgery Center Maple Grove</strong>     <br>Contact: Site Public Contact <br>Phone: 952-993-1517 <br>Email: <a href=""mailto:mmcorc@healthpartners.com"">mmcorc@healthpartners.com</a>   </span> </div>                                       <h5 class=""locationCity"">Maplewood</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Minnesota Oncology Hematology PA-Maplewood</strong>     <br>Contact: Site Public Contact <br>Phone: 952-993-1517 <br>Email: <a href=""mailto:mmcorc@healthpartners.com"">mmcorc@healthpartners.com</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint John's Hospital - Healtheast</strong>     <br>Contact: Site Public Contact <br>Phone: 952-993-1517 <br>Email: <a href=""mailto:mmcorc@healthpartners.com"">mmcorc@healthpartners.com</a>   </span> </div>                                       <h5 class=""locationCity"">Minneapolis</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Abbott-Northwestern Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 952-993-1517 <br>Email: <a href=""mailto:mmcorc@healthpartners.com"">mmcorc@healthpartners.com</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Health Partners Inc</strong>     <br>Contact: Site Public Contact <br>Phone: 952-993-1517 <br>Email: <a href=""mailto:mmcorc@healthpartners.com"">mmcorc@healthpartners.com</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Hennepin County Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 952-993-1517 <br>Email: <a href=""mailto:mmcorc@healthpartners.com"">mmcorc@healthpartners.com</a>   </span> </div>                                       <h5 class=""locationCity"">Monticello</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Monticello Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 952-993-1517 <br>Email: <a href=""mailto:mmcorc@healthpartners.com"">mmcorc@healthpartners.com</a>   </span> </div>                                       <h5 class=""locationCity"">New Ulm</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">New Ulm Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 952-993-1517 <br>Email: <a href=""mailto:mmcorc@healthpartners.com"">mmcorc@healthpartners.com</a>   </span> </div>                                       <h5 class=""locationCity"">Princeton</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Fairview Northland Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 952-993-1517 <br>Email: <a href=""mailto:mmcorc@healthpartners.com"">mmcorc@healthpartners.com</a>   </span> </div>                                       <h5 class=""locationCity"">Robbinsdale</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">North Memorial Medical Health Center</strong>     <br>Contact: Site Public Contact <br>Phone: 952-993-1517 <br>Email: <a href=""mailto:mmcorc@healthpartners.com"">mmcorc@healthpartners.com</a>   </span> </div>                                       <h5 class=""locationCity"">Saint Louis Park</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Park Nicollet Clinic - Saint Louis Park</strong>     <br>Contact: Site Public Contact <br>Phone: 952-993-1517 <br>Email: <a href=""mailto:mmcorc@healthpartners.com"">mmcorc@healthpartners.com</a>   </span> </div>                                       <h5 class=""locationCity"">Saint Paul</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Regions Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 952-993-1517 <br>Email: <a href=""mailto:mmcorc@healthpartners.com"">mmcorc@healthpartners.com</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">United Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 952-993-1517 <br>Email: <a href=""mailto:mmcorc@healthpartners.com"">mmcorc@healthpartners.com</a>   </span> </div>                                       <h5 class=""locationCity"">Shakopee</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Francis Regional Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 952-993-1517 <br>Email: <a href=""mailto:mmcorc@healthpartners.com"">mmcorc@healthpartners.com</a>   </span> </div>                                       <h5 class=""locationCity"">Stillwater</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Lakeview Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 952-993-1517 <br>Email: <a href=""mailto:mmcorc@healthpartners.com"">mmcorc@healthpartners.com</a>   </span> </div>                                       <h5 class=""locationCity"">Thief River Falls</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Sanford Thief River Falls Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 605-312-3320   </span> </div>                                       <h5 class=""locationCity"">Waconia</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Ridgeview Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 952-993-1517 <br>Email: <a href=""mailto:mmcorc@healthpartners.com"">mmcorc@healthpartners.com</a>   </span> </div>                                       <h5 class=""locationCity"">Willmar</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Rice Memorial Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 952-993-1517 <br>Email: <a href=""mailto:mmcorc@healthpartners.com"">mmcorc@healthpartners.com</a>   </span> </div>                                       <h5 class=""locationCity"">Woodbury</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Minnesota Oncology Hematology PA-Woodbury</strong>     <br>Contact: Site Public Contact <br>Phone: 952-993-1517 <br>Email: <a href=""mailto:mmcorc@healthpartners.com"">mmcorc@healthpartners.com</a>   </span> </div>                                       <h5 class=""locationCity"">Worthington</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Sanford Cancer Center Worthington</strong>     <br>Contact: Site Public Contact <br>Phone: 605-312-3320   </span> </div>                                       <h5 class=""locationCity"">Wyoming</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Fairview Lakes Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 952-993-1517 <br>Email: <a href=""mailto:mmcorc@healthpartners.com"">mmcorc@healthpartners.com</a>   </span> </div>                                   <h4>Mississippi</h4>                           <h5 class=""locationCity"">Columbus</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Baptist Memorial Hospital and Cancer Center-Golden Triangle</strong>     <br>Contact: Site Public Contact <br>Phone: 901-226-1366 <br>Email: <a href=""mailto:BCCclintrials@bmhcc.org"">BCCclintrials@bmhcc.org</a>   </span> </div>                                       <h5 class=""locationCity"">Grenada</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Baptist Cancer Center-Grenada</strong>     <br>Contact: Site Public Contact <br>Phone: 901-226-1366 <br>Email: <a href=""mailto:BCCclintrials@bmhcc.org"">BCCclintrials@bmhcc.org</a>   </span> </div>                                       <h5 class=""locationCity"">New Albany</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Baptist Memorial Hospital and Cancer Center-Union County</strong>     <br>Contact: Site Public Contact <br>Phone: 901-226-1366 <br>Email: <a href=""mailto:BCCclintrials@bmhcc.org"">BCCclintrials@bmhcc.org</a>   </span> </div>                                       <h5 class=""locationCity"">Oxford</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Baptist Memorial Hospital and Cancer Center-Oxford</strong>     <br>Contact: Site Public Contact <br>Phone: 901-226-1366 <br>Email: <a href=""mailto:BCCclintrials@bmhcc.org"">BCCclintrials@bmhcc.org</a>   </span> </div>                                       <h5 class=""locationCity"">Southhaven</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Baptist Memorial Hospital and Cancer Center-Desoto</strong>     <br>Contact: Site Public Contact <br>Phone: 901-226-1366 <br>Email: <a href=""mailto:BCCclintrials@bmhcc.org"">BCCclintrials@bmhcc.org</a>   </span> </div>                                   <h4>Missouri</h4>                           <h5 class=""locationCity"">Ballwin</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Louis Cancer and Breast Institute-Ballwin</strong>     <br>Contact: Site Public Contact <br>Phone: 314-251-7058   </span> </div>                                       <h5 class=""locationCity"">Bolivar</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Central Care Cancer Center - Bolivar</strong>     <br>Contact: Site Public Contact <br>Phone: 913-948-5588 <br>Email: <a href=""mailto:aroland@kccop.org"">aroland@kccop.org</a>   </span> </div>                                       <h5 class=""locationCity"">Cape Girardeau</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Francis Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 573-334-2230 <br>Email: <a href=""mailto:sfmc@sfmc.net"">sfmc@sfmc.net</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Southeast Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 573-651-5550   </span> </div>                                       <h5 class=""locationCity"">Chesterfield</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Luke's Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 314-205-6936   </span> </div>                                       <h5 class=""locationCity"">Farmington</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Parkland Health Center - Farmington</strong>     <br>Contact: Site Public Contact <br>Phone: 314-996-5569   </span> </div>                                       <h5 class=""locationCity"">Jefferson City</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">MU Health Care Goldschmidt Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 573-632-4851 <br>Email: <a href=""mailto:amy.franken@health.missouri.edu"">amy.franken@health.missouri.edu</a>   </span> </div>                                       <h5 class=""locationCity"">Joplin</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Freeman Health System</strong>     <br>Contact: Site Public Contact <br>Phone: 417-347-4030 <br>Email: <a href=""mailto:LJCrockett@freemanhealth.com"">LJCrockett@freemanhealth.com</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Mercy Hospital Joplin</strong>     <br>Contact: Site Public Contact <br>Phone: 417-556-3074 <br>Email: <a href=""mailto:esmeralda.carrillo@mercy.net"">esmeralda.carrillo@mercy.net</a>   </span> </div>                                       <h5 class=""locationCity"">Rolla</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Delbert Day Cancer Institute at PCRMC</strong>     <br>Contact: Site Public Contact <br>Phone: 573-458-7504 <br>Email: <a href=""mailto:research@phelpshealth.org"">research@phelpshealth.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Mercy Clinic-Rolla-Cancer and Hematology</strong>     <br>Contact: Site Public Contact <br>Phone: 573-458-6379   </span> </div>                                       <h5 class=""locationCity"">Saint Joseph</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Heartland Regional Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 816-271-7937 <br>Email: <a href=""mailto:Trisha.England2@mymlc.com"">Trisha.England2@mymlc.com</a>   </span> </div>                                       <h5 class=""locationCity"">Saint Louis</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Mercy Hospital Saint Louis</strong>     <br>Contact: Site Public Contact <br>Phone: 314-251-7066   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Mercy Hospital South</strong>     <br>Contact: Site Public Contact <br>Phone: 314-525-6042 <br>Email: <a href=""mailto:Danielle.Werle@mercy.net"">Danielle.Werle@mercy.net</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Missouri Baptist Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 314-996-5569   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Louis Cancer and Breast Institute-South City</strong>     <br>Contact: Site Public Contact <br>Phone: 314-353-1870   </span> </div>                                       <h5 class=""locationCity"">Sainte Genevieve</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Sainte Genevieve County Memorial Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 314-996-5569   </span> </div>                                       <h5 class=""locationCity"">Springfield</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">CoxHealth South Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 417-269-4520   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Mercy Hospital Springfield</strong>     <br>Contact: Site Public Contact <br>Phone: 417-269-4520   </span> </div>                                       <h5 class=""locationCity"">Sullivan</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Missouri Baptist Sullivan Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 314-996-5569   </span> </div>                                       <h5 class=""locationCity"">Sunset Hills</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">BJC Outpatient Center at Sunset Hills</strong>     <br>Contact: Site Public Contact <br>Phone: 314-996-5569   </span> </div>                                       <h5 class=""locationCity"">Washington</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Mercy Hospital Washington</strong>     <br>Contact: Site Public Contact <br>Phone: 636-390-1600   </span> </div>                                   <h4>Montana</h4>                           <h5 class=""locationCity"">Anaconda</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Community Hospital of Anaconda</strong>     <br>Contact: Site Public Contact <br>Phone: 406-969-6060 <br>Email: <a href=""mailto:mccinfo@mtcancer.org"">mccinfo@mtcancer.org</a>   </span> </div>                                       <h5 class=""locationCity"">Billings</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Billings Clinic Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 800-996-2663 <br>Email: <a href=""mailto:research@billingsclinic.org"">research@billingsclinic.org</a>   </span> </div>                                       <h5 class=""locationCity"">Bozeman</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Bozeman Health Deaconess Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 406-969-6060 <br>Email: <a href=""mailto:mccinfo@mtcancer.org"">mccinfo@mtcancer.org</a>   </span> </div>                                       <h5 class=""locationCity"">Great Falls</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Benefis Sletten Cancer Institute</strong>     <br>Contact: Site Public Contact <br>Phone: 406-969-6060 <br>Email: <a href=""mailto:mccinfo@mtcancer.org"">mccinfo@mtcancer.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Great Falls Clinic</strong>     <br>Contact: Site Public Contact <br>Phone: 406-969-6060 <br>Email: <a href=""mailto:mccinfo@mtcancer.org"">mccinfo@mtcancer.org</a>   </span> </div>                                       <h5 class=""locationCity"">Kalispell</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Logan Health Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 406-969-6060 <br>Email: <a href=""mailto:mccinfo@mtcancer.org"">mccinfo@mtcancer.org</a>   </span> </div>                                       <h5 class=""locationCity"">Missoula</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Community Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 406-969-6060 <br>Email: <a href=""mailto:mccinfo@mtcancer.org"">mccinfo@mtcancer.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Patrick Hospital - Community Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 406-327-3118 <br>Email: <a href=""mailto:amy.hanneman@providence.org"">amy.hanneman@providence.org</a>   </span> </div>                                   <h4>Nebraska</h4>                           <h5 class=""locationCity"">Grand Island</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Nebraska Cancer Specialists/Oncology Hematology West PC</strong>     <br>Contact: Site Public Contact <br>Phone: 402-334-4773   </span> </div>                                       <h5 class=""locationCity"">Kearney</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">CHI Health Good Samaritan</strong>     <br>Contact: Site Public Contact <br>Phone: 720-874-1881 <br>Email: <a href=""mailto:ResearchInstituteInquiries@CommonSpirit.org"">ResearchInstituteInquiries@CommonSpirit.org</a>   </span> </div>                                       <h5 class=""locationCity"">Lincoln</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Cancer Partners of Nebraska</strong>     <br>Contact: Site Public Contact <br>Phone: 402-327-7363 <br>Email: <a href=""mailto:research@cancerpartners.com"">research@cancerpartners.com</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Cancer Partners of Nebraska - Pine Lake</strong>     <br>Contact: Site Public Contact <br>Phone: 402-327-7363 <br>Email: <a href=""mailto:research@cancerpartners.com"">research@cancerpartners.com</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Elizabeth Regional Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 855-313-2409 <br>Email: <a href=""mailto:ResearchInstituteInquiries@CommonSpirit.org"">ResearchInstituteInquiries@CommonSpirit.org</a>   </span> </div>                                       <h5 class=""locationCity"">Omaha</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Alegent Health Bergan Mercy Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 720-874-1881 <br>Email: <a href=""mailto:ResearchInstituteInquiries@CommonSpirit.org"">ResearchInstituteInquiries@CommonSpirit.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Alegent Health Immanuel Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 720-874-1881 <br>Email: <a href=""mailto:ResearchInstituteInquiries@CommonSpirit.org"">ResearchInstituteInquiries@CommonSpirit.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Alegent Health Lakeside Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 720-874-1881 <br>Email: <a href=""mailto:ResearchInstituteInquiries@CommonSpirit.org"">ResearchInstituteInquiries@CommonSpirit.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Creighton University Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 720-874-1881 <br>Email: <a href=""mailto:ResearchInstituteInquiries@CommonSpirit.org"">ResearchInstituteInquiries@CommonSpirit.org</a>   </span> </div>                                       <h5 class=""locationCity"">Papillion</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Midlands Community Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 402-717-1510 <br>Email: <a href=""mailto:ResearchInstituteInquiries@CommonSpirit.org"">ResearchInstituteInquiries@CommonSpirit.org</a>   </span> </div>                                   <h4>New Jersey</h4>                           <h5 class=""locationCity"">Basking Ridge</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Memorial Sloan Kettering Basking Ridge</strong>     <br>Contact: Site Public Contact <br>Phone: 212-639-7592   </span> </div>                                       <h5 class=""locationCity"">Englewood</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Englewood Hospital and Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 201-894-3456   </span> </div>                                       <h5 class=""locationCity"">Jersey City</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Jersey City Medical Center</strong>     <br>Contact: Site Public Contact <br>Email: <a href=""mailto:ecog.rss@jimmy.harvard.edu"">ecog.rss@jimmy.harvard.edu</a>   </span> </div>                                       <h5 class=""locationCity"">Lakewood</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Monmouth Medical Center Southern Campus</strong>     <br>Contact: Site Public Contact <br>Phone: 732-923-6564 <br>Email: <a href=""mailto:mary.danish@rwjbh.org"">mary.danish@rwjbh.org</a>   </span> </div>                                       <h5 class=""locationCity"">Livingston</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Barnabas Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 973-322-2934 <br>Email: <a href=""mailto:joanne.loeb@rwjbh.org"">joanne.loeb@rwjbh.org</a>   </span> </div>                                       <h5 class=""locationCity"">Long Branch</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Monmouth Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 732-923-6564 <br>Email: <a href=""mailto:mary.danish@rwjbh.org"">mary.danish@rwjbh.org</a>   </span> </div>                                       <h5 class=""locationCity"">Middletown</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Memorial Sloan Kettering Monmouth</strong>     <br>Contact: Site Public Contact <br>Phone: 212-639-7592   </span> </div>                                       <h5 class=""locationCity"">Montvale</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Memorial Sloan Kettering Bergen</strong>     <br>Contact: Site Public Contact <br>Phone: 212-639-7592   </span> </div>                                       <h5 class=""locationCity"">New Brunswick</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Rutgers Cancer Institute of New Jersey</strong>     <br>Contact: Site Public Contact <br>Phone: 732-235-7356   </span> </div>                                       <h5 class=""locationCity"">Paramus</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">The Valley Hospital - Luckow Pavilion</strong>     <br>Contact: Site Public Contact <br>Phone: 201-634-5792 <br>Email: <a href=""mailto:clinicaltrialsresearch@valleyhealth.com"">clinicaltrialsresearch@valleyhealth.com</a>   </span> </div>                                       <h5 class=""locationCity"">Ridgewood</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Neurosurgeons of New Jersey-Ridgewood</strong>     <br>Contact: Site Public Contact <br>Phone: 888-823-5923 <br>Email: <a href=""mailto:ctsucontact@westat.com"">ctsucontact@westat.com</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Valley Health System  Ridgewood Campus</strong>     <br>Contact: Site Public Contact <br>Phone: 201-634-5792 <br>Email: <a href=""mailto:clinicaltrialsresearch@valleyhealth.com"">clinicaltrialsresearch@valleyhealth.com</a>   </span> </div>                                       <h5 class=""locationCity"">Somerville</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Robert Wood Johnson University Hospital Somerset</strong>     <br>Contact: Site Public Contact <br>Phone: 908-685-2481 <br>Email: <a href=""mailto:Siby.Varughese@rwjbh.org"">Siby.Varughese@rwjbh.org</a>   </span> </div>                                       <h5 class=""locationCity"">Westwood</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Valley Health System-Hematology/Oncology</strong>     <br>Contact: Site Public Contact <br>Phone: 888-823-5923 <br>Email: <a href=""mailto:ctsucontact@westat.com"">ctsucontact@westat.com</a>   </span> </div>                                   <h4>New Mexico</h4>                           <h5 class=""locationCity"">Albuquerque</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">New Mexico Oncology Hematology Consultants</strong>     <br>Contact: Site Public Contact <br>Phone: 505-272-0530 <br>Email: <a href=""mailto:CLee@nmcca.org"">CLee@nmcca.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">University of New Mexico Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 505-925-0348 <br>Email: <a href=""mailto:HSC-ClinicalTrialInfo@salud.unm.edu"">HSC-ClinicalTrialInfo@salud.unm.edu</a>   </span> </div>                                   <h4>New York</h4>                           <h5 class=""locationCity"">Bronx</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Montefiore Medical Center - Moses Campus</strong>     <br>Contact: Site Public Contact <br>Phone: 718-379-6866 <br>Email: <a href=""mailto:eskwak@montefiore.org"">eskwak@montefiore.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Montefiore Medical Center-Einstein Campus</strong>     <br>Contact: Site Public Contact <br>Phone: 718-379-6866 <br>Email: <a href=""mailto:eskwak@montefiore.org"">eskwak@montefiore.org</a>   </span> </div>                                       <h5 class=""locationCity"">Buffalo</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Roswell Park Cancer Institute</strong>     <br>Contact: Site Public Contact <br>Phone: 800-767-9355 <br>Email: <a href=""mailto:askroswell@roswellpark.org"">askroswell@roswellpark.org</a>   </span> </div>                                       <h5 class=""locationCity"">Commack</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Memorial Sloan Kettering Commack</strong>     <br>Contact: Site Public Contact <br>Phone: 212-639-7592   </span> </div>                                       <h5 class=""locationCity"">East Hills</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">The Cancer Institute at Saint Francis Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 516-325-7514 <br>Email: <a href=""mailto:Stephanie.Solito@chsli.org"">Stephanie.Solito@chsli.org</a>   </span> </div>                                       <h5 class=""locationCity"">Glens Falls</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Glens Falls Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 518-926-6700   </span> </div>                                       <h5 class=""locationCity"">New York</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Memorial Sloan Kettering Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 212-639-7592   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Mount Sinai Chelsea</strong>     <br>Contact: Site Public Contact <br>Phone: 212-824-7309 <br>Email: <a href=""mailto:CCTO@mssm.edu"">CCTO@mssm.edu</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Mount Sinai Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 212-824-7309 <br>Email: <a href=""mailto:CCTO@mssm.edu"">CCTO@mssm.edu</a>   </span> </div>                                       <h5 class=""locationCity"">Oswego</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Upstate Cancer Center at Oswego</strong>     <br>Contact: Site Public Contact <br>Phone: 315-464-8230 <br>Email: <a href=""mailto:McDowelE@upstate.edu"">McDowelE@upstate.edu</a>   </span> </div>                                       <h5 class=""locationCity"">Syracuse</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">State University of New York Upstate Medical University</strong>     <br>Contact: Site Public Contact <br>Phone: 315-464-5476   </span> </div>                                       <h5 class=""locationCity"">Uniondale</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Memorial Sloan Kettering Nassau</strong>     <br>Contact: Site Public Contact <br>Phone: 212-639-7592   </span> </div>                                       <h5 class=""locationCity"">Verona</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Upstate Cancer Center at Verona</strong>     <br>Contact: Site Public Contact <br>Phone: 315-464-8230 <br>Email: <a href=""mailto:McDowelE@upstate.edu"">McDowelE@upstate.edu</a>   </span> </div>                                       <h5 class=""locationCity"">West Harrison</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Memorial Sloan Kettering Westchester</strong>     <br>Contact: Site Public Contact <br>Phone: 212-639-7592   </span> </div>                                       <h5 class=""locationCity"">West Islip</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Good Samaritan University Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 516-326-7514   </span> </div>                                       <h5 class=""locationCity"">White Plains</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Dickstein Cancer Treatment Center</strong>     <br>Contact: Site Public Contact <br>Phone: 914-849-7582 <br>Email: <a href=""mailto:mcortese@wphospital.org"">mcortese@wphospital.org</a>   </span> </div>                                   <h4>North Carolina</h4>                           <h5 class=""locationCity"">Charlotte</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Novant Health Presbyterian Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 980-201-6360 <br>Email: <a href=""mailto:kashah@novanthealth.org"">kashah@novanthealth.org</a>   </span> </div>                                       <h5 class=""locationCity"">Clinton</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Southeastern Medical Oncology Center-Clinton</strong>     <br>Contact: Site Public Contact <br>Phone: 919-587-9084 <br>Email: <a href=""mailto:jfields@cancersmoc.com"">jfields@cancersmoc.com</a>   </span> </div>                                       <h5 class=""locationCity"">Goldsboro</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Southeastern Medical Oncology Center-Goldsboro</strong>     <br>Contact: Site Public Contact <br>Phone: 919-587-9084 <br>Email: <a href=""mailto:jfields@cancersmoc.com"">jfields@cancersmoc.com</a>   </span> </div>                                       <h5 class=""locationCity"">Huntersville</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Novant Health Cancer Institute - Huntersville</strong>     <br>Contact: Site Public Contact <br>Phone: 980-201-6360 <br>Email: <a href=""mailto:kashah@novanthealth.org"">kashah@novanthealth.org</a>   </span> </div>                                       <h5 class=""locationCity"">Jacksonville</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Southeastern Medical Oncology Center-Jacksonville</strong>     <br>Contact: Site Public Contact <br>Phone: 910-587-9084 <br>Email: <a href=""mailto:jfields@cancersmoc.com"">jfields@cancersmoc.com</a>   </span> </div>                                       <h5 class=""locationCity"">Kenansville</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">ECU Health Oncology Kenansville</strong>     <br>Contact: Site Public Contact <br>Email: <a href=""mailto:research@ecuhealth.org"">research@ecuhealth.org</a>   </span> </div>                                       <h5 class=""locationCity"">Kernersville</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Novant Health Cancer Institute - Kernersville</strong>     <br>Contact: Site Public Contact <br>Phone: 336-718-8335 <br>Email: <a href=""mailto:asmarrs@novanthealth.org"">asmarrs@novanthealth.org</a>   </span> </div>                                       <h5 class=""locationCity"">Kinston</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">ECU Health Oncology Kinston</strong>     <br>Contact: Site Public Contact <br>Phone: 252-559-2201 <br>Email: <a href=""mailto:research@ecuhealth.org"">research@ecuhealth.org</a>   </span> </div>                                       <h5 class=""locationCity"">Matthews</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Novant Health Cancer Institute - Matthews</strong>     <br>Contact: Site Public Contact <br>Phone: 980-201-6360 <br>Email: <a href=""mailto:kashah@novanthealth.org"">kashah@novanthealth.org</a>   </span> </div>                                       <h5 class=""locationCity"">Mooresville</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Novant Health Cancer Institute - Mooresville</strong>     <br>Contact: Site Public Contact <br>Phone: 980-201-6360 <br>Email: <a href=""mailto:kashah@novanthealth.org"">kashah@novanthealth.org</a>   </span> </div>                                       <h5 class=""locationCity"">Mount Airy</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Novant Health Cancer Institute - Mount Airy</strong>     <br>Contact: Site Public Contact <br>Phone: 336-718-8335 <br>Email: <a href=""mailto:asmarrs@novanthealth.org"">asmarrs@novanthealth.org</a>   </span> </div>                                       <h5 class=""locationCity"">North Wilkesboro</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Novant Health Cancer Institute - Wilkesboro</strong>     <br>Contact: Site Public Contact <br>Phone: 336-718-8335 <br>Email: <a href=""mailto:pjordan@novanthealth.org"">pjordan@novanthealth.org</a>   </span> </div>                                       <h5 class=""locationCity"">Richlands</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">ECU Health Oncology Richlands</strong>     <br>Contact: Site Public Contact <br>Email: <a href=""mailto:research@ecuhealth.org"">research@ecuhealth.org</a>   </span> </div>                                       <h5 class=""locationCity"">Stateville</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Novant Health Cancer Institute - Statesville</strong>     <br>Contact: Site Public Contact <br>Phone: 336-718-8335 <br>Email: <a href=""mailto:pjordan@novanthealth.org"">pjordan@novanthealth.org</a>   </span> </div>                                       <h5 class=""locationCity"">Thomasville</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Novant Health Cancer Institute - Thomasville</strong>     <br>Contact: Site Public Contact <br>Phone: 336-718-8335 <br>Email: <a href=""mailto:pjordan@novanthealth.org"">pjordan@novanthealth.org</a>   </span> </div>                                       <h5 class=""locationCity"">Winston-Salem</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Novant Health Forsyth Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 336-718-8335 <br>Email: <a href=""mailto:pjordan@novanthealth.org"">pjordan@novanthealth.org</a>   </span> </div>                                   <h4>North Dakota</h4>                           <h5 class=""locationCity"">Bismarck</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Sanford Bismarck Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 701-323-5760 <br>Email: <a href=""mailto:OncologyClinicalTrialsFargo@sanfordhealth.org"">OncologyClinicalTrialsFargo@sanfordhealth.org</a>   </span> </div>                                       <h5 class=""locationCity"">Fargo</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Sanford Broadway Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 701-323-5760 <br>Email: <a href=""mailto:OncologyClinicalTrialsFargo@sanfordhealth.org"">OncologyClinicalTrialsFargo@sanfordhealth.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Sanford Medical Center Fargo</strong>     <br>Contact: Site Public Contact <br>Phone: 800-437-4010   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Sanford Roger Maris Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 701-234-6161 <br>Email: <a href=""mailto:OncologyClinicalTrialsFargo@sanfordhealth.org"">OncologyClinicalTrialsFargo@sanfordhealth.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Sanford South University Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 701-234-6161   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Southpointe-Sanford Medical Center Fargo</strong>     <br>Contact: Site Public Contact <br>Phone: 605-312-3320   </span> </div>                                   <h4>Ohio</h4>                           <h5 class=""locationCity"">Avon</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">UH Seidman Cancer Center at UH Avon Health Center</strong>     <br>Contact: Site Public Contact <br>Phone: 800-641-2422   </span> </div>                                       <h5 class=""locationCity"">Beachwood</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">UHHS-Chagrin Highlands Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 800-641-2422 <br>Email: <a href=""mailto:CTUReferral@UHhospitals.org"">CTUReferral@UHhospitals.org</a>   </span> </div>                                       <h5 class=""locationCity"">Beavercreek</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Indu and Raj Soin Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 937-528-2900 <br>Email: <a href=""mailto:clinical.trials@daytonncorp.org"">clinical.trials@daytonncorp.org</a>   </span> </div>                                       <h5 class=""locationCity"">Belpre</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Strecker Cancer Center-Belpre</strong>     <br>Contact: Site Public Contact <br>Phone: 614-488-2745 <br>Email: <a href=""mailto:Jeffh@columbusccop.org"">Jeffh@columbusccop.org</a>   </span> </div>                                       <h5 class=""locationCity"">Boardman</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Elizabeth Boardman Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 937-528-2900 <br>Email: <a href=""mailto:clinical.trials@daytonncorp.org"">clinical.trials@daytonncorp.org</a>   </span> </div>                                       <h5 class=""locationCity"">Centerville</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Dayton Physicians LLC-Miami Valley South</strong>     <br>Contact: Site Public Contact <br>Phone: 937-528-2900 <br>Email: <a href=""mailto:clinical.trials@daytonncorp.org"">clinical.trials@daytonncorp.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Miami Valley Hospital South</strong>     <br>Contact: Site Public Contact <br>Phone: 937-528-2900 <br>Email: <a href=""mailto:clinical.trials@daytonncorp.org"">clinical.trials@daytonncorp.org</a>   </span> </div>                                       <h5 class=""locationCity"">Chardon</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Geauga Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 800-641-2422 <br>Email: <a href=""mailto:CTUReferral@UHhospitals.org"">CTUReferral@UHhospitals.org</a>   </span> </div>                                       <h5 class=""locationCity"">Chillicothe</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Adena Regional Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 877-779-7585 <br>Email: <a href=""mailto:Jeffh@columbusccop.org"">Jeffh@columbusccop.org</a>   </span> </div>                                       <h5 class=""locationCity"">Cincinnati</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Bethesda North Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 720-874-1881 <br>Email: <a href=""mailto:ResearchInstituteInquiries@CommonSpirit.org"">ResearchInstituteInquiries@CommonSpirit.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Good Samaritan Hospital - Cincinnati</strong>     <br>Contact: Site Public Contact <br>Phone: 720-874-1881 <br>Email: <a href=""mailto:ResearchInstituteInquiries@CommonSpirit.org"">ResearchInstituteInquiries@CommonSpirit.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Oncology Hematology Care Inc-Kenwood</strong>     <br>Contact: Site Public Contact <br>Phone: 937-528-2900 <br>Email: <a href=""mailto:clinical.trials@daytonncorp.org"">clinical.trials@daytonncorp.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">TriHealth Cancer Institute-Anderson</strong>     <br>Contact: Site Public Contact <br>Phone: 720-874-1881 <br>Email: <a href=""mailto:ResearchInstituteInquiries@CommonSpirit.org"">ResearchInstituteInquiries@CommonSpirit.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">TriHealth Cancer Institute-Westside</strong>     <br>Contact: Site Public Contact <br>Phone: 720-874-1881 <br>Email: <a href=""mailto:ResearchInstituteInquiries@CommonSpirit.org"">ResearchInstituteInquiries@CommonSpirit.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">University of Cincinnati Cancer Center-UC Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 513-584-7698 <br>Email: <a href=""mailto:cancer@uchealth.com"">cancer@uchealth.com</a>   </span> </div>                                       <h5 class=""locationCity"">Cleveland</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Case Western Reserve University</strong>     <br>Contact: Site Public Contact <br>Phone: 800-641-2422 <br>Email: <a href=""mailto:CTUReferral@UHhospitals.org"">CTUReferral@UHhospitals.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Cleveland Clinic Foundation</strong>     <br>Contact: Site Public Contact <br>Phone: 866-223-8100 <br>Email: <a href=""mailto:TaussigResearch@ccf.org"">TaussigResearch@ccf.org</a>   </span> </div>                                       <h5 class=""locationCity"">Columbus</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Columbus Oncology and Hematology Associates Inc</strong>     <br>Contact: Site Public Contact <br>Phone: 614-788-3860 <br>Email: <a href=""mailto:Jennifer.Sexton@ohiohealth.com"">Jennifer.Sexton@ohiohealth.com</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Doctors Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 614-788-3860 <br>Email: <a href=""mailto:Jennifer.Sexton@ohiohealth.com"">Jennifer.Sexton@ohiohealth.com</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Grant Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 614-788-3860 <br>Email: <a href=""mailto:Jennifer.Sexton@ohiohealth.com"">Jennifer.Sexton@ohiohealth.com</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Mount Carmel East Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 614-488-2745 <br>Email: <a href=""mailto:Jeffh@columbusccop.org"">Jeffh@columbusccop.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Mount Carmel Health Center West</strong>     <br>Contact: Site Public Contact <br>Phone: 614-488-2745 <br>Email: <a href=""mailto:Jeffh@columbusccop.org"">Jeffh@columbusccop.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Riverside Methodist Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 614-788-3860 <br>Email: <a href=""mailto:Jennifer.Sexton@ohiohealth.com"">Jennifer.Sexton@ohiohealth.com</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">The Mark H Zangmeister Center</strong>     <br>Contact: Site Public Contact <br>Phone: 614-488-2745 <br>Email: <a href=""mailto:Jeffh@columbusccop.org"">Jeffh@columbusccop.org</a>   </span> </div>                                       <h5 class=""locationCity"">Dayton</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Dayton Physician LLC - Englewood</strong>     <br>Contact: Site Public Contact <br>Phone: 937-528-2900 <br>Email: <a href=""mailto:clinical.trials@daytonncorp.org"">clinical.trials@daytonncorp.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Miami Valley Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 937-528-2900 <br>Email: <a href=""mailto:clinical.trials@daytonncorp.org"">clinical.trials@daytonncorp.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Miami Valley Hospital North</strong>     <br>Contact: Site Public Contact <br>Phone: 937-528-2900 <br>Email: <a href=""mailto:clinical.trials@daytonncorp.org"">clinical.trials@daytonncorp.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Premier Blood and Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 937-276-8320   </span> </div>                                       <h5 class=""locationCity"">Delaware</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Delaware Health Center-Grady Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 614-788-3860 <br>Email: <a href=""mailto:Jennifer.Sexton@ohiohealth.com"">Jennifer.Sexton@ohiohealth.com</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Grady Memorial Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 614-788-3860 <br>Email: <a href=""mailto:Jennifer.Sexton@ohiohealth.com"">Jennifer.Sexton@ohiohealth.com</a>   </span> </div>                                       <h5 class=""locationCity"">Dublin</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Dublin Methodist Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 614-788-3860 <br>Email: <a href=""mailto:Jennifer.Sexton@ohiohealth.com"">Jennifer.Sexton@ohiohealth.com</a>   </span> </div>                                       <h5 class=""locationCity"">Findlay</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Armes Family Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 937-528-2900 <br>Email: <a href=""mailto:clinical.trials@daytonncorp.org"">clinical.trials@daytonncorp.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Blanchard Valley Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 937-528-2900 <br>Email: <a href=""mailto:clinical.trials@daytonncorp.org"">clinical.trials@daytonncorp.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Orion Cancer Care</strong>     <br>Contact: Site Public Contact <br>Phone: 937-528-2900 <br>Email: <a href=""mailto:clinical.trials@daytonncorp.org"">clinical.trials@daytonncorp.org</a>   </span> </div>                                       <h5 class=""locationCity"">Franklin</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Atrium Medical Center-Middletown Regional Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 937-528-2900 <br>Email: <a href=""mailto:clinical.trials@daytonncorp.org"">clinical.trials@daytonncorp.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Dayton Physicians LLC-Atrium</strong>     <br>Contact: Site Public Contact <br>Phone: 937-528-2900 <br>Email: <a href=""mailto:clinical.trials@daytonncorp.org"">clinical.trials@daytonncorp.org</a>   </span> </div>                                       <h5 class=""locationCity"">Gahanna</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Central Ohio Breast and Endocrine Surgery</strong>     <br>Contact: Site Public Contact <br>Phone: 614-488-2745 <br>Email: <a href=""mailto:Jeffh@columbusccop.org"">Jeffh@columbusccop.org</a>   </span> </div>                                       <h5 class=""locationCity"">Greenville</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Dayton Physicians LLC-Wayne</strong>     <br>Contact: Site Public Contact <br>Phone: 937-528-2900 <br>Email: <a href=""mailto:clinical.trials@daytonncorp.org"">clinical.trials@daytonncorp.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Miami Valley Cancer Care and Infusion</strong>     <br>Contact: Site Public Contact <br>Phone: 937-569-7515   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Wayne Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 937-528-2900 <br>Email: <a href=""mailto:clinical.trials@daytonncorp.org"">clinical.trials@daytonncorp.org</a>   </span> </div>                                       <h5 class=""locationCity"">Grove City</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Mount Carmel Grove City Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 614-488-2745 <br>Email: <a href=""mailto:Jeffh@columbusccop.org"">Jeffh@columbusccop.org</a>   </span> </div>                                       <h5 class=""locationCity"">Kettering</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Greater Dayton Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 937-528-2900 <br>Email: <a href=""mailto:clinical.trials@daytonncorp.org"">clinical.trials@daytonncorp.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Kettering Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 937-528-2900 <br>Email: <a href=""mailto:clinical.trials@daytonncorp.org"">clinical.trials@daytonncorp.org</a>   </span> </div>                                       <h5 class=""locationCity"">Lancaster</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Fairfield Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 614-488-2745 <br>Email: <a href=""mailto:Jeffh@columbusccop.org"">Jeffh@columbusccop.org</a>   </span> </div>                                       <h5 class=""locationCity"">Lima</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Rita's Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 614-488-2745 <br>Email: <a href=""mailto:Jeffh@columbusccop.org"">Jeffh@columbusccop.org</a>   </span> </div>                                       <h5 class=""locationCity"">Mansfield</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">OhioHealth Mansfield Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 614-788-3860 <br>Email: <a href=""mailto:Jennifer.Sexton@ohiohealth.com"">Jennifer.Sexton@ohiohealth.com</a>   </span> </div>                                       <h5 class=""locationCity"">Marietta</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Marietta Memorial Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 614-488-2745 <br>Email: <a href=""mailto:Jeffh@columbusccop.org"">Jeffh@columbusccop.org</a>   </span> </div>                                       <h5 class=""locationCity"">Marion</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">OhioHealth Marion General Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 614-788-3860 <br>Email: <a href=""mailto:Jennifer.Sexton@ohiohealth.com"">Jennifer.Sexton@ohiohealth.com</a>   </span> </div>                                       <h5 class=""locationCity"">Marysville</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Memorial Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 614-488-2745 <br>Email: <a href=""mailto:Jeffh@columbusccop.org"">Jeffh@columbusccop.org</a>   </span> </div>                                       <h5 class=""locationCity"">Mayfield Heights</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Hillcrest Hospital Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 866-223-8100 <br>Email: <a href=""mailto:TaussigResearch@ccf.org"">TaussigResearch@ccf.org</a>   </span> </div>                                       <h5 class=""locationCity"">Mentor</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">UH Seidman Cancer Center at Lake Health Mentor Campus</strong>     <br>Contact: Site Public Contact <br>Phone: 800-641-2422 <br>Email: <a href=""mailto:CTUReferral@UHhospitals.org"">CTUReferral@UHhospitals.org</a>   </span> </div>                                       <h5 class=""locationCity"">Middleburg Heights</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">UH Seidman Cancer Center at Southwest General Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 800-641-2422 <br>Email: <a href=""mailto:CTUReferral@UHhospitals.org"">CTUReferral@UHhospitals.org</a>   </span> </div>                                       <h5 class=""locationCity"">Mount Vernon</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Knox Community Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 614-488-2745 <br>Email: <a href=""mailto:Jeffh@columbusccop.org"">Jeffh@columbusccop.org</a>   </span> </div>                                       <h5 class=""locationCity"">Newark</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Licking Memorial Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 614-488-2745 <br>Email: <a href=""mailto:Jeffh@columbusccop.org"">Jeffh@columbusccop.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Newark Radiation Oncology</strong>     <br>Contact: Site Public Contact <br>Phone: 614-488-2745 <br>Email: <a href=""mailto:Jeffh@columbusccop.org"">Jeffh@columbusccop.org</a>   </span> </div>                                       <h5 class=""locationCity"">Parma</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">University Hospitals Parma Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 800-641-2422 <br>Email: <a href=""mailto:CTUReferral@UHhospitals.org"">CTUReferral@UHhospitals.org</a>   </span> </div>                                       <h5 class=""locationCity"">Portsmouth</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Southern Ohio Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 614-488-2745 <br>Email: <a href=""mailto:Jeffh@columbusccop.org"">Jeffh@columbusccop.org</a>   </span> </div>                                       <h5 class=""locationCity"">Sandusky</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">UH Seidman Cancer Center at Firelands Regional Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 800-641-2422 <br>Email: <a href=""mailto:CTUReferral@UHhospitals.org"">CTUReferral@UHhospitals.org</a>   </span> </div>                                       <h5 class=""locationCity"">Springfield</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Springfield Regional Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 614-488-2745 <br>Email: <a href=""mailto:Jeffh@columbusccop.org"">Jeffh@columbusccop.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Springfield Regional Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 614-488-2745 <br>Email: <a href=""mailto:Jeffh@columbusccop.org"">Jeffh@columbusccop.org</a>   </span> </div>                                       <h5 class=""locationCity"">Toledo</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Mercy Health - Saint Anne Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 614-488-2745 <br>Email: <a href=""mailto:Jeffh@columbusccop.org"">Jeffh@columbusccop.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Mercy Health - Saint Vincent Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 614-488-2745 <br>Email: <a href=""mailto:Jeffh@columbusccop.org"">Jeffh@columbusccop.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Toledo Clinic Cancer Centers-Toledo</strong>     <br>Contact: Site Public Contact <br>Phone: 800-444-3561   </span> </div>                                       <h5 class=""locationCity"">Troy</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Dayton Physicians LLC - Troy</strong>     <br>Contact: Site Public Contact <br>Phone: 937-528-2900 <br>Email: <a href=""mailto:clinical.trials@daytonncorp.org"">clinical.trials@daytonncorp.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Upper Valley Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 937-528-2900 <br>Email: <a href=""mailto:clinical.trials@daytonncorp.org"">clinical.trials@daytonncorp.org</a>   </span> </div>                                       <h5 class=""locationCity"">Wadsworth</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">University Hospitals Sharon Health Center</strong>     <br>Contact: Site Public Contact <br>Phone: 800-641-2422 <br>Email: <a href=""mailto:CTUReferral@UHhospitals.org"">CTUReferral@UHhospitals.org</a>   </span> </div>                                       <h5 class=""locationCity"">Warren</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Joseph Warren Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 937-528-2900 <br>Email: <a href=""mailto:clinical.trials@daytonncorp.org"">clinical.trials@daytonncorp.org</a>   </span> </div>                                       <h5 class=""locationCity"">West Chester</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">University of Cincinnati Cancer Center-West Chester</strong>     <br>Contact: Site Public Contact <br>Phone: 513-584-7698 <br>Email: <a href=""mailto:cancer@uchealth.com"">cancer@uchealth.com</a>   </span> </div>                                       <h5 class=""locationCity"">Westerville</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Ann's Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 614-488-2745 <br>Email: <a href=""mailto:Jeffh@columbusccop.org"">Jeffh@columbusccop.org</a>   </span> </div>                                       <h5 class=""locationCity"">Westlake</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">UH Seidman Cancer Center at Saint John Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 800-641-2422 <br>Email: <a href=""mailto:CTUReferral@UHhospitals.org"">CTUReferral@UHhospitals.org</a>   </span> </div>                                       <h5 class=""locationCity"">Youngstown</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Elizabeth Youngstown Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 937-528-2900 <br>Email: <a href=""mailto:clinical.trials@daytonncorp.org"">clinical.trials@daytonncorp.org</a>   </span> </div>                                       <h5 class=""locationCity"">Zanesville</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Genesis Healthcare System Cancer Care Center</strong>     <br>Contact: Site Public Contact <br>Phone: 614-488-2745 <br>Email: <a href=""mailto:Jeffh@columbusccop.org"">Jeffh@columbusccop.org</a>   </span> </div>                                   <h4>Oklahoma</h4>                           <h5 class=""locationCity"">Oklahoma City</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Integris Cancer Institute of Oklahoma</strong>     <br>Contact: Site Public Contact <br>Phone: 405-773-6613   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Integris Southwest Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 888-823-5923 <br>Email: <a href=""mailto:ctsucontact@westat.com"">ctsucontact@westat.com</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Mercy Hospital Oklahoma City</strong>     <br>Contact: Site Public Contact <br>Phone: 405-752-3402   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">University of Oklahoma Health Sciences Center</strong>     <br>Contact: Site Public Contact <br>Phone: 405-271-8777 <br>Email: <a href=""mailto:ou-clinical-trials@ouhsc.edu"">ou-clinical-trials@ouhsc.edu</a>   </span> </div>                                   <h4>Oregon</h4>                           <h5 class=""locationCity"">Baker City</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Alphonsus Cancer Care Center-Baker City</strong>     <br>Contact: Site Public Contact <br>Phone: 406-969-6060 <br>Email: <a href=""mailto:mccinfo@mtcancer.org"">mccinfo@mtcancer.org</a>   </span> </div>                                       <h5 class=""locationCity"">Bend</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Charles Health System</strong>     <br>Contact: Site Public Contact <br>Phone: 541-706-2909 <br>Email: <a href=""mailto:nosall@stcharleshealthcare.org"">nosall@stcharleshealthcare.org</a>   </span> </div>                                       <h5 class=""locationCity"">Clackamas</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Clackamas Radiation Oncology Center</strong>     <br>Contact: Site Public Contact <br>Phone: 503-215-2614 <br>Email: <a href=""mailto:CanRsrchStudies@providence.org"">CanRsrchStudies@providence.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Providence Cancer Institute Clackamas Clinic</strong>     <br>Contact: Site Public Contact <br>Phone: 503-215-2614 <br>Email: <a href=""mailto:CanRsrchStudies@providence.org"">CanRsrchStudies@providence.org</a>   </span> </div>                                       <h5 class=""locationCity"">Coos Bay</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Bay Area Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 541-269-8392 <br>Email: <a href=""mailto:cherie.cox@bayareahospital.org"">cherie.cox@bayareahospital.org</a>   </span> </div>                                       <h5 class=""locationCity"">Newberg</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Providence Newberg Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 503-215-2614 <br>Email: <a href=""mailto:CanRsrchStudies@providence.org"">CanRsrchStudies@providence.org</a>   </span> </div>                                       <h5 class=""locationCity"">Ontario</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Alphonsus Cancer Care Center-Ontario</strong>     <br>Contact: Site Public Contact <br>Phone: 406-969-6060 <br>Email: <a href=""mailto:mccinfo@mtcancer.org"">mccinfo@mtcancer.org</a>   </span> </div>                                       <h5 class=""locationCity"">Oregon City</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Providence Willamette Falls Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 503-215-2614 <br>Email: <a href=""mailto:CanRsrchStudies@providence.org"">CanRsrchStudies@providence.org</a>   </span> </div>                                       <h5 class=""locationCity"">Portland</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Providence Portland Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 503-215-2614 <br>Email: <a href=""mailto:CanRsrchStudies@providence.org"">CanRsrchStudies@providence.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Providence Saint Vincent Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 503-215-2614 <br>Email: <a href=""mailto:CanRsrchStudies@providence.org"">CanRsrchStudies@providence.org</a>   </span> </div>                                       <h5 class=""locationCity"">Redmond</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Charles Health System-Redmond</strong>     <br>Contact: Site Public Contact <br>Phone: 541-706-2909   </span> </div>                                   <h4>Pennsylvania</h4>                           <h5 class=""locationCity"">Allentown</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Lehigh Valley Hospital-Cedar Crest</strong>     <br>Contact: Site Public Contact <br>Phone: 610-402-9543 <br>Email: <a href=""mailto:Morgan_M.Horton@lvhn.org"">Morgan_M.Horton@lvhn.org</a>   </span> </div>                                       <h5 class=""locationCity"">Bethlehem</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Lehigh Valley Hospital - Muhlenberg</strong>     <br>Contact: Site Public Contact <br>Phone: 610-402-9543 <br>Email: <a href=""mailto:Morgan_M.Horton@lvhn.org"">Morgan_M.Horton@lvhn.org</a>   </span> </div>                                       <h5 class=""locationCity"">Bryn Mawr</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Bryn Mawr Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 484-476-2649 <br>Email: <a href=""mailto:turzoe@mlhs.org"">turzoe@mlhs.org</a>   </span> </div>                                       <h5 class=""locationCity"">Chambersburg</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Chambersburg Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 888-823-5923 <br>Email: <a href=""mailto:ctsucontact@westat.com"">ctsucontact@westat.com</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">WellSpan Medical Oncology and Hematology</strong>     <br>Contact: Site Public Contact <br>Phone: 717-217-6020   </span> </div>                                       <h5 class=""locationCity"">Collegeville</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Main Line Health Center-Collegeville</strong>     <br>Contact: Site Public Contact <br>Phone: 484-476-2649 <br>Email: <a href=""mailto:turzoe@mlhs.org"">turzoe@mlhs.org</a>   </span> </div>                                       <h5 class=""locationCity"">East Stroudsburg</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Pocono Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 610-402-9543 <br>Email: <a href=""mailto:Morgan_M.Horton@lvhn.org"">Morgan_M.Horton@lvhn.org</a>   </span> </div>                                       <h5 class=""locationCity"">Ephrata</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Ephrata Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 717-721-4840   </span> </div>                                       <h5 class=""locationCity"">Exton</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Main Line Health Center-Exton</strong>     <br>Contact: Site Public Contact <br>Phone: 484-476-2649 <br>Email: <a href=""mailto:turzoe@mlhs.org"">turzoe@mlhs.org</a>   </span> </div>                                       <h5 class=""locationCity"">Gettysburg</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Adams Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 877-441-7957   </span> </div>                                       <h5 class=""locationCity"">Hanover</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">WellSpan Medical Oncology and Hematology</strong>     <br>Contact: Site Public Contact <br>Phone: 717-632-1559   </span> </div>                                       <h5 class=""locationCity"">Hazleton</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Lehigh Valley Hospital-Hazleton</strong>     <br>Contact: Site Public Contact <br>Phone: 610-402-9543 <br>Email: <a href=""mailto:Morgan_M.Horton@lvhn.org"">Morgan_M.Horton@lvhn.org</a>   </span> </div>                                       <h5 class=""locationCity"">Lebanon</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Sechler Family Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 717-741-8303 <br>Email: <a href=""mailto:doxenberg@wellspan.org"">doxenberg@wellspan.org</a>   </span> </div>                                       <h5 class=""locationCity"">Media</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Riddle  Memorial  Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 484-476-2649 <br>Email: <a href=""mailto:turzoe@mlhs.org"">turzoe@mlhs.org</a>   </span> </div>                                       <h5 class=""locationCity"">Paoli</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Paoli Memorial Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 484-476-2649 <br>Email: <a href=""mailto:turzoe@mlhs.org"">turzoe@mlhs.org</a>   </span> </div>                                       <h5 class=""locationCity"">Philadelphia</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Fox Chase Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 215-728-4790   </span> </div>                                       <h5 class=""locationCity"">Sayre</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Guthrie Medical Group PC-Robert Packer Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 800-836-0388   </span> </div>                                       <h5 class=""locationCity"">Wynnewood</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Lankenau Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 484-476-2649 <br>Email: <a href=""mailto:turzoe@mlhs.org"">turzoe@mlhs.org</a>   </span> </div>                                       <h5 class=""locationCity"">York</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Cancer Care Associates of York</strong>     <br>Contact: Site Public Contact <br>Phone: 717-741-9229   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">WellSpan Health-York Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 877-441-7957   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">WellSpan Health-York Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 877-441-7957   </span> </div>                                   <h4>Rhode Island</h4>                           <h5 class=""locationCity"">Westerly</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Smilow Cancer Hospital Care Center - Westerly</strong>     <br>Contact: Site Public Contact <br>Phone: 203-785-5702 <br>Email: <a href=""mailto:canceranswers@yale.edu"">canceranswers@yale.edu</a>   </span> </div>                                   <h4>South Dakota</h4>                           <h5 class=""locationCity"">Sioux Falls</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Sanford Cancer Center Oncology Clinic</strong>     <br>Contact: Site Public Contact <br>Phone: 605-312-3320 <br>Email: <a href=""mailto:OncologyClinicTrialsSF@sanfordhealth.org"">OncologyClinicTrialsSF@sanfordhealth.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Sanford USD Medical Center - Sioux Falls</strong>     <br>Contact: Site Public Contact <br>Phone: 605-312-3320 <br>Email: <a href=""mailto:OncologyClinicalTrialsSF@SanfordHealth.org"">OncologyClinicalTrialsSF@SanfordHealth.org</a>   </span> </div>                                   <h4>Tennessee</h4>                           <h5 class=""locationCity"">Collierville</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Baptist Memorial Hospital and Cancer Center-Collierville</strong>     <br>Contact: Site Public Contact <br>Phone: 901-226-1366 <br>Email: <a href=""mailto:BCCclintrials@bmhcc.org"">BCCclintrials@bmhcc.org</a>   </span> </div>                                       <h5 class=""locationCity"">Memphis</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Baptist Memorial Hospital and Cancer Center-Memphis</strong>     <br>Contact: Site Public Contact <br>Phone: 901-226-1366 <br>Email: <a href=""mailto:BCCclintrials@bmhcc.org"">BCCclintrials@bmhcc.org</a>   </span> </div>                                   <h4>Texas</h4>                           <h5 class=""locationCity"">Baytown</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Houston Methodist San Jacinto Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 888-823-5923 <br>Email: <a href=""mailto:ctsucontact@westat.com"">ctsucontact@westat.com</a>   </span> </div>                                       <h5 class=""locationCity"">Bryan</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Joseph Regional Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 855-313-2409 <br>Email: <a href=""mailto:ResearchInstituteInquiries@CommonSpirit.org"">ResearchInstituteInquiries@CommonSpirit.org</a>   </span> </div>                                       <h5 class=""locationCity"">Dallas</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Parkland Memorial Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 214-590-5582 <br>Email: <a href=""mailto:canceranswerline@UTSouthwestern.edu"">canceranswerline@UTSouthwestern.edu</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">UT Southwestern Simmons Cancer Center - RedBird</strong>     <br>Contact: Site Public Contact <br>Phone: 214-648-7097 <br>Email: <a href=""mailto:canceranswerline@utsouthwestern.edu"">canceranswerline@utsouthwestern.edu</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">UT Southwestern/Simmons Cancer Center-Dallas</strong>     <br>Contact: Site Public Contact <br>Phone: 214-648-7097 <br>Email: <a href=""mailto:canceranswerline@UTSouthwestern.edu"">canceranswerline@UTSouthwestern.edu</a>   </span> </div>                                       <h5 class=""locationCity"">Fort Worth</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">UT Southwestern/Simmons Cancer Center-Fort Worth</strong>     <br>Contact: Site Public Contact <br>Phone: 214-648-7097 <br>Email: <a href=""mailto:canceranswerline@UTSouthwestern.edu"">canceranswerline@UTSouthwestern.edu</a>   </span> </div>                                       <h5 class=""locationCity"">Houston</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Houston Methodist Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 713-790-2700   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Houston Methodist West Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 832-522-2873   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Methodist Willowbrook Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 888-823-5923 <br>Email: <a href=""mailto:ctsucontact@westat.com"">ctsucontact@westat.com</a>   </span> </div>                                       <h5 class=""locationCity"">Nassau Bay</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Houston Methodist Saint John Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 888-823-5923 <br>Email: <a href=""mailto:ctsucontact@westat.com"">ctsucontact@westat.com</a>   </span> </div>                                       <h5 class=""locationCity"">Richardson</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">UT Southwestern Clinical Center at Richardson/Plano</strong>     <br>Contact: Site Public Contact <br>Phone: 972-669-7044 <br>Email: <a href=""mailto:Suzanne.cole@utsouthwestern.edu"">Suzanne.cole@utsouthwestern.edu</a>   </span> </div>                                       <h5 class=""locationCity"">Sugar Land</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Houston Methodist Sugar Land Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 281-242-2873   </span> </div>                                       <h5 class=""locationCity"">The Woodlands</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Houston Methodist The Woodlands Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 713-790-2700 <br>Email: <a href=""mailto:hmthewoodlands@houstonmethodist.org"">hmthewoodlands@houstonmethodist.org</a>   </span> </div>                                   <h4>Virginia</h4>                           <h5 class=""locationCity"">Charlottesville</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">University of Virginia Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 434-243-6303 <br>Email: <a href=""mailto:uvacancertrials@hscmail.mcc.virginia.edu"">uvacancertrials@hscmail.mcc.virginia.edu</a>   </span> </div>                                   <h4>Washington</h4>                           <h5 class=""locationCity"">Aberdeen</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Providence Regional Cancer System-Aberdeen</strong>     <br>Contact: Site Public Contact <br>Phone: 360-412-8958 <br>Email: <a href=""mailto:deidre.dillon@providence.org"">deidre.dillon@providence.org</a>   </span> </div>                                       <h5 class=""locationCity"">Bellingham</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">PeaceHealth Saint Joseph Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 360-788-8223   </span> </div>                                       <h5 class=""locationCity"">Bremerton</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Harrison HealthPartners Hematology and Oncology-Bremerton</strong>     <br>Contact: Site Public Contact <br>Phone: 308-398-6518 <br>Email: <a href=""mailto:clinicaltrials@sfmc-gi.org"">clinicaltrials@sfmc-gi.org</a>   </span> </div>                                       <h5 class=""locationCity"">Burien</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Highline Medical Center-Main Campus</strong>     <br>Contact: Site Public Contact <br>Phone: 253-426-6882 <br>Email: <a href=""mailto:ResearchInstituteInquiries@CommonSpirit.org"">ResearchInstituteInquiries@CommonSpirit.org</a>   </span> </div>                                       <h5 class=""locationCity"">Centralia</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Providence Regional Cancer System-Centralia</strong>     <br>Contact: Site Public Contact <br>Phone: 360-412-8958 <br>Email: <a href=""mailto:deidre.dillon@providence.org"">deidre.dillon@providence.org</a>   </span> </div>                                       <h5 class=""locationCity"">Edmonds</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Swedish Cancer Institute-Edmonds</strong>     <br>Contact: Site Public Contact <br>Phone: 206-215-3086 <br>Email: <a href=""mailto:PCRC-NCORP@Swedish.org"">PCRC-NCORP@Swedish.org</a>   </span> </div>                                       <h5 class=""locationCity"">Enumclaw</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Elizabeth Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 253-426-6882 <br>Email: <a href=""mailto:ResearchInstituteInquiries@CommonSpirit.org"">ResearchInstituteInquiries@CommonSpirit.org</a>   </span> </div>                                       <h5 class=""locationCity"">Everett</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Providence Regional Cancer Partnership</strong>     <br>Contact: Site Public Contact <br>Phone: 425-261-3529 <br>Email: <a href=""mailto:marilyn.birchman@providence.org"">marilyn.birchman@providence.org</a>   </span> </div>                                       <h5 class=""locationCity"">Federal Way</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Francis Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 253-426-6882 <br>Email: <a href=""mailto:ResearchInstituteInquiries@CommonSpirit.org"">ResearchInstituteInquiries@CommonSpirit.org</a>   </span> </div>                                       <h5 class=""locationCity"">Issaquah</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Swedish Cancer Institute-Issaquah</strong>     <br>Contact: Site Public Contact <br>Phone: 206-215-3086 <br>Email: <a href=""mailto:PCRC-NCORP@Swedish.org"">PCRC-NCORP@Swedish.org</a>   </span> </div>                                       <h5 class=""locationCity"">Kennewick</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Kadlec Clinic Hematology and Oncology</strong>     <br>Contact: Site Public Contact <br>Phone: 509-783-4637 <br>Email: <a href=""mailto:research@kadlecmed.org"">research@kadlecmed.org</a>   </span> </div>                                       <h5 class=""locationCity"">Lacey</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Providence Regional Cancer System-Lacey</strong>     <br>Contact: Site Public Contact <br>Phone: 360-412-8958 <br>Email: <a href=""mailto:deidre.dillon@providence.org"">deidre.dillon@providence.org</a>   </span> </div>                                       <h5 class=""locationCity"">Lakewood</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Clare Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 253-426-6882 <br>Email: <a href=""mailto:ResearchInstituteInquiries@CommonSpirit.org"">ResearchInstituteInquiries@CommonSpirit.org</a>   </span> </div>                                       <h5 class=""locationCity"">Longview</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">PeaceHealth Saint John Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 360-514-2016 <br>Email: <a href=""mailto:kmakin-bond@peacehealth.org"">kmakin-bond@peacehealth.org</a>   </span> </div>                                       <h5 class=""locationCity"">Port Townsend</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Jefferson Healthcare</strong>     <br>Contact: Site Public Contact <br>Phone: 360-344-3091   </span> </div>                                       <h5 class=""locationCity"">Seattle</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Pacific Gynecology Specialists</strong>     <br>Contact: Site Public Contact <br>Phone: 206-215-3086 <br>Email: <a href=""mailto:PCRC-NCORP@Swedish.org"">PCRC-NCORP@Swedish.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Swedish Medical Center-Ballard Campus</strong>     <br>Contact: Site Public Contact <br>Phone: 206-215-3086 <br>Email: <a href=""mailto:PCRC-NCORP@Swedish.org"">PCRC-NCORP@Swedish.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Swedish Medical Center-Cherry Hill</strong>     <br>Contact: Site Public Contact <br>Phone: 206-215-3086 <br>Email: <a href=""mailto:PCRC-NCORP@Swedish.org"">PCRC-NCORP@Swedish.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Swedish Medical Center-First Hill</strong>     <br>Contact: Site Public Contact <br>Phone: 206-215-3086 <br>Email: <a href=""mailto:PCRC-NCORP@Swedish.org"">PCRC-NCORP@Swedish.org</a>   </span> </div>                                       <h5 class=""locationCity"">Sedro-Woolley</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">PeaceHealth United General Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 360-788-8223 <br>Email: <a href=""mailto:rcrompton@peacehealth.org"">rcrompton@peacehealth.org</a>   </span> </div>                                       <h5 class=""locationCity"">Shelton</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Providence Regional Cancer System-Shelton</strong>     <br>Contact: Site Public Contact <br>Phone: 360-412-8958 <br>Email: <a href=""mailto:deidre.dillon@providence.org"">deidre.dillon@providence.org</a>   </span> </div>                                       <h5 class=""locationCity"">Silverdale</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Michael Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 720-874-1881 <br>Email: <a href=""mailto:ResearchInstituteInquiries@CommonSpirit.org"">ResearchInstituteInquiries@CommonSpirit.org</a>   </span> </div>                                       <h5 class=""locationCity"">Tacoma</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Franciscan Research Center-Northwest Medical Plaza</strong>     <br>Contact: Site Public Contact <br>Phone: 253-426-6882 <br>Email: <a href=""mailto:ResearchInstituteInquiries@CommonSpirit.org"">ResearchInstituteInquiries@CommonSpirit.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Northwest Medical Specialties PLLC</strong>     <br>Contact: Site Public Contact <br>Phone: 253-306-0532 <br>Email: <a href=""mailto:research@southsoundcare.org"">research@southsoundcare.org</a>   </span> </div>                                       <h5 class=""locationCity"">Vancouver</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">PeaceHealth Southwest Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 360-514-3940 <br>Email: <a href=""mailto:kmakin-bond@peacehealth.org"">kmakin-bond@peacehealth.org</a>   </span> </div>                                       <h5 class=""locationCity"">Walla Walla</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Providence Saint Mary Regional Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 509-897-5993 <br>Email: <a href=""mailto:Cheryl.Dodd@providence.org"">Cheryl.Dodd@providence.org</a>   </span> </div>                                       <h5 class=""locationCity"">Yelm</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Providence Regional Cancer System-Yelm</strong>     <br>Contact: Site Public Contact <br>Phone: 360-412-8958 <br>Email: <a href=""mailto:deidre.dillon@providence.org"">deidre.dillon@providence.org</a>   </span> </div>                                   <h4>West Virginia</h4>                           <h5 class=""locationCity"">Charleston</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">West Virginia University Charleston Division</strong>     <br>Contact: Site Public Contact <br>Phone: 304-388-9944   </span> </div>                                   <h4>Wisconsin</h4>                           <h5 class=""locationCity"">Eau Claire</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Marshfield Medical Center-EC Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 800-782-8581 <br>Email: <a href=""mailto:oncology.clinical.trials@marshfieldresearch.org"">oncology.clinical.trials@marshfieldresearch.org</a>   </span> </div>                                       <h5 class=""locationCity"">Janesville</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Mercyhealth Hospital and Cancer Center - Janesville</strong>     <br>Contact: Site Public Contact <br>Phone: 608-756-6871 <br>Email: <a href=""mailto:oncologyclinicaltrials@mhemail.org"">oncologyclinicaltrials@mhemail.org</a>   </span> </div>                                       <h5 class=""locationCity"">La Crosse</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Gundersen Lutheran Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 608-775-2385 <br>Email: <a href=""mailto:cancerctr@gundersenhealth.org"">cancerctr@gundersenhealth.org</a>   </span> </div>                                       <h5 class=""locationCity"">Marshfield</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Marshfield Medical Center-Marshfield</strong>     <br>Contact: Site Public Contact <br>Phone: 800-782-8581 <br>Email: <a href=""mailto:oncology.clinical.trials@marshfieldresearch.org"">oncology.clinical.trials@marshfieldresearch.org</a>   </span> </div>                                       <h5 class=""locationCity"">Milwaukee</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Medical College of Wisconsin</strong>     <br>Contact: Site Public Contact <br>Phone: 414-805-3666   </span> </div>                                       <h5 class=""locationCity"">Minocqua</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Marshfield Medical Center - Minocqua</strong>     <br>Contact: Site Public Contact <br>Phone: 800-782-8581 <br>Email: <a href=""mailto:oncology.clinical.trials@marshfieldresearch.org"">oncology.clinical.trials@marshfieldresearch.org</a>   </span> </div>                                       <h5 class=""locationCity"">Mukwonago</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">ProHealth D N Greenwald Center</strong>     <br>Contact: Site Public Contact <br>Email: <a href=""mailto:research.institute@phci.org"">research.institute@phci.org</a>   </span> </div>                                       <h5 class=""locationCity"">New Richmond</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Cancer Center of Western Wisconsin</strong>     <br>Contact: Site Public Contact <br>Phone: 952-993-1517 <br>Email: <a href=""mailto:mmcorc@healthpartners.com"">mmcorc@healthpartners.com</a>   </span> </div>                                       <h5 class=""locationCity"">Oconomowoc</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">ProHealth Oconomowoc Memorial Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 262-928-7878   </span> </div>                                       <h5 class=""locationCity"">Rice Lake</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Marshfield Medical Center-Rice Lake</strong>     <br>Contact: Site Public Contact <br>Phone: 800-782-8581 <br>Email: <a href=""mailto:oncology.clinical.trials@marshfieldresearch.org"">oncology.clinical.trials@marshfieldresearch.org</a>   </span> </div>                                       <h5 class=""locationCity"">Stevens Point</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Marshfield Medical Center-River Region at Stevens Point</strong>     <br>Contact: Site Public Contact <br>Phone: 800-782-8581 <br>Email: <a href=""mailto:oncology.clinical.trials@marshfieldresearch.org"">oncology.clinical.trials@marshfieldresearch.org</a>   </span> </div>                                       <h5 class=""locationCity"">Waukesha</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">ProHealth Waukesha Memorial Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 262-928-7632   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">UW Cancer Center at ProHealth Care</strong>     <br>Contact: Site Public Contact <br>Phone: 262-928-5539 <br>Email: <a href=""mailto:Chanda.miller@phci.org"">Chanda.miller@phci.org</a>   </span> </div>                                       <h5 class=""locationCity"">Weston</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Marshfield Medical Center - Weston</strong>     <br>Contact: Site Public Contact <br>Phone: 800-782-8581 <br>Email: <a href=""mailto:oncology.clinical.trials@marshfieldresearch.org"">oncology.clinical.trials@marshfieldresearch.org</a>   </span> </div>                                   <h4>Wyoming</h4>                           <h5 class=""locationCity"">Cheyenne</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Cheyenne Regional Medical Center-West</strong>     <br>Contact: Site Public Contact <br>Phone: 303-777-2663 <br>Email: <a href=""mailto:ccrp@co-cancerresearch.org"">ccrp@co-cancerresearch.org</a>   </span> </div>                                       <h5 class=""locationCity"">Cody</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Billings Clinic-Cody</strong>     <br>Contact: Site Public Contact <br>Phone: 800-996-2663 <br>Email: <a href=""mailto:research@billingsclinic.org"">research@billingsclinic.org</a>   </span> </div>                                       <h5 class=""locationCity"">Sheridan</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Welch Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 406-969-6060 <br>Email: <a href=""mailto:mccinfo@mtcancer.org"">mccinfo@mtcancer.org</a>   </span> </div>                           			</div> 		</div> 			<div class=""trialContainer""> 			<h2 class=""hangingIndent"">12. Testing Osimertinib as a Treatment for Lung Cancers with an EGFR Exon 20 Change</h2> 						<a class=""hangingIndent print-check-for-updates"" href=""/research/participate/clinical-trials-search/v?d=C1967&d=C2167&d=C93259&d=C199379&d=C172809&d=C82379&d=C116377&d=C1855&d=C65530&d=C124993&d=C148147&d=C66940&d=C2693&d=C97273&loc=0&pn=7&rl=2&st=C162158&st=C153201&st=C176727&st=C147924&st=C202131&st=C3512&st=C155908&st=C156093&st=C156094&st=C157364&st=C128798&st=C9133&st=C133254&st=C135017&st=C174510&st=C155901&st=C171612&st=C162642&t=C2926&id=NCI-2017-01017""><span>Check for Updates</span></a> 			<table class=""trialDataTable""> 				<tr class=""trialDataHeaderRow""> 					<td>Phase</td> 					<td>Type</td> 					<td>Status</td> 					<td>Age</td> 					<td>Trial IDs</td> 				</tr> 				<tr> 					<td>Phase II</td> 					<td>Treatment</td> 					<td>Active</td> 					<td>18 													and over 						 						</td> 					<td class=""trialIDCell""> 						<span class = ""dataTableIDLabel"">Primary ID</span> EA5162<br> 						<span class = ""dataTableIDLabel"">Secondary IDs</span> NCI-2017-01017<br> 						<span class = ""dataTableIDLabel"">Clinicaltrials.gov ID</span> <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT03191149"" target=""_blank"">NCT03191149</a><br> 					</td> 			</table>  			<h3>Description</h3> 			<div>This phase II trial studies how well osimertinib works in treating patients with non-small cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back after a period of improvement (recurrent). Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.</div>  			<h3 class=""printHeading"">Eligibility Criteria</h3>  																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																		<h4>Inclusion Criteria</h4> 										<div> 							<ul> 															<li>Participants must have a pathologically-confirmed diagnosis of non-small cell lung cancer (NSCLC)</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Participants must have advanced disease - either stage IV disease, stage IIIB disease not amenable to definitive multi-modality therapy, or recurrent disease after a prior diagnosis of stage I-III disease. All staging is via the American Joint Committee on Cancer (AJCC)/International Association for the Study of Lung Cancer (IASLC) 7th edition staging criteria</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>An EGFR exon 20 insertion mutation must be detected in the tumor tissue. Patients may be enrolled in the study based on an exon 20 insertion EGFR mutation detected by any Clinical Laboratory Improvement Act (CLIA)-certified tissue assay * NOTE: Testing results are to be submitted via Medidata Rave and the study chair or delegate will review the reports</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patients must have measurable disease; baseline measurements and ALL sites of disease must be obtained within 4 weeks to registration</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patients must have previously received at least one line of therapy for their advanced lung cancer; there are no restrictions on the maximum number of prior therapies allowed</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Participants must not have previously received osimertinib</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Participants must have not previously received therapies targeting PDL1, PD1 or CTLA4 within 6 months (180 days) prior to registration</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Age &gt;= 18 years</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 1</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Hemoglobin &gt;= 9.0 g/L (within 4 weeks before registration)</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Leukocytes/white blood cells &gt;= 3,000/mcL (within 4 weeks before registration)</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Absolute neutrophil count &gt;= 1,500/mcL (within 4 weeks before registration)</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Platelets &gt;= 100,000/mcL (within 4 weeks before registration)</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Total bilirubin =&lt; 1.5 x upper limit of normal (ULN) if no liver metastases or =&lt; 3 times ULN in the presence of documented Gilbert’s syndrome (unconjugated hyperbilirubinemia) or liver metastases (within 4 weeks before registration)</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =&lt; 3 x institutional upper limit of normal; for patients with known hepatic metastases AST and/or ALT =&lt; 5 x ULN (within 4 weeks before registration)</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Creatinine =&lt; 1.5 x institutional upper limit of normal (within 4 weeks before registration)</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Participants may not have clinically active or symptomatic interstitial lung disease or interstitial pneumonitis (i.e., affecting activities of daily living or requiring therapeutic intervention), or a history of clinically significant interstitial lung disease or radiation pneumonitis</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Participants may not have had radiation to the lung fields within four weeks (28 days) of starting treatment. For patients receiving palliative radiation to thoracic vertebrae, ribs or other sites where the radiation field includes the lungs, radiation must be completed at least two weeks before starting treatment. For all palliative radiation to all other sites, at least 7 days must have elapsed prior to starting treatment. At least six months (180 days) must have elapsed prior to starting treatment for radiation given with curative intent. Palliative radiotherapy to control symptoms (including gamma knife technique) is permitted. For stereotactic radiosurgery (SRS) to central nervous system (CNS) lesions, osimertinib can be held on the day of radiation only. For palliative radiotherapy (RT) to other sites of disease outside of the thorax osimertinib (osi) should be held for a minimum of 3 days before radiation and 3 days after RT is completed, but the duration of washout can be adjusted at the investigator&#39;s discretion with the approval of the study principal investigator (PI). For thoracic radiation, a 7-10 day washout period before the procedure and one week period after procedure before restarting osimertinib is advised to minimize the risk of pneumonitis. All radiotherapy related toxicities should be managed and ideally resolved before restarting osimertinib. Investigators should consider the radiotherapy when assessing causality if there are any localized adverse events (AEs) following the procedure</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Participants may not have clinically symptomatic brain metastases, leptomeningeal disease, or spinal cord compression. Patients may be on a stable dose of corticosteroids to control brain metastases if they have been on a stable dose for two weeks (14 days) prior to study treatment and are clinically asymptomatic</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patients must have an ECHO or a nuclear study (MUGA or first pass) within 4 weeks (28 days) prior to registration to treatment and must not have a left ventricular ejection fraction (LVEF) &lt; institutional lower limit of normal (LLN). If the LLN is not defined at a site, the LVEF must be &gt;= 50% for the patient to be eligible</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Participants may not have any of the following cardiac criteria: * Mean resting corrected QT interval (QTc) &gt;= 470 msec obtained from 3 electrocardiograms (ECGs) using the screening clinic ECG machine-derived QTc value * No history of QT prolongation associated with other medications that required discontinuation of that medication * Patient must not be receiving any concomitant medications that are known to be associated with Torsades de Pointes * Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG e.g., complete left bundle branch block, third degree heart block, second degree heart block, any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, electrolyte abnormalities (including: serum/plasma potassium &lt; LLN; serum/plasma magnesium &lt; LLN; serum/plasma calcium &lt; LLN), congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval * Symptomatic heart failure – New York Heart Association (NYHA) grade II-IV</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Participants may not have a second, clinically active, cancer. Patients with second cancers which have been treated with curative intent and/or are currently inactive are allowed</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Participants may not be receiving any other investigational agents. Patients previously treated with investigational agents must complete a washout period of at least two weeks or five half-lives, whichever is longer, before starting treatment</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Participants may not have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patients must have no history of hypersensitivity active or inactive excipients of osimertinib (AZD9291) or drugs with a similar chemical structure or class to osimertinib (AZD9291)</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patients must not currently be receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be potent inducers of CYP3A4 (at least 3 week prior). All patients must try to avoid concomitant use of any medications, herbal supplements and/or ingestion of foods with known inducer effects on CYP3A4</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>If medically feasible, patients taking regular medication, with the exception of potent inducers of CYP3A4, should be maintained on it throughout the study period. Patients taking concomitant medications whose disposition is dependent upon breast cancer resistance protein (BCRP) or P-glycoprotein (Pgp) and which have a narrow therapeutic index should be closely monitored for signs of changed tolerability as a result of increased exposure of the concomitant medication whilst receiving osimertinib (AZD9291) * NOTE: Use of St John’s wort is a contra-indication for osimertinib (AZD9291) use</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>If applicable, it is recommended that the starting and maintenance dose of rosuvastatin (due to BCRP inhibition by AZD9291 [osimertinib]) should be as low as possible and should be guided by the statin label. Monitoring of low-density lipoprotein (LDL) cholesterol levels is advised. If the subject experiences any potentially relevant adverse events suggestive of muscle toxicity including unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever, the statin should be stopped, creatine kinase (CK) levels should be checked, and any appropriate further management should be taken</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Subjects taking warfarin should be monitored regularly for changes in prothrombin time or international normalized ratio (INR)</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>No unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) grade 1 at the time of starting study treatment, with the exception of alopecia and grade 2, prior platinum-therapy–related neuropathy</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patients with refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of osimertinib (AZD9291) are ineligible</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Women must not be pregnant or breast-feeding because osimertinib (AZD9291) has been shown to cause fetal harm in animal models. All females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy. A female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Women of childbearing potential (WOCBP) and sexually active males must use an accepted and effective method of contraception while receiving protocol treatment or abstain from sexual intercourse for the duration of their participation in the study. WOCBP must use birth control for two weeks prior to the start of the treatment and continue for 6 weeks after the last dose of the study drug. Sexually active male patients must use effective contraception from day 1 of treatment and continue for 4 months after the last dose of the study drug</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Other anticancer agents and investigational agents should not be given while the subject is on study treatment</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Supportive care and other medications that are considered necessary for the subject’s wellbeing may be given at the discretion of the investigator</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>A guidance regarding potential interactions with concomitant medications is provided</li> 												</ul> 						</div> 										 							<h3 class=""printHeading"">Trial Objectives and Outlines</h3> 				<div id=""trialObjectives""><p class='ctrp'>PRIMARY OBJECTIVE:</p><p class='ctrp'>I. To evaluate the best objective response rate of osimertinib (AZD9291) among patients with EGFR exon 20 insertions.</p><p class='ctrp'></p><p class='ctrp'>SECONDARY OBJECTIVES:</p><p class='ctrp'>I. To determine the safety profile of 160 mg once daily (QD) dose of osimertinib (AZD9291) in patients with EGFR Exon 20 insertion mutations. </p><p class='ctrp'>II. To determine the progression-free survival.</p><p class='ctrp'>III. To determine the overall survival.</p><p class='ctrp'></p><p class='ctrp'>TERTIARY OBJECTIVES:</p><p class='ctrp'>I. To characterize molecular markers of response to treatment in circulating tumor deoxyribonucleic acid (DNA).</p><p class='ctrp'>II. To evaluate biomarkers of response to treatment through retrospective analyses of pre-treatment tumor tissue.</p><p class='ctrp'>III. To identify resistance mechanisms to osimertinib (AZD9291) through post-progression tumor biopsies and circulating tumor (ct)DNA.</p><p class='ctrp'></p><p class='ctrp'>OUTLINE:</p><p class='ctrp'>Patients receive osimertinib orally (PO) once daily (QD) on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo echocardiography (ECHO) or multigated acquisition scan (MUGA), magnetic resonance imaging (MRI) or computed tomography (CT) with contrast, and collection of blood samples throughout the trial.</p><p class='ctrp'></p><p class='ctrp'>After completion of study treatment, patients are followed up at 30 days and every 3 months for up to 5 years.</p></div> 			 							<h3 class=""printHeading"">Lead Organization</h3> 									<div>ECOG-ACRIN Cancer Research Group</div> 													<div>Principal Investigator: Zofia Piotrowska</div> 										<h3 class=""printHeading"">Locations & Contacts</h3> 			<div class=""locationNoteBlock""> 				<span>Note:</span> Information about participating sites on pharmaceutical industry trials may be incomplete, so please look up the <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT03191149"" target=""_blank"">NCT number</a> on ClinicalTrials.gov 			</div> 			<div> 								           <h3 class=""locationCountryLabel"">U.S.A.</h3>               <h4>Arkansas</h4>                           <h5 class=""locationCity"">Ft. Smith</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Mercy Hospital Fort Smith</strong>     <br>Contact: Site Public Contact <br>Phone: 800-378-9373   </span> </div>                                       <h5 class=""locationCity"">Little Rock</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">CARTI Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 501-906-4199 <br>Email: <a href=""mailto:Research@CARTI.com"">Research@CARTI.com</a>   </span> </div>                                   <h4>District of Columbia</h4>                           <h5 class=""locationCity"">Washington</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">MedStar Georgetown University Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 202-444-2223   </span> </div>                                   <h4>Florida</h4>                           <h5 class=""locationCity"">Fort Lauderdale</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Holy Cross Hospital</strong>     <br>Contact: Site Public Contact <br>Email: <a href=""mailto:eileen.georgi@holy-cross.com"">eileen.georgi@holy-cross.com</a>   </span> </div>                                   <h4>Georgia</h4>                           <h5 class=""locationCity"">Atlanta</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Emory Saint Joseph's Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 404-851-7115   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Emory University Hospital Midtown</strong>     <br>Contact: Site Public Contact <br>Phone: 888-946-7447   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Emory University Hospital/Winship Cancer Institute</strong>     <br>Contact: Site Public Contact <br>Phone: 404-778-1868   </span> </div>                                   <h4>Idaho</h4>                           <h5 class=""locationCity"">Boise</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Alphonsus Cancer Care Center-Boise</strong>     <br>Contact: Site Public Contact <br>Phone: 734-712-3671 <br>Email: <a href=""mailto:stephanie.couch@stjoeshealth.org"">stephanie.couch@stjoeshealth.org</a>   </span> </div>                                       <h5 class=""locationCity"">Caldwell</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Alphonsus Cancer Care Center-Caldwell</strong>     <br>Contact: Site Public Contact <br>Phone: 734-712-3671 <br>Email: <a href=""mailto:stephanie.couch@stjoeshealth.org"">stephanie.couch@stjoeshealth.org</a>   </span> </div>                                       <h5 class=""locationCity"">Coeur D'Alene</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Kootenai Health - Coeur d'Alene</strong>     <br>Contact: Site Public Contact <br>Phone: 406-969-6060 <br>Email: <a href=""mailto:mccinfo@mtcancer.org"">mccinfo@mtcancer.org</a>   </span> </div>                                       <h5 class=""locationCity"">Emmett</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Walter Knox Memorial Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 734-712-3671 <br>Email: <a href=""mailto:stephanie.couch@stjoeshealth.org"">stephanie.couch@stjoeshealth.org</a>   </span> </div>                                       <h5 class=""locationCity"">Meridian</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Idaho Urologic Institute-Meridian</strong>     <br>Contact: Site Public Contact <br>Phone: 734-712-3671 <br>Email: <a href=""mailto:stephanie.couch@stjoeshealth.org"">stephanie.couch@stjoeshealth.org</a>   </span> </div>                                       <h5 class=""locationCity"">Nampa</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Alphonsus Cancer Care Center-Nampa</strong>     <br>Contact: Site Public Contact <br>Phone: 406-969-6060 <br>Email: <a href=""mailto:mccinfo@mtcancer.org"">mccinfo@mtcancer.org</a>   </span> </div>                                       <h5 class=""locationCity"">Post Falls</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Kootenai Clinic Cancer Services - Post Falls</strong>     <br>Contact: Site Public Contact <br>Phone: 406-969-6060 <br>Email: <a href=""mailto:mccinfo@mtcancer.org"">mccinfo@mtcancer.org</a>   </span> </div>                                       <h5 class=""locationCity"">Sandpoint</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Kootenai Clinic Cancer Services - Sandpoint</strong>     <br>Contact: Site Public Contact <br>Phone: 406-969-6060 <br>Email: <a href=""mailto:mccinfo@mtcancer.org"">mccinfo@mtcancer.org</a>   </span> </div>                                   <h4>Illinois</h4>                           <h5 class=""locationCity"">Alton</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">OSF Saint Anthony's Health Center</strong>     <br>Contact: Site Public Contact <br>Phone: 618-463-5623   </span> </div>                                       <h5 class=""locationCity"">Aurora</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Rush - Copley Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 630-978-6212 <br>Email: <a href=""mailto:Cancer.Research@rushcopley.com"">Cancer.Research@rushcopley.com</a>   </span> </div>                                       <h5 class=""locationCity"">Bloomington</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Illinois CancerCare-Bloomington</strong>     <br>Contact: Site Public Contact <br>Phone: 309-243-3605 <br>Email: <a href=""mailto:andersonj@illinoiscancercare.com"">andersonj@illinoiscancercare.com</a>   </span> </div>                                       <h5 class=""locationCity"">Canton</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Illinois CancerCare-Canton</strong>     <br>Contact: Site Public Contact <br>Phone: 309-243-3605 <br>Email: <a href=""mailto:andersonj@illinoiscancercare.com"">andersonj@illinoiscancercare.com</a>   </span> </div>                                       <h5 class=""locationCity"">Carbondale</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Memorial Hospital of Carbondale</strong>     <br>Contact: Site Public Contact <br>Phone: 618-457-5200 <br>Email: <a href=""mailto:clinical.research@sih.net"">clinical.research@sih.net</a>   </span> </div>                                       <h5 class=""locationCity"">Carterville</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">SIH Cancer Institute</strong>     <br>Contact: Site Public Contact <br>Phone: 618-985-3333 <br>Email: <a href=""mailto:clinical.research@sih.net"">clinical.research@sih.net</a>   </span> </div>                                       <h5 class=""locationCity"">Carthage</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Illinois CancerCare-Carthage</strong>     <br>Contact: Site Public Contact <br>Phone: 309-243-3605 <br>Email: <a href=""mailto:andersonj@illinoiscancercare.com"">andersonj@illinoiscancercare.com</a>   </span> </div>                                       <h5 class=""locationCity"">Centralia</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Centralia Oncology Clinic</strong>     <br>Contact: Site Public Contact <br>Phone: 217-876-4762 <br>Email: <a href=""mailto:morganthaler.jodi@mhsil.com"">morganthaler.jodi@mhsil.com</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Mary's Hospital</strong>     <br>Contact: Site Public Contact <br>Email: <a href=""mailto:ecog.rss@jimmy.harvard.edu"">ecog.rss@jimmy.harvard.edu</a>   </span> </div>                                       <h5 class=""locationCity"">Danville</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Carle at The Riverfront</strong>     <br>Contact: Site Public Contact <br>Phone: 800-446-5532 <br>Email: <a href=""mailto:Research@Carle.com"">Research@Carle.com</a>   </span> </div>                                       <h5 class=""locationCity"">Decatur</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Cancer Care Specialists of Illinois - Decatur</strong>     <br>Contact: Site Public Contact <br>Phone: 217-876-4762 <br>Email: <a href=""mailto:morganthaler.jodi@mhsil.com"">morganthaler.jodi@mhsil.com</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Decatur Memorial Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 217-876-4762 <br>Email: <a href=""mailto:morganthaler.jodi@mhsil.com"">morganthaler.jodi@mhsil.com</a>   </span> </div>                                       <h5 class=""locationCity"">Dixon</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Illinois CancerCare-Dixon</strong>     <br>Contact: Site Public Contact <br>Phone: 815-285-7800   </span> </div>                                       <h5 class=""locationCity"">Effingham</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Carle Physician Group-Effingham</strong>     <br>Contact: Site Public Contact <br>Phone: 800-446-5532 <br>Email: <a href=""mailto:Research@carle.com"">Research@carle.com</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Crossroads Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 217-876-4762 <br>Email: <a href=""mailto:morganthaler.jodi@mhsil.com"">morganthaler.jodi@mhsil.com</a>   </span> </div>                                       <h5 class=""locationCity"">Eureka</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Illinois CancerCare-Eureka</strong>     <br>Contact: Site Public Contact <br>Phone: 309-243-3605 <br>Email: <a href=""mailto:andersonj@illinoiscancercare.com"">andersonj@illinoiscancercare.com</a>   </span> </div>                                       <h5 class=""locationCity"">Galesburg</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Illinois CancerCare-Galesburg</strong>     <br>Contact: Site Public Contact <br>Phone: 309-243-3605 <br>Email: <a href=""mailto:andersonj@illinoiscancercare.com"">andersonj@illinoiscancercare.com</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Western Illinois Cancer Treatment Center</strong>     <br>Contact: Site Public Contact <br>Phone: 309-344-2831   </span> </div>                                       <h5 class=""locationCity"">Kewanee</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Illinois CancerCare-Kewanee Clinic</strong>     <br>Contact: Site Public Contact <br>Phone: 309-243-3605 <br>Email: <a href=""mailto:andersonj@illinoiscancercare.com"">andersonj@illinoiscancercare.com</a>   </span> </div>                                       <h5 class=""locationCity"">Macomb</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Illinois CancerCare-Macomb</strong>     <br>Contact: Site Public Contact <br>Phone: 309-243-3605 <br>Email: <a href=""mailto:andersonj@illinoiscancercare.com"">andersonj@illinoiscancercare.com</a>   </span> </div>                                       <h5 class=""locationCity"">Mattoon</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Carle Physician Group-Mattoon/Charleston</strong>     <br>Contact: Site Public Contact <br>Phone: 800-446-5532 <br>Email: <a href=""mailto:Research@carle.com"">Research@carle.com</a>   </span> </div>                                       <h5 class=""locationCity"">Mount Vernon</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Good Samaritan Regional Health Center</strong>     <br>Contact: Site Public Contact <br>Phone: 618-242-4600   </span> </div>                                       <h5 class=""locationCity"">O'Fallon</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Cancer Care Center of O'Fallon</strong>     <br>Contact: Site Public Contact <br>Phone: 217-876-4762 <br>Email: <a href=""mailto:morganthaler.jodi@mhsil.com"">morganthaler.jodi@mhsil.com</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">HSHS Saint Elizabeth's Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 217-876-4762 <br>Email: <a href=""mailto:morganthaler.jodi@mhsil.com"">morganthaler.jodi@mhsil.com</a>   </span> </div>                                       <h5 class=""locationCity"">Ottawa</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Illinois CancerCare-Ottawa Clinic</strong>     <br>Contact: Site Public Contact <br>Phone: 309-243-3605 <br>Email: <a href=""mailto:andersonj@illinoiscancercare.com"">andersonj@illinoiscancercare.com</a>   </span> </div>                                       <h5 class=""locationCity"">Pekin</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Illinois CancerCare-Pekin</strong>     <br>Contact: Site Public Contact <br>Phone: 309-243-3605 <br>Email: <a href=""mailto:andersonj@illinoiscancercare.com"">andersonj@illinoiscancercare.com</a>   </span> </div>                                       <h5 class=""locationCity"">Peoria</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Illinois CancerCare-Peoria</strong>     <br>Contact: Site Public Contact <br>Phone: 309-243-3605 <br>Email: <a href=""mailto:andersonj@illinoiscancercare.com"">andersonj@illinoiscancercare.com</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Methodist Medical Center of Illinois</strong>     <br>Contact: Site Public Contact <br>Phone: 309-243-3605 <br>Email: <a href=""mailto:andersonj@illinoiscancercare.com"">andersonj@illinoiscancercare.com</a>   </span> </div>                                       <h5 class=""locationCity"">Peru</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Illinois CancerCare-Peru</strong>     <br>Contact: Site Public Contact <br>Phone: 309-243-3605 <br>Email: <a href=""mailto:andersonj@illinoiscancercare.com"">andersonj@illinoiscancercare.com</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Valley Radiation Oncology</strong>     <br>Contact: Site Public Contact <br>Phone: 815-664-4141   </span> </div>                                       <h5 class=""locationCity"">Princeton</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Illinois CancerCare-Princeton</strong>     <br>Contact: Site Public Contact <br>Phone: 309-243-3605 <br>Email: <a href=""mailto:andersonj@illinoiscancercare.com"">andersonj@illinoiscancercare.com</a>   </span> </div>                                       <h5 class=""locationCity"">Springfield</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Southern Illinois University School of Medicine</strong>     <br>Contact: Site Public Contact <br>Phone: 217-545-7929   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Springfield Clinic</strong>     <br>Contact: Site Public Contact <br>Phone: 800-444-7541   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Springfield Memorial Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 217-528-7541 <br>Email: <a href=""mailto:pallante.beth@mhsil.com"">pallante.beth@mhsil.com</a>   </span> </div>                                       <h5 class=""locationCity"">Swansea</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Southwest Illinois Health Services LLP</strong>     <br>Contact: Site Public Contact <br>Phone: 618-236-1000 <br>Email: <a href=""mailto:lynns@thecancercenter.com"">lynns@thecancercenter.com</a>   </span> </div>                                       <h5 class=""locationCity"">Urbana</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Carle Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 800-446-5532 <br>Email: <a href=""mailto:Research@carle.com"">Research@carle.com</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">The Carle Foundation Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 800-446-5532 <br>Email: <a href=""mailto:Research@carle.com"">Research@carle.com</a>   </span> </div>                                       <h5 class=""locationCity"">Washington</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Illinois CancerCare - Washington</strong>     <br>Contact: Site Public Contact <br>Phone: 309-243-3605 <br>Email: <a href=""mailto:andersonj@illinoiscancercare.com"">andersonj@illinoiscancercare.com</a>   </span> </div>                                       <h5 class=""locationCity"">Yorkville</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Rush-Copley Healthcare Center</strong>     <br>Contact: Site Public Contact <br>Phone: 630-978-6212 <br>Email: <a href=""mailto:Cancer.Research@rushcopley.com"">Cancer.Research@rushcopley.com</a>   </span> </div>                                       <h5 class=""locationCity"">Zion</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Midwestern Regional Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 844-793-0745   </span> </div>                                   <h4>Iowa</h4>                           <h5 class=""locationCity"">Council Bluffs</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Heartland Oncology and Hematology LLP</strong>     <br>Contact: Site Public Contact <br>Phone: 712-322-4136   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Methodist Jennie Edmundson Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 402-354-7939 <br>Email: <a href=""mailto:kathryn.bartz@nmhs.org"">kathryn.bartz@nmhs.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Nebraska Cancer Specialists/Oncology Hematology West PC - MEJ</strong>     <br>Contact: Site Public Contact <br>Phone: 402-354-5892 <br>Email: <a href=""mailto:Liza.brandes@nmhs.org"">Liza.brandes@nmhs.org</a>   </span> </div>                                   <h4>Kansas</h4>                           <h5 class=""locationCity"">Garden City</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Central Care Cancer Center - Garden City</strong>     <br>Contact: Site Public Contact <br>Phone: 913-948-5588 <br>Email: <a href=""mailto:aroland@kccop.org"">aroland@kccop.org</a>   </span> </div>                                       <h5 class=""locationCity"">Great Bend</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Central Care Cancer Center - Great Bend</strong>     <br>Contact: Site Public Contact <br>Phone: 913-948-5588 <br>Email: <a href=""mailto:aroland@kccop.org"">aroland@kccop.org</a>   </span> </div>                                   <h4>Massachusetts</h4>                           <h5 class=""locationCity"">Boston</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Beth Israel Deaconess Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 617-667-9925   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Brigham and Women's Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 617-724-5200   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Dana-Farber Cancer Institute</strong>     <br>Contact: Site Public Contact <br>Phone: 877-442-3324   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Massachusetts General Hospital Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 877-726-5130   </span> </div>                                       <h5 class=""locationCity"">Springfield</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Mercy Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 413-748-9234   </span> </div>                                   <h4>Michigan</h4>                           <h5 class=""locationCity"">Ann Arbor</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Trinity Health Saint Joseph Mercy Hospital Ann Arbor</strong>     <br>Contact: Site Public Contact <br>Phone: 734-712-7251 <br>Email: <a href=""mailto:MCRCwebsitecontactform@stjoeshealth.org"">MCRCwebsitecontactform@stjoeshealth.org</a>   </span> </div>                                       <h5 class=""locationCity"">Battle Creek</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Bronson Battle Creek</strong>     <br>Contact: Site Public Contact <br>Phone: 616-391-1230 <br>Email: <a href=""mailto:crcwm-regulatory@crcwm.org"">crcwm-regulatory@crcwm.org</a>   </span> </div>                                       <h5 class=""locationCity"">Brighton</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Trinity Health  IHA Medical Group Hematology Oncology - Brighton</strong>     <br>Contact: Site Public Contact <br>Phone: 734-712-7251 <br>Email: <a href=""mailto:MCRCwebsitecontactform@stjoeshealth.org"">MCRCwebsitecontactform@stjoeshealth.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Trinity Health Medical Center - Brighton</strong>     <br>Contact: Site Public Contact <br>Phone: 734-712-7251 <br>Email: <a href=""mailto:MCRCwebsitecontactform@stjoeshealth.org"">MCRCwebsitecontactform@stjoeshealth.org</a>   </span> </div>                                       <h5 class=""locationCity"">Canton</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Trinity Health  IHA Medical Group Hematology Oncology - Canton</strong>     <br>Contact: Site Public Contact <br>Phone: 734-712-7251 <br>Email: <a href=""mailto:MCRCwebsitecontactform@stjoeshealth.org"">MCRCwebsitecontactform@stjoeshealth.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Trinity Health Medical Center - Canton</strong>     <br>Contact: Site Public Contact <br>Phone: 734-712-7251 <br>Email: <a href=""mailto:MCRCwebsitecontactform@stjoeshealth.org"">MCRCwebsitecontactform@stjoeshealth.org</a>   </span> </div>                                       <h5 class=""locationCity"">Caro</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Caro Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 989-907-8411 <br>Email: <a href=""mailto:lori.srebinski@ascension.org"">lori.srebinski@ascension.org</a>   </span> </div>                                       <h5 class=""locationCity"">Chelsea</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Chelsea Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 734-712-7251 <br>Email: <a href=""mailto:MCRCwebsitecontactform@stjoeshealth.org"">MCRCwebsitecontactform@stjoeshealth.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Trinity Health  IHA Medical Group Hematology Oncology - Chelsea Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 734-712-7251 <br>Email: <a href=""mailto:MCRCwebsitecontactform@stjoeshealth.org"">MCRCwebsitecontactform@stjoeshealth.org</a>   </span> </div>                                       <h5 class=""locationCity"">Clarkston</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Hematology Oncology Consultants-Clarkston</strong>     <br>Contact: Site Public Contact <br>Phone: 734-712-7251 <br>Email: <a href=""mailto:MCRCwebsitecontactform@stjoeshealth.org"">MCRCwebsitecontactform@stjoeshealth.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Newland Medical Associates-Clarkston</strong>     <br>Contact: Site Public Contact <br>Phone: 734-712-7251 <br>Email: <a href=""mailto:MCRCwebsitecontactform@stjoeshealth.org"">MCRCwebsitecontactform@stjoeshealth.org</a>   </span> </div>                                       <h5 class=""locationCity"">Detroit</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Henry Ford Health Saint John Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 313-343-3166 <br>Email: <a href=""mailto:Kkeenan1@hfhs.org"">Kkeenan1@hfhs.org</a>   </span> </div>                                       <h5 class=""locationCity"">East China</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Henry Ford River District Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 313-343-3166 <br>Email: <a href=""mailto:kforman1@hfhs.org"">kforman1@hfhs.org</a>   </span> </div>                                       <h5 class=""locationCity"">Flint</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Genesee Cancer and Blood Disease Treatment Center</strong>     <br>Contact: Site Public Contact <br>Phone: 810-762-8038 <br>Email: <a href=""mailto:wstrong@ghci.org"">wstrong@ghci.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Genesee Hematology Oncology PC</strong>     <br>Contact: Site Public Contact <br>Phone: 810-762-8038 <br>Email: <a href=""mailto:wstrong@ghci.org"">wstrong@ghci.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Genesys Hurley Cancer Institute</strong>     <br>Contact: Site Public Contact <br>Phone: 810-762-8038 <br>Email: <a href=""mailto:wstrong@ghci.org"">wstrong@ghci.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Hurley Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 810-762-8038 <br>Email: <a href=""mailto:wstrong@ghci.org"">wstrong@ghci.org</a>   </span> </div>                                       <h5 class=""locationCity"">Grand Rapids</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Corewell Health Grand Rapids Hospitals - Butterworth Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 616-391-1230 <br>Email: <a href=""mailto:crcwm-regulatory@crcwm.org"">crcwm-regulatory@crcwm.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 616-267-1925 <br>Email: <a href=""mailto:crcwm-regulatory@crcwm.org"">crcwm-regulatory@crcwm.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Trinity Health Grand Rapids Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 616-391-1230 <br>Email: <a href=""mailto:crcwm-regulatory@crcwm.org"">crcwm-regulatory@crcwm.org</a>   </span> </div>                                       <h5 class=""locationCity"">Grosse Pointe Woods</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Great Lakes Cancer Management Specialists-Van Elslander Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 313-343-3166 <br>Email: <a href=""mailto:kforman1@hfhs.org"">kforman1@hfhs.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Henry Ford Saint John Hospital - Academic</strong>     <br>Contact: Site Public Contact <br>Phone: 313-343-3166 <br>Email: <a href=""mailto:kforman1@hfhs.org"">kforman1@hfhs.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Henry Ford Saint John Hospital - Breast</strong>     <br>Contact: Site Public Contact <br>Phone: 313-343-3166 <br>Email: <a href=""mailto:karen.forman@ascension.org"">karen.forman@ascension.org</a>   </span> </div>                                       <h5 class=""locationCity"">Kalamazoo</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Ascension Borgess Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 616-391-1230 <br>Email: <a href=""mailto:crcwm-regulatory@crcwm.org"">crcwm-regulatory@crcwm.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Ascension Borgess Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 616-391-1230 <br>Email: <a href=""mailto:crcwm-regulatory@crcwm.org"">crcwm-regulatory@crcwm.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Bronson Methodist Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 616-391-1230 <br>Email: <a href=""mailto:crcwm-regulatory@crcwm.org"">crcwm-regulatory@crcwm.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">West Michigan Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 616-391-1230 <br>Email: <a href=""mailto:crcwm-regulatory@crcwm.org"">crcwm-regulatory@crcwm.org</a>   </span> </div>                                       <h5 class=""locationCity"">Lansing</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">University of Michigan Health - Sparrow Lansing</strong>     <br>Contact: Site Public Contact <br>Phone: 517-364-3712 <br>Email: <a href=""mailto:harsha.trivedi@umhsparrow.org"">harsha.trivedi@umhsparrow.org</a>   </span> </div>                                       <h5 class=""locationCity"">Livonia</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Hope Cancer Clinic</strong>     <br>Contact: Site Public Contact <br>Phone: 734-712-3671 <br>Email: <a href=""mailto:stephanie.couch@stjoeshealth.org"">stephanie.couch@stjoeshealth.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Trinity Health Saint Mary Mercy Livonia Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 734-712-7251 <br>Email: <a href=""mailto:MCRCwebsitecontactform@stjoeshealth.org"">MCRCwebsitecontactform@stjoeshealth.org</a>   </span> </div>                                       <h5 class=""locationCity"">Macomb Township</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Henry Ford Saint John Hospital - Macomb Medical</strong>     <br>Contact: Site Public Contact <br>Phone: 313-343-3166 <br>Email: <a href=""mailto:kforman1@hfhs.org"">kforman1@hfhs.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Henry Ford Warren Hospital - Breast Macomb</strong>     <br>Contact: Site Public Contact <br>Phone: 313-343-3166 <br>Email: <a href=""mailto:kforman1@hfhs.org"">kforman1@hfhs.org</a>   </span> </div>                                       <h5 class=""locationCity"">Marlette</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Mary's Oncology/Hematology Associates of Marlette</strong>     <br>Contact: Site Public Contact <br>Phone: 989-907-8411 <br>Email: <a href=""mailto:lori.srebinski@ascension.org"">lori.srebinski@ascension.org</a>   </span> </div>                                       <h5 class=""locationCity"">Muskegon</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Trinity Health Muskegon Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 616-391-1230 <br>Email: <a href=""mailto:crcwm-regulatory@crcwm.org"">crcwm-regulatory@crcwm.org</a>   </span> </div>                                       <h5 class=""locationCity"">Niles</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Corewell Health Lakeland Hospitals - Niles Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 616-391-1230   </span> </div>                                       <h5 class=""locationCity"">Norton Shores</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Cancer and Hematology Centers of Western Michigan - Norton Shores</strong>     <br>Contact: Site Public Contact <br>Phone: 616-391-1230 <br>Email: <a href=""mailto:connie.szczepanek@crcwm.org"">connie.szczepanek@crcwm.org</a>   </span> </div>                                       <h5 class=""locationCity"">Novi</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Henry Ford Health Providence Novi Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 248-849-5332 <br>Email: <a href=""mailto:kfife3@hfhs.org"">kfife3@hfhs.org</a>   </span> </div>                                       <h5 class=""locationCity"">Pontiac</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Hope Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 734-712-7251 <br>Email: <a href=""mailto:MCRCwebsitecontactform@stjoeshealth.org"">MCRCwebsitecontactform@stjoeshealth.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Michigan Healthcare Professionals Pontiac</strong>     <br>Contact: Site Public Contact <br>Phone: 248-858-6215 <br>Email: <a href=""mailto:Emily.Crofts@trinity-health.org"">Emily.Crofts@trinity-health.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Newland Medical Associates-Pontiac</strong>     <br>Contact: Site Public Contact <br>Phone: 734-712-7251 <br>Email: <a href=""mailto:MCRCwebsitecontactform@stjoeshealth.org"">MCRCwebsitecontactform@stjoeshealth.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Trinity Health Saint Joseph Mercy Oakland Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 734-712-7251 <br>Email: <a href=""mailto:MCRCwebsitecontactform@stjoeshealth.org"">MCRCwebsitecontactform@stjoeshealth.org</a>   </span> </div>                                       <h5 class=""locationCity"">Reed City</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Corewell Health Reed City Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 616-391-1230 <br>Email: <a href=""mailto:crcwm-regulatory@crcwm.org"">crcwm-regulatory@crcwm.org</a>   </span> </div>                                       <h5 class=""locationCity"">Rochester Hills</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Great Lakes Cancer Management Specialists-Rochester Hills</strong>     <br>Contact: Site Public Contact <br>Phone: 734-712-3671 <br>Email: <a href=""mailto:stephanie.couch@stjoeshealth.org"">stephanie.couch@stjoeshealth.org</a>   </span> </div>                                       <h5 class=""locationCity"">Saginaw</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">MyMichigan Medical Center Saginaw</strong>     <br>Contact: Site Public Contact <br>Phone: 734-712-7251 <br>Email: <a href=""mailto:MCRCwebsitecontactform@stjoeshealth.org"">MCRCwebsitecontactform@stjoeshealth.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Oncology Hematology Associates of Saginaw Valley PC</strong>     <br>Contact: Site Public Contact <br>Phone: 989-907-8411 <br>Email: <a href=""mailto:lori.srebinski@ascension.org"">lori.srebinski@ascension.org</a>   </span> </div>                                       <h5 class=""locationCity"">Saint Joseph</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 616-391-1230 <br>Email: <a href=""mailto:crcwm-regulatory@crcwm.org"">crcwm-regulatory@crcwm.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Corewell Health Lakeland Hospitals - Saint Joseph Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 616-391-1230 <br>Email: <a href=""mailto:crcwm-regulatory@crcwm.org"">crcwm-regulatory@crcwm.org</a>   </span> </div>                                       <h5 class=""locationCity"">Southfield</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Henry Ford Health Providence Southfield Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 248-849-5332 <br>Email: <a href=""mailto:kfife3@hfhs.org"">kfife3@hfhs.org</a>   </span> </div>                                       <h5 class=""locationCity"">Sterling Heights</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Bhadresh Nayak MD PC-Sterling Heights</strong>     <br>Contact: Site Public Contact <br>Phone: 313-343-3166 <br>Email: <a href=""mailto:karen.forman@ascension.org"">karen.forman@ascension.org</a>   </span> </div>                                       <h5 class=""locationCity"">Tawas City</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">MyMichigan Medical Center Tawas</strong>     <br>Contact: Site Public Contact <br>Phone: 734-712-7251 <br>Email: <a href=""mailto:MCRCwebsitecontactform@stjoeshealth.org"">MCRCwebsitecontactform@stjoeshealth.org</a>   </span> </div>                                       <h5 class=""locationCity"">Traverse City</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Munson Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 616-391-1230 <br>Email: <a href=""mailto:crcwm-regulatory@crcwm.org"">crcwm-regulatory@crcwm.org</a>   </span> </div>                                       <h5 class=""locationCity"">Warren</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Advanced Breast Care Center PLLC</strong>     <br>Contact: Site Public Contact <br>Phone: 313-343-3166 <br>Email: <a href=""mailto:karen.forman@ascension.org"">karen.forman@ascension.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Henry Ford Health Warren Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 313-343-3166 <br>Email: <a href=""mailto:kforman1@hfhs.org"">kforman1@hfhs.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Henry Ford Madison Heights Hospital - Breast</strong>     <br>Contact: Site Public Contact <br>Phone: 313-343-3166 <br>Email: <a href=""mailto:kforman1@hfhs.org"">kforman1@hfhs.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Henry Ford Warren Hospital - GLCMS</strong>     <br>Contact: Site Public Contact <br>Phone: 313-343-3166 <br>Email: <a href=""mailto:kforman1@hfhs.org"">kforman1@hfhs.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Macomb Hematology Oncology PC</strong>     <br>Contact: Site Public Contact <br>Phone: 313-343-3166 <br>Email: <a href=""mailto:karen.forman@ascension.org"">karen.forman@ascension.org</a>   </span> </div>                                       <h5 class=""locationCity"">West Branch</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Mary's Oncology/Hematology Associates of West Branch</strong>     <br>Contact: Site Public Contact <br>Phone: 989-907-8411 <br>Email: <a href=""mailto:lori.srebinski@ascension.org"">lori.srebinski@ascension.org</a>   </span> </div>                                       <h5 class=""locationCity"">Wyoming</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">University of Michigan Health - West</strong>     <br>Contact: Site Public Contact <br>Phone: 616-391-1230 <br>Email: <a href=""mailto:crcwm-regulatory@crcwm.org"">crcwm-regulatory@crcwm.org</a>   </span> </div>                                       <h5 class=""locationCity"">Ypsilanti</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Huron Gastroenterology PC</strong>     <br>Contact: Site Public Contact <br>Phone: 734-712-7251 <br>Email: <a href=""mailto:MCRCwebsitecontactform@stjoeshealth.org"">MCRCwebsitecontactform@stjoeshealth.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Trinity Health  IHA Medical Group Hematology Oncology  Ann Arbor Campus</strong>     <br>Contact: Site Public Contact <br>Phone: 734-712-7251 <br>Email: <a href=""mailto:MCRCwebsitecontactform@stjoeshealth.org"">MCRCwebsitecontactform@stjoeshealth.org</a>   </span> </div>                                   <h4>Minnesota</h4>                           <h5 class=""locationCity"">Burnsville</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Fairview Ridges Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 952-993-1517 <br>Email: <a href=""mailto:mmcorc@healthpartners.com"">mmcorc@healthpartners.com</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Minnesota Oncology - Burnsville</strong>     <br>Contact: Site Public Contact <br>Phone: 952-993-1517 <br>Email: <a href=""mailto:mmcorc@healthpartners.com"">mmcorc@healthpartners.com</a>   </span> </div>                                       <h5 class=""locationCity"">Cambridge</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Cambridge Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 952-993-1517 <br>Email: <a href=""mailto:mmcorc@healthpartners.com"">mmcorc@healthpartners.com</a>   </span> </div>                                       <h5 class=""locationCity"">Coon Rapids</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Mercy Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 952-993-1517 <br>Email: <a href=""mailto:mmcorc@healthpartners.com"">mmcorc@healthpartners.com</a>   </span> </div>                                       <h5 class=""locationCity"">Edina</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Fairview Southdale Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 952-993-1517 <br>Email: <a href=""mailto:mmcorc@healthpartners.com"">mmcorc@healthpartners.com</a>   </span> </div>                                       <h5 class=""locationCity"">Maple Grove</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Fairview Clinics and Surgery Center Maple Grove</strong>     <br>Contact: Site Public Contact <br>Phone: 952-993-1517 <br>Email: <a href=""mailto:mmcorc@healthpartners.com"">mmcorc@healthpartners.com</a>   </span> </div>                                       <h5 class=""locationCity"">Maplewood</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Minnesota Oncology Hematology PA-Maplewood</strong>     <br>Contact: Site Public Contact <br>Phone: 952-993-1517 <br>Email: <a href=""mailto:mmcorc@healthpartners.com"">mmcorc@healthpartners.com</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint John's Hospital - Healtheast</strong>     <br>Contact: Site Public Contact <br>Phone: 952-993-1517 <br>Email: <a href=""mailto:mmcorc@healthpartners.com"">mmcorc@healthpartners.com</a>   </span> </div>                                       <h5 class=""locationCity"">Minneapolis</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Abbott-Northwestern Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 952-993-1517 <br>Email: <a href=""mailto:mmcorc@healthpartners.com"">mmcorc@healthpartners.com</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Health Partners Inc</strong>     <br>Contact: Site Public Contact <br>Phone: 952-993-1517 <br>Email: <a href=""mailto:mmcorc@healthpartners.com"">mmcorc@healthpartners.com</a>   </span> </div>                                       <h5 class=""locationCity"">Monticello</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Monticello Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 952-993-1517 <br>Email: <a href=""mailto:mmcorc@healthpartners.com"">mmcorc@healthpartners.com</a>   </span> </div>                                       <h5 class=""locationCity"">New Ulm</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">New Ulm Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 952-993-1517 <br>Email: <a href=""mailto:mmcorc@healthpartners.com"">mmcorc@healthpartners.com</a>   </span> </div>                                       <h5 class=""locationCity"">Princeton</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Fairview Northland Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 952-993-1517 <br>Email: <a href=""mailto:mmcorc@healthpartners.com"">mmcorc@healthpartners.com</a>   </span> </div>                                       <h5 class=""locationCity"">Robbinsdale</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">North Memorial Medical Health Center</strong>     <br>Contact: Site Public Contact <br>Phone: 952-993-1517 <br>Email: <a href=""mailto:mmcorc@healthpartners.com"">mmcorc@healthpartners.com</a>   </span> </div>                                       <h5 class=""locationCity"">Saint Louis Park</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Park Nicollet Clinic - Saint Louis Park</strong>     <br>Contact: Site Public Contact <br>Phone: 952-993-1517 <br>Email: <a href=""mailto:mmcorc@healthpartners.com"">mmcorc@healthpartners.com</a>   </span> </div>                                       <h5 class=""locationCity"">Saint Paul</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Regions Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 952-993-1517 <br>Email: <a href=""mailto:mmcorc@healthpartners.com"">mmcorc@healthpartners.com</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">United Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 952-993-1517 <br>Email: <a href=""mailto:mmcorc@healthpartners.com"">mmcorc@healthpartners.com</a>   </span> </div>                                       <h5 class=""locationCity"">Shakopee</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Francis Regional Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 952-993-1517 <br>Email: <a href=""mailto:mmcorc@healthpartners.com"">mmcorc@healthpartners.com</a>   </span> </div>                                       <h5 class=""locationCity"">Stillwater</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Lakeview Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 952-993-1517 <br>Email: <a href=""mailto:mmcorc@healthpartners.com"">mmcorc@healthpartners.com</a>   </span> </div>                                       <h5 class=""locationCity"">Waconia</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Ridgeview Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 952-993-1517 <br>Email: <a href=""mailto:mmcorc@healthpartners.com"">mmcorc@healthpartners.com</a>   </span> </div>                                       <h5 class=""locationCity"">Willmar</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Rice Memorial Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 952-993-1517 <br>Email: <a href=""mailto:mmcorc@healthpartners.com"">mmcorc@healthpartners.com</a>   </span> </div>                                       <h5 class=""locationCity"">Woodbury</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Minnesota Oncology Hematology PA-Woodbury</strong>     <br>Contact: Site Public Contact <br>Phone: 952-993-1517 <br>Email: <a href=""mailto:mmcorc@healthpartners.com"">mmcorc@healthpartners.com</a>   </span> </div>                                       <h5 class=""locationCity"">Wyoming</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Fairview Lakes Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 952-993-1517 <br>Email: <a href=""mailto:mmcorc@healthpartners.com"">mmcorc@healthpartners.com</a>   </span> </div>                                   <h4>Missouri</h4>                           <h5 class=""locationCity"">Ballwin</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Louis Cancer and Breast Institute-Ballwin</strong>     <br>Contact: Site Public Contact <br>Phone: 314-251-7058   </span> </div>                                       <h5 class=""locationCity"">Bolivar</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Central Care Cancer Center - Bolivar</strong>     <br>Contact: Site Public Contact <br>Phone: 913-948-5588 <br>Email: <a href=""mailto:aroland@kccop.org"">aroland@kccop.org</a>   </span> </div>                                       <h5 class=""locationCity"">Bonne Terre</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Parkland Health Center-Bonne Terre</strong>     <br>Contact: Site Public Contact <br>Phone: 314-996-5569   </span> </div>                                       <h5 class=""locationCity"">Branson</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Cox Cancer Center Branson</strong>     <br>Contact: Site Public Contact <br>Phone: 417-269-4520   </span> </div>                                       <h5 class=""locationCity"">Cape Girardeau</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Francis Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 573-334-2230 <br>Email: <a href=""mailto:sfmc@sfmc.net"">sfmc@sfmc.net</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Southeast Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 573-651-5550   </span> </div>                                       <h5 class=""locationCity"">Farmington</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Parkland Health Center - Farmington</strong>     <br>Contact: Site Public Contact <br>Phone: 314-996-5569   </span> </div>                                       <h5 class=""locationCity"">Jefferson City</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">MU Health Care Goldschmidt Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 573-632-4851 <br>Email: <a href=""mailto:amy.franken@health.missouri.edu"">amy.franken@health.missouri.edu</a>   </span> </div>                                       <h5 class=""locationCity"">Joplin</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Freeman Health System</strong>     <br>Contact: Site Public Contact <br>Phone: 417-347-4030 <br>Email: <a href=""mailto:LJCrockett@freemanhealth.com"">LJCrockett@freemanhealth.com</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Mercy Hospital Joplin</strong>     <br>Contact: Site Public Contact <br>Phone: 417-556-3074 <br>Email: <a href=""mailto:esmeralda.carrillo@mercy.net"">esmeralda.carrillo@mercy.net</a>   </span> </div>                                       <h5 class=""locationCity"">Osage Beach</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Lake Regional Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 573-302-2768 <br>Email: <a href=""mailto:clinicaltrials@lakeregional.com"">clinicaltrials@lakeregional.com</a>   </span> </div>                                       <h5 class=""locationCity"">Rolla</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Delbert Day Cancer Institute at PCRMC</strong>     <br>Contact: Site Public Contact <br>Phone: 573-458-7504 <br>Email: <a href=""mailto:research@phelpshealth.org"">research@phelpshealth.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Mercy Clinic-Rolla-Cancer and Hematology</strong>     <br>Contact: Site Public Contact <br>Phone: 573-458-6379   </span> </div>                                       <h5 class=""locationCity"">Saint Joseph</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Heartland Regional Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 816-271-7937 <br>Email: <a href=""mailto:Trisha.England2@mymlc.com"">Trisha.England2@mymlc.com</a>   </span> </div>                                       <h5 class=""locationCity"">Saint Louis</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Mercy Hospital Saint Louis</strong>     <br>Contact: Site Public Contact <br>Phone: 314-251-7066   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Mercy Hospital South</strong>     <br>Contact: Site Public Contact <br>Phone: 314-525-6042 <br>Email: <a href=""mailto:Danielle.Werle@mercy.net"">Danielle.Werle@mercy.net</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Missouri Baptist Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 314-996-5569   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Louis Cancer and Breast Institute-South City</strong>     <br>Contact: Site Public Contact <br>Phone: 314-353-1870   </span> </div>                                       <h5 class=""locationCity"">Sainte Genevieve</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Sainte Genevieve County Memorial Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 314-996-5569   </span> </div>                                       <h5 class=""locationCity"">Springfield</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">CoxHealth South Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 417-269-4520   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Mercy Hospital Springfield</strong>     <br>Contact: Site Public Contact <br>Phone: 417-269-4520   </span> </div>                                       <h5 class=""locationCity"">Sullivan</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Missouri Baptist Sullivan Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 314-996-5569   </span> </div>                                       <h5 class=""locationCity"">Sunset Hills</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">BJC Outpatient Center at Sunset Hills</strong>     <br>Contact: Site Public Contact <br>Phone: 314-996-5569   </span> </div>                                       <h5 class=""locationCity"">Washington</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Mercy Hospital Washington</strong>     <br>Contact: Site Public Contact <br>Phone: 636-390-1600   </span> </div>                                   <h4>Montana</h4>                           <h5 class=""locationCity"">Anaconda</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Community Hospital of Anaconda</strong>     <br>Contact: Site Public Contact <br>Phone: 406-969-6060 <br>Email: <a href=""mailto:mccinfo@mtcancer.org"">mccinfo@mtcancer.org</a>   </span> </div>                                       <h5 class=""locationCity"">Billings</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Billings Clinic Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 800-996-2663 <br>Email: <a href=""mailto:research@billingsclinic.org"">research@billingsclinic.org</a>   </span> </div>                                       <h5 class=""locationCity"">Bozeman</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Bozeman Health Deaconess Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 406-969-6060 <br>Email: <a href=""mailto:mccinfo@mtcancer.org"">mccinfo@mtcancer.org</a>   </span> </div>                                       <h5 class=""locationCity"">Great Falls</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Benefis Sletten Cancer Institute</strong>     <br>Contact: Site Public Contact <br>Phone: 406-969-6060 <br>Email: <a href=""mailto:mccinfo@mtcancer.org"">mccinfo@mtcancer.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Great Falls Clinic</strong>     <br>Contact: Site Public Contact <br>Phone: 406-969-6060 <br>Email: <a href=""mailto:mccinfo@mtcancer.org"">mccinfo@mtcancer.org</a>   </span> </div>                                       <h5 class=""locationCity"">Helena</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Peter's Community Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 406-969-6060 <br>Email: <a href=""mailto:mccinfo@mtcancer.org"">mccinfo@mtcancer.org</a>   </span> </div>                                       <h5 class=""locationCity"">Kalispell</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Logan Health Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 406-969-6060 <br>Email: <a href=""mailto:mccinfo@mtcancer.org"">mccinfo@mtcancer.org</a>   </span> </div>                                       <h5 class=""locationCity"">Missoula</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Community Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 406-969-6060 <br>Email: <a href=""mailto:mccinfo@mtcancer.org"">mccinfo@mtcancer.org</a>   </span> </div>                                   <h4>Nebraska</h4>                           <h5 class=""locationCity"">Omaha</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Nebraska Cancer Specialists/Oncology Hematology West PC - MECC</strong>     <br>Contact: Site Public Contact <br>Phone: 402-334-4773   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Nebraska Methodist Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 402-354-5144   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Oncology Associates PC</strong>     <br>Contact: Site Public Contact <br>Phone: 402-354-5860 <br>Email: <a href=""mailto:info@oa-oc.com"">info@oa-oc.com</a>   </span> </div>                                   <h4>New York</h4>                           <h5 class=""locationCity"">Middletown</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Garnet Health Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 845-333-1133 <br>Email: <a href=""mailto:jgerlach@garnethealth.org"">jgerlach@garnethealth.org</a>   </span> </div>                                   <h4>Ohio</h4>                           <h5 class=""locationCity"">Dayton</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Good Samaritan Hospital - Dayton</strong>     <br>Contact: Site Public Contact <br>Phone: 937-416-9270 <br>Email: <a href=""mailto:clinical.trials@daytonncorp.org"">clinical.trials@daytonncorp.org</a>   </span> </div>                                   <h4>Oklahoma</h4>                           <h5 class=""locationCity"">Oklahoma City</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Mercy Hospital Oklahoma City</strong>     <br>Contact: Site Public Contact <br>Phone: 405-752-3402   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">University of Oklahoma Health Sciences Center</strong>     <br>Contact: Site Public Contact <br>Phone: 405-271-8777 <br>Email: <a href=""mailto:ou-clinical-trials@ouhsc.edu"">ou-clinical-trials@ouhsc.edu</a>   </span> </div>                                   <h4>Oregon</h4>                           <h5 class=""locationCity"">Baker City</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Alphonsus Cancer Care Center-Baker City</strong>     <br>Contact: Site Public Contact <br>Phone: 406-969-6060 <br>Email: <a href=""mailto:mccinfo@mtcancer.org"">mccinfo@mtcancer.org</a>   </span> </div>                                       <h5 class=""locationCity"">Corvallis</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Good Samaritan Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 541-768-4352 <br>Email: <a href=""mailto:stmock@samhealth.org"">stmock@samhealth.org</a>   </span> </div>                                       <h5 class=""locationCity"">Ontario</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Saint Alphonsus Cancer Care Center-Ontario</strong>     <br>Contact: Site Public Contact <br>Phone: 406-969-6060 <br>Email: <a href=""mailto:mccinfo@mtcancer.org"">mccinfo@mtcancer.org</a>   </span> </div>                                   <h4>Pennsylvania</h4>                           <h5 class=""locationCity"">Allentown</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Lehigh Valley Hospital-Cedar Crest</strong>     <br>Contact: Site Public Contact <br>Phone: 610-402-9543 <br>Email: <a href=""mailto:Morgan_M.Horton@lvhn.org"">Morgan_M.Horton@lvhn.org</a>   </span> </div>                                       <h5 class=""locationCity"">Bethlehem</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Lehigh Valley Hospital - Muhlenberg</strong>     <br>Contact: Site Public Contact <br>Phone: 610-402-9543 <br>Email: <a href=""mailto:Morgan_M.Horton@lvhn.org"">Morgan_M.Horton@lvhn.org</a>   </span> </div>                                       <h5 class=""locationCity"">Bryn Mawr</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Bryn Mawr Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 484-476-2649 <br>Email: <a href=""mailto:turzoe@mlhs.org"">turzoe@mlhs.org</a>   </span> </div>                                       <h5 class=""locationCity"">Collegeville</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Main Line Health Center-Collegeville</strong>     <br>Contact: Site Public Contact <br>Phone: 484-476-2649 <br>Email: <a href=""mailto:turzoe@mlhs.org"">turzoe@mlhs.org</a>   </span> </div>                                       <h5 class=""locationCity"">East Stroudsburg</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Pocono Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 610-402-9543 <br>Email: <a href=""mailto:Morgan_M.Horton@lvhn.org"">Morgan_M.Horton@lvhn.org</a>   </span> </div>                                       <h5 class=""locationCity"">Exton</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Main Line Health Center-Exton</strong>     <br>Contact: Site Public Contact <br>Phone: 484-476-2649 <br>Email: <a href=""mailto:turzoe@mlhs.org"">turzoe@mlhs.org</a>   </span> </div>                                       <h5 class=""locationCity"">Hazleton</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Lehigh Valley Hospital-Hazleton</strong>     <br>Contact: Site Public Contact <br>Phone: 610-402-9543 <br>Email: <a href=""mailto:Morgan_M.Horton@lvhn.org"">Morgan_M.Horton@lvhn.org</a>   </span> </div>                                       <h5 class=""locationCity"">Media</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Riddle  Memorial  Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 484-476-2649 <br>Email: <a href=""mailto:turzoe@mlhs.org"">turzoe@mlhs.org</a>   </span> </div>                                       <h5 class=""locationCity"">Newtown Square</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Bryn Mawr Health Center</strong>     <br>Contact: Site Public Contact <br>Phone: 484-476-2649 <br>Email: <a href=""mailto:turzoe@mlhs.org"">turzoe@mlhs.org</a>   </span> </div>                                       <h5 class=""locationCity"">Paoli</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Paoli Memorial Hospital</strong>     <br>Contact: Site Public Contact <br>Phone: 484-476-2649 <br>Email: <a href=""mailto:turzoe@mlhs.org"">turzoe@mlhs.org</a>   </span> </div>                                       <h5 class=""locationCity"">Reading</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Penn State Health Saint Joseph Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 610-378-2336 <br>Email: <a href=""mailto:dward1@pennstatehealth.psu.edu"">dward1@pennstatehealth.psu.edu</a>   </span> </div>                                       <h5 class=""locationCity"">Wynnewood</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Lankenau Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 484-476-2649 <br>Email: <a href=""mailto:turzoe@mlhs.org"">turzoe@mlhs.org</a>   </span> </div>                                   <h4>Virginia</h4>                           <h5 class=""locationCity"">Charlottesville</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">University of Virginia Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 434-243-6303 <br>Email: <a href=""mailto:uvacancertrials@hscmail.mcc.virginia.edu"">uvacancertrials@hscmail.mcc.virginia.edu</a>   </span> </div>                                   <h4>Washington</h4>                           <h5 class=""locationCity"">Seattle</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Fred Hutchinson Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 800-804-8824   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Pacific Gynecology Specialists</strong>     <br>Contact: Site Public Contact <br>Phone: 206-215-3086 <br>Email: <a href=""mailto:PCRC-NCORP@Swedish.org"">PCRC-NCORP@Swedish.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">University of Washington Medical Center - Montlake</strong>     <br>Contact: Site Public Contact <br>Phone: 800-804-8824   </span> </div>                                   <h4>Wisconsin</h4>                           <h5 class=""locationCity"">Burlington</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Aurora Cancer Care-Southern Lakes VLCC</strong>     <br>Contact: Site Public Contact <br>Phone: 414-302-2304 <br>Email: <a href=""mailto:ncorp@aurora.org"">ncorp@aurora.org</a>   </span> </div>                                       <h5 class=""locationCity"">Chippewa Falls</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Marshfield Clinic-Chippewa Center</strong>     <br>Contact: Site Public Contact <br>Phone: 800-782-8581 <br>Email: <a href=""mailto:oncology.clinical.trials@marshfieldresearch.org"">oncology.clinical.trials@marshfieldresearch.org</a>   </span> </div>                                       <h5 class=""locationCity"">Cudahy</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Aurora Saint Luke's South Shore</strong>     <br>Contact: Site Public Contact <br>Phone: 414-302-2304 <br>Email: <a href=""mailto:ncorp@aurora.org"">ncorp@aurora.org</a>   </span> </div>                                       <h5 class=""locationCity"">Eau Claire</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Marshfield Medical Center-EC Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 800-782-8581 <br>Email: <a href=""mailto:oncology.clinical.trials@marshfieldresearch.org"">oncology.clinical.trials@marshfieldresearch.org</a>   </span> </div>                                       <h5 class=""locationCity"">Fond Du Lac</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Aurora Health Center-Fond du Lac</strong>     <br>Contact: Site Public Contact <br>Phone: 414-302-2304 <br>Email: <a href=""mailto:ncorp@aurora.org"">ncorp@aurora.org</a>   </span> </div>                                       <h5 class=""locationCity"">Germantown</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Aurora Health Care Germantown Health Center</strong>     <br>Contact: Site Public Contact <br>Phone: 414-302-2304 <br>Email: <a href=""mailto:ncorp@aurora.org"">ncorp@aurora.org</a>   </span> </div>                                       <h5 class=""locationCity"">Grafton</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Aurora Cancer Care-Grafton</strong>     <br>Contact: Site Public Contact <br>Phone: 414-302-2304 <br>Email: <a href=""mailto:ncorp@aurora.org"">ncorp@aurora.org</a>   </span> </div>                                       <h5 class=""locationCity"">Green Bay</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Aurora BayCare Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 414-302-2304 <br>Email: <a href=""mailto:ncorp@aurora.org"">ncorp@aurora.org</a>   </span> </div>                                       <h5 class=""locationCity"">Kenosha</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Aurora Cancer Care-Kenosha South</strong>     <br>Contact: Site Public Contact <br>Phone: 414-302-2304 <br>Email: <a href=""mailto:ncorp@aurora.org"">ncorp@aurora.org</a>   </span> </div>                                       <h5 class=""locationCity"">La Crosse</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Gundersen Lutheran Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 608-775-2385 <br>Email: <a href=""mailto:cancerctr@gundersenhealth.org"">cancerctr@gundersenhealth.org</a>   </span> </div>                                       <h5 class=""locationCity"">Ladysmith</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Marshfield Medical Center - Ladysmith</strong>     <br>Contact: Site Public Contact <br>Phone: 800-782-8581 <br>Email: <a href=""mailto:oncology.clinical.trials@marshfieldresearch.org"">oncology.clinical.trials@marshfieldresearch.org</a>   </span> </div>                                       <h5 class=""locationCity"">Marinette</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Aurora Bay Area Medical Group-Marinette</strong>     <br>Contact: Site Public Contact <br>Phone: 414-302-2304 <br>Email: <a href=""mailto:ncorp@aurora.org"">ncorp@aurora.org</a>   </span> </div>                                       <h5 class=""locationCity"">Marshfield</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Marshfield Medical Center-Marshfield</strong>     <br>Contact: Site Public Contact <br>Phone: 800-782-8581 <br>Email: <a href=""mailto:oncology.clinical.trials@marshfieldresearch.org"">oncology.clinical.trials@marshfieldresearch.org</a>   </span> </div>                                       <h5 class=""locationCity"">Milwaukee</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Aurora Cancer Care-Milwaukee</strong>     <br>Contact: Site Public Contact <br>Phone: 414-302-2304 <br>Email: <a href=""mailto:ncorp@aurora.org"">ncorp@aurora.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Aurora Saint Luke's Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 414-302-2304 <br>Email: <a href=""mailto:ncorp@aurora.org"">ncorp@aurora.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Aurora Sinai Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 414-302-2304 <br>Email: <a href=""mailto:ncorp@aurora.org"">ncorp@aurora.org</a>   </span> </div>                                       <h5 class=""locationCity"">Minocqua</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Marshfield Medical Center - Minocqua</strong>     <br>Contact: Site Public Contact <br>Phone: 800-782-8581 <br>Email: <a href=""mailto:oncology.clinical.trials@marshfieldresearch.org"">oncology.clinical.trials@marshfieldresearch.org</a>   </span> </div>                                       <h5 class=""locationCity"">New Richmond</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Cancer Center of Western Wisconsin</strong>     <br>Contact: Site Public Contact <br>Phone: 952-993-1517 <br>Email: <a href=""mailto:mmcorc@healthpartners.com"">mmcorc@healthpartners.com</a>   </span> </div>                                       <h5 class=""locationCity"">Oshkosh</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Vince Lombardi Cancer Clinic - Oshkosh</strong>     <br>Contact: Site Public Contact <br>Phone: 414-302-2304 <br>Email: <a href=""mailto:ncorp@aurora.org"">ncorp@aurora.org</a>   </span> </div>                                       <h5 class=""locationCity"">Racine</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Aurora Cancer Care-Racine</strong>     <br>Contact: Site Public Contact <br>Phone: 414-302-2304 <br>Email: <a href=""mailto:ncorp@aurora.org"">ncorp@aurora.org</a>   </span> </div>                                       <h5 class=""locationCity"">Rice Lake</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Marshfield Medical Center-Rice Lake</strong>     <br>Contact: Site Public Contact <br>Phone: 800-782-8581 <br>Email: <a href=""mailto:oncology.clinical.trials@marshfieldresearch.org"">oncology.clinical.trials@marshfieldresearch.org</a>   </span> </div>                                       <h5 class=""locationCity"">Sheboygan</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Vince Lombardi Cancer Clinic-Sheboygan</strong>     <br>Contact: Site Public Contact <br>Phone: 414-302-2304 <br>Email: <a href=""mailto:ncorp@aurora.org"">ncorp@aurora.org</a>   </span> </div>                                       <h5 class=""locationCity"">Stevens Point</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Marshfield Medical Center-River Region at Stevens Point</strong>     <br>Contact: Site Public Contact <br>Phone: 800-782-8581 <br>Email: <a href=""mailto:oncology.clinical.trials@marshfieldresearch.org"">oncology.clinical.trials@marshfieldresearch.org</a>   </span> </div>                                       <h5 class=""locationCity"">Summit</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Aurora Medical Center in Summit</strong>     <br>Contact: Site Public Contact <br>Phone: 414-302-2304 <br>Email: <a href=""mailto:ncorp@aurora.org"">ncorp@aurora.org</a>   </span> </div>                                       <h5 class=""locationCity"">Two Rivers</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Vince Lombardi Cancer Clinic-Two Rivers</strong>     <br>Contact: Site Public Contact <br>Phone: 414-302-2304 <br>Email: <a href=""mailto:ncorp@aurora.org"">ncorp@aurora.org</a>   </span> </div>                                       <h5 class=""locationCity"">Wausau</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Marshfield Clinic-Wausau Center</strong>     <br>Contact: Site Public Contact <br>Phone: 800-782-8581 <br>Email: <a href=""mailto:oncology.clinical.trials@marshfieldresearch.org"">oncology.clinical.trials@marshfieldresearch.org</a>   </span> </div>                                       <h5 class=""locationCity"">Wauwatosa</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Aurora Cancer Care-Milwaukee West</strong>     <br>Contact: Site Public Contact <br>Phone: 414-302-2304 <br>Email: <a href=""mailto:ncorp@aurora.org"">ncorp@aurora.org</a>   </span> </div>                                       <h5 class=""locationCity"">West Allis</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Aurora West Allis Medical Center</strong>     <br>Contact: Site Public Contact <br>Phone: 414-302-2304 <br>Email: <a href=""mailto:ncorp@aurora.org"">ncorp@aurora.org</a>   </span> </div>                                       <h5 class=""locationCity"">Weston</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Marshfield Medical Center - Weston</strong>     <br>Contact: Site Public Contact <br>Phone: 800-782-8581 <br>Email: <a href=""mailto:oncology.clinical.trials@marshfieldresearch.org"">oncology.clinical.trials@marshfieldresearch.org</a>   </span> </div>                                       <h5 class=""locationCity"">Wisconsin Rapids</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Marshfield Clinic - Wisconsin Rapids Center</strong>     <br>Contact: Site Public Contact <br>Phone: 800-782-8581 <br>Email: <a href=""mailto:oncology.clinical.trials@marshfieldresearch.org"">oncology.clinical.trials@marshfieldresearch.org</a>   </span> </div>                                   <h4>Wyoming</h4>                           <h5 class=""locationCity"">Cody</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Billings Clinic-Cody</strong>     <br>Contact: Site Public Contact <br>Phone: 800-996-2663 <br>Email: <a href=""mailto:research@billingsclinic.org"">research@billingsclinic.org</a>   </span> </div>                                       <h5 class=""locationCity"">Sheridan</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Welch Cancer Center</strong>     <br>Contact: Site Public Contact <br>Phone: 406-969-6060 <br>Email: <a href=""mailto:mccinfo@mtcancer.org"">mccinfo@mtcancer.org</a>   </span> </div>                           			</div> 		</div> 			<div class=""trialContainer""> 			<h2 class=""hangingIndent"">13. A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)</h2> 						<a class=""hangingIndent print-check-for-updates"" href=""/research/participate/clinical-trials-search/v?d=C1967&d=C2167&d=C93259&d=C199379&d=C172809&d=C82379&d=C116377&d=C1855&d=C65530&d=C124993&d=C148147&d=C66940&d=C2693&d=C97273&loc=0&pn=7&rl=2&st=C162158&st=C153201&st=C176727&st=C147924&st=C202131&st=C3512&st=C155908&st=C156093&st=C156094&st=C157364&st=C128798&st=C9133&st=C133254&st=C135017&st=C174510&st=C155901&st=C171612&st=C162642&t=C2926&id=NCI-2022-05419""><span>Check for Updates</span></a> 			<table class=""trialDataTable""> 				<tr class=""trialDataHeaderRow""> 					<td>Phase</td> 					<td>Type</td> 					<td>Status</td> 					<td>Age</td> 					<td>Trial IDs</td> 				</tr> 				<tr> 					<td>Phase I/II</td> 					<td>Treatment</td> 					<td>Active</td> 					<td>12 													and over 						 						</td> 					<td class=""trialIDCell""> 						<span class = ""dataTableIDLabel"">Primary ID</span> NVL-655-01<br> 						<span class = ""dataTableIDLabel"">Secondary IDs</span> NCI-2022-05419<br> 						<span class = ""dataTableIDLabel"">Clinicaltrials.gov ID</span> <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT05384626"" target=""_blank"">NCT05384626</a><br> 					</td> 			</table>  			<h3>Description</h3> 			<div>Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-655, determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ALK- positive (ALK+) NSCLC and other solid tumors.  Phase 1 will evaluate the overall safety and tolerability of NVL-655 and will determine the RP2D and, if applicable, the MTD of NVL-655 in patients with advanced ALK+ solid tumors.  Phase 2 will determine the objective response rate (ORR) as assessed by Blinded Independent Central Review (BICR) of NVL-655 at the RP2D. Secondary objectives will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS), and clinical benefit rate (CBR) of NVL-655 in patients with advanced ALK-positive NSCLC and other solid tumors.</div>  			<h3 class=""printHeading"">Eligibility Criteria</h3>  																																																																																																																																																																																																																																																																																																											<h4>Inclusion Criteria</h4> 										<div> 							<ul> 															<li>Age ≥18 years, Phase 2 Cohort 2f only: Age ≥12 years and weighing &gt;40 kg.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Phase 1: Histologically or cytologically confirmed locally advanced or metastatic solid tumor with a documented ALK rearrangement or activating ALK mutation.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Phase 2</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Phase 2 Cohorts except 2f: Histologically or cytologically confirmed locally advanced or metastatic NSCLC with a documented ALK rearrangement</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Phase 2 Cohort 2f: Histologically or cytologically confirmed locally advanced or metastatic solid tumor with a documented ALK rearrangement or activating ALK mutation detected by certified assay.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Phase 1: Must have evaluable disease (target or nontarget) according to RECIST 1.1 Phase 2: Must have measurable disease according to RECIST 1.1</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Adequate organ function and bone marrow reserve</li> 												</ul> 						</div> 														<h4>Exclusion Criteria</h4> 										<div> 							<ul> 																<li>Patient&#39;s cancer has a known oncogenic driver alteration other than ALK.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Known allergy/hypersensitivity to excipients of NVL-655.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Major surgery within 4 weeks of the study entry</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Ongoing or anticancer therapy</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Actively receiving systemic treatment or direct medical intervention on another therapeutic clinical study.</li> 												</ul> 						</div> 							 							<h3 class=""printHeading"">Trial Objectives and Outlines</h3> 				<div id=""trialObjectives""><p class='ctrp'>In Phase 2, study patients will be enrolled into 6 distinct cohorts:</p><p class='ctrp'></p><p class='ctrp'>  -  Cohort 2a: Patients with locally advanced or metastatic NSCLC harboring an ALK</p><p class='ctrp'>     rearrangement who have received 1 prior 2nd-generation ALK TKI (ceritinib,</p><p class='ctrp'>     alectinib, or brigatinib). Up to 2 prior lines of chemotherapy and/or immunotherapy</p><p class='ctrp'>     are allowed.</p><p class='ctrp'></p><p class='ctrp'>  -  Cohort 2b: Patients with locally advanced or metastatic NSCLC harboring an ALK</p><p class='ctrp'>     rearrangement, who have received 2-3 prior ALK TKIs (crizotinib, ceritinib,</p><p class='ctrp'>     alectinib, brigatinib, or lorlatinib). Up to 2 prior lines of chemotherapy and/or</p><p class='ctrp'>     immunotherapy are allowed.</p><p class='ctrp'></p><p class='ctrp'>  -  Cohort 2c: Patients with locally advanced or metastatic NSCLC harboring an ALK</p><p class='ctrp'>     rearrangement, who have received lorlatinib as the only prior ALK TKI therapy. Up to</p><p class='ctrp'>     one prior line of chemotherapy and/or immunotherapy received prior to lorlatinib is</p><p class='ctrp'>     allowed.</p><p class='ctrp'></p><p class='ctrp'>  -  Cohort 2d: Patients with locally advanced or metastatic NSCLC harboring an ALK</p><p class='ctrp'>     rearrangement, who are na&#239;ve to ALK TKI therapy. Up to one prior line of</p><p class='ctrp'>     chemotherapy and/or immunotherapy is allowed.</p><p class='ctrp'></p><p class='ctrp'>  -  Cohort 2e: Patients with locally advanced or metastatic NSCLC harboring an ALK</p><p class='ctrp'>     rearrangement, not eligible for other Phase 2 cohorts.</p><p class='ctrp'></p><p class='ctrp'>  -  Cohort 2f: Patients with other solid tumors harboring an ALK rearrangement or</p><p class='ctrp'>     activating ALK mutation, who have received ≥1 prior systemic anticancer therapy, or</p><p class='ctrp'>     for whom no satisfactory standard therapy exists.</p></div> 			 							<h3 class=""printHeading"">Lead Organization</h3> 									<div>Nuvalent Inc.</div> 														<h3 class=""printHeading"">Locations & Contacts</h3> 			<div class=""locationNoteBlock""> 				<span>Note:</span> Information about participating sites on pharmaceutical industry trials may be incomplete, so please look up the <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT05384626"" target=""_blank"">NCT number</a> on ClinicalTrials.gov 			</div> 			<div> 								           <h3 class=""locationCountryLabel"">U.S.A.</h3>               <h4>California</h4>                           <h5 class=""locationCity"">Orange</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">UC Irvine Health/Chao Family Comprehensive Cancer Center</strong>     <br>Contact: Mason Michael Huynh <br>Phone: 714-509-2979 <br>Email: <a href=""mailto:masonmh@hs.uci.edu"">masonmh@hs.uci.edu</a>   </span> </div>                                       <h5 class=""locationCity"">Palo Alto</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Stanford Cancer Institute Palo Alto</strong>     <br>Name Not Available   </span> </div>                                       <h5 class=""locationCity"">Sacramento</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">University of California Davis Comprehensive Cancer Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>Colorado</h4>                           <h5 class=""locationCity"">Aurora</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">UCHealth University of Colorado Hospital</strong>     <br>Contact: Stephanie Biller <br>Phone: 720-848-0729 <br>Email: <a href=""mailto:stephanie.biller@cuanschutz.edu"">stephanie.biller@cuanschutz.edu</a>   </span> </div>                                   <h4>District of Columbia</h4>                           <h5 class=""locationCity"">Washington</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">MedStar Georgetown University Hospital</strong>     <br>Name Not Available   </span> </div>                                   <h4>Florida</h4>                           <h5 class=""locationCity"">Miami</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">University of Miami Miller School of Medicine-Sylvester Cancer Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>Georgia</h4>                           <h5 class=""locationCity"">Atlanta</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Emory University Hospital/Winship Cancer Institute</strong>     <br>Name Not Available   </span> </div>                                   <h4>Illinois</h4>                           <h5 class=""locationCity"">Chicago</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">University of Chicago Comprehensive Cancer Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>Maryland</h4>                           <h5 class=""locationCity"">Baltimore</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Johns Hopkins University/Sidney Kimmel Cancer Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>Massachusetts</h4>                           <h5 class=""locationCity"">Boston</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Brigham and Women's Hospital</strong>     <br>Name Not Available   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Dana-Farber Cancer Institute</strong>     <br>Name Not Available   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Massachusetts General Hospital Cancer Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>Missouri</h4>                           <h5 class=""locationCity"">Saint Louis</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Siteman Cancer Center at Washington University</strong>     <br>Name Not Available   </span> </div>                                   <h4>New York</h4>                           <h5 class=""locationCity"">New York</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Laura and Isaac Perlmutter Cancer Center at NYU Langone</strong>     <br>Name Not Available   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Memorial Sloan Kettering Cancer Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>North Carolina</h4>                           <h5 class=""locationCity"">Durham</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Duke University Medical Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>Ohio</h4>                           <h5 class=""locationCity"">Columbus</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Ohio State University Comprehensive Cancer Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>Pennsylvania</h4>                           <h5 class=""locationCity"">Philadelphia</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">University of Pennsylvania/Abramson Cancer Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>Texas</h4>                           <h5 class=""locationCity"">Houston</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">M D Anderson Cancer Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>Washington</h4>                           <h5 class=""locationCity"">Seattle</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Fred Hutch/University of Washington/Seattle Children's Cancer Consortium</strong>     <br>Name Not Available   </span> </div>                           			</div> 		</div> 			<div class=""trialContainer""> 			<h2 class=""hangingIndent"">14. Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors</h2> 						<a class=""hangingIndent print-check-for-updates"" href=""/research/participate/clinical-trials-search/v?d=C1967&d=C2167&d=C93259&d=C199379&d=C172809&d=C82379&d=C116377&d=C1855&d=C65530&d=C124993&d=C148147&d=C66940&d=C2693&d=C97273&loc=0&pn=7&rl=2&st=C162158&st=C153201&st=C176727&st=C147924&st=C202131&st=C3512&st=C155908&st=C156093&st=C156094&st=C157364&st=C128798&st=C9133&st=C133254&st=C135017&st=C174510&st=C155901&st=C171612&st=C162642&t=C2926&id=NCI-2022-05617""><span>Check for Updates</span></a> 			<table class=""trialDataTable""> 				<tr class=""trialDataHeaderRow""> 					<td>Phase</td> 					<td>Type</td> 					<td>Status</td> 					<td>Age</td> 					<td>Trial IDs</td> 				</tr> 				<tr> 					<td>Phase I</td> 					<td>Treatment</td> 					<td>Active</td> 					<td>18 													and over 						 						</td> 					<td class=""trialIDCell""> 						<span class = ""dataTableIDLabel"">Primary ID</span> XL092-002<br> 						<span class = ""dataTableIDLabel"">Secondary IDs</span> NCI-2022-05617, 2023-510061-10-00<br> 						<span class = ""dataTableIDLabel"">Clinicaltrials.gov ID</span> <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT05176483"" target=""_blank"">NCT05176483</a><br> 					</td> 			</table>  			<h3>Description</h3> 			<div>This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, PK, preliminary antitumor activity, and effect of biomarkers of XL092 administered alone, and in combination with nivolumab (doublet), nivolumab + ipilimumab (triplet) and nivolumab + relatlimab (triplet) in subjects with advanced solid tumors.  In the Expansion Stage, the safety and efficacy of XL092 as monotherapy and in combination therapy will be further evaluated in tumor-specific Expansion Cohorts.</div>  			<h3 class=""printHeading"">Eligibility Criteria</h3>  																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																														<h4>Inclusion Criteria</h4> 										<div> 							<ul> 															<li>Cytologically or histologically confirmed solid tumor that is unresectable, locally advanced or metastatic.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Dose-Escalation Cohorts: Subjects with a solid tumor that is unresectable or metastatic and for which life-prolonging therapies do not exist or available therapies are intolerable or no longer effective.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Expansion Cohort 1 (ccRCC): Subjects with unresectable advanced or metastatic RCC with a clear cell component who have not received prior systemic therapy.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Note: Prior non-VEGF targeted adjuvant or neoadjuvant is allowed if disease recurrence occurred 6 months after the last dose.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Expansion Cohort 2 (ccRCC): Subjects with unresectable advanced or metastatic RCC with a clear cell component.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Must have radiographically progressed after a combination therapy consisting of a PD-1/PD-L1 targeting mAb with a VEGFR-TKI or a PD-1 targeting mAb with a CTLA-4 mAb as the preceding line of therapy.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Must have received no more than one prior systemic anticancer therapy for unresectable advanced or metastatic renal cell carcinoma.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Expansion Cohort 3 (mCRPC): Men with metastatic adenocarcinoma of the prostate.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Must have progressed during or after one novel hormone therapy (NHT) given for castration-sensitive locally advanced (T3 or T4) or metastatic castration-sensitive prostate cancer (CSPC), M0 CRPC, or mCRPC.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Expansion Cohort 4 (UC, ICI-naive): Subjects with histologically confirmed unresectable, locally advanced or metastatic transitional cell carcinoma of the urothelium (including the renal pelvis, ureter, urinary bladder, or urethra).</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Must have progressed during or after prior first-line platinum-based combination therapy, including subjects who received prior neoadjuvant or adjuvant platinum-containing therapy with disease recurrence &lt; 12 months from the end of last therapy.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Must have received no more than 1 prior line of systemic anticancer therapy for unresectable, locally advanced or metastatic disease.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Expansion Cohort 5 (UC, ICI-experienced): Subjects with histologically confirmed unresectable, locally advanced or metastatic transitional cell carcinoma of the urothelium (including the renal pelvis, ureter, urinary bladder, or urethra).</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Must have progressed during or after prior PD-1/PD-L1 targeting ICI therapy given as monotherapy, combination therapy, maintenance therapy or adjuvant therapy.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Must have received no more than 2 prior lines of systemic anticancer therapy for unresectable advanced or metastatic disease.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Expansion Cohort 6 (nccRCC): Subjects with unresectable advanced or metastatic nccRCC of the following subtypes: Papillary, unclassified RCC, and translocation-associated, FH deficient and SDH deficient. Among the eligible histologic subtypes, sarcomatoid features are allowed.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>No prior systemic anticancer therapy is allowed except adjuvant or neoadjuvant therapy if disease recurrence occurred at least 6 months after the last dose.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Expansion Cohort 7 (HCC): Subjects with locally advanced, or metastatic and/or unresectable HCC that is not amenable to curative treatment or locoregional therapy.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Expansion Cohort 8 (NSCLC): Subjects with Stage IV non-squamous NSCLC with positive PD-L1 expression (tumor proportion score [TPS] 1-49%) and without prior systemic anticancer therapy for metastatic disease.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Expansion Cohort 9 (NSCLC): Subjects with Stage IV non-squamous NSCLC who have radiologically progressed following treatment with one prior immune checkpoint inhibitor (anti-PD-1 or anti-PD-L1) for metastatic disease.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Expansion Cohort 10 (CRC): Subjects with histologically confirmed unresectable, locally advanced, or metastatic adenocarcinoma of the colon or rectum.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Expansion Cohort 11 (HNSCC): Subject with inoperable, refractory, recurrent or metastatic HNSCC of the oral cavity, oropharynx, hypopharynx, and larynx. PD-L1 combined positive score (CPS) ≥1.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Expansion Cohort 12 (ccRCC): Subjects with unresectable advance or metastatic RCC with a clear cell component, including subjects who also have a sacromatoid feature.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Must have received no more than two prior lines of systemic anticancer therapy for unresectable advanced or metastatic renal cell carcinoma</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Expansion Cohort 13 (ccRCC): Subjects with unresectable advanced or metastatic RCC with a clear component, including subjects who also have a sacromatoid feature.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>For all Expansion Cohorts except Cohort 3: Measurable disease per RECIST 1.1 as determined by the Investigator.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>For Expansion Cohorts 1 - 11 Only: Archival tumor tissue material, if available, or fresh tumor tissue if it can be safely obtained.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Recovery to baseline or ≤ Grade 1 common terminology criteria for adverse events (CTCAE) v5 from AE(s) related to any prior treatments unless AE(s) are deemed clinically nonsignificant by the Investigator and/or stable on supportive therapy.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Karnofsky Performance Status (KPS) ≥ 70%.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Adequate organ and marrow function.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Sexually active fertile subjects and their partners must agree to use highly effective methods of contraception.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Female subjects of childbearing potential must not be pregnant at screening.</li> 												</ul> 						</div> 														<h4>Exclusion Criteria</h4> 										<div> 							<ul> 																<li>For all Dose-Escalation cohorts: Prior treatment with XL092. For all Expansion Cohorts: Prior treatment with XL092, nivolumab, ipilimumab or relatlimab with the following exceptions: Prior PD-1/PD-L1, LAG-3 and CTLA-4 targeting therapy for locally advanced or metastatic disease is allowed for Cohort 2 (ccRCC), Cohort 5 (UC), Cohort 9 (NSCLC), and Cohort 12 (ccRCC), and prior treatment in the neoadjuvant or adjuvant setting is allowed for Cohort 13 (ccRCC).</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>For all Dose-Escalation Cohorts and Expansion Cohort 2 (ccRCC), 3 (mCRPC), Cohort 5 (UC), Cohort 9 (NSCLC), Cohort 10 (CRC), and Cohort 12: Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before first dose of study treatment.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>For Cohort 3 (mCRPC): Receipt of abiraterone within 1 week; cyproterone within 10 days; or receipt of flutamide, nilutamide, bicalutamide, enzalutamide, or other androgen receptor inhibitors within 2 weeks before first dose of study treatment.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>For all Dose-Escalation Cohorts and Expansion Cohort 2 (ccRCC), Cohort 3 (mCRPC), Cohort 5 (UC), Cohort 9 (NSCLC) and Cohort 10 (CRC), and Cohort 12: Receipt of any type of anticancer antibody or systemic chemotherapy within 4 weeks before first dose of study treatment.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Any complementary medications (eg, herbal supplements or traditional Chinese medicines) to treat the disease under study within 2 weeks before first dose of study treatment.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Prior external radiation therapy for bone metastasis within 2 weeks, for other tumor sites within 4 weeks, and prior radium-223 therapy within 6 weeks before first dose of study treatment, unless otherwise specified.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before first dose of study treatment.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Concomitant anticoagulation with oral anticoagulants, except for specified direct factor Xa inhibitors.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Administration of a live, attenuated vaccine within 30 days prior to first dose.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Uncontrolled, significant intercurrent or recent illness.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Corrected QT interval calculated by the Fridericia formula (QTcF) &gt; 460 ms for females and &gt; 450 ms for males per electrocardiogram (ECG) within 14 days before first dose of study treatment.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Subjects with inadequately treated adrenal insufficiency.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Pregnant or lactating females.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Any other active malignancy within two years before first dose of study treatment, except for superficial skin cancers, or localized, low-grade tumors deemed cured and not treated with systemic therapy. Incidentally diagnosed prostate cancer is allowed if assessed as stage ≤ T2N0M0 and Gleason score ≤ 6.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>For Cohort 2 (ccRCC, 2L): Receipt of a prior triplet therapy including a VEGFR-TKI, a PD1 targeting mAb, and a CTLA-4 mAb.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>For Cohort 3 (mCRPC): Receipt of a taxane-based chemotherapy for mCRPC.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>For Cohort 4 (UC, ICI-na&#239;ve): Subjects who have had recurrence within the 6 months of completing adjuvant anti-PD-(L)1 treatment.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>For Cohort 6 (nccRCC, 1L): Subjects with chromophobe, renal medullary carcinoma, or pure collecting duct nccRCC.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>For Cohort 7 (HCC):</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Documented hepatic encephalopathy (HE) within 6 months before the first dose.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Clinically meaningful ascites (ie, ascites requiring paracentesis or escalation in diuretics) within 6 months before randomization.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Subjects who have received any local anticancer therapy including surgery, PEI, RFA, MWA, transarterial chemoembolization (TACE), or transarterial radioembolization (TARE) within 28 days prior to first dose.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Subjects with known fibrolamellar carcinoma, sarcomatoid HCC, or mixed hepatocellular cholangiocarcinoma</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>For Cohort 10 (CRC, 2L+): Receipt of prior therapy with regorafenib and/or trifluridine + tipiracil (TAS-102).</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>For Cohort 11 (HNSCC): Primary tumor site of the nasopharyngeal area.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>For Cohorts 1 (ccRCC, 1L), 2 (ccRCC, 2L), 4, 5 (UC), 7 (HCC), 8 (NSCLC 1L PD-L1 low), 9 (NSCLC, 2L+), 10 (CRC, MSS, 2L+), and 11 (HNSCC):</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Troponin T (TnT) or I (TnI) &gt; 2 &#215; institutional ULN. Note: Additional Inclusion and Exclusion criteria may apply.</li> 												</ul> 						</div> 							 			 							<h3 class=""printHeading"">Lead Organization</h3> 									<div>Exelixis Inc</div> 														<h3 class=""printHeading"">Locations & Contacts</h3> 			<div class=""locationNoteBlock""> 				<span>Note:</span> Information about participating sites on pharmaceutical industry trials may be incomplete, so please look up the <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT05176483"" target=""_blank"">NCT number</a> on ClinicalTrials.gov 			</div> 			<div> 								           <h3 class=""locationCountryLabel"">U.S.A.</h3>               <h4>Arizona</h4>                           <h5 class=""locationCity"">Scottsdale</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Mayo Clinic in Arizona</strong>     <br>Name Not Available   </span> </div>                                   <h4>California</h4>                           <h5 class=""locationCity"">Palo Alto</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Stanford Cancer Institute Palo Alto</strong>     <br>Name Not Available   </span> </div>                                   <h4>Connecticut</h4>                           <h5 class=""locationCity"">Greenwich</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Smilow Cancer Hospital Care Center at Greenwich</strong>     <br>Name Not Available   </span> </div>                                       <h5 class=""locationCity"">New Haven</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Yale University</strong>     <br>Name Not Available   </span> </div>                                   <h4>Florida</h4>                           <h5 class=""locationCity"">Gainesville</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">University of Florida Health Science Center - Gainesville</strong>     <br>Name Not Available   </span> </div>                                       <h5 class=""locationCity"">Jacksonville</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Mayo Clinic in Florida</strong>     <br>Name Not Available   </span> </div>                                       <h5 class=""locationCity"">Miami</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">University of Miami Miller School of Medicine-Sylvester Cancer Center</strong>     <br>Name Not Available   </span> </div>                                       <h5 class=""locationCity"">Tampa</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Moffitt Cancer Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>Massachusetts</h4>                           <h5 class=""locationCity"">Boston</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Brigham and Women's Hospital</strong>     <br>Name Not Available   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Dana-Farber Cancer Institute</strong>     <br>Contact: Bradley A. McGregor <br>Phone: 877-442-3324   </span> </div>                                   <h4>Michigan</h4>                           <h5 class=""locationCity"">Detroit</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Wayne State University/Karmanos Cancer Institute</strong>     <br>Name Not Available   </span> </div>                                   <h4>Minnesota</h4>                           <h5 class=""locationCity"">Rochester</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Mayo Clinic in Rochester</strong>     <br>Name Not Available   </span> </div>                                   <h4>New Jersey</h4>                           <h5 class=""locationCity"">Hackensack</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Hackensack University Medical Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>New York</h4>                           <h5 class=""locationCity"">New York</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>North Carolina</h4>                           <h5 class=""locationCity"">Durham</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Duke University Medical Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>Ohio</h4>                           <h5 class=""locationCity"">Cleveland</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Case Comprehensive Cancer Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>Oregon</h4>                           <h5 class=""locationCity"">Portland</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">OHSU Knight Cancer Institute</strong>     <br>Name Not Available   </span> </div>                                   <h4>Pennsylvania</h4>                           <h5 class=""locationCity"">Philadelphia</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">University of Pennsylvania/Abramson Cancer Center</strong>     <br>Name Not Available   </span> </div>                                       <h5 class=""locationCity"">Pittsburgh</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">University of Pittsburgh Cancer Institute (UPCI)</strong>     <br>Name Not Available   </span> </div>                                   <h4>Texas</h4>                           <h5 class=""locationCity"">Dallas</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">UT Southwestern/Simmons Cancer Center-Dallas</strong>     <br>Name Not Available   </span> </div>                                   <h4>Virginia</h4>                           <h5 class=""locationCity"">Charlottesville</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">University of Virginia Cancer Center</strong>     <br>Name Not Available   </span> </div>                           			</div> 		</div> 			<div class=""trialContainer""> 			<h2 class=""hangingIndent"">15. Osimertinib Alone or with Chemotherapy for EGFR-Mutant Lung Cancers</h2> 						<a class=""hangingIndent print-check-for-updates"" href=""/research/participate/clinical-trials-search/v?d=C1967&d=C2167&d=C93259&d=C199379&d=C172809&d=C82379&d=C116377&d=C1855&d=C65530&d=C124993&d=C148147&d=C66940&d=C2693&d=C97273&loc=0&pn=7&rl=2&st=C162158&st=C153201&st=C176727&st=C147924&st=C202131&st=C3512&st=C155908&st=C156093&st=C156094&st=C157364&st=C128798&st=C9133&st=C133254&st=C135017&st=C174510&st=C155901&st=C171612&st=C162642&t=C2926&id=NCI-2020-04069""><span>Check for Updates</span></a> 			<table class=""trialDataTable""> 				<tr class=""trialDataHeaderRow""> 					<td>Phase</td> 					<td>Type</td> 					<td>Status</td> 					<td>Age</td> 					<td>Trial IDs</td> 				</tr> 				<tr> 					<td>Phase II</td> 					<td>Treatment</td> 					<td>Active</td> 					<td>18 													and over 						 						</td> 					<td class=""trialIDCell""> 						<span class = ""dataTableIDLabel"">Primary ID</span> 20-011<br> 						<span class = ""dataTableIDLabel"">Secondary IDs</span> NCI-2020-04069<br> 						<span class = ""dataTableIDLabel"">Clinicaltrials.gov ID</span> <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT04410796"" target=""_blank"">NCT04410796</a><br> 					</td> 			</table>  			<h3>Description</h3> 			<div>This phase II trial studies how well osimertinib alone or with chemotherapy (carboplatin and pemetrexed) works in treating people that have lung cancer which has spread to another part of the body (metastatic) and has a change (mutation) in the EGFR gene. Osimertinib binds to the EGFR protein and blocks its activity, which slows the tumor growth. Carboplatin and pemetrexed work by targeting the processes that tumor cells use to grow and spread. Giving these chemotherapy drugs may slow the production of new tumor cells which researchers believe are resistant to osimertinib.</div>  			<h3 class=""printHeading"">Eligibility Criteria</h3>  																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																														<h4>Inclusion Criteria</h4> 										<div> 							<ul> 															<li>INITIAL: Age &gt;= 18 years</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>INITIAL: Biopsy proven metastatic non-small cell lung cancer, confirmed at enrolling institution</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>INITIAL: Somatic activating mutation in EGFR in pre-treatment tumor biopsy/cytology from pleural fluid or cell-free deoxyribonucleic acid (cfDNA)</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>INITIAL: Either have not started a prior EGFR tyrosine kinase inhibitor (TKI) therapy or may have started osimertinib within 3 weeks of confirming eligibility and enrollment of measurable disease per approval of principal investigator (PI) with no prior chemotherapy for treatment of metastatic disease (adjuvant therapy &gt; 6 months prior to study start is acceptable)</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>INITIAL: Measurable (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) indicator lesion not previously irradiated, with measurable disease determined by treating investigator. If a patient has already started on osimertinib there must be available pre-osimertinib baseline tumor assessments, to be utilized for RECIST 1.1 assessment</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>INITIAL: Karnofsky performance status (KPS) &gt;= 70%</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>INITIAL: Ability to swallow oral medications</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>INITIAL: Hemoglobin &gt;= 9 g/dL (use of granulocyte-colony stimulating factor [G-CSF] and/or transfusion to meet these criteria are not allowed)</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>INITIAL: Platelets &gt;= 150,000mm^3 or 150 x 10^9/L (use of G-CSF and/or transfusion to meet these criteria are not allowed)</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>INITIAL: Aspartate transaminase (AST), aspartate transaminase (ALT) =&lt; 2.5 x upper limit of normal (ULN) with no liver metastases or =&lt; 5 x ULN with the presence of liver metastases</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>INITIAL: Total bilirubin =&lt; 1.5 X ULN if no liver metastases or =&lt; 3 X ULN in the presence of documented Gilbert&#39;s syndrome (unconjugated hyperbilirubinemia) or liver metastases</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>INITIAL: Absolute neutrophil count (ANC) &gt;= 1500 cells/mm^3 (use of G-CSF and/or transfusion to meet these criteria are not allowed)</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>INITIAL: Creatinine =&lt; upper limit of normal (ULN) OR creatinine clearance &gt;= 60 mL/min calculated by Cockcroft and Gault equation</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>INITIAL: Willing to use highly effective contraceptive measures if of child-bearing potential or if the patient’s sexual partner is a woman of child-bearing potential: * Female subjects should be using highly effective contraceptive measures, and must have a negative pregnancy test and not be breast-feeding prior to start of dosing if of child-bearing potential or must have evidence of non-child-bearing potential by fulfilling one of the following criteria at screening: * Post-menopausal defined as aged more than 50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments * Women under 50 years old would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and with luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels in the post-menopausal range for the institution * Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation * Male subjects should be willing to use barrier contraception</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>RANDOMIZATION: Patients with detectable plasma EGFR mutations at cycle (C) 2 day (D) 1</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>RANDOMIZATION: Karnofsky performance status (KPS) &gt;= 70%</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>RANDOMIZATION: Hemoglobin &gt;= 9 g/dL</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>RANDOMIZATION: Platelets &gt;= 150,000mm^3 or 150 x 10^9/L</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>RANDOMIZATION: Creatinine =&lt; ULN OR calculated creatinine clearance &gt;= 60 mL/min</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>RANDOMIZATION: AST, ALT =&lt; 3 x ULN with no liver metastases or =&lt; 5 x ULN with the presence of liver metastases</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>RANDOMIZATION: Total bilirubin =&lt; 1.5 x ULN if no liver metastases or =&lt; 3 x ULN in the presence of documented Gilbert&#39;s syndrome (unconjugated hyperbilirubinemia) or liver metastases</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>RANDOMIZATION: Absolute neutrophil count (ANC) &gt;= 1500 cells/mm^3</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>RANDOMIZATION: Must have at least stable disease per RECIST 1.1 assessment prior to initiating chemotherapy at C4D1</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>RANDOMIZATION: Eligibility testing (KPS, bloodwork) should be tested at C3D1. If the subject’s evaluation does not meet eligibility criteria, any result obtained between C3 and C4 can be used</li> 												</ul> 						</div> 														<h4>Exclusion Criteria</h4> 										<div> 							<ul> 																<li>INITIAL: Pregnant or lactating women</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>INITIAL: Any radiotherapy within 1 week prior to starting treatment on protocol. The washout window only applies for patients who have not started Osimertinib</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>INITIAL: Any major surgery within 2 weeks of starting treatment on protocol. The washout window only applies for patients who have not started Osimertinib</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>INITIAL: Any evidence of clinically significant interstitial lung disease</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>INITIAL: Treatment with an investigational drug within five half-lives of the compound or 3 months, whichever is greater</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>INITIAL: Currently receiving (or unable to stop prior to receiving the first dose of study treatment) medications or herbal supplements known to be strong inducers of CYP3A4. All patients must try to avoid concomitant use of any medications, herbal supplements and/or ingestion of foods with known inducer effects on CYP3A4</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>INITIAL: Any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) grade 1 at the time of starting study treatment, with the exception of alopecia and grade 2 prior platinum-therapy-related neuropathy</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>INITIAL: Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the investigator’s opinion makes it undesirable for the patient to participate in the trial</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>INITIAL: Active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV). Screening for chronic conditions is not required</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>INITIAL: Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the tablets or previous significant bowel resection that would preclude adequate absorption of osimertinib</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>INITIAL: Any of the following cardiac criteria: * Mean resting corrected QT interval (QTc) &gt; 470 msec, where QT interval is corrected for heart rate using Frederica’s formula (QTcF) * Any clinically important abnormalities in rhythm, conduction or morphology of resting electrocardiogram (ECG) e.g. complete left bundle branch block, third degree heart block and second degree heart block. * Patient with any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, electrolyte abnormalities (including: serum/plasma potassium &lt; lower limit of normal [LLN], serum/plasma magnesium &lt; LLN; serum/plasma calcium &lt; LLN), congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval and cause torsades de pointes</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>INITIAL: Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>INITIAL: History of hypersensitivity to active or inactive excipients of osimertinib or drugs with a similar chemical structure or class to osimertinib</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>INITIAL: Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Please note: All ‘Initial’ exclusion criteria must be re-confirmed prior to randomization</li> 												</ul> 						</div> 							 							<h3 class=""printHeading"">Trial Objectives and Outlines</h3> 				<div id=""trialObjectives""><p class='ctrp'>PRIMARY OBJECTIVE:</p><p class='ctrp'>I. Determine the progression-free survival of osimertinib versus osimertinib, carboplatin and pemetrexed in patients with metastatic EGFR mutant lung cancers with persistent detectable EGFR mutations in plasma despite initiation of osimertinib.</p><p class='ctrp'></p><p class='ctrp'>SECONDARY OBJECTIVES:</p><p class='ctrp'>I. Overall response rate.</p><p class='ctrp'>II. Overall survival.</p><p class='ctrp'>III. Progression-free survival at 12 months.</p><p class='ctrp'>IV. Clearance of plasma EGFR mutations.</p><p class='ctrp'>V. Intracranial progression-free survival.</p><p class='ctrp'>VI. Identify resistance mechanisms to study treatment.</p><p class='ctrp'>VII. Safety and tolerability of the treatment.</p><p class='ctrp'></p><p class='ctrp'>OUTLINE: Patients are randomized to 1 of 2 arms.</p><p class='ctrp'></p><p class='ctrp'>ARM A: Patients receive osimertinib orally (PO) once daily (QD) on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.</p><p class='ctrp'></p><p class='ctrp'>ARM B: Patients receive osimertinib PO QD on days 1-21. Beginning cycle 4, patients also receive carboplatin intravenously (IV) over 30 minutes on day 1 (cycles 4-7 only) and pemetrexed IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) scan, magnetic resonance imaging (MRI), echocardiography blood sample collection and may undergo positron emission tomography (PET) scan and tumor biopsy throughout the study. </p><p class='ctrp'></p><p class='ctrp'>After completion of study treatment, patients are followed for 30 days.</p></div> 			 							<h3 class=""printHeading"">Lead Organization</h3> 									<div>Memorial Sloan Kettering Cancer Center</div> 													<div>Principal Investigator: Helena A. Yu</div> 										<h3 class=""printHeading"">Locations & Contacts</h3> 			<div class=""locationNoteBlock""> 				<span>Note:</span> Information about participating sites on pharmaceutical industry trials may be incomplete, so please look up the <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT04410796"" target=""_blank"">NCT number</a> on ClinicalTrials.gov 			</div> 			<div> 								           <h3 class=""locationCountryLabel"">U.S.A.</h3>               <h4>California</h4>                           <h5 class=""locationCity"">Sacramento</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">University of California Davis Comprehensive Cancer Center</strong>     <br>Contact: Jonathan W. Riess <br>Phone: 916-734-3772 <br>Email: <a href=""mailto:jwriess@ucdavis.edu"">jwriess@ucdavis.edu</a>   </span> </div>                                   <h4>Florida</h4>                           <h5 class=""locationCity"">Tampa</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Moffitt Cancer Center</strong>     <br>Contact: Bruna Pellini Ferreira <br>Phone: 888-663-3488   </span> </div>                                   <h4>Maryland</h4>                           <h5 class=""locationCity"">Baltimore</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Johns Hopkins University/Sidney Kimmel Cancer Center</strong>     <br>Contact: Kristen A Marrone <br>Phone: 410-464-6641   </span> </div>                                   <h4>Massachusetts</h4>                           <h5 class=""locationCity"">Boston</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Massachusetts General Hospital Cancer Center</strong>     <br>Contact: Zofia Piotrowska <br>Phone: 617-724-4000 <br>Email: <a href=""mailto:zpiotrowska@partners.org"">zpiotrowska@partners.org</a>   </span> </div>                                   <h4>New Jersey</h4>                           <h5 class=""locationCity"">Basking Ridge</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Memorial Sloan Kettering Basking Ridge</strong>     <br>Contact: Helena A. Yu <br>Phone: 646-608-2252 <br>Email: <a href=""mailto:yuh@mskcc.org"">yuh@mskcc.org</a>   </span> </div>                                       <h5 class=""locationCity"">Hackensack</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Hackensack University Medical Center</strong>     <br>Contact: Kaushal Parikh <br>Email: <a href=""mailto:kaushal.parikh@hmhn.org"">kaushal.parikh@hmhn.org</a>   </span> </div>                                       <h5 class=""locationCity"">Middletown</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Memorial Sloan Kettering Monmouth</strong>     <br>Contact: Helena A. Yu <br>Phone: 646-608-2252 <br>Email: <a href=""mailto:yuh@mskcc.org"">yuh@mskcc.org</a>   </span> </div>                                       <h5 class=""locationCity"">Montvale</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Memorial Sloan Kettering Bergen</strong>     <br>Contact: Helena A. Yu <br>Phone: 646-608-2252 <br>Email: <a href=""mailto:yuh@mskcc.org"">yuh@mskcc.org</a>   </span> </div>                                   <h4>New York</h4>                           <h5 class=""locationCity"">Commack</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Memorial Sloan Kettering Commack</strong>     <br>Contact: Helena A. Yu <br>Phone: 646-608-2252 <br>Email: <a href=""mailto:yuh@mskcc.org"">yuh@mskcc.org</a>   </span> </div>                                       <h5 class=""locationCity"">New York</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Laura and Isaac Perlmutter Cancer Center at NYU Langone</strong>     <br>Contact: Joshua K. Sabari <br>Phone: 212-731-5662   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Memorial Sloan Kettering Cancer Center</strong>     <br>Contact: Helena A. Yu <br>Phone: 646-608-2252 <br>Email: <a href=""mailto:yuh@mskcc.org"">yuh@mskcc.org</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center</strong>     <br>Contact: Catherine Ann Shu <br>Phone: 212-305-3997 <br>Email: <a href=""mailto:cas2145@cumc.columbia.edu"">cas2145@cumc.columbia.edu</a>   </span> </div>                                       <h5 class=""locationCity"">Uniondale</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Memorial Sloan Kettering Nassau</strong>     <br>Contact: Helena A. Yu <br>Phone: 646-608-2252 <br>Email: <a href=""mailto:yuh@mskcc.org"">yuh@mskcc.org</a>   </span> </div>                                       <h5 class=""locationCity"">West Harrison</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Memorial Sloan Kettering Westchester</strong>     <br>Contact: Helena A. Yu <br>Phone: 646-608-2252 <br>Email: <a href=""mailto:yuh@mskcc.org"">yuh@mskcc.org</a>   </span> </div>                                   <h4>Tennessee</h4>                           <h5 class=""locationCity"">Nashville</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Sarah Cannon Cancer Center</strong>     <br>Contact: Melissa Lynne Johnson <br>Phone: 615-329-7274   </span> </div>                                   <h4>Washington</h4>                           <h5 class=""locationCity"">Seattle</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Fred Hutch/University of Washington/Seattle Children's Cancer Consortium</strong>     <br>Contact: Christina S Baik <br>Phone: 206-288-7557 <br>Email: <a href=""mailto:cbaik2@uw.edu"">cbaik2@uw.edu</a>   </span> </div>                           			</div> 		</div> 			<div class=""trialContainer""> 			<h2 class=""hangingIndent"">16. Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations</h2> 						<a class=""hangingIndent print-check-for-updates"" href=""/research/participate/clinical-trials-search/v?d=C1967&d=C2167&d=C93259&d=C199379&d=C172809&d=C82379&d=C116377&d=C1855&d=C65530&d=C124993&d=C148147&d=C66940&d=C2693&d=C97273&loc=0&pn=7&rl=2&st=C162158&st=C153201&st=C176727&st=C147924&st=C202131&st=C3512&st=C155908&st=C156093&st=C156094&st=C157364&st=C128798&st=C9133&st=C133254&st=C135017&st=C174510&st=C155901&st=C171612&st=C162642&t=C2926&id=NCI-2022-04465""><span>Check for Updates</span></a> 			<table class=""trialDataTable""> 				<tr class=""trialDataHeaderRow""> 					<td>Phase</td> 					<td>Type</td> 					<td>Status</td> 					<td>Age</td> 					<td>Trial IDs</td> 				</tr> 				<tr> 					<td>Phase I/II</td> 					<td>Treatment</td> 					<td>Active</td> 					<td>18 													and over 						 						</td> 					<td class=""trialIDCell""> 						<span class = ""dataTableIDLabel"">Primary ID</span> BDTX-1535-101<br> 						<span class = ""dataTableIDLabel"">Secondary IDs</span> NCI-2022-04465<br> 						<span class = ""dataTableIDLabel"">Clinicaltrials.gov ID</span> <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT05256290"" target=""_blank"">NCT05256290</a><br> 					</td> 			</table>  			<h3>Description</h3> 			<div>BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), optimal dosage, central nervous system (CNS) activity, and antitumor activity of BDTX-1535. The study population comprises adults with either advanced/metastatic non-small cell lung cancer (NSCLC) with non-classical or acquired epidermal growth factor receptor (EGFR) resistance (EGFR C797S) mutations with or without CNS disease (in Phase 1 and Phase 2), or glioblastoma (GBM) expressing EGFR alterations (Phase 1 only). All patients will self-administer BDTX-1535 monotherapy by mouth in 21-day cycles.  Phase 1 enrollment is now complete. Phase 2 is currently enrolling.</div>  			<h3 class=""printHeading"">Eligibility Criteria</h3>  																																													<h4>Inclusion Criteria</h4> 										<div> 							<ul> 															<li>Phase 2 Eligibility:  Key Inclusion Criteria Required for locally advanced or metastatic NSCLC:    -  Measurable disease by RECIST 1.1 criteria.    -  Adequate bone marrow or organ function.    -  Life expectancy of ≥ 3 months.    -  Sufficient performance status.    -  Confirmed NSCLC, without small cell lung cancer transformation with or without brain      metastases.    -  Disease progression following or intolerance of standard of care (excluding patients      in the treatment-na&#239;ve non-classical driver cohort):         -  Cohort 1 (Non-Classical driver cohort): Advanced/metastatic NSCLC with a           non-classical driver EGFR mutation (eg, G719X) following up to 2 lines of           therapy with only 1 prior EGFR TKI regimen (third-generation preferred; other           approved EGFR TKI acceptable).         -  Cohort 2 (Acquired resistance C797S cohort): Advanced/metastatic NSCLC with the           acquired resistance C797S EGFR mutation following up to 2 lines of therapy,           including only one EGFR TKI, which must be a third generation EGFR TKI (eg,           osimertinib).         -  Cohort 3 (First-line non-classical driver cohort): Treatment-na&#239;ve           advanced/metastatic NSCLC with a non-classical driver EGFR mutation (1 cycle of           chemotherapy or immune checkpoint inhibitor are permitted). Patients with           co-occurring L858R mutations and a non-classical mutation are eligible for           inclusion.    -  Identification of one (or more) of the following EGFR mutations by Next Generation      Sequencing (NGS) as determined by a local assay performed in a validated laboratory      in the absence of other known resistance mutations (eg, T790M, MET):         -  Non-classical driver EGFR mutations (eg, L861R, S768I, G719X).         -  EGFR acquired resistance mutation (eg, C797S) to a 3rd generation EGFR TKI.         -  For Phase 2, dose expansion, patients in Cohort 1 who received 3rd generation           EGFR TKI (eg, osimertinib), the NGS report within 6 months prior to the start           of Screening is acceptable. For patients in Cohort 2, the NGS report must be           from the last disease progression on the immediate prior therapy. For patients           in Cohort 3, the NGS report must be at the time of diagnosis.  Key Exclusion Criteria:    -  Known resistant mutations in tumor tissue or by liquid biopsy (eg, T790M, MET).    -  Received more than 1 EGFR TKI therapy (ie, erlotinib or gefitinib) for the treatment      of metastatic or recurrent EGFR NSCLC.    -  Any history of interstitial lung disease related to EGFR TKI use.    -  Symptomatic or radiographic leptomeningeal disease.    -  Symptomatic brain metastases or spinal cord compression requiring urgent clinical      intervention.    -  Unresolved toxicity from prior therapy.    -  Significant cardiovascular disease.    -  Major surgery within 4 weeks of study entry or planned during study.    -  Ongoing or recent anticancer therapy or radiation therapy.    -  Evidence of malignancy (other than study-specific malignancies) requiring active      therapy within the next 2 years.    -  Active hepatitis B or C infection and/or known human immunodeficiency virus (HIV)      carrier.    -  Poorly controlled gastrointestinal disorders.</li> 												</ul> 						</div> 										 			 							<h3 class=""printHeading"">Lead Organization</h3> 									<div>Black Diamond Therapeutics, Inc.</div> 														<h3 class=""printHeading"">Locations & Contacts</h3> 			<div class=""locationNoteBlock""> 				<span>Note:</span> Information about participating sites on pharmaceutical industry trials may be incomplete, so please look up the <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT05256290"" target=""_blank"">NCT number</a> on ClinicalTrials.gov 			</div> 			<div> 								           <h3 class=""locationCountryLabel"">U.S.A.</h3>               <h4>Alabama</h4>                           <h5 class=""locationCity"">Birmingham</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">University of Alabama at Birmingham Cancer Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>California</h4>                           <h5 class=""locationCity"">Duarte</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">City of Hope Comprehensive Cancer Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>Georgia</h4>                           <h5 class=""locationCity"">Atlanta</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Emory University Hospital/Winship Cancer Institute</strong>     <br>Name Not Available   </span> </div>                                   <h4>Illinois</h4>                           <h5 class=""locationCity"">Chicago</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Northwestern University</strong>     <br>Name Not Available   </span> </div>                                   <h4>Kansas</h4>                           <h5 class=""locationCity"">Kansas City</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">University of Kansas Cancer Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>Maryland</h4>                           <h5 class=""locationCity"">Baltimore</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Johns Hopkins University/Sidney Kimmel Cancer Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>Massachusetts</h4>                           <h5 class=""locationCity"">Boston</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Brigham and Women's Hospital</strong>     <br>Name Not Available   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Dana-Farber Cancer Institute</strong>     <br>Name Not Available   </span> </div>                                   <h4>Missouri</h4>                           <h5 class=""locationCity"">Saint Louis</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Siteman Cancer Center at Washington University</strong>     <br>Name Not Available   </span> </div>                                   <h4>New York</h4>                           <h5 class=""locationCity"">Bronx</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Montefiore Medical Center-Weiler Hospital</strong>     <br>Name Not Available   </span> </div>                                       <h5 class=""locationCity"">New York</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Memorial Sloan Kettering Cancer Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>North Carolina</h4>                           <h5 class=""locationCity"">Chapel Hill</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">UNC Lineberger Comprehensive Cancer Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>Ohio</h4>                           <h5 class=""locationCity"">Cleveland</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Case Comprehensive Cancer Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>Pennsylvania</h4>                           <h5 class=""locationCity"">Philadelphia</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Thomas Jefferson University Hospital</strong>     <br>Name Not Available   </span> </div>                                   <h4>Washington</h4>                           <h5 class=""locationCity"">Seattle</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Fred Hutch/University of Washington/Seattle Children's Cancer Consortium</strong>     <br>Name Not Available   </span> </div>                           			</div> 		</div> 			<div class=""trialContainer""> 			<h2 class=""hangingIndent"">17. A Study of EP0031 in Patients With Advanced RET-altered Malignancies</h2> 						<a class=""hangingIndent print-check-for-updates"" href=""/research/participate/clinical-trials-search/v?d=C1967&d=C2167&d=C93259&d=C199379&d=C172809&d=C82379&d=C116377&d=C1855&d=C65530&d=C124993&d=C148147&d=C66940&d=C2693&d=C97273&loc=0&pn=7&rl=2&st=C162158&st=C153201&st=C176727&st=C147924&st=C202131&st=C3512&st=C155908&st=C156093&st=C156094&st=C157364&st=C128798&st=C9133&st=C133254&st=C135017&st=C174510&st=C155901&st=C171612&st=C162642&t=C2926&id=NCI-2022-10316""><span>Check for Updates</span></a> 			<table class=""trialDataTable""> 				<tr class=""trialDataHeaderRow""> 					<td>Phase</td> 					<td>Type</td> 					<td>Status</td> 					<td>Age</td> 					<td>Trial IDs</td> 				</tr> 				<tr> 					<td>Phase I/II</td> 					<td>Treatment</td> 					<td>Active</td> 					<td>18 													and over 						 						</td> 					<td class=""trialIDCell""> 						<span class = ""dataTableIDLabel"">Primary ID</span> EP0031-101<br> 						<span class = ""dataTableIDLabel"">Secondary IDs</span> NCI-2022-10316<br> 						<span class = ""dataTableIDLabel"">Clinicaltrials.gov ID</span> <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT05443126"" target=""_blank"">NCT05443126</a><br> 					</td> 			</table>  			<h3>Description</h3> 			<div>The aim of this study is to assess the safety, side effects and effectiveness of EP0031 in patients with advanced RET-altered malignancies</div>  			<h3 class=""printHeading"">Eligibility Criteria</h3>  																																													<h4>Inclusion Criteria</h4> 										<div> 							<ul> 															<li>Inclusion Criteria:  Applicable to all patients:    1. Must be ≥18 years of age, with documented RET-altered cancers    2. Patients should be well informed and consented about alternative treatment options      including approved RET-targeted therapies    3. ECOG performance status of 0 or 1 and life expectancy &gt;3 months at screening    4. Ability to understand and provide written informed consent and able to participate      in all required evaluations and procedures    5. Additional cohort specific criteria apply  Exclusion Criteria:  Patients with any of the following will not be included in the study:    1. Any known major driver gene alterations other than RET.    2. Spinal cord compression or brain metastases. Patients with stable brain metastases      can be enrolled.    3. Active infection requiring systemic antibiotic, antifungal, or antiviral medication    4. Severe or uncontrolled medical condition or psychiatric condition    5. Chronic glomerulonephritis or renal transplant    6. Patients with active hepatitis B infection or active hepatitis C    7. Patients with active HIV infection. Patients living with HIV may be eligible if they      have adequate CD4+ T-cell count and no history of AIDS-defining opportunistic      infections in the past 12 months    8. Receipt of any strong inhibitor or inducer of CYP3A4    9. Impaired hepatic or renal function, inadequate bone marrow reserve or organ function   10. Any clinically important abnormalities in rhythm, conduction, or morphology on      resting ECG or any factor that increases the risk of QTc prolongation or of      arrhythmic events , or congestive heart failure Grade II-IV according to the New      York Heart Association, myocardial infarction, or unstable angina within the      previous 6 months   11. Uncontrolled hypertension   12. Corneal ulceration at screening</li> 												</ul> 						</div> 										 							<h3 class=""printHeading"">Trial Objectives and Outlines</h3> 				<div id=""trialObjectives""><p class='ctrp'>EP0031 is being investigated in this modular, interventional Phase I/II dose escalation</p><p class='ctrp'>and dose expansion study to investigate the optimal dose in adult patients with advanced</p><p class='ctrp'>RET-altered malignancies. Currently there are no approved RET-targeted treatments for</p><p class='ctrp'>patients who progress on first-generation SRIs. However, it is proposed that EP0031 can</p><p class='ctrp'>overcome resistance mechanisms to first generation SRIs, as EP0031 is a potent and</p><p class='ctrp'>selective RET inhibitor with broad activity against common RET fusions and mutations.</p><p class='ctrp'>Phase I (dose escalation and optimization) has completed and a RP2D has been selected for</p><p class='ctrp'>Phase II.</p></div> 			 							<h3 class=""printHeading"">Lead Organization</h3> 									<div>Ellipses Pharma</div> 														<h3 class=""printHeading"">Locations & Contacts</h3> 			<div class=""locationNoteBlock""> 				<span>Note:</span> Information about participating sites on pharmaceutical industry trials may be incomplete, so please look up the <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT05443126"" target=""_blank"">NCT number</a> on ClinicalTrials.gov 			</div> 			<div> 								           <h3 class=""locationCountryLabel"">U.S.A.</h3>               <h4>California</h4>                           <h5 class=""locationCity"">Palo Alto</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Stanford Cancer Institute Palo Alto</strong>     <br>Name Not Available   </span> </div>                                   <h4>District of Columbia</h4>                           <h5 class=""locationCity"">Washington</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">MedStar Georgetown University Hospital</strong>     <br>Name Not Available   </span> </div>                                   <h4>Illinois</h4>                           <h5 class=""locationCity"">Chicago</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Northwestern University</strong>     <br>Name Not Available   </span> </div>                                   <h4>Kentucky</h4>                           <h5 class=""locationCity"">Lexington</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">University of Kentucky/Markey Cancer Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>Massachusetts</h4>                           <h5 class=""locationCity"">Boston</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Massachusetts General Hospital Cancer Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>Michigan</h4>                           <h5 class=""locationCity"">Detroit</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Wayne State University/Karmanos Cancer Institute</strong>     <br>Name Not Available   </span> </div>                                   <h4>Missouri</h4>                           <h5 class=""locationCity"">Saint Louis</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Siteman Cancer Center at Washington University</strong>     <br>Name Not Available   </span> </div>                                   <h4>New York</h4>                           <h5 class=""locationCity"">New York</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Laura and Isaac Perlmutter Cancer Center at NYU Langone</strong>     <br>Name Not Available   </span> </div>                                   <h4>Pennsylvania</h4>                           <h5 class=""locationCity"">Philadelphia</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Jefferson Torresdale Hospital</strong>     <br>Name Not Available   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Thomas Jefferson University Hospital</strong>     <br>Name Not Available   </span> </div>                                   <h4>Texas</h4>                           <h5 class=""locationCity"">Houston</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">M D Anderson Cancer Center</strong>     <br>Contact: Vivek Subbiah <br>Email: <a href=""mailto:vsubbiah@mdanderson.org"">vsubbiah@mdanderson.org</a>   </span> </div>                                   <h4>Washington</h4>                           <h5 class=""locationCity"">Seattle</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Fred Hutch/University of Washington/Seattle Children's Cancer Consortium</strong>     <br>Name Not Available   </span> </div>                           			</div> 		</div> 			<div class=""trialContainer""> 			<h2 class=""hangingIndent"">18. A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer</h2> 						<a class=""hangingIndent print-check-for-updates"" href=""/research/participate/clinical-trials-search/v?d=C1967&d=C2167&d=C93259&d=C199379&d=C172809&d=C82379&d=C116377&d=C1855&d=C65530&d=C124993&d=C148147&d=C66940&d=C2693&d=C97273&loc=0&pn=7&rl=2&st=C162158&st=C153201&st=C176727&st=C147924&st=C202131&st=C3512&st=C155908&st=C156093&st=C156094&st=C157364&st=C128798&st=C9133&st=C133254&st=C135017&st=C174510&st=C155901&st=C171612&st=C162642&t=C2926&id=NCI-2023-00566""><span>Check for Updates</span></a> 			<table class=""trialDataTable""> 				<tr class=""trialDataHeaderRow""> 					<td>Phase</td> 					<td>Type</td> 					<td>Status</td> 					<td>Age</td> 					<td>Trial IDs</td> 				</tr> 				<tr> 					<td>Phase II</td> 					<td>Treatment</td> 					<td>Active</td> 					<td>18 													and over 						 						</td> 					<td class=""trialIDCell""> 						<span class = ""dataTableIDLabel"">Primary ID</span> CR109264<br> 						<span class = ""dataTableIDLabel"">Secondary IDs</span> NCI-2023-00566, 2022-000526-21, 2023-505065-91-00, 61186372NSC2002<br> 						<span class = ""dataTableIDLabel"">Clinicaltrials.gov ID</span> <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT05498428"" target=""_blank"">NCT05498428</a><br> 					</td> 			</table>  			<h3>Description</h3> 			<div>The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) (subcutaneous co-formulation [SC-CF]) in combination treatment (all cohorts except Cohort 4) and to characterize the safety of amivantamab SC-CF (Cohort 4).</div>  			<h3 class=""printHeading"">Eligibility Criteria</h3>  																																																																																																																																																																																																																																																																																																																																																							<h4>Inclusion Criteria</h4> 										<div> 							<ul> 															<li>Participant must have histologically or cytologically confirmed, locally advanced or metastatic, non-small cell lung cancer (NSCLC) that is not amenable to curative therapy including surgical resection or chemoradiation. Additional Cohort specific disease requirements include: Cohorts 1, 3, 3b, 5, 6 and 7: epidermal growth factor receptor (EGFR) exon 19 deletion (Exon19del) or Exon 21 L858R mutation; Cohort 2: EGFR Exon 20ins mutation. Cohorts 1,5,and6: Participant should not have received any prior systemic therapy for locally advanced or metastatic NSCLC. Cohort 2: Participant should not have received any prior systemic therapy for locally advanced or metastatic NSCLC. Cohorts 3and3b: Participant must have progressed on or after osimertinib monotherapy as the most recent line of treatment. Osimertinib must have been administered as either the first-line treatment for locally advanced or metastatic disease or in the second-line setting after prior treatment with first- or second-generation EGFR tyrosine kinase inhibitor (TKI) as a monotherapy. Cohort 4: Participants need to currently be on an amivantamab IV Q2W regimen (1,050 mg or 1,400 mg depending on weight) for at least 8 weeks, as part of standard of care, an expanded access program, or as a rollover from a long-term extension, without any amivantamab dose reduction. Cohort 7: Participants must have progressed on or after the combination of amivantamab and lazertinib as the most recent line of treatment. The combination of amivantamab and lazertinib must have been administered as the first-line treatment for locally advanced or metastatic disease. Cohort 2, 3, 3b, and 7 only: Squamous NSCLC are excluded. EGFR mutation must have been identified as determined by Food and Drug Administration (FDA) approved or other validated test of either circulating tumor deoxyribonucleic acid (ctDNA) or tumor tissue in a clinical laboratory improvement amendments (CLIA) certified laboratory (sites in the United states [US]) or an accredited local laboratory (sites outside of the US). A copy of the initial test report documenting the EGFR mutation must be included in the participant records and a deidentified copy must also be submitted to the sponsor</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>All cohorts except Cohort 4: Participants must have at least 1 measurable lesion, according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. If the only target lesion has been previously irradiated, it must show signs of disease progression since radiation was completed If only 1 non-irradiated measurable lesion exists, which undergoes a biopsy and is acceptable as a target lesion, the baseline tumor assessment scans should be performed at least 14 days after the biopsy</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>May have a prior or concurrent second malignancy (other than the disease under study) which natural history or treatment is unlikely to interfere with any study endpoints of safety or the efficacy of the study treatment(s)</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Have adequate organ (renal, hepatic, hematological, coagulation and cardiac) functions</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Participant must have eastern cooperative oncology group (ECOG) status of 0 or 1</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Cohort 6: Must be eligible for, and agree to comply with, the use of prophylactic anticoagulation with a direct oral anticoagulant or a low molecular weight heparin during the first 4 months of study treatment</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>A participant must agree not to donate eggs (ova, oocytes) or freeze for future use for the purposes of assisted reproduction during the study and for a period of 6 months after receiving the last dose of study treatment. Female participants should consider preservation of eggs prior to study treatment as anti-cancer treatments may impair fertility</li> 												</ul> 						</div> 														<h4>Exclusion Criteria</h4> 										<div> 							<ul> 																<li>Participant has a medical history of interstitial lung disease (ILD), including drug induced ILD or radiation pneumonitis</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Participant has a history of hypersensitivity to any excipients of the investigational products to be used in their enrollment cohort</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Participant has received a live or live attenuated vaccine within 3 months before Cycle 1 Day 1. The seasonal influenza vaccine and non-live vaccines against Coronavirus disease 19 (COVID-19) are not exclusionary</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>For all cohorts (with regimens potentially including lazertinib): Participant is currently receiving medications or herbal supplements known to be potent Cytochrome (CYP3A4/5) inducers and is unable to stop use for an appropriate washout period prior to Cycle 1 Day 1</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Other clinically active liver disease of infectious origin</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Participant has a history of clinically significant cardiovascular disease including, but not limited to: a) All cohorts: diagnosis of deep vein thrombosis or pulmonary embolism within 1 month prior to the first dose of study treatment(s), or any of the following within 6 months prior to the first dose of study treatment(s): myocardial infarction, unstable angina, stroke, transient ischemic attack, coronary/peripheral artery bypass graft, or any acute coronary syndrome. Clinically non-significant thrombosis, such as non-obstructive catheter-associated clots, are not exclusionary; b) All cohorts (with regimens potentially including lazertinib): Participant has a significant genetic predisposition to venous thromboembolic events (VTE; such as Factor V Leiden); c) All cohorts (with regimens potentially including lazertinib): Participant has a prior history of VTE and is not on appropriate therapeutic anticoagulation as per NCCN or local guidelines; d) prolonged corrected QT interval by Fridericia (QTcF) interval greater than (&gt;) 480 milliseconds (msec) or clinically significant cardiac arrhythmia or electrophysiologic disease (example, placement of implantable cardioverter defibrillator or atrial fibrillation with uncontrolled rate); e) uncontrolled (persistent) hypertension: systolic blood pressure &gt;160 millimeter(s) of mercury (mmHg); diastolic blood pressure &gt;100 mmHg; f) Congestive heart failure defined as NYHA class III-IV or hospitalization for congestive heart failure (CHF) (any New York Heart Association [NYHA] class) within 6 months of treatment initiation at Cycle 1/day 1 (C1D1); g) pericarditis/clinically significant pericardial effusion; h) myocarditis; i) baseline left ventricular ejection fraction (LVEF) below the institution&#39;s lower limit of normal at screening, as assessed by echocardiogram or multigated acquisition (MUGA) scan</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Participant has symptomatic brain metastases. A participant with asymptomatic or previously treated and stable brain metastases may participate in this study. Participants who have received definitive radiation or surgical treatment for symptomatic or unstable brain metastases and have been clinically stable and asymptomatic for at least 2 weeks before Screening are eligible, provided they have been either off corticosteroid treatment or are receiving low-dose corticosteroid treatment (less than or equal to [&lt;=] 10 milligrams per day [mg/day] prednisone or equivalent) for at least 2 weeks prior to treatment allocation</li> 												</ul> 						</div> 							 			 							<h3 class=""printHeading"">Lead Organization</h3> 									<div>Janssen Pharmaceuticals</div> 														<h3 class=""printHeading"">Locations & Contacts</h3> 			<div class=""locationNoteBlock""> 				<span>Note:</span> Information about participating sites on pharmaceutical industry trials may be incomplete, so please look up the <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT05498428"" target=""_blank"">NCT number</a> on ClinicalTrials.gov 			</div> 			<div> 								           <h3 class=""locationCountryLabel"">U.S.A.</h3>               <h4>California</h4>                           <h5 class=""locationCity"">La Jolla</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">UC San Diego Moores Cancer Center</strong>     <br>Name Not Available   </span> </div>                                       <h5 class=""locationCity"">Orange</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">UC Irvine Health/Chao Family Comprehensive Cancer Center</strong>     <br>Contact: Grant T Huttar <br>Phone: 714-509-2424 <br>Email: <a href=""mailto:ghuttar@hs.uci.edu"">ghuttar@hs.uci.edu</a>   </span> </div>                                       <h5 class=""locationCity"">Palo Alto</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Stanford Cancer Institute Palo Alto</strong>     <br>Name Not Available   </span> </div>                                   <h4>Florida</h4>                           <h5 class=""locationCity"">Tampa</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Moffitt Cancer Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>Kansas</h4>                           <h5 class=""locationCity"">Kansas City</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">University of Kansas Cancer Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>Maryland</h4>                           <h5 class=""locationCity"">Baltimore</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Johns Hopkins University/Sidney Kimmel Cancer Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>Missouri</h4>                           <h5 class=""locationCity"">Saint Louis</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Siteman Cancer Center at Washington University</strong>     <br>Name Not Available   </span> </div>                                   <h4>New Jersey</h4>                           <h5 class=""locationCity"">Hackensack</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Hackensack University Medical Center</strong>     <br>Name Not Available   </span> </div>                                       <h5 class=""locationCity"">New Brunswick</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Rutgers Cancer Institute of New Jersey</strong>     <br>Name Not Available   </span> </div>                                   <h4>Utah</h4>                           <h5 class=""locationCity"">Salt Lake City</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Huntsman Cancer Institute/University of Utah</strong>     <br>Name Not Available   </span> </div>                           			</div> 		</div> 			<div class=""trialContainer""> 			<h2 class=""hangingIndent"">19. First in Human Study of AZD9592 in Solid Tumors</h2> 						<a class=""hangingIndent print-check-for-updates"" href=""/research/participate/clinical-trials-search/v?d=C1967&d=C2167&d=C93259&d=C199379&d=C172809&d=C82379&d=C116377&d=C1855&d=C65530&d=C124993&d=C148147&d=C66940&d=C2693&d=C97273&loc=0&pn=7&rl=2&st=C162158&st=C153201&st=C176727&st=C147924&st=C202131&st=C3512&st=C155908&st=C156093&st=C156094&st=C157364&st=C128798&st=C9133&st=C133254&st=C135017&st=C174510&st=C155901&st=C171612&st=C162642&t=C2926&id=NCI-2022-10927""><span>Check for Updates</span></a> 			<table class=""trialDataTable""> 				<tr class=""trialDataHeaderRow""> 					<td>Phase</td> 					<td>Type</td> 					<td>Status</td> 					<td>Age</td> 					<td>Trial IDs</td> 				</tr> 				<tr> 					<td>Phase I</td> 					<td>Treatment</td> 					<td>Active</td> 					<td>18 													and over 						 						</td> 					<td class=""trialIDCell""> 						<span class = ""dataTableIDLabel"">Primary ID</span> D9350C00001<br> 						<span class = ""dataTableIDLabel"">Secondary IDs</span> NCI-2022-10927<br> 						<span class = ""dataTableIDLabel"">Clinicaltrials.gov ID</span> <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT05647122"" target=""_blank"">NCT05647122</a><br> 					</td> 			</table>  			<h3>Description</h3> 			<div>This is a first-in-human (FIH) Phase I, multi-center, open-label, study of AZD9592, in patients with advanced solid tumors. The study consists of several study modules, each evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics (PK), pharmacodynamics, anti-tumor activity, and immunogenicity of AZD9592, as monotherapy or in combination with anti-cancer agents.</div>  			<h3 class=""printHeading"">Eligibility Criteria</h3>  																																																																																																																																																																																																																																																													<h4>Inclusion Criteria</h4> 										<div> 							<ul> 															<li>Age ≥ 18 years</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-1</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Life expectancy ≥ 12 weeks</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Measurable disease per RECIST v1.1</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Adequate organ and marrow function as defined in the protocol Additional Inclusion Criteria for Module 1: • Histologically or cytologically confirmed metastatic or locally advanced EGFRmut., NSCLC; metastatic EGFRwt. NSCLC; recurrent or metastatic HNSCC of the oral cavity; metastatic CRC. Additional Inclusion Criteria for Module 2: • Histologically or cytologically confirmed metastatic NSCLC EGFRmut. Additional Inclusion Criteria for Module 3: • Histologically or cytologically confirmed metastatic CRC. Key</li> 												</ul> 						</div> 														<h4>Exclusion Criteria</h4> 										<div> 							<ul> 																<li>History of (non-infectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Spinal cord compression or a history of leptomeningeal carcinomatosis.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Active infection including tuberculosis and HBV, HCV or HIV</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Brain metastases unless treated (prior treatment required only for Module 1), asymptomatic, stable, and not requiring continuous corticosteroids at a dose of &gt; 10 mg prednisone/day or equivalent for at least 4 weeks prior to start of study treatment.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Participants with cardiac comorbidities as defined in the study protocol</li> 												</ul> 						</div> 							 			 							<h3 class=""printHeading"">Lead Organization</h3> 									<div>AstraZeneca Pharmaceuticals LP</div> 														<h3 class=""printHeading"">Locations & Contacts</h3> 			<div class=""locationNoteBlock""> 				<span>Note:</span> Information about participating sites on pharmaceutical industry trials may be incomplete, so please look up the <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT05647122"" target=""_blank"">NCT number</a> on ClinicalTrials.gov 			</div> 			<div> 								           <h3 class=""locationCountryLabel"">U.S.A.</h3>               <h4>California</h4>                           <h5 class=""locationCity"">Duarte</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">City of Hope Comprehensive Cancer Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>Connecticut</h4>                           <h5 class=""locationCity"">New Haven</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Yale University</strong>     <br>Name Not Available   </span> </div>                                   <h4>Massachusetts</h4>                           <h5 class=""locationCity"">Boston</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Brigham and Women's Hospital</strong>     <br>Name Not Available   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Dana-Farber Cancer Institute</strong>     <br>Name Not Available   </span> </div>                                   <h4>New York</h4>                           <h5 class=""locationCity"">New York</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Icahn School of Medicine at Mount Sinai</strong>     <br>Name Not Available   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Laura and Isaac Perlmutter Cancer Center at NYU Langone</strong>     <br>Name Not Available   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Memorial Sloan Kettering Cancer Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>Pennsylvania</h4>                           <h5 class=""locationCity"">Philadelphia</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">University of Pennsylvania/Abramson Cancer Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>Texas</h4>                           <h5 class=""locationCity"">Houston</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">M D Anderson Cancer Center</strong>     <br>Name Not Available   </span> </div>                           			</div> 		</div> 			<div class=""trialContainer""> 			<h2 class=""hangingIndent"">20. Cabozantinib-s-malate in Treating Patients with Non-small Cell Lung Cancer That Is Metastatic or Cannot Be Removed by Surgery</h2> 						<a class=""hangingIndent print-check-for-updates"" href=""/research/participate/clinical-trials-search/v?d=C1967&d=C2167&d=C93259&d=C199379&d=C172809&d=C82379&d=C116377&d=C1855&d=C65530&d=C124993&d=C148147&d=C66940&d=C2693&d=C97273&loc=0&pn=7&rl=2&st=C162158&st=C153201&st=C176727&st=C147924&st=C202131&st=C3512&st=C155908&st=C156093&st=C156094&st=C157364&st=C128798&st=C9133&st=C133254&st=C135017&st=C174510&st=C155901&st=C171612&st=C162642&t=C2926&id=NCI-2012-01187""><span>Check for Updates</span></a> 			<table class=""trialDataTable""> 				<tr class=""trialDataHeaderRow""> 					<td>Phase</td> 					<td>Type</td> 					<td>Status</td> 					<td>Age</td> 					<td>Trial IDs</td> 				</tr> 				<tr> 					<td>Phase II</td> 					<td>Treatment</td> 					<td>Active</td> 					<td>18 													and over 						 						</td> 					<td class=""trialIDCell""> 						<span class = ""dataTableIDLabel"">Primary ID</span> 12-097<br> 						<span class = ""dataTableIDLabel"">Secondary IDs</span> NCI-2012-01187<br> 						<span class = ""dataTableIDLabel"">Clinicaltrials.gov ID</span> <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT01639508"" target=""_blank"">NCT01639508</a><br> 					</td> 			</table>  			<h3>Description</h3> 			<div>This phase II trial studies how well cabozantinib-s-malate works in treating patients with non-small cell lung cancer that has spread to other parts of the body (metastatic) or cannot be removed by surgery. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.</div>  			<h3 class=""printHeading"">Eligibility Criteria</h3>  																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																									<h4>Inclusion Criteria</h4> 										<div> 							<ul> 															<li>The subject has a pathologic diagnosis of non-small cell lung carcinoma that is metastatic or unresectable</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Documented presence * GROUP A: kinesin family member 5B (KIF5B)-RET or related variant RET fusions * GROUP B: any of the following aberrations ** NTRK fusion ** MET overexpression, amplification, or mutation ** AXL overexpression, amplification, or mutation * GROUP C: ROS1 fusion * GROUP D: RET-fusion post-progression on selective RET inhibitor</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Measurable disease by RECIST1.1</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>The subject has a Karnofsky performance status of &gt; 70%</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Absolute neutrophil count (ANC) &gt;= 1500/mm^3 without colony stimulating factor support</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Platelets &gt;= 100,000/mm^3</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Hemoglobin &gt;= 9 g/dL</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Bilirubin =&lt; 1.5 x the upper limit of normal (ULN); for subjects with known Gilbert&#39;s disease, bilirubin =&lt; 3.0 mg/dL</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Serum creatinine =&lt; 1.5 x ULN, or creatinine clearance (CrCl) &gt;= 30 mL/min; for creatinine clearance estimation, the Cockcroft and Gault equation should be used</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =&lt; 3.0 x ULN if no liver involvement, or =&lt; 5 x ULN with liver involvement</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Urine protein/creatinine ratio (UPCR) =&lt; 1 mg/mg (113.2 mg/mmol) creatinine or 24-hour (hr) urine protein of &lt; 1 g</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Serum phosphorus, magnesium, and potassium &gt;= lower limit of normal (LLN) after adequate supplementation if necessary</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>The subject is capable of understanding and complying with the protocol requirements and has signed the informed consent document</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Sexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (e.g., male or female condom) during the course of the study and for 4 months after the last dose of study drug(s), even if oral contraceptives are also used; all subjects of reproductive potential must agree to use both a barrier method and a second method of birth control; women of childbearing potential must have a negative pregnancy test at screening</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Women of childbearing potential include women who have experienced menarche and who have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or are not postmenopausal; postmenopause is defined as amenorrhea &gt;= 12 consecutive months; Note: women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, antiestrogens, ovarian suppression or any other reversible reason</li> 												</ul> 						</div> 														<h4>Exclusion Criteria</h4> 										<div> 							<ul> 																<li>Any type of systemic anticancer agent (including investigational) within 3 weeks of first dose of study treatment, or within 5 half-lives of the agent whichever is shorter; subjects on luteinizing-hormone-releasing hormone (LHRH) or gonadotropin-releasing hormone (GnRH) agonists may be maintained on these agents</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Prior treatment with cabozantinib</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Radiation therapy for bone or brain metastasis within 2 weeks, any other external radiation therapy within 4 weeks of first dose of study drug; systemic treatment with radionuclides within 4 weeks; subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>The subject has not recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =&lt; grade 1 from toxicity due to all prior therapies except alopecia and other non-clinically significant adverse events (AEs)</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Known uncontrolled symptomatic brain metastases or cranial epidural disease; subjects previously treated and on stable dose of corticosteroids and/or anticonvulsants for &gt; 10 days, or not requiring such medications, are eligible; baseline brain scans are not required to confirm eligibility</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>The subject requires concomitant treatment, in therapeutic doses, unless deemed clinically unsafe to discontinue, with anticoagulants such as warfarin or warfarin-related agents, unfractionated heparin, thrombin or factor Xa inhibitors, or antiplatelet agents (e.g., clopidogrel); low dose aspirin (=&lt; 100 mg/day), low-dose warfarin (=&lt; 1 mg/day) are permitted; both prophylactic and/or treatment dose low molecular weight (fractionated) heparin (LMWH) are permitted and are the preferred agents to administer</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>The subject has experienced any of the following within 3 months before the first dose of study treatment: * Clinically-significant hematemesis or gastrointestinal bleeding * Clinically-significant hemoptysis of &gt;= 0.5 teaspoon (2.5 ml) of red blood * Any other signs indicative of pulmonary hemorrhage</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>The subject has radiographic evidence of cavitating pulmonary lesion(s)</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>The subject has tumor invading major blood vessels</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>The subject has any evidence of an endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinib</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Cardiovascular disorders including * Congestive heart failure (CHF): New York Heart Association (NYHA) class III (moderate) or class IV (severe) at the time of screening * Concurrent uncontrolled hypertension defined as sustained blood pressure (BP) &gt;= 150 mm Hg systolic, or &gt;= 90 mm Hg diastolic despite optimal antihypertensive treatment (Note: if there is any BP measurement that is performed within the screening period that is &lt; 150 mm Hg systolic and &lt; 90 mm Hg diastolic, then BP does not meet definition of sustained) * Any congenital history of long QT syndrome * Any of the following within 6 months before the first dose of study treatment: ** Unstable angina pectoris ** Clinically-significant cardiac arrhythmias ** Stroke (including transient ischemic attack [TIA], or other ischemic event) ** Myocardial infarction ** Thromboembolic event requiring therapeutic anticoagulation (Note: subjects with a venous filter [e.g. vena cava filter] are not eligible for this study)</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Gastrointestinal disorders particularly those associated with a high risk of perforation or fistula formation including: * Any of the following within 28 days before the first dose of study treatment ** Intra-abdominal tumor/metastases invading gastrointestinal (GI) mucosa (malignant abdominal ascites does not constitute mucosal invasion) ** Active peptic ulcer disease ** Inflammatory bowel disease (including ulcerative colitis and Crohn&#39;s disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis ** Malabsorption syndrome * Any of the following within 6 months before the first dose of study treatment: ** History of abdominal fistula ** Gastrointestinal perforation ** Bowel obstruction or gastric outlet obstruction ** Intra-abdominal abscess; Note: complete resolution of an intra-abdominal abscess must be confirmed prior to initiating treatment with cabozantinib even if the abscess occurred more than 6 months ago</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>GI surgery (particularly when associated with delayed or incomplete healing) within 28 days; Note: complete healing following abdominal surgery must be confirmed prior to initiating treatment with cabozantinib even if surgery occurred more than 28 days ago</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Other disorders associated with a high risk of fistula formation including percutaneous endoscopic gastrostomy (PEG) tube placement within 3 months before the first dose of study therapy or concurrent evidence of intraluminal tumor involving the trachea and esophagus</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Other clinically significant disorders such as: * Active infection requiring systemic treatment within 28 days before the first dose of study treatment * Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment * History of organ transplant * Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment * Major surgery (e.g., thoracotomy, removal or biopsy of brain metastasis) within 3 months before week 1 day 1; complete wound healing from major surgery must have occurred 1 month before week 1 day 1 and from minor surgery (e.g., simple excision, tooth extraction) at least 10 days before week 1 day 1; subjects with clinically relevant ongoing complications from prior surgery are not eligible</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>The subject is unable to swallow tablets</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>The subject has a corrected QT interval calculated by the Fridericia formula (QTcF) &gt; 500 ms within 14 days before week 1 day 1</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>The subject is pregnant or breastfeeding</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>The subject has a previously identified allergy or hypersensitivity to components of the study treatment formulation</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>The subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Uncontrolled concurrent malignancy that would limit assessment of efficacy of cabozantinib</li> 												</ul> 						</div> 							 							<h3 class=""printHeading"">Trial Objectives and Outlines</h3> 				<div id=""trialObjectives""><p class='ctrp'>PRIMARY OBJECTIVES:</p><p class='ctrp'>I. To determine the objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 criteria to cabozantinib (cabozantinib-s-malate) in patients with advanced non-small cell lung cancer (NSCLC) whose tumor test positive for a rearranged during transfection proto-oncogene (RET) fusion. (Group A)</p><p class='ctrp'>II. To determine the objective response rate (ORR) by RECIST v1.1 criteria to cabozantinib in patients with advanced NSCLC whose tumors test positive for a neurotrophic tyrosine receptor kinase (NTRK) fusion or MET proto-oncogene, receptor tyrosine kinase (MET) or AXL receptor tyrosine kinase (AXL) overexpression, amplification, or mutation. (Group B)</p><p class='ctrp'>III. To determine the objective response rate (ORR) by RECIST v1.1 criteria to cabozantinib in patients with advanced NSCLC whose tumors test positive for a ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) fusion. (Group C)</p><p class='ctrp'>IV. To perform a single-arm Simon two-stage phase II study of cabozantinib, in patients with advanced RET-fusion-positive NSCLCs following progression with a selective RET inhibitors. (Group D)</p><p class='ctrp'></p><p class='ctrp'>SECONDARY OBJECTIVES:</p><p class='ctrp'>I. To evaluate progression-free survival (PFS) and overall survival (OS) of patients with RET fusion-positive NSCLCs who were treated with cabozantinib. (Group A)</p><p class='ctrp'>II. To evaluate ORR at 12 weeks, the safety of cabozantinib in patients with RET fusion-positive NSCLCs. (Group A)</p><p class='ctrp'>III. To evaluate ORR at 12 weeks, progression-free survival (PFS) and overall survival (OS) of patients with advanced NSCLCs whose tumors test positive for a NTRK fusion or MET or AXL overexpression or amplification who were treated with cabozantinib. (Group B)</p><p class='ctrp'>IV. To evaluate the safety of cabozantinib in patients advanced NSCLCs with a NTRK fusion or MET or AXL overexpression, amplification, or mutation. (Group B)</p><p class='ctrp'>V. To evaluate ORR at 12 weeks, progression-free survival (PFS) and overall survival (OS) of patients with RET fusion-positive NSCLCs who were treated with cabozantinib. (Group C)</p><p class='ctrp'>VI. To evaluate the safety of cabozantinib in patients with ROS1 fusion-positive NSCLCs. (Group C)</p><p class='ctrp'></p><p class='ctrp'>OUTLINE:</p><p class='ctrp'>Patients receive cabozantinib-s-malate orally (PO) once daily (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who continue to benefit from treatment based on the investigator&#39;s assessment may continue to receive cabozantinib-s-malate after evidence of radiographic progression via RECIST v1.1.</p><p class='ctrp'></p><p class='ctrp'>After completion of study treatment, patients are followed up at 30 days.</p></div> 			 							<h3 class=""printHeading"">Lead Organization</h3> 									<div>Memorial Sloan Kettering Cancer Center</div> 													<div>Principal Investigator: Alexander Edward Dela C. Drilon</div> 										<h3 class=""printHeading"">Locations & Contacts</h3> 			<div class=""locationNoteBlock""> 				<span>Note:</span> Information about participating sites on pharmaceutical industry trials may be incomplete, so please look up the <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT01639508"" target=""_blank"">NCT number</a> on ClinicalTrials.gov 			</div> 			<div> 								           <h3 class=""locationCountryLabel"">U.S.A.</h3>               <h4>New Jersey</h4>                           <h5 class=""locationCity"">Basking Ridge</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Memorial Sloan Kettering Basking Ridge</strong>     <br>Contact: Alexander Edward Dela C. Drilon <br>Phone: 646-888-4206   </span> </div>                                       <h5 class=""locationCity"">Middletown</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Memorial Sloan Kettering Monmouth</strong>     <br>Contact: Alexander Edward Dela C. Drilon <br>Phone: 646-888-4206   </span> </div>                                       <h5 class=""locationCity"">Montvale</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Memorial Sloan Kettering Bergen</strong>     <br>Contact: Alexander Edward Dela C. Drilon <br>Phone: 646-888-4206   </span> </div>                                   <h4>New York</h4>                           <h5 class=""locationCity"">Commack</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Memorial Sloan Kettering Commack</strong>     <br>Contact: Alexander Edward Dela C. Drilon <br>Phone: 646-888-4206   </span> </div>                                       <h5 class=""locationCity"">New York</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Memorial Sloan Kettering Cancer Center</strong>     <br>Contact: Alexander Edward Dela C. Drilon <br>Phone: 646-888-4206   </span> </div>                                       <h5 class=""locationCity"">Sleepy Hollow</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Memorial Sloan Kettering Sleepy Hollow</strong>     <br>Contact: Alexander Edward Dela C. Drilon <br>Phone: 646-888-4206   </span> </div>                                       <h5 class=""locationCity"">Uniondale</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Memorial Sloan Kettering Nassau</strong>     <br>Contact: Alexander Edward Dela C. Drilon <br>Phone: 646-888-4206   </span> </div>                                       <h5 class=""locationCity"">West Harrison</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Memorial Sloan Kettering Westchester</strong>     <br>Contact: Alexander Edward Dela C. Drilon <br>Phone: 646-888-4206   </span> </div>                           			</div> 		</div> 			<div class=""trialContainer""> 			<h2 class=""hangingIndent"">21. APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors</h2> 						<a class=""hangingIndent print-check-for-updates"" href=""/research/participate/clinical-trials-search/v?d=C1967&d=C2167&d=C93259&d=C199379&d=C172809&d=C82379&d=C116377&d=C1855&d=C65530&d=C124993&d=C148147&d=C66940&d=C2693&d=C97273&loc=0&pn=7&rl=2&st=C162158&st=C153201&st=C176727&st=C147924&st=C202131&st=C3512&st=C155908&st=C156093&st=C156094&st=C157364&st=C128798&st=C9133&st=C133254&st=C135017&st=C174510&st=C155901&st=C171612&st=C162642&t=C2926&id=NCI-2017-01648""><span>Check for Updates</span></a> 			<table class=""trialDataTable""> 				<tr class=""trialDataHeaderRow""> 					<td>Phase</td> 					<td>Type</td> 					<td>Status</td> 					<td>Age</td> 					<td>Trial IDs</td> 				</tr> 				<tr> 					<td>Phase II</td> 					<td>Treatment</td> 					<td>Active</td> 					<td>18 													and over 						 						</td> 					<td class=""trialIDCell""> 						<span class = ""dataTableIDLabel"">Primary ID</span> APL-101-01<br> 						<span class = ""dataTableIDLabel"">Secondary IDs</span> NCI-2017-01648, APL-101-01 (CBT-101-01), CBT-101-01<br> 						<span class = ""dataTableIDLabel"">Clinicaltrials.gov ID</span> <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT03175224"" target=""_blank"">NCT03175224</a><br> 					</td> 			</table>  			<h3>Description</h3> 			<div>To assess:    -  efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14      skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET      amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET      alterations, solid tumors harboring wild-type MET with overexpression of HGF and MET    -  efficacy of APL-101 as an add-on therapy to EGFR inhibitor for the treatment of      NSCLC harboring EGFR activating mutations and developed acquired resistance with MET      amplification and disease progression after documented CR or PR with 1st line EGFR      inhibitors (EGFR-I)</div>  			<h3 class=""printHeading"">Eligibility Criteria</h3>  																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																											<h4>Inclusion Criteria</h4> 										<div> 							<ul> 															<li>Men and women 18 years of age or older.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>9 cohorts will be enrolled:</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Cohort A1 / Exon 14 NSCLC MET inhibitor naive in first line: Histologically or cytologically confirmed NSCLC with Exon 14 skipping mutations; all histologies; unresectable or metastatic disease (Stage 3b/4); treatment-naive subjects in first line; not received any MET inhibitor and no known MET kinase inhibitor resistance mutations</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Cohort A2 / Exon 14 NSCLC - MET inhibitor na&#239;ve: Histologically or cytologically confirmed NSCLC with Exon 14 skipping mutations; all histologies; unresectable or metastatic disease (Stage 3b/4); pretreated subjects refractory to or intolerant of standard therapies with no more than three lines of prior therapy in the unresectable or metastatic setting; not received any MET inhibitor and no known MET kinase inhibitor resistance mutations</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Cohort B / Exon 14 NSCLC MET inhibitor experienced: ENROLLMENT COMPLETED</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Cohort C / MET amplification basket tumor types excluding primary CNS tumors: Any solid tumor type regardless of histology excluding primary CNS tumors, with MET amplification; unresectable or metastatic disease, refractory to or intolerant of standard therapies, or refused standard therapies, or if therapy was unavailable or unfeasible, with no more than 3 prior lines of therapy in the unresectable or metastatic setting; not received any MET inhibitor and no known MET kinase inhibitor resistance mutations</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Cohort C1 / MET amplification and wild-type EGFR NSCLC: NSCLC regardless of histology, harboring MET amplification and wild-type EGFR; unresectable or metastatic disease, previously untreated or treated with no more than 3 prior lines of therapy in the unresectable or metastatic setting; not received any MET inhibitor and no known MET kinase inhibitor resistance mutations</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Cohort C2 / EGFR positive NSCLC with acquired MET amplification (APL-101 Add-on Therapy): Unresectable or metastatic NSCLC regardless of histology, harboring EGFR activating mutations with acquired MET-Amplification as resistance mechanism to the EGFR-I; developed resistance to first-line EGFR-inhibitor therapy after an initial response (documented PR for at least 12 weeks); radiological documentation of disease progression per RECIST on first-line EGFR inhibitor therapy; currently on an EGFR-inhibitor therapy and agrees to receive APL-101 as an add-on therapy during the study; no history of interstitial lung disease (ILD)/pneumonitis, Grade ≥3 liver toxicity or QT prolongation with EGFR-I therapy; not received any MET inhibitor and no known MET kinase inhibitor resistance mutations</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Cohort D / MET fusion basket tumor types excluding primary CNS tumors: any solid tumor type regardless of histology excluding primary CNS tumors; unresectable or metastatic disease, refractory to or intolerant of standard therapies, or refused standard therapies, or if therapy was unavailable or unfeasible, with no more than 3 prior lines of therapy in the unresectable or metastatic setting; not received any MET inhibitor and no known MET kinase inhibitor resistance mutations</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Cohort E / Primary CNS tumors with MET alterations: subjects with primary CNS tumors who meet inclusion criteria of MET dysregulations defined as single or co-occurred MET fusion including PTPRZ1-MET (ZM) fusion, MET Exon 14 skipping mutations, or MET amplification; refractory to or intolerant of standard therapies, or refused standard therapies, or if therapy was unavailable or unfeasible, with no more than 3 prior lines of therapy in the unresectable or metastatic setting; not received any MET inhibitor and no known MET kinase inhibitor resistance mutations; neurological symptoms controlled on a stable/decreasing dose of steroids for at least 2 weeks before C1D1</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Cohort F / Basket tumor types harboring wild-type MET with over-expression of HGF and MET: any solid tumor type regardless of histology harboring wild-type MET with overexpression of HGF and MET; Unresectable or metastatic disease, refractory to or intolerant of standard therapies, or refused standard therapies, or if therapy was unavailable or unfeasible, with no more than 3 prior lines of therapy in the unresectable or metastatic setting; not received any MET inhibitor and no known MET kinase inhibitor resistance mutations</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Treated or untreated asymptomatic parenchymal CNS disease or leptomeningeal disease is allowed.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Presence of ≥1 measurable lesion (scan done ≤28 days of C1D1) to serve as target lesion according to relevant criteria</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>ECOG performance status of 0-1. For subjects with primary CNS tumors, KPS score ≥70.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Acceptable organ function</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>For all prior anticancer treatment, a duration of 30 days or 5 half-lives of the agents used, whichever is shorter, must have elapsed, and any encountered toxicity must have resolved to levels meeting all the other eligibility criteria prior to the first dose of study treatment. Palliative radiotherapy to non-target lesions should be completed within 2 weeks prior to APL-101 administration.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Adequate cardiac function</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Women of child-bearing potential must have a negative serum or Beta-hCG at screening or evidence of surgical sterility or evidence of post-menopausal status</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>No planned major surgery within 4 weeks of first dose of APL-101</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Expected survival (life expectancy) ≥ 3 months from C1D1</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Provision of sample; e.g. archival or a fresh tumor biopsy sample (if safe and feasible) either from the primary or a metastatic site) or liquid biopsy sample (if tumor tissue is insufficient or lacking, and approved by the sponsor) is required for prospective central lab confirmation for study entry (subjects with previously confirmed molecular status by the Sponsor designated central lab or FDA approved NGS based MET testing may be exempted, subjected to Sponsor approval. Major</li> 												</ul> 						</div> 														<h4>Exclusion Criteria</h4> 										<div> 							<ul> 																<li>Hypersensitivity to APL-101, excipients of the drug product, or other components of the study treatment regimen.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Known actionable mutation/gene rearrangement of EGFR (except for NSCLC subjects in Cohort C and C-2), ALK, ROS1, RET, NTRK, KRAS, and BRAF.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Use or intended use of any other investigational product, including herbal medications, through Study Treatment Termination.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Active uncontrolled systemic bacterial, viral, or fungal infection or clinically significant, active disease process, which in the opinion of the investigator makes the risk: benefit unfavorable for the participation of the trial.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Life-threatening illness, significant organ system dysfunction or comorbid conditions, or other reasons that, in the investigator&#39;s opinion, could compromise the subject&#39;s safety or the integrity of the study outcomes, or interfere with the absorption or metabolism of APL-101.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Unstable angina or myocardial infarction within 1 year prior to first dose of APL-101, symptomatic or unstable arrhythmia requiring medical therapy, history of congenital prolonged QT syndrome, prolonged QT interval corrected by Fridericia formula (QTcF) at screening, or concurrent treatment with a medication that is a known risk for prolonging the QT interval. Chronic controlled atrial fibrillation is not excluded.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Historical seropositive results consistent with active infection for hepatitis C virus (HCV) or hepatitis B virus (HBV) with high viral loads not actively managed with antiviral therapy and human immunodeficiency virus (HIV) positive subjects who are not clinically stable or controlled on their medication (asymptomatic subjects with CD4+ T-cell (CD4+) counts ≥ 350 cells/μL and have not had an opportunistic infection within the past 12 months prior to first dose of APL-101 would be eligible for study entry. If history is unclear, relevant test(s) at Screening will be required to confirm eligibility.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Known significant mental illness or other conditions such as active alcohol or other substance abuse that, in the opinion of the investigator, predisposes the subject to high risk of noncompliance with the protocol treatment or assessments.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Unable to swallow orally administered medication whole.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter drug absorption</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Women who are breastfeeding</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>History of another malignancy within 3 years prior to C1D1. A subject with the following malignancies is allowed if considered cured or unlikely to recur within 3 years:</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Carcinoma of the skin without melanomatous features.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Curatively treated cervical carcinoma in situ.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Bladder tumors considered superficial such as noninvasive (T1a) and carcinoma in situ (T1s), thyroid papillary cancer with prior treatment, prostate cancer which has been surgically or medically treated and not likely to recur within 3 years.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Subjects who are unable or unwilling to discontinue excluded medications (drugs with known QTc risk and known strong cytochrome P450 [CYP]3A4 inducer and/or strong inhibitors) for at least 5 half-lives prior to first dose of study drug. Subjects may qualify if such medication(s) can be safely replaced with alternate medications with less risk of drug-drug interaction.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Subjects with active COVID-19 infection.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Symptomatic and/or neurologically unstable CNS metastases, or who require an increase in steroid dose to control CNS disease. Subjects who have been receiving a stable steroid dose for at least 2 weeks prior to C1D1 may be allowed.</li> 												</ul> 						</div> 							 							<h3 class=""printHeading"">Trial Objectives and Outlines</h3> 				<div id=""trialObjectives""><p class='ctrp'>Phase 1 (lead-in stage of this study) enrollment has been completed.</p><p class='ctrp'></p><p class='ctrp'>In this Phase 2 study, efficacy, safety, and tolerability will be assessed in the</p><p class='ctrp'>following cohorts:</p><p class='ctrp'></p><p class='ctrp'>  -  Cohort A-1: NSCLC EXON 14 skip mutation, previously untreated, MET inhibitor naive</p><p class='ctrp'>     (c-Met na&#239;ve, 1L)</p><p class='ctrp'></p><p class='ctrp'>  -  Cohort A-2: NSCLC EXON 14 skip mutation, previously treated with ≤ 3 prior lines in</p><p class='ctrp'>     unresectable or metastatic setting, MET inhibitor naive (c-Met na&#239;ve, 2/3L)</p><p class='ctrp'></p><p class='ctrp'>  -  Cohort B: NSCLC EXON 14 skip mutation, previously treated with ≤ 3 prior lines in</p><p class='ctrp'>     unresectable or metastatic setting, MET inhibitor experienced (c-Met experienced;</p><p class='ctrp'>     progressed on prior c-Met inhibitor)</p><p class='ctrp'></p><p class='ctrp'>  -  Cohort C: basket of tumor types (e.g., NSCLC, upper gastrointestinal [GI],</p><p class='ctrp'>     colorectal, hepatobiliary cancer) harboring MET amplification except for primary CNS</p><p class='ctrp'>     tumors, previously treated or previously untreated but refused standard treatment,</p><p class='ctrp'>     or if treatment was unavailable or unfeasible (≤ 3 prior lines in unresectable or</p><p class='ctrp'>     metastatic setting), MET inhibitor na&#239;ve</p><p class='ctrp'></p><p class='ctrp'>  -  Cohort C-1: NSCLC harboring MET amplification and wild-type epidermal growth factor</p><p class='ctrp'>     receptor (EGFR), previously treated; or untreated but refused standard treatment, or</p><p class='ctrp'>     if treatment was unavailable or unfeasible (≤ 3 prior lines in unresectable or</p><p class='ctrp'>     metastatic setting), MET inhibitor na&#239;ve</p><p class='ctrp'></p><p class='ctrp'>  -  Cohort C-2: EGFR positive NSCLC harboring MET amplification as an acquired</p><p class='ctrp'>     resistance, documented response with first-line EGFR-Inhibitor (PR or CR per RECIST</p><p class='ctrp'>     ≥ 12 weeks), radiological documentation of disease progression per RECIST on</p><p class='ctrp'>     first-line EGFR inhibitor therapy, MET inhibitor na&#239;ve</p><p class='ctrp'></p><p class='ctrp'>  -  Cohort D: basket of tumor types except for primary CNS tumors harboring MET gene</p><p class='ctrp'>     fusions (e.g., NSCLC, upper GI, colorectal, hepatobiliary cancer), previously</p><p class='ctrp'>     treated; or previously untreated but refused standard treatment, or if treatment was</p><p class='ctrp'>     unavailable or unfeasible (≤ 3 prior lines in unresectable or metastatic setting),</p><p class='ctrp'>     MET inhibitor na&#239;ve</p><p class='ctrp'></p><p class='ctrp'>  -  Cohort E: primary CNS tumors with MET alterations (single or co-occurred MET fusion</p><p class='ctrp'>     including PTPRZ1-MET [ZM] fusion, MET Exon 14 skipping mutation, or MET</p><p class='ctrp'>     amplification), previously treated or previously untreated but refused standard</p><p class='ctrp'>     treatment, or if treatment was unavailable or unfeasible (≤ 3 prior lines), MET</p><p class='ctrp'>     inhibitor na&#239;ve</p><p class='ctrp'></p><p class='ctrp'>  -  Cohort F: basket of tumor types harboring wild-type MET with over-expression of HGF</p><p class='ctrp'>     and MET (e.g., NSCLC, upper GI, colorectal, hepatobiliary cancer or primary CNS</p><p class='ctrp'>     tumors), previously treated; or previously untreated but refused standard treatment,</p><p class='ctrp'>     or if treatment was unavailable or unfeasible (≤ 3 prior lines in unresectable or</p><p class='ctrp'>     metastatic setting), MET inhibitor na&#239;ve</p></div> 			 							<h3 class=""printHeading"">Lead Organization</h3> 									<div>Apollomics Inc.</div> 														<h3 class=""printHeading"">Locations & Contacts</h3> 			<div class=""locationNoteBlock""> 				<span>Note:</span> Information about participating sites on pharmaceutical industry trials may be incomplete, so please look up the <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT03175224"" target=""_blank"">NCT number</a> on ClinicalTrials.gov 			</div> 			<div> 								           <h3 class=""locationCountryLabel"">U.S.A.</h3>               <h4>North Carolina</h4>                           <h5 class=""locationCity"">Chapel Hill</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">UNC Lineberger Comprehensive Cancer Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>Ohio</h4>                           <h5 class=""locationCity"">Columbus</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Ohio State University Comprehensive Cancer Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>Wisconsin</h4>                           <h5 class=""locationCity"">Madison</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">University of Wisconsin Carbone Cancer Center - Eastpark Medical Center</strong>     <br>Contact: Mark Edward Burkard <br>Email: <a href=""mailto:mburkard@wisc.edu"">mburkard@wisc.edu</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">University of Wisconsin Carbone Cancer Center - University Hospital</strong>     <br>Name Not Available   </span> </div>                           			</div> 		</div> 			<div class=""trialContainer""> 			<h2 class=""hangingIndent"">22. WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer with Central Nervous System Metastases</h2> 						<a class=""hangingIndent print-check-for-updates"" href=""/research/participate/clinical-trials-search/v?d=C1967&d=C2167&d=C93259&d=C199379&d=C172809&d=C82379&d=C116377&d=C1855&d=C65530&d=C124993&d=C148147&d=C66940&d=C2693&d=C97273&loc=0&pn=7&rl=2&st=C162158&st=C153201&st=C176727&st=C147924&st=C202131&st=C3512&st=C155908&st=C156093&st=C156094&st=C157364&st=C128798&st=C9133&st=C133254&st=C135017&st=C174510&st=C155901&st=C171612&st=C162642&t=C2926&id=NCI-2019-07825""><span>Check for Updates</span></a> 			<table class=""trialDataTable""> 				<tr class=""trialDataHeaderRow""> 					<td>Phase</td> 					<td>Type</td> 					<td>Status</td> 					<td>Age</td> 					<td>Trial IDs</td> 				</tr> 				<tr> 					<td>Phase I</td> 					<td>Treatment</td> 					<td>Active</td> 					<td>18 													and over 						 						</td> 					<td class=""trialIDCell""> 						<span class = ""dataTableIDLabel"">Primary ID</span> MC1914<br> 						<span class = ""dataTableIDLabel"">Secondary IDs</span> NCI-2019-07825, 19-005001<br> 						<span class = ""dataTableIDLabel"">Clinicaltrials.gov ID</span> <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT04197934"" target=""_blank"">NCT04197934</a><br> 					</td> 			</table>  			<h3>Description</h3> 			<div>This phase I trial studies the side effects and best dose of WSD0922-FU for the treatment of glioblastoma, anaplastic astrocytoma, or non-small cell lung cancer that has spread to the central nervous system (central nervous system metastases). WSD0922-FU is a targeted treatment which blocks the EGFR protein - a strategy that has led to a lot of benefit in patients with many different cancers. WSD0922-FU may also be able to get into cancers in the brain and spinal cord and help patients with brain and spinal cord cancers.</div>  			<h3 class=""printHeading"">Eligibility Criteria</h3>  																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																							<h4>Inclusion Criteria</h4> 										<div> 							<ul> 															<li>Pre-Registration – Inclusion Criteria Specific to Dose Escalation Cohort</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Histolopathological and/or molecular confirmation of either glioblastoma, IDH wildtype (GBM), (as defined by either the 2016 or 2021 World Health Organization [WHO] classifications) anaplastic astrocytoma, IDH wildtype (AA) (as defined by the 2016 WHO classification) or non-small cell lung cancer (NSCLC)</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>EGFR Status: * GBM/AA must  either EGFR amplification and/or any activating EGFR mutation (e.g. A289T, EGFRvIII , etc.) * NSCLC must have a confirmed activating EGFR mutation (e.g. Del19, L858R, EGFRvIII, G719A, L861Q, T790M, C797S, etc.)</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Pre-Registration - Inclusion Criteria Specific to Dose Expansion Cohorts</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Glioblastoma, IDH wildtype/Anaplastic astrocytoma, IDH wildtype (GBM/AA) Cohort: * Diagnosis: Histological or molecular confirmation of either glioblastoma, IDH wildtype (GBM) (as defined by either the 2016 or 2021 WHO classifications) or anaplastic astrocytoma, IDH wildtype (AA) (as defined by the 2016 WHO classification) * EGFR status: GBM/AA must have EGFRvIII mutation</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Brain Tumor Penetration (BTP) Cohort: • Diagnosis: Histopathological or molecular confirmation of either glioblastoma, IDH wildtype (GBM) (as defined by either the 2016 or 2021 WHO classifications) or anaplastic astrocytoma, IDH wildtype (AA) (as defined by the 2016 WHO classification) • EGFR status: GBM/AA must have been previously demonstrated to have either EGFR amplification and/or any activating EGFR mutation based on any prior resection</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Non-Small Cell Lung Cancer (NSCLC) cohort: * Diagnosis: Histological confirmation of non-small cell lung cancer (NSCLC) • EGFR status: NSCLC must have confirmed activating EGFR mutation. Following protocol amendment #7, NSCLC must have EGFR C797S mutation</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Registration -Inclusion Criteria Specific to Dose Escalation Cohort</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Previous treatments: * Patients with GBM/AA must have been previously treated with radiation and temozolomide * Patients with NSCLC must have been previously treated with at least one line of single-agent therapy with an EGFR TKI e.g. gefitinib, erlotinib, afatinib, or osimertinib)</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Radiographic progression: * Patients with GBM/AA must have radiographic progression based on RANO criteria * Patients with NSCLC must have new or radiographic progression in the central nervous system (brain metastases and/or leptomeningeal metastases). Positive confirmation of CSF cytology is both necessary and sufficient to define the presence of leptomeningeal metastases for patients in this study. Patients with positive CSF cytology and brain metastases will be categorized as “leptomeningeal metastases.”</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Measurable disease</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Eastern Cooperative Oncology Group (ECOG) 0 or 1. For patients with NSCLC with leptomeningeal metastases, ECOG 2 is also acceptable</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Registration - Inclusion Criteria Specific to Dose Expansion Cohorts</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Glioblastoma, IDH wildtype/Anaplastic astrocytoma, IDH wildtype (GBM/AA) Cohort: * Previous treatments: Patients must have been previously treated with radiation and temozolomide. First recurrence only (no additional systemic therapies have been administered for recurrent disease) * Radiographic progression: Patients with GBM/AA must have radiographic progression based on RANO criteria * Patients remain eligible for enrollment if the recurrent disease has been surgically removed * Performance status: ECOG 0 or 1</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Brain Tumor Penetration (BTP) Cohort: * Previous treatments: Patients must have been previously treated with radiation and temozolomide * Radiographic progression: Patients with GBM/AA must have radiographic progression based on RANO criteria * Therapeutic surgical resection of GBM/AA required as part of routine clinical care * Performance status: ECOG 0 or 1</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Non-Small Cell Lung Cancer (NSCLC) cohort: * Previous treatments: No limitations * Radiographic progression: Patients must have radiographic progression based on RECIST 1.1 criteria * Measurable Disease * Performance Status: ECOG 0 or 1</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Registration – Inclusion Criteria Common to Dose Escalation and Dose Expansion Cohorts:</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Age &gt;= 18 years old</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Ability to understand and the willingness to sign a written informed consent document</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Hemoglobin &gt;= 9.0 g/dL (obtained =&lt; 14 days prior to registration)</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Leukocytes &gt;= 3.0 x 10^9/L (obtained =&lt; 14 days prior to registration)</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Absolute neutrophil count &gt;= 1.5 x 10^9/L (obtained =&lt; 14 days prior to registration)</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Platelets &gt;= 100 x 10^9/L (obtained =&lt; 14 days prior to registration)</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>International normalized ratio (INR) =&lt; 1.5 x upper limit of normal (ULN) (obtained =&lt; 14 days prior to registration) * Patients on a stable dose of anti-coagulation therapy will be allowed to participate if they have no signs of bleeding or clotting and the INR/prothrombin time (PT) and partial thromboplastin time (PTT)/activated (a)PTT results are compatible with an acceptable risk-benefit ratio as per the investigator’s discretion</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>aPTT =&lt; 1.5 x ULN (obtained =&lt; 14 days prior to registration) * Patients on a stable dose of anti-coagulation therapy will be allowed to participate if they have no signs of bleeding or clotting and the INR/PT and PTT/aPTT results are compatible with an acceptable risk-benefit ratio as per the investigator’s discretion</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Total bilirubin =&lt; 1.5 x ULN and =&lt; 3 mg/dL for patients with Gilbert’s disease (obtained =&lt; 14 days prior to registration)</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =&lt; 3 x ULN or =&lt; 5 x ULN if due to liver involvement by tumor (obtained =&lt; 14 days prior to registration)</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Creatinine =&lt; 1.5 x ULN or estimated glomerular filtration rate (estimated glomerular filtration rate [eGFR]) &gt;= 60 mL/minute (obtained =&lt; 14 days prior to registration)</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Negative pregnancy test done =&lt; 7 days prior to registration, for persons of childbearing potential only</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Provision of signed and dated written informed consent prior to any study specific procedures, sampling, and analyses</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Willingness to provide mandatory blood specimens for correlative research</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Willingness to return to enrolling institution for follow-up (during the active monitoring phase of the study i.e., active treatment and clinical follow-up)</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Male and female patients of child bearing potential must be willing to use contraception, (i.e., condoms, birth control) while on study and until 3 months after the last dose of study drug is taken</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Must be willing to take light-protective measures during the study and for 2 weeks after their last dose of WSD0922-FU</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Must have a minimum life expectancy of &gt;= 3 months</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Must be stable on no more than 2 mg of dexamethasone (or equivalent steroids) per day. Steroid dose adjustments should be minimized during cycle 1 of therapy. Patients enrolling to the BTP expansion cohort do not have any restrictions on current steroid/dexamethasone dosing</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Must not take enzyme-inducing anticonvulsants treatment for at least 2 weeks prior to enrollment. Patients on enzyme-inducing anticonvulsants will be changed to non-enzyme inducing anticonvulsants</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Strong inducers and strong inhibitors of CYP3A should be discontinued at least 14 days prior to registration</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Willingness to provide mandatory tissue specimens for correlative research (BTP cohort only)</li> 												</ul> 						</div> 														<h4>Exclusion Criteria</h4> 										<div> 							<ul> 																<li>Registration – Exclusion Criteria for Dose Escalation and Dose Expansion</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown: * Pregnant persons * Nursing persons * Persons of childbearing potential who are unwilling to employ adequate contraception</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Any of the following prior therapies: * Any cytotoxic chemotherapy or other anticancer drugs for the treatment of advanced NSCLC from a previous treatment regimen =&lt; 14 days prior to registration * In patients with NSCLC, treatment with an EGFR TKI (e.g., erlotinib, gefitinib, afatinib or osimertinib) must be discontinued prior to registration. Additionally, prior EGFR TKI therapy must be discontinued within 8 days or 5 half-lives, whichever is longer, prior to study therapy initiation. If sufficient wash-out time has not occurred due to schedule or PK properties, an alternative appropriate wash-out time based on known duration and time to reversibility of drug related adverse events could be agreed upon by the Investigator and Wayshine * Radiation therapy to the brain =&lt; 12 weeks prior to registration * Patients with GBM/AA must not have received (i) nitrosoureas within 42 days of registration, (ii) any chemotherapy or experimental therapy within 28 days or 5 half-lives, whichever is longer, prior to registration * Patients with GBM/AA must not have received prior anti-EGFR or EGFRvIII therapies (erlotinib, gefitinib, afatinib, osimertinib, ABT-414, ABBV-221, AMG-595, AMG-596 etc.)  * Patients with GBM/AA who have been treated with bevacizumab within the last four months are not eligible * Received prior systemic biologic therapy (CAR-T, anti-PD-1 / anti-PD-L1, anti-CTLA-4, etc.) within 28 days prior to registration.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens including uncontrolled hypertension and active bleeding diatheses, which in the investigator’s opinion makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the protocol. Screening for chronic conditions is not required</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Subjects who are human immunodeficiency virus (HIV), hepatitis virus B (HBV), and/or hepatitis virus C (HCV) positive</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Uncontrolled inter-current illness including, but not limited to: * Symptomatic CNS complications that require urgent neurosurgical or medical (e.g. mannitol) intervention * Seizures requiring a change in anti-epileptic medications (addition of new anti-epileptic or increase in dose) =&lt; 2 weeks of registration * Known intracranial hemorrhage which is unrelated to tumor * Significant medical or psychiatric illness that would interfere with compliance and ability to tolerate treatment as outlined in the protocol * Illness/social situations that would limit compliance with study requirements</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Patients with a “currently active” second malignancy other than non-melanoma skin cancers and carcinoma-in-situ of the cervix. Patients are not considered to have a “currently active” malignancy if they have completed therapy and are free of disease for more than three years prior to registration</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Any of the following cardiac criteria: * A marked baseline prolongation of QT/corrected QT (QTc) interval * (e.g., repeated demonstration of a QTc interval &gt; 480 milliseconds (ms) (Common Terminology Criteria for Adverse Events [CTCAE] grade 1) using Fridericia’s QT correction formula * A history of additional risk factors for torsade de pointes (TdP) (e.g., heart failure, hypokalemia, family history of long QT syndrome) * The use of concomitant medications that prolong the QT/QTc interval</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Patients confirmed to have a cis double mutation (Del19/T790M or L858R/T790M) or cis triple mutation (Del19/T790m/C797S or L858R/T790M/C797S)</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease. History of hypersensitivity to active or inactive excipients of WSD0922-FU or drugs with a similar chemical structure or class to WSD0922-FU</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Refractory nausea and vomiting if not controlled by supportive therapy, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of WSD0922-FU</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Inadequate bone marrow reserve or organ function</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Patients with NSCLC LM who are unable to undergo collection of CSF</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Patients who are unable to tolerate dairy (GBM/AA cohort only). This is to ensure that patients on this cohort can participate in the food effect study</li> 												</ul> 						</div> 							 							<h3 class=""printHeading"">Trial Objectives and Outlines</h3> 				<div id=""trialObjectives""><p class='ctrp'>PRIMARY OBJECTIVE:</p><p class='ctrp'>I. To determine the maximum tolerated dose (MTD) and/or the recommended phase 2 dose (RP2D) of EGFR/EGFRvIII inhibitor WSD0922-FU (WSD0922-FU) in subjects with recurrent glioblastoma, IDH wildtype (GBM), anaplastic astrocytoma, IDH wildtype (AA) and central nervous system (CNS) metastases of non-small cell lung cancer (NSCLC).</p><p class='ctrp'></p><p class='ctrp'>SECONDARY OBJECTIVES:</p><p class='ctrp'>I. To evaluate the incidence of treatment-emergent adverse events (TEAEs) related to WSD0922-FU.</p><p class='ctrp'>II. To assess anti-tumor activity: intracranial and extracranial overall response rate (ORR), and change in tumor size compared with baseline according to Response Assessment in Neuro-Oncology (RANO) criteria for GBM/AA and Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for NSCLC.</p><p class='ctrp'>III. To assess anti-tumor activity: intracranial and extracranial disease control rate (DCR) and change in tumor size compared with baseline according to RANO criteria for GBM/AA and RECIST 1.1 for NSCLC.</p><p class='ctrp'>IV. To assess anti-tumor activity: intracranial and extracranial duration of response (DOR) and change in tumor size compared with baseline according to RANO criteria for GBM/AA and RECIST 1.1 for NSCLC.</p><p class='ctrp'>V. To assess anti-tumor activity: intracranial and extracranial progression-free survival (PFS) and change in tumor size compared with baseline according to RANO criteria for GBM/AA and RECIST 1.1 for NSCLC.</p><p class='ctrp'></p><p class='ctrp'>EXPLORATORY/CORRELATIVE RESEARCH OBJECTIVES:</p><p class='ctrp'>I. To investigate the presence and/or identity of the drug metabolites of WSD0922-FU, and the concentrations of these in the plasma, cerebrospinal fluid (CSF), and tumor.</p><p class='ctrp'>II. To assess plasma concentration of WSD0922-FU and metabolite SN16110801P1 and pharmacokinetics (PK) parameters after single and multiple doses of WSD0922-FU.</p><p class='ctrp'>III. To assess the brain tumor pharmacokinetics of WSD0922-FU and SN16110801P1 after a single dose of WSD0922-FU (Dose Expansion - Brain tumor penetration [BTP] cohort only).</p><p class='ctrp'>IV. To assess cerebrospinal fluid (CSF) concentration of WSD0922-FU and SN16110801P1 after multiple doses of WSD0922-FU (Dose Expansion – NSCLC cohort only).</p><p class='ctrp'>V. To explore the impact of tumor markers (e.g. MGMT promoter methylation, EGFR mutation [including EGFR vIII], PTEN deletion, TP53 mutation, etc.) on clinical parameters associated with WSD0922-FU treatment.</p><p class='ctrp'>VI. To evaluate and measure pharmacodynamic biomarkers of inhibition of EGFR and downstream signals in tumor samples after a single dose of WSD0922-FU (Dose Expansion Cohort – BTP cohort only).</p><p class='ctrp'>VII. To evaluate the effect of food on the pharmacokinetics of single dose of WSD0922-FU in plasma (Dose Expansion – GBM/AA cohort only).</p><p class='ctrp'></p><p class='ctrp'>OUTLINE: This is a dose-escalation study.</p><p class='ctrp'></p><p class='ctrp'>DOSE ESCALATION: Patients receive WSD0922-FU orally (PO) once daily (QD) or twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo computed tomography (CT), magnetic resonance imaging (MRI), and collection of blood samples on study. Patients with NSCLC with leptomeningeal metastases (LM) also undergo collection of CSF samples on study.</p><p class='ctrp'></p><p class='ctrp'>DOSE EXPANSION: Patients are assigned to 1 of 3 cohorts.</p><p class='ctrp'></p><p class='ctrp'>COHORT I: Patients with GBM/AA receive WSD0922-FU PO on days 1 and 4 of cycle 0. Patients then receive WSD0922-FU PO BID on days 1-28 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI during screening and on study, as well as blood sample collection on study. Patients may undergo additional optional blood sample collection on study.</p><p class='ctrp'></p><p class='ctrp'>COHORT II: Patients with BTP receive a single dose of WSD0922-FU prior to surgery. Patients then undergo surgical resection of brain tumor. After surgery, patients receive WSD0922-FU PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI during screening and on study, as well as blood sample collection on study.</p><p class='ctrp'></p><p class='ctrp'>COHORT III: Patients with NSCLC receive WSD0922-FU PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI and CT during screening and on study, as well as blood sample collection on study. Patients with LM also undergo collection of CSF samples on study. Patients may also undergo optional blood sample collection on study.</p><p class='ctrp'></p><p class='ctrp'>After completion of study treatment, patients are followed up at 4-6 weeks, then every 2 months until progressive disease, at progressive disease, and then every 3 months after progressive disease for up to 5 years.</p></div> 			 							<h3 class=""printHeading"">Lead Organization</h3> 									<div>Mayo Clinic in Rochester</div> 													<div>Principal Investigator: Sani Haider Kizilbash</div> 										<h3 class=""printHeading"">Locations & Contacts</h3> 			<div class=""locationNoteBlock""> 				<span>Note:</span> Information about participating sites on pharmaceutical industry trials may be incomplete, so please look up the <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT04197934"" target=""_blank"">NCT number</a> on ClinicalTrials.gov 			</div> 			<div> 								           <h3 class=""locationCountryLabel"">U.S.A.</h3>               <h4>Arizona</h4>                           <h5 class=""locationCity"">Scottsdale</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Mayo Clinic in Arizona</strong>     <br>Contact: Maciej Michal Mrugala <br>Email: <a href=""mailto:mrugala.maciej@mayo.edu"">mrugala.maciej@mayo.edu</a>   </span> </div>                                   <h4>Florida</h4>                           <h5 class=""locationCity"">Jacksonville</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Mayo Clinic in Florida</strong>     <br>Contact: Kurt A. Jaeckle <br>Email: <a href=""mailto:jaeckle.kurt@mayo.edu"">jaeckle.kurt@mayo.edu</a>   </span> </div>                                   <h4>Minnesota</h4>                           <h5 class=""locationCity"">Rochester</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Mayo Clinic in Rochester</strong>     <br>Contact: Sani Haider Kizilbash <br>Phone: 507-284-2511   </span> </div>                           			</div> 		</div> 			<div class=""trialContainer""> 			<h2 class=""hangingIndent"">23. A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)</h2> 						<a class=""hangingIndent print-check-for-updates"" href=""/research/participate/clinical-trials-search/v?d=C1967&d=C2167&d=C93259&d=C199379&d=C172809&d=C82379&d=C116377&d=C1855&d=C65530&d=C124993&d=C148147&d=C66940&d=C2693&d=C97273&loc=0&pn=7&rl=2&st=C162158&st=C153201&st=C176727&st=C147924&st=C202131&st=C3512&st=C155908&st=C156093&st=C156094&st=C157364&st=C128798&st=C9133&st=C133254&st=C135017&st=C174510&st=C155901&st=C171612&st=C162642&t=C2926&id=NCI-2024-02778""><span>Check for Updates</span></a> 			<table class=""trialDataTable""> 				<tr class=""trialDataHeaderRow""> 					<td>Phase</td> 					<td>Type</td> 					<td>Status</td> 					<td>Age</td> 					<td>Trial IDs</td> 				</tr> 				<tr> 					<td>Phase III</td> 					<td>Treatment</td> 					<td>Active</td> 					<td>18 													and over 						 						</td> 					<td class=""trialIDCell""> 						<span class = ""dataTableIDLabel"">Primary ID</span> CA127-1030<br> 						<span class = ""dataTableIDLabel"">Secondary IDs</span> NCI-2024-02778, U1111-1292-0487<br> 						<span class = ""dataTableIDLabel"">Clinicaltrials.gov ID</span> <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT06140836"" target=""_blank"">NCT06140836</a><br> 					</td> 			</table>  			<h3>Description</h3> 			<div>The purpose of this study is to evaluate the efficacy and safety of repotrectinib and crizotinib in participants with locally advanced or metastatic TKI-na&#239;ve ROS1-positive non-small cell lung cancer (NSCLC).</div>  			<h3 class=""printHeading"">Eligibility Criteria</h3>  																																																																																																																																																																																																																																																														<h4>Inclusion Criteria</h4> 										<div> 							<ul> 															<li>Participant has histologically or cytologically confirmed diagnosis of locally advanced or metastatic NSCLC</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Participant has a ROS1 gene rearrangement/fusion as detected by a local test.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>At least 1 measurable lesion according to RECIST v1.1, as assessed by the investigator.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Participants must not be exposed previously with TKIs that demonstrated activities in ROS1-positive NSCLC</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Up to 1 prior line of systemic treatment for NSCLC is permitted</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>ECOG Performance Status ≤ 2</li> 												</ul> 						</div> 														<h4>Exclusion Criteria</h4> 										<div> 							<ul> 																<li>Symptomatic brain metastases or symptomatic leptomeningeal involvement.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>History of previous cancer requiring therapy within the previous 2 years, except for NSCLC under study, squamous cell or basal-cell carcinoma of the skin, or any in situ carcinoma that has been completely resected.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Known tumor targetable co-mutations or rearrangements</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Clinically significant cardiovascular disease (either active or within 6 months prior to enrollment) Note: Other protocol-defined inclusion/exclusion criteria apply</li> 												</ul> 						</div> 							 			 							<h3 class=""printHeading"">Lead Organization</h3> 									<div>Bristol-Myers Squibb</div> 														<h3 class=""printHeading"">Locations & Contacts</h3> 			<div class=""locationNoteBlock""> 				<span>Note:</span> Information about participating sites on pharmaceutical industry trials may be incomplete, so please look up the <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT06140836"" target=""_blank"">NCT number</a> on ClinicalTrials.gov 			</div> 			<div> 								           <h3 class=""locationCountryLabel"">U.S.A.</h3>               <h4>Massachusetts</h4>                           <h5 class=""locationCity"">Boston</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Massachusetts General Hospital Cancer Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>New York</h4>                           <h5 class=""locationCity"">New York</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Laura and Isaac Perlmutter Cancer Center at NYU Langone</strong>     <br>Name Not Available   </span> </div>                           			</div> 		</div> 			<div class=""trialContainer""> 			<h2 class=""hangingIndent"">24. Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment</h2> 						<a class=""hangingIndent print-check-for-updates"" href=""/research/participate/clinical-trials-search/v?d=C1967&d=C2167&d=C93259&d=C199379&d=C172809&d=C82379&d=C116377&d=C1855&d=C65530&d=C124993&d=C148147&d=C66940&d=C2693&d=C97273&loc=0&pn=7&rl=2&st=C162158&st=C153201&st=C176727&st=C147924&st=C202131&st=C3512&st=C155908&st=C156093&st=C156094&st=C157364&st=C128798&st=C9133&st=C133254&st=C135017&st=C174510&st=C155901&st=C171612&st=C162642&t=C2926&id=NCI-2024-06506""><span>Check for Updates</span></a> 			<table class=""trialDataTable""> 				<tr class=""trialDataHeaderRow""> 					<td>Phase</td> 					<td>Type</td> 					<td>Status</td> 					<td>Age</td> 					<td>Trial IDs</td> 				</tr> 				<tr> 					<td>Phase III</td> 					<td>Treatment</td> 					<td>Active</td> 					<td>18 													and over 						 						</td> 					<td class=""trialIDCell""> 						<span class = ""dataTableIDLabel"">Primary ID</span> 1479-0008<br> 						<span class = ""dataTableIDLabel"">Secondary IDs</span> NCI-2024-06506, 2023-504308-27-00, U1111-1294-1407<br> 						<span class = ""dataTableIDLabel"">Clinicaltrials.gov ID</span> <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT06151574"" target=""_blank"">NCT06151574</a><br> 					</td> 			</table>  			<h3>Description</h3> 			<div>This study is open to adults 18 years and older with advanced or metastatic non-small cell lung cancer. People can join the study if they have tumours with HER2 mutations and have not yet received any systemic therapy including chemotherapy for advanced or metastatic lung cancer. The purpose of this study is to find out whether a medicine called zongertinib (BI 1810631) can slow down the worsening of advanced non-small cell lung cancer better than the standard treatment available. Zongertinib may slow cancer cell growth by inhibiting HER2. This would prolong cancer re-occurrence and increase survival. Current standard treatment is pembrolizumab plus platinum-pemetrexed chemotherapy.  Participants are put into 2 groups by chance. One group receives zongertinib at regular times throughout the study and the other group receives infusions of pembrolizumab, pemetrexed and cisplatin or carboplatin (pembrolizumab plus platinum-pemetrexed chemotherapy) into a vein.  Participants may be in the study up to a maximum of 70 months. During this time, they visit the study site about every 3 weeks for study procedures. The doctors regularly check the size of the tumour with a CT or MRI scan, at the beginning of the study and every 6 weeks. After 18 months they check the tumour size every 12 weeks. Doctors regularly check whether the cancer has spread to other parts of the body. The doctors also regularly check participants&#39; health and take note of any unwanted effects. The time it takes for the cancer to worsen is compared between the 2 groups to see whether the treatment works. The participants also fill in questionnaires about their symptoms and quality of life.</div>  			<h3 class=""printHeading"">Eligibility Criteria</h3>  																																																																																																																																																																																																																																																																																																																																																																																																																																																																																												<h4>Inclusion Criteria</h4> 										<div> 							<ul> 															<li>Signed and dated written informed consent form (ICF) in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patients ≥18 years of age or over the legal age of consent in countries where that is greater than 18 years at the time of signature of the ICF.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Histologically or cytologically confirmed diagnosis of an advanced and/or metastatic non-squamous Non-small cell lung cancer (NSCLC).</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Documented Human epidermal growth factor receptor 2 (HER2) mutation in the Tyrosine kinase domain (TKD) as per local lab results.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>An archival tumor tissue sample must be submitted to the central laboratory after inclusion of the patient to retrospectively confirm the HER2 status. If no archival tissue is available, this may be acceptable in exceptional cases after written agreement with the sponsor.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patients who have not received any systemic treatment for unresectable, locally advanced or metastatic disease and are not eligible for curative therapy.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Presence of at least one measurable lesion according to Response evaluation criteria in solid tumors (RECIST) 1.1, as determined by the local site investigator/radiology assessment.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Eligible to receive treatment with the selected platinum-based doublet-chemotherapy (i.e. cisplatin/pemetrexed or carboplatin/pemetrexed) and pembrolizumab in accordance with the Summaries of Product Characteristics (SmPC)/Product Information. Further inclusion criteria apply.</li> 												</ul> 						</div> 														<h4>Exclusion Criteria</h4> 										<div> 							<ul> 																<li>Previous or concomitant malignancies other than the one treated in this trial within the last 5 years, except;</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>effectively treated non-melanoma skin cancers</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>effectively treated carcinoma in situ of the cervix</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>effectively treated ductal carcinoma in situ</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>other effectively treated malignancy that is considered cured by local treatment</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Tumors with targetable alterations with approved available therapy.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Lung-specific intercurrent clinically significant severe illness based on investigators assessment.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Major surgery (major according to the investigator&#39;s assessment) performed within 4 weeks prior to randomization or planned within 6 months after screening, e.g. hip replacement.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Any history of or concomitant condition that, in the opinion of the investigator, would compromise the patient&#39;s ability to comply with the trial or interfere with the evaluation of the safety and efficacy of the test drug.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>History or presence of cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure New York Heart Association (NYHA) classification of ≥ III or IV, unstable angina or poorly controlled arrhythmia which are considered as clinically relevant by the investigator. Myocardial infarction, stroke, or pulmonary embolism within 6 months prior to randomization.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Any clinically important abnormalities (as assessed by the investigator) in rhythm, conduction, or morphology of resting electrocardiograms, e.g. complete left bundle branch block, third degree heart block. Further exclusion criteria apply.</li> 												</ul> 						</div> 							 			 							<h3 class=""printHeading"">Lead Organization</h3> 									<div>Boehringer Ingelheim Pharmaceuticals Inc</div> 														<h3 class=""printHeading"">Locations & Contacts</h3> 			<div class=""locationNoteBlock""> 				<span>Note:</span> Information about participating sites on pharmaceutical industry trials may be incomplete, so please look up the <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT06151574"" target=""_blank"">NCT number</a> on ClinicalTrials.gov 			</div> 			<div> 								           <h3 class=""locationCountryLabel"">U.S.A.</h3>               <h4>New York</h4>                           <h5 class=""locationCity"">Bronx</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Montefiore Medical Center-Weiler Hospital</strong>     <br>Name Not Available   </span> </div>                                   <h4>Utah</h4>                           <h5 class=""locationCity"">Salt Lake City</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Huntsman Cancer Institute/University of Utah</strong>     <br>Name Not Available   </span> </div>                           			</div> 		</div> 			<div class=""trialContainer""> 			<h2 class=""hangingIndent"">25. Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib</h2> 						<a class=""hangingIndent print-check-for-updates"" href=""/research/participate/clinical-trials-search/v?d=C1967&d=C2167&d=C93259&d=C199379&d=C172809&d=C82379&d=C116377&d=C1855&d=C65530&d=C124993&d=C148147&d=C66940&d=C2693&d=C97273&loc=0&pn=7&rl=2&st=C162158&st=C153201&st=C176727&st=C147924&st=C202131&st=C3512&st=C155908&st=C156093&st=C156094&st=C157364&st=C128798&st=C9133&st=C133254&st=C135017&st=C174510&st=C155901&st=C171612&st=C162642&t=C2926&id=NCI-2023-10662""><span>Check for Updates</span></a> 			<table class=""trialDataTable""> 				<tr class=""trialDataHeaderRow""> 					<td>Phase</td> 					<td>Type</td> 					<td>Status</td> 					<td>Age</td> 					<td>Trial IDs</td> 				</tr> 				<tr> 					<td>Phase II</td> 					<td>Treatment</td> 					<td>Active</td> 					<td>18 													and over 						 						</td> 					<td class=""trialIDCell""> 						<span class = ""dataTableIDLabel"">Primary ID</span> 61186372NSC2007<br> 						<span class = ""dataTableIDLabel"">Secondary IDs</span> NCI-2023-10662, 2023-505863-35-00<br> 						<span class = ""dataTableIDLabel"">Clinicaltrials.gov ID</span> <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT06120140"" target=""_blank"">NCT06120140</a><br> 					</td> 			</table>  			<h3>Description</h3> 			<div>The purpose of this study is to evaluate whether enhanced dermatologic management can reduce incidence of grade greater than or equal to (&gt;=) 2 dermatologic adverse events of interest (DAEIs) when compared with standard-of-care skin management in participants with locally advanced or metastatic stage IIIB/C-IV epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) treated first-line with amivantamab and lazertinib.</div>  			<h3 class=""printHeading"">Eligibility Criteria</h3>  																																																																																																																																																																																																																																																													<h4>Inclusion Criteria</h4> 										<div> 							<ul> 															<li>Have histologically or cytologically confirmed, locally advanced or metastatic non-small cell lung cancer (NSCLC); Is treatment naive and not amenable to curative therapy including surgical resection or (chemo) radiation. Adjuvant or neoadjuvant therapy for Stage I, Stage II or Stage IIIA disease is allowed if last dose administered more than 12 months prior to the development of locally advanced or metastatic disease</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Have a tumor that harbors an epidermal growth factor receptor (EGFR) exon 19del or exon 21 L858R substitution, as detected by an Food and Drug Administration (FDA)-approved or other validated test in a clinical laboratory improvement amendments (CLIA)-certified laboratory (sites in the United States) or an accredited local laboratory (sites outside of the United States) in accordance with site standard of care</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>A participant with asymptomatic or previously treated and stable brain metastases may participate in this study. Participants with a history of symptomatic brain metastases must have had all lesions treated as clinically indicated (that is, no current indication for further definitive local therapy). Any definitive local therapy to brain metastases must have been completed at least 14 days prior to randomization, and the participant can be receiving no greater than 10 milligram (mg) prednisone or equivalent daily for the treatment of intracranial disease</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Can have prior or concurrent second malignancy (other than the disease under study)which natural history or treatment is unlikely to interfere with any study endpoints, safety, or the efficacy of the study treatment(s)</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1</li> 												</ul> 						</div> 														<h4>Exclusion Criteria</h4> 										<div> 							<ul> 																<li>History of uncontrolled illness, including but not limited to uncontrolled diabetes; ongoing or active infection (includes infection requiring treatment with antimicrobial therapy [participants will be required to complete antibiotics 1 week prior to starting background anticancer treatment] or diagnosed or suspected viral infection); active bleeding diathesis; impaired oxygenation requiring continuous oxygen supplementation; refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of background anticancer treatment or doxycycline/minocycline; psychiatric illness, social situation, or any other circumstances that would limit compliance with study requirements; any ophthalmologic condition that is clinically unstable; pre-existing skin condition that would prevent adequate evaluations of dermatologic toxicity, as determined by the investigator</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Medical history of interstitial lung disease (ILD), including drug-induced ILD or radiation pneumonitis</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Known allergy, hypersensitivity, or intolerance to the excipients of amivantamab, lazertinib, or to tetracyclines, doxycycline, minocycline, or their excipients or to any component of the enhanced dermatologic management</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Participant has received any prior systemic treatment at any time for locally advanced stage III B/C or metastatic stage IV disease (adjuvant or neoadjuvant therapy for stage I, II or IIIA disease is allowed if last dose administered more than 12 months prior to the development of locally advanced or metastatic disease)</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Participant has an active or past medical history of leptomeningeal disease</li> 												</ul> 						</div> 							 			 							<h3 class=""printHeading"">Lead Organization</h3> 									<div>Janssen Pharmaceuticals</div> 														<h3 class=""printHeading"">Locations & Contacts</h3> 			<div class=""locationNoteBlock""> 				<span>Note:</span> Information about participating sites on pharmaceutical industry trials may be incomplete, so please look up the <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT06120140"" target=""_blank"">NCT number</a> on ClinicalTrials.gov 			</div> 			<div> 								           <h3 class=""locationCountryLabel"">U.S.A.</h3>               <h4>California</h4>                           <h5 class=""locationCity"">Duarte</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">City of Hope Comprehensive Cancer Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>Ohio</h4>                           <h5 class=""locationCity"">Cleveland</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Case Comprehensive Cancer Center</strong>     <br>Name Not Available   </span> </div>                           			</div> 		</div> 			<div class=""trialContainer""> 			<h2 class=""hangingIndent"">26. To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations</h2> 						<a class=""hangingIndent print-check-for-updates"" href=""/research/participate/clinical-trials-search/v?d=C1967&d=C2167&d=C93259&d=C199379&d=C172809&d=C82379&d=C116377&d=C1855&d=C65530&d=C124993&d=C148147&d=C66940&d=C2693&d=C97273&loc=0&pn=7&rl=2&st=C162158&st=C153201&st=C176727&st=C147924&st=C202131&st=C3512&st=C155908&st=C156093&st=C156094&st=C157364&st=C128798&st=C9133&st=C133254&st=C135017&st=C174510&st=C155901&st=C171612&st=C162642&t=C2926&id=NCI-2024-05975""><span>Check for Updates</span></a> 			<table class=""trialDataTable""> 				<tr class=""trialDataHeaderRow""> 					<td>Phase</td> 					<td>Type</td> 					<td>Status</td> 					<td>Age</td> 					<td>Trial IDs</td> 				</tr> 				<tr> 					<td>Phase II</td> 					<td>Treatment</td> 					<td>Active</td> 					<td>18 													to 130 years 						 						</td> 					<td class=""trialIDCell""> 						<span class = ""dataTableIDLabel"">Primary ID</span> D516AC00003<br> 						<span class = ""dataTableIDLabel"">Secondary IDs</span> NCI-2024-05975, 2023-507798-16-00<br> 						<span class = ""dataTableIDLabel"">Clinicaltrials.gov ID</span> <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT06194448"" target=""_blank"">NCT06194448</a><br> 					</td> 			</table>  			<h3>Description</h3> 			<div>The purpose of this study is to measure efficacy and safety of osimertinib as induction therapy prior to curative intent CRT and maintenance osimertinib in adult patients with Stage III, unresectable NSCLC with common EGFR mutations (exon 19 deletion or L858R).</div>  			<h3 class=""printHeading"">Eligibility Criteria</h3>  																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																<h4>Inclusion Criteria</h4> 										<div> 							<ul> 															<li>Patients must be 18 or the legal age of consent in the jurisdiction in which the study is taking place, at the time of signing the informed consent form.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patients with histologically documented NSCLC of predominantly non-squamous, squamous, and adenosquamous pathology who present with locally advanced, unresectable (Stage III) disease (according to Version 8 of the IASLC Staging Manual in Thoracic Oncology). It is recommended but not required that except for overt cT4 disease, nodal status N2, or N3 should have been proven by biopsy, via endobronchial ultrasound, mediastinoscopy, thoracoscopy, or in absence of biopsy, should have been confirmed with whole body 18FDG PET plus contrast-enhanced CT in addition to or in combination with PET.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patient who are eligible for and - planning to undergo CCRT or SCRT treatment.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patients who had recurred from Stage I/II/III after complete surgery or had gross incomplete resections can be included if they didn&#39;t receive treatment with any chemotherapy, radiation therapy, immunotherapy, targeted therapy, or investigational agents.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patients with HBV are only eligible for inclusion if they meet all the following criteria:</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Demonstrate absence of HCV co-infection or history of HCV co-infection</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Demonstrate absence of HIV co-infection</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patients with active HBV infection are eligible if they are:</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Receiving anti-viral treatment for at least 6 weeks prior to study treatment, HBV DNA is suppressed to &lt;100 IU/mL and transaminase levels are below ULN. Participants with a resolved or chronic HBV infection are eligible if they are:</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Negative for HBsAg and positive for hepatitis B core antibody [anti-HBc IgG or total anti-HBc Ab]. In addition, patients must be receiving anti-viral prophylaxis for 2-4 weeks prior to study treatment or</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Positive for HBsAg, but for &gt; 6 months have had transaminases levels below ULN and HBV DNA levels below &lt;100 IU/mL (i.e., are in an inactive carrier state). In addition, patients must be receiving anti-viral prophylaxis for 2-4 weeks prior to study treatment.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patients with HIV are only eligible for inclusion if they meet all the following criteria:</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Demonstrate absence of HBV/ HCV co-infection</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Undetectable viral RNA load for 6 months</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>CD4+ count of &gt;350 cells/μL</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>No history of AIDS-defining opportunistic infection within the past 12 months</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Stable for at least 4 weeks on the same anti-HIV medications</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Availability of the EGFRm test results confirming that the tumour harbours one of the two common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations including de novo T790M</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>WHO performance status of 0 or 1 with no deterioration over the previous 2 weeks prior to baseline at screening and prior to first dose.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Minimum life expectancy of &gt; 12 weeks at Day 1.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>At least one lesion that can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes, which must have short axis ≥ 15 mm) with CT or MRI and is suitable for accurate repeated measurements.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Male and/or female. Contraceptive use by males or females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies and/or SoC CRT</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this CSP.</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Provision of signed and dated written Optional Genomics Initiative Research Information and Consent Form prior to collection of samples for optional genomics initiative research that supports the Genomic Initiative. Note: If a patient declines to participate in optional genetic research, there will be no penalty or loss of benefit to the patient, and he/she will not be excluded from other aspects of the study.</li> 												</ul> 						</div> 														<h4>Exclusion Criteria</h4> 										<div> 							<ul> 																<li>Any presence of small cell and mixed small-cell and non-small cell histology.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Past medical history of ILD/pneumonitis, drug-induced ILD, radiation pneumonitis that required steroid treatment, or any evidence of clinically active ILD/pneumonitis.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Any unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of starting study treatment with the exception of alopecia and Grade 2 prior platinum-therapy related neuropathy. Patients with irreversible toxicity that is not reasonably expected to be exacerbated by study intervention in the opinion of the investigator may be included after consultation with the AstraZeneca medical monitor (eg, hearing loss).</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the investigator&#39;s opinion makes it undesirable for the patient to participate in the trial or which would jeopardise compliance with the protocol, or active infection (eg, patients receiving treatment for infection, including HCV, HIV, and tuberculosis) or active uncontrolled HBV infection.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of osimertinib.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>History of another primary malignancy except for malignancy treated with curative intent with no known active disease ≥ 2 years before the first dose of study intervention and of low potential risk for recurrence. Exceptions include adequately resected non-melanoma skin cancer and curatively treated in situ disease. Patients who have received RT with overlapping fields (eg, cured breast cancer) should be excluded.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Patient meets any of the following cardiac criteria:</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Mean resting QTc &gt; 470 msec, obtained from 3 ECGs, using the screening clinic ECG machine-derived QTc value.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG eg, complete left bundle branch block, third degree heart block and second-degree heart block. Patients with atrial fibrillation controlled by medication or arrhythmias controlled by pacemakers may be permitted based on the investigator judgement with cardiologist consultation recommended.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>History of QT prolongation associated with other medications that required discontinuation of that medication.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Congenital long QT syndrome, family history of long QT syndrome, unexplained sudden death under 40 years of age in first-degree relatives or patients with any factors that increase the risk of QTc prolongation/arrhythmic events such as electrolyte abnormalities, heart failure or any concomitant medication known to prolong the QT interval and cause TdP.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Absolute neutrophil count &lt;1.5 &#215; 10^9/L</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Platelet count &lt;100 &#215; 10^9/L</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Haemoglobin &lt;90 g/L</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Alanine transferase &gt;2.5 times the upper limit of normal (ULN)</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Aspartate transferase &gt;2.5 times ULN</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Total bilirubin &gt;1.5 times ULN or &gt;3 times ULN in the presence of documented Gilbert&#39;s Syndrome (unconjugated hyperbilirubinaemia)</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Creatinine &gt;1.5 times ULN concurrent with creatinine clearance &lt;50 mL/min (measured or calculated by Cockcroft and Gault formula); confirmation of creatinine clearance is only required when creatinine is &gt;1.5 times ULN.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Patients currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be strong inducers of CYP3A4 (at least 3-week prior to dosing). All patients must try to avoid concomitant use of any medications, herbal supplements and/or ingestion of foods with known inducer effects on CYP3A4.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Prior treatment with any chemotherapy, radiation therapy, immunotherapy or investigational agents for locally advanced, unresectable Stage III NSCLC. Prior surgical resection (ie, Stage I, II, or III) with no systemic treatment with residual disease or a recurrence is permitted.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Prior exposure to EGFR-TKI therapy</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Major surgical procedure (excluding placement of vascular access) or significant traumatic injury within 4 weeks of the first dose of study intervention or an anticipated need for major surgery during the study.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Participation in another clinical study with a study intervention or investigational medicinal device administered in the last 4 weeks (unless the safety profile is known prior to first dose of study intervention), or concurrent enrolment in another clinical study (unless the study is observational [noninterventional], or the patient is in the followup period of an interventional study).</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>History of hypersensitivity to active or inactive excipients of osimertinib or drugs with a similar chemical structure or class to osimertinib.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>History of hypersensitivity to active or inactive excipients of the chemotherapy regimen of choice (pemetrexed or paclitaxel; cisplatin or carboplatin) or RT or drugs with a similar chemical structure or class to the chemotherapy.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Previous enrolment in the present study. Rescreening of individuals who were screen failures is allowed.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>For females only: Currently pregnant (confirmed with positive pregnancy test) or breastfeeding.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Patients should refrain from breastfeeding from enrolment throughout the study and until 6 weeks after last dose of study intervention.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>In addition, the following are considered criteria for exclusion from the exploratory genetic research:</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Prior allogeneic bone marrow transplant.</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Non-leukocyte depleted whole blood transfusion within 120 days of genetic sample collection.</li> 												</ul> 						</div> 							 							<h3 class=""printHeading"">Trial Objectives and Outlines</h3> 				<div id=""trialObjectives""><p class='ctrp'>The study duration will be approximately 2 years for recruitment and 2 years of follow-up</p><p class='ctrp'>from the last patient&#39;s initiation into the study.</p><p class='ctrp'></p><p class='ctrp'>The induction treatment with osimertinib will be up to 8 weeks, followed by 6 weeks of</p><p class='ctrp'>CRT treatment and osimertinib maintenance treatment until PD or death.</p><p class='ctrp'></p><p class='ctrp'>The visit frequency will be every 2 weeks to 4 weeks during the induction treatment</p><p class='ctrp'>period, every 3 weeks during the CRT period (every 3 weeks for chemotherapy and daily</p><p class='ctrp'>visits for RT), and every 12 weeks during the osimertinib maintenance treatment period.</p></div> 			 							<h3 class=""printHeading"">Lead Organization</h3> 									<div>AstraZeneca Pharmaceuticals LP</div> 														<h3 class=""printHeading"">Locations & Contacts</h3> 			<div class=""locationNoteBlock""> 				<span>Note:</span> Information about participating sites on pharmaceutical industry trials may be incomplete, so please look up the <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT06194448"" target=""_blank"">NCT number</a> on ClinicalTrials.gov 			</div> 			<div> 								           <h3 class=""locationCountryLabel"">U.S.A.</h3>               <h4>California</h4>                           <h5 class=""locationCity"">La Jolla</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">UC San Diego Moores Cancer Center</strong>     <br>Name Not Available   </span> </div>                                       <h5 class=""locationCity"">Palo Alto</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Stanford Cancer Institute Palo Alto</strong>     <br>Name Not Available   </span> </div>                           			</div> 		</div> 			<div class=""trialContainer""> 			<h2 class=""hangingIndent"">27. Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer</h2> 						<a class=""hangingIndent print-check-for-updates"" href=""/research/participate/clinical-trials-search/v?d=C1967&d=C2167&d=C93259&d=C199379&d=C172809&d=C82379&d=C116377&d=C1855&d=C65530&d=C124993&d=C148147&d=C66940&d=C2693&d=C97273&loc=0&pn=7&rl=2&st=C162158&st=C153201&st=C176727&st=C147924&st=C202131&st=C3512&st=C155908&st=C156093&st=C156094&st=C157364&st=C128798&st=C9133&st=C133254&st=C135017&st=C174510&st=C155901&st=C171612&st=C162642&t=C2926&id=NCI-2024-04302""><span>Check for Updates</span></a> 			<table class=""trialDataTable""> 				<tr class=""trialDataHeaderRow""> 					<td>Phase</td> 					<td>Type</td> 					<td>Status</td> 					<td>Age</td> 					<td>Trial IDs</td> 				</tr> 				<tr> 					<td>Phase II</td> 					<td>Treatment</td> 					<td>Active</td> 					<td>18 													and over 						 						</td> 					<td class=""trialIDCell""> 						<span class = ""dataTableIDLabel"">Primary ID</span> WINSHIP5947-23<br> 						<span class = ""dataTableIDLabel"">Secondary IDs</span> NCI-2024-04302, STUDY00006144<br> 						<span class = ""dataTableIDLabel"">Clinicaltrials.gov ID</span> <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT06495125"" target=""_blank"">NCT06495125</a><br> 					</td> 			</table>  			<h3>Description</h3> 			<div>This phase II trial tests how well defactinib and avutometinib in combination with nivolumab works in treating patients with LKB1-mutant non-small cell lung cancer that has not responded (refractory) to an anti-PD1 treatment and may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Defactinib and avutometinib belong to a class of drugs called kinase inhibitors. These drugs target kinase proteins found in tumor cells. Tumor cells need these proteins to survive and grow. By blocking these proteins, defactinib and avutometinib may cause tumors to stop growing or grow more slowly. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body&#39;s immune system attack the tumor and may interfere with the ability of tumor cells to grow and spread. Giving defactinib and avutometinib in combination with nivolumab may kill more tumor cells in patients with anti-PD1 refractory LKB1-mutant advanced non-small cell lung cancer.</div>  			<h3 class=""printHeading"">Eligibility Criteria</h3>  																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																	<h4>Inclusion Criteria</h4> 										<div> 							<ul> 															<li>Patients must have been histologically or cytologically diagnosed with non-small cell lung cancer, specifically lung adenocarcinoma</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patients must have advanced stage disease that is not amenable to combined modality therapy or surgical resection</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patients must have known LKB1 mutation</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>COHORT A ONLY: Patients must have known KRAS mutation</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patients must have progressed on prior therapy with immune checkpoint inhibitor alone and first line chemotherapy, either combined or sequentially, for advanced stage disease. No other lines of chemotherapy in the advanced stage therapy is allowed. The exception is patients with KRAS G12C are also allowed the use of one line of targeted Food and Drug Administration (FDA) approved therapy</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥ 20 mm with conventional techniques or as ≥ 10 mm with spiral CT scan</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Age ≥ 18 years</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Adequate recovery from toxicities related to prior treatments to at least grade 1 by Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0. Exceptions include alopecia and peripheral neuropathy grade ≤ 2</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Absolute neutrophil count ≥ 1,500/mcL</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Hemoglobin ≥ 8.0</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Platelets ≥ 100,000/mcL</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for the institution; patients with Gilbert syndrome may enroll if total bilirubin &lt; 3.0 mg/dL (51 umole/L)</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT)(serum glutamic pyruvic transaminase [SGPT]) alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 x ULN (or &lt; 5 x ULN in patients with liver metastases)</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Creatinine clearance ≥ 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patients must have the ability to ingest oral medications</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>The effects of defactinib and avutometinib on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry,for the duration of study participation, for 3 months following the last dose of study therapy for male patients, and 1 month following the last dose of study therapy for female patients. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Patients must be able to understand and be willing to sign a written informed consent document</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Baseline corrected QT (QTc) interval &lt; 460 ms for women and ≤ 450 ms for men (average of triplicate readings) (CTCAE grade 1) using Fredericia’s QT correction formula. NOTE: This criterion does not apply to patients with a right or left bundle branch block</li> 												</ul> 						</div> 														<h4>Exclusion Criteria</h4> 										<div> 							<ul> 																<li>Patients who have had systemic therapy within 3 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Patients who are receiving any other investigational agents</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Patients with unstable or symptomatic brain metastasis or known leptomeningeal disease. Asymptomatic brain metastases are allowed if they meet the following criteria:  * Have been treated and have been stable for greater than or equal to 4 weeks as documented by radiologic imaging * Have not required increasing doses of corticosteroids within 2 weeks prior to study treatment</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Patients with history of pre-existing auto-immune conditions that would pose a higher risk for toxicity with nivolumab will be excluded</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Patients who experienced serious auto-immune toxicity with prior immune checkpoint inhibitor therapy</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>History of allergic reactions attributed to compounds of similar chemical or biologic composition to avutometinib or defactinib</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Known hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection that is active and/or requires therapy</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Active skin disorder that has required systemic therapy within the past 1 year. Surgically removed early stage skin cancers are allowed. Topical creams are allowed as well</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>History of rhabdomyolysis</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Concurrent ocular disorders: * Patients with history of glaucoma, history of retinal vein occlusion (RVO), predisposing factors for RVO, including uncontrolled hypertension, uncontrolled diabetes * Patients with history of retinal pathology or evidence of visible retinal pathology that is considered a risk factor for RVO, intraocular pressure &gt; 21 mm Hg as measured by tonometry, or other significant ocular pathology, such as anatomical abnormalities that increase the risk for RVO * Patients with active or chronic, visually significant corneal disorders, other active ocular conditions requiring ongoing therapy or clinically significant corneal disease that prevents adequate monitoring of drug-induced keratopathy. Examples of visually significant corneal disorders include corneal degeneration, active or recurrent keratitis, and other forms of serious ocular surface inflammatory conditions. Visually significant corneal disorders do NOT include dry eyes, blepharitis, and uncomplicated corneal erosions</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Patients with the inability to swallow oral medications or impaired gastrointestinal absorption due to gastrectomy or active inflammatory bowel disease</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Treatment with warfarin. Patients on warfarin for deep vein thrombosis/pulmonary embolism should be converted to low-molecular-weight heparin (LMWH) or direct oral anticoagulants (DOACs). Exposure to medications (with or without prescriptions), supplements, herbal remedies, or foods with potential for drug-drug interactions with defactinib within 14 days prior to the first dose of avutometinib or defactinib and during the course of therapy, including: * Strong CYP3A4 inhibitors or inducers, strong CYP2C9 inhibitors or inducers, strong P-glycoprotein (P-gp) inhibitors or inducers</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Patients with a known &quot;treatable driver mutation&quot; with FDA approved targeted therapy (such as EGFR, ALK, ROS1, NTRK, BRAF, RET, MET exon 14, HER2). The exception is KRAS as listed in the inclusion section</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>History of prior malignancy within past 2 years prior to study entry, with the exception of curatively treated malignancies or malignancies with very low potential for recurrence or progression</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Female patients who are pregnant or breastfeeding</li> 												</ul> 						</div> 							 							<h3 class=""printHeading"">Trial Objectives and Outlines</h3> 				<div id=""trialObjectives""><p class='ctrp'>PRIMARY OBJECTIVE:</p><p class='ctrp'>I. To determine the efficacy (6-months progression free survival [PFS] rate) of defactinib and avutometinib when combined with nivolumab in patients with LKB1 mutated lung adenocarcinoma.</p><p class='ctrp'></p><p class='ctrp'>SECONDARY OBJECTIVE:</p><p class='ctrp'>I. To evaluate response rate, overall survival and toxicity assessment. </p><p class='ctrp'></p><p class='ctrp'>TERTIARY/EXPLORATORY OBJECTIVE:</p><p class='ctrp'>I. Biomarker evaluation will be conducted on archived tumor samples and on-study biopsies obtained in a subset of patients.</p><p class='ctrp'></p><p class='ctrp'>OUTLINE:</p><p class='ctrp'>Patients receive defactinib orally (PO) twice daily (BID) on days 1-21, avutometinib PO twice weekly on Monday and Thursday, Tuesday and Friday or Wednesday and Saturday for 21 days and nivolumab intravenously (IV) on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo biopsy, blood sample collection, computed tomography (CT) or positron emission tomography (PET) on study.</p><p class='ctrp'></p><p class='ctrp'>After completion of study treatment, patients are followed up every 3 months for up to 5 years.</p></div> 			 							<h3 class=""printHeading"">Lead Organization</h3> 									<div>Emory University Hospital/Winship Cancer Institute</div> 													<div>Principal Investigator: Conor E. Steuer</div> 										<h3 class=""printHeading"">Locations & Contacts</h3> 			<div class=""locationNoteBlock""> 				<span>Note:</span> Information about participating sites on pharmaceutical industry trials may be incomplete, so please look up the <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT06495125"" target=""_blank"">NCT number</a> on ClinicalTrials.gov 			</div> 			<div> 								           <h3 class=""locationCountryLabel"">U.S.A.</h3>               <h4>Georgia</h4>                           <h5 class=""locationCity"">Atlanta</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Emory Saint Joseph's Hospital</strong>     <br>Contact: Conor E. Steuer <br>Phone: 404-778-5378 <br>Email: <a href=""mailto:csteuer@emory.edu"">csteuer@emory.edu</a>   </span> </div>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Emory University Hospital/Winship Cancer Institute</strong>     <br>Contact: Conor E. Steuer <br>Phone: 404-778-5378 <br>Email: <a href=""mailto:csteuer@emory.edu"">csteuer@emory.edu</a>   </span> </div>                           			</div> 		</div> 			<div class=""trialContainer""> 			<h2 class=""hangingIndent"">28. A Study of FWD1509 in Adults With Non-Small Cell Lung Cancer</h2> 						<a class=""hangingIndent print-check-for-updates"" href=""/research/participate/clinical-trials-search/v?d=C1967&d=C2167&d=C93259&d=C199379&d=C172809&d=C82379&d=C116377&d=C1855&d=C65530&d=C124993&d=C148147&d=C66940&d=C2693&d=C97273&loc=0&pn=7&rl=2&st=C162158&st=C153201&st=C176727&st=C147924&st=C202131&st=C3512&st=C155908&st=C156093&st=C156094&st=C157364&st=C128798&st=C9133&st=C133254&st=C135017&st=C174510&st=C155901&st=C171612&st=C162642&t=C2926&id=NCI-2021-11191""><span>Check for Updates</span></a> 			<table class=""trialDataTable""> 				<tr class=""trialDataHeaderRow""> 					<td>Phase</td> 					<td>Type</td> 					<td>Status</td> 					<td>Age</td> 					<td>Trial IDs</td> 				</tr> 				<tr> 					<td>Phase I/II</td> 					<td>Treatment</td> 					<td>Active</td> 					<td>18 													and over 						 						</td> 					<td class=""trialIDCell""> 						<span class = ""dataTableIDLabel"">Primary ID</span> FWDCT-001<br> 						<span class = ""dataTableIDLabel"">Secondary IDs</span> NCI-2021-11191<br> 						<span class = ""dataTableIDLabel"">Clinicaltrials.gov ID</span> <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT05068024"" target=""_blank"">NCT05068024</a><br> 					</td> 			</table>  			<h3>Description</h3> 			<div>The purpose of this study is to characterize the safety and tolerability of FWD1509 MsOH in advanced NSCLC patients and establish the maximum tolerable dose (MTD), recommended phase 2 dose (RP2D) in advanced NSCLC patients.</div>  			<h3 class=""printHeading"">Eligibility Criteria</h3>  																																													<h4>Inclusion Criteria</h4> 										<div> 							<ul> 															<li>Key Inclusion Criteria: Study-Wide Eligibility (Across All Study Parts):  A subject will be eligible for inclusion in this study only if all of the following criteria apply.    1. Have histologically or cytologically confirmed locally advanced or metastatic NSCLC      (Stage IIIB/IIIC or IV) [JACC edition 8], and inclusion of Stage IIIB only if not a      candidate for curative therapy    2. Must have sufficient tumor tissue (either archived sample or recent biopsy)      available for analysis:         1. Phase 1 Dose-escalation part: EGFR and HER2 mutations (including but not           limited toL858R, exon 19 deletion, T790M, ex20ins, 21exon, G719X, S768I, L861Q,           etc. for EGFR and A775YVMG, C776insVC, P780ins GSP etc. for HER2) should be           confirmed by previously documented evidence or central lab         2. Patients with both EGFR and HER2 mutations may be included in the dose           escalation phase         3. Phase 1 Dose-expansion part and Phase 2: Have an EGFR in-frame exon 20           insertion test by any central lab    3. Must have at least one measurable lesion as defined by response evaluation criteria      in solid tumors (RECIST v1.1)    4. Prior anti-cancer therapies:         1. Previously treated with one or more regimens of systemic therapy for locally           advanced or metastatic disease         2. Disease progressed or intolerant to at least one line of systematic therapies           including but not limited to any EGFR-target therapies or immunotherapies, for           metastatic / local relapsed settings    5. Male or female adult participants (aged 18 years or older, or as defined per local      regulations)    6. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1    7. Minimum life expectancy of 3 months or more    8. Adequate organ function at baseline         1. Bone marrow function              -  Absolute neutrophil count (ANC)≥1.5 x 10^9/L              -  Platelets ≥100 x 10^9/L              -  Hemoglobin ≥9 g/dL, criteria must be met without a transfusion within 2                weeks of the blood draw         2. Hepatic function              -  AST and ALT ≤3 x upper limit of normal (ULN); if liver metastases, then ≤                5 x ULN              -  Bilirubin ≤1.5 x ULN or ≤3 x ULN in the presence of documented Gilbert&#39;s                Syndrome         3. Renal function              -  Creatinine clearance ≥50 ml/min (calculated by Cockcroft and Gault                equation (Cockcroft DW, 1976) (Appendix 3)    9. Willingness and ability to comply with scheduled visits and study procedures  Exclusion Criteria:  A subject will be not eligible for inclusion in this study if any of the following criteria apply:    1. Received anticancer therapy including cytotoxic chemotherapy, biological products      and investigational agents, ≤ 21 days prior to first dose of FWD1509 MsOH; or      received prior EGFR TKIs (e.g., gefitinib, erlotinib or osimertinib) ≤7 days prior      to the first dose FWD1509 MsOH    2. Have been diagnosed with another primary malignancy other than NSCLC except for      patients with adequately treated non-melanoma skin cancer, cervical cancer in situ      or definitively treated non-metastatic prostate cancer, or participants with another      primary malignancy who are definitively relapse-free with at least 3 years elapsed      since the diagnosis of the other primary malignancy    3. Received radiotherapy ≤14 days prior to the first dose of FWD1509 MsOH or have not      recovered from radiotherapy-related toxicities; palliative radiation administered      outside the chest and brain, stereotactic radiosurgery (SRS), and stereotactic body      radiotherapy are allowed up to 7 days prior to the first dose of FWD1509 MsOH    4. Received strong CYP3A inhibitors and inducers within 2 weeks prior to the first dose      of FWD1509 MsOH; they should be discontinued at least 2 weeks prior to the first      dose of FWD1509 MsOH and avoided throughout the study duration (see Appendix 6)    5. Received concomitant medications (e.g., statins) which are substrates of BCRP,      p-glycoprotein or OATP1B1/1B3 (dose escalation part of phase 1 study)    6. Have undergone major surgery within 28 days prior to first dose of FWD1509 MsOH.      Minor surgical procedures, such as catheter placement or minimally invasive biopsy,      are allowed    7. Brain Metastasis: Have known active brain metastases (have either previously      untreated intracranial CNS metastases or previously treated intracranial CNS      metastases with radiologically documented new or progressing CNS lesions), except      for the following conditions         1. Brain metastases are allowed if they have been treated with surgery and/or           radiation and have been stable without requiring corticosteroids to control           symptoms within 7 days before the first dose of FWD1509 MsOH and have no           evidence of new or enlarging brain metastases         2. Requiring corticosteroids to control symptoms within 7 days prior to the first           dose of FWD1509 MsOH or during study period; patients previously treated for           CNS metastases who are clinically stable, have no new lesions, and who do not           need treatment with a corticosteroid within the 7 days before the first dose of           FWD1509 MsOH and during study period are allowed to be enrolled    8. Have current spinal cord compression (symptomatic or asymptomatic and detected by      radiographic imaging) or leptomeningeal disease (symptomatic or asymptomatic)    9. Have significant, uncontrolled, or active cardiovascular disease   10. QCc-related criteria:         1. A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration           of a QTc interval &gt;480 milliseconds (ms) (CTCAE grade 1) using Fredericia&#39;s QT           correction formula         2. A history of additional risk factors for Torsades de Pointes (TdP) (e.g., heart           failure, hypokalemia, family history of Long QT Syndrome   11. Have significant, uncontrolled, or active renal disease   12. Have a known history of uncontrolled hypertension (per institution practice);      participants with hypertension should be under treatment on study entry to control      blood pressure   13. Have any abnormal changes in the cornea or retina that may increase the risk of      ocular toxicity during screening   14. Have an ongoing or active infection, including but not limited to, the requirement      for intravenous (IV) antibiotics, or a known history of human immunodeficiency virus      (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV). Testing is not required      in the absence of history   15. Currently have or have a history of interstitial lung disease, radiation pneumonitis      that required steroid treatment, or drug-related pneumonitis   16. Female participants who are lactating and breastfeeding or have a positive urine or      serum pregnancy test during the screening period   17. Have gastrointestinal illness or disorder that could affect oral absorption of      FWD1509 MsOH   18. Have any condition or illness that, in the opinion of the investigator, might      compromise participant safety or interfere with the evaluation of the safety of the      drug</li> 												</ul> 						</div> 										 							<h3 class=""printHeading"">Trial Objectives and Outlines</h3> 				<div id=""trialObjectives""><p class='ctrp'>This study will be a first-in-human study evaluating the safety and tolerability of</p><p class='ctrp'>FWD1509 MsOH in subjects with advanced NSCLC, when FWD1509 MsOH is administered once</p><p class='ctrp'>daily as a single agent. FWD1509 MsOH is an oral TKI (Tyrosine Kinase Inhibitor) that</p><p class='ctrp'>blocks the function of tyrosine kinase. TKIs such as gefitinib, erlotinib or afatinib are</p><p class='ctrp'>recommended as the first-line therapy for EGFR mutated (exon 19 deletions or L858R point</p><p class='ctrp'>mutations in exon 21) NSCLC patients. However, the majority (&gt;50%) of patients will</p><p class='ctrp'>develop acquired resistance after initially responding to gefitinib or erlotinib due to</p><p class='ctrp'>the occurrence of secondary mutations (mostly T709M) in EGFR. Osimertinib was</p><p class='ctrp'>subsequently developed to such secondary mutations, but for EGFRex20ins mutations, on</p><p class='ctrp'>which there is still no effective therapies focusing. FWD1509 MsOH is new generation</p><p class='ctrp'>EGFR-TKI targeting EGFR mutations such as exon 19 deletion, L858R substitution as well as</p><p class='ctrp'>T790M mutations. In particular, FWD1509 MsOH targets the EGFRex20ins mutation in NSCLC.</p><p class='ctrp'>In addition to activity against EGFR mutations, FWD1509 MsOH is also active against a</p><p class='ctrp'>variety of HER2 mutations.</p><p class='ctrp'></p><p class='ctrp'>The development of FWD1509 MsOH at this stage is mainly focused on treatment of NSCLC</p><p class='ctrp'>tumors with EGFRex20ins mutations, followed by further exploration against other targets.</p></div> 			 							<h3 class=""printHeading"">Lead Organization</h3> 									<div>Forward Pharmaceuticals Co., Ltd.</div> 														<h3 class=""printHeading"">Locations & Contacts</h3> 			<div class=""locationNoteBlock""> 				<span>Note:</span> Information about participating sites on pharmaceutical industry trials may be incomplete, so please look up the <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT05068024"" target=""_blank"">NCT number</a> on ClinicalTrials.gov 			</div> 			<div> 								           <h3 class=""locationCountryLabel"">U.S.A.</h3>               <h4>New York</h4>                           <h5 class=""locationCity"">Bronx</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Montefiore Medical Center-Weiler Hospital</strong>     <br>Name Not Available   </span> </div>                                   <h4>Texas</h4>                           <h5 class=""locationCity"">Houston</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">M D Anderson Cancer Center</strong>     <br>Name Not Available   </span> </div>                           			</div> 		</div> 			<div class=""trialContainer""> 			<h2 class=""hangingIndent"">29. APL-101 and Osimertinib for the Treatment of EGFR-Mutated Metastatic Non-small Cell Lung Cancer</h2> 						<a class=""hangingIndent print-check-for-updates"" href=""/research/participate/clinical-trials-search/v?d=C1967&d=C2167&d=C93259&d=C199379&d=C172809&d=C82379&d=C116377&d=C1855&d=C65530&d=C124993&d=C148147&d=C66940&d=C2693&d=C97273&loc=0&pn=7&rl=2&st=C162158&st=C153201&st=C176727&st=C147924&st=C202131&st=C3512&st=C155908&st=C156093&st=C156094&st=C157364&st=C128798&st=C9133&st=C133254&st=C135017&st=C174510&st=C155901&st=C171612&st=C162642&t=C2926&id=NCI-2021-04226""><span>Check for Updates</span></a> 			<table class=""trialDataTable""> 				<tr class=""trialDataHeaderRow""> 					<td>Phase</td> 					<td>Type</td> 					<td>Status</td> 					<td>Age</td> 					<td>Trial IDs</td> 				</tr> 				<tr> 					<td>Phase I/II</td> 					<td>Treatment</td> 					<td>Active</td> 					<td>18 													and over 						 						</td> 					<td class=""trialIDCell""> 						<span class = ""dataTableIDLabel"">Primary ID</span> 202104039<br> 						<span class = ""dataTableIDLabel"">Secondary IDs</span> NCI-2021-04226<br> 						<span class = ""dataTableIDLabel"">Clinicaltrials.gov ID</span> <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT04743505"" target=""_blank"">NCT04743505</a><br> 					</td> 			</table>  			<h3>Description</h3> 			<div>This phase I/II trial is to find out the best dose of APL-101 given together with osimertinib and the effect of APL-101 and osimertinib in treating patients with EGFR-mutated non-small cell lung cancer that has spread to other places in the body (metastatic). APL-101 and osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving APL-101 together with osimertinib may work better than osimertinib alone in treating patients with non-small cell lung cancer.</div>  			<h3 class=""printHeading"">Eligibility Criteria</h3>  																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																															<h4>Inclusion Criteria</h4> 										<div> 							<ul> 															<li>Histologically confirmed metastatic non-small cell lung cancer, or locally advanced disease that is not amenable for curative intent therapy, with tyrosine kinase inhibitor (TKI)-sensitive EGFR mutation through Clinical Laboratory Improvement Act (CLIA) certified lab</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 with at least one lesion accessible for core biopsy</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Planning to initiate treatment with standard of care osimertinib 80 mg QD. In order to continue treatment with osimertinib + APL-101, patients must have received at least 8 and no more than 16 weeks of standard of care (SOC) osimertinib without disease progression</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>At least 18 years of age</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 1</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Absolute neutrophil count &gt;= 1,500/mcL</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Platelets &gt;= 100,000/mcL</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Hemoglobin &gt;= 9 g/dL (transfused hemoglobin [Hgb] allowed)</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Total bilirubin =&lt; 1.5 mg/dL or =&lt; 26 umol/L</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Aspartate aminotransferase (AST)(serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT)(SGPT) =&lt; 2.5 x institutional upper limit of normal (IULN) (=&lt; 5.0 x IULN if liver metastases)</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Creatinine =&lt; 2 x IULN or creatinine clearance calculated by Cockcroft-Gault formula &gt;= 60 ml/min</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Serum calcium (after correcting for albumin level) =&lt; IULN</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Serum phosphorus =&lt; IULN</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>The effects of APL-101 on the developing human fetus are unknown. For this reason, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study and for the duration of the study</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Ability to understand and willingness to sign an Institutional Review Board (IRB) approved written informed consent document (or that of legally authorized representative, if applicable)</li> 												</ul> 						</div> 														<h4>Exclusion Criteria</h4> 										<div> 							<ul> 																<li>Prior treatment with osimertinib in the metastatic setting (outside of osimertinib given immediately prior to and during the enrollment period). Prior treatment with chemotherapy in the neoadjuvant, adjuvant, or first-line metastatic setting is however allowed</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Prior immunotherapy and/or frontline EGFR-directed treatment in the metastatic setting. EGFR directed therapy in the adjuvant setting is permitted, as long as the disease-free interval between completion of adjuvant therapy with EGFR directed therapy and initiation of osimertinib is more than or equal to 1 year</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Disease refractory to osimertinib, given immediately prior to and during enrollment period</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>A history of other malignancy with the exception of: * Malignancies for which all treatment was completed at least 1 year before registration and the patient has no evidence of disease; or * Known indolent malignancies, or malignancies that do not require active treatment and are unlikely not alter the course of treatment of metastatic NSCLC per treating physician</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Currently receiving any other investigational agents or herbal medications</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Presence of symptomatic central nervous system metastases or neurologically unstable central nervous system (CNS) symptoms (unable to taper steroids). Patients with treated brain metastases are eligible. Patients with asymptomatic brain metastases prior to initiation of osimertinib will be eligible to receive combination therapy as long as their disease is shown to be responsive to osimertinib</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>A history of allergic reactions attributed to compounds of similar chemical or biologic composition to APL-101, osimertinib, or other agents used in the study</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, immune deficiencies, hepatitis B, untreated hepatitis C, uncontrolled diabetes, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within the past 6 months, uncontrolled cardiac arrhythmia, or prolonged QTcF interval &gt; 450 ms (based on Fridericia formula)</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Uncontrolled or symptomatic pleural or pericardial effusion. Effusion controlled by presence of an indwelling pleural catheter is not exclusionary</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Decompensated heart failure or heart failure with reduced ejection fraction (&lt; 50%)</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Major surgery within 30 days prior to first day of study treatment (osimertinib + APL-101)</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Poorly controlled diarrheal or gastrointestinal disorders (grade 2 or higher diarrhea, nausea, or vomiting at baseline)</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of study entry</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Unresolved grade 2 or higher treatment-related toxicities (with the exception of endocrine abnormalities as a result of immunotherapies that are being managed with hormonal supplementation). However, if the treating physician is under the impression that the toxicity under question is unlikely to affect study participation, patient eligibility can be discussed with the principal investigator (PI) on a subject by subject basis. After enrollment to this study, osimertinib-related toxicities must resolve to =&lt; grade 1 before patient may begin combination therapy</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Presence of interstitial lung disease</li> 												</ul> 						</div> 							 							<h3 class=""printHeading"">Trial Objectives and Outlines</h3> 				<div id=""trialObjectives""><p class='ctrp'>PRIMARY OBJECTIVES:</p><p class='ctrp'>I. To determine the safety of combining vebreltinib (APL-101) with osimertinib in patients with EGFR-mutated metastatic non-small cell lung cancer (NSCLC). (Phase I)</p><p class='ctrp'>II. To determine the progression-free survival (PFS) in patients with EGFR-mutated metastatic NSCLC who receive the combination of APL-101 and osimertinib. (Phase II or received maximum tolerated dose [MTD])</p><p class='ctrp'></p><p class='ctrp'>SECONDARY OBJECTIVES:</p><p class='ctrp'>I. To determine the maximum tolerated dose of the combination of APL-101 and osimertinib in patients with EGFR-mutated metastatic NSCLC. (Phase I)</p><p class='ctrp'>II. To assess the efficacy of the combination of APL101 and osimertinib in patients with EGFR-mutated metastatic NSCLC. (Phase II or received MTD)</p><p class='ctrp'></p><p class='ctrp'>CORRELATIVE OBJECTIVES:</p><p class='ctrp'>I. To identify genomic alterations leading to persistent activation of bypass activation of RAS/RTK/RAF signaling and drug tolerance following initiation of treatment with osimertinib.</p><p class='ctrp'>II. To identify if biomarkers such as the presence of MET amplification in pretreatment and on treatment biopsies and circulating tumor DNA testing will predict for improved progression-free survival with combination therapy of osimertinib and APL101.</p><p class='ctrp'>III. To determine if there is a change in osimertinib concentration from baseline after the addition of APL-101.</p><p class='ctrp'></p><p class='ctrp'>CORRELATIVE (EXPLORAOTRY) OBJECTIVSI. To identify genomic alterations leading to bypass activation of RAS/RTK/RAF signaling and drug tolerance following initiation of treatment with osimertinib.</p><p class='ctrp'>II. To identify if biomarkers such as the presence of MET amplification in pre-treatment and on treatment biopsies and circulating tumor DNA testing will predict improved progression-free survival with combination therapy of osimertinib and APL-101.</p><p class='ctrp'>III. To determine if there is a change in osimertinib concentration from baseline after the addition of APL-101</p><p class='ctrp'></p><p class='ctrp'>OUTLINE: This is a phase I, dose-escalation study of vebreltinib followed by a phase II study.</p><p class='ctrp'></p><p class='ctrp'>LEAD-IN: Patients receive osimertinib mesylate orally (PO) once daily (QD) for 8-16 weeks in the absence of disease progression or unacceptable toxicity. Patients who do not experience disease progression move on to combination therapy.</p><p class='ctrp'></p><p class='ctrp'>COMBINATION: Patients receive osimertinib mesylate PO QD and vebreltinib PO twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.</p><p class='ctrp'></p><p class='ctrp'>Patients undergo computed tomography (CT) scan or magnetic resonance imaging (MRI), tumor biopsy, and collection of blood samples during treatment with osimertinib mesylate.</p><p class='ctrp'></p><p class='ctrp'>After completion of study treatment, patients are followed up every 3 months for up to 3 years.</p></div> 			 							<h3 class=""printHeading"">Lead Organization</h3> 									<div>Siteman Cancer Center at Washington University</div> 													<div>Principal Investigator: Anjali Rohatgi</div> 										<h3 class=""printHeading"">Locations & Contacts</h3> 			<div class=""locationNoteBlock""> 				<span>Note:</span> Information about participating sites on pharmaceutical industry trials may be incomplete, so please look up the <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT04743505"" target=""_blank"">NCT number</a> on ClinicalTrials.gov 			</div> 			<div> 								           <h3 class=""locationCountryLabel"">U.S.A.</h3>               <h4>Illinois</h4>                           <h5 class=""locationCity"">Shiloh</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Memorial Hospital East</strong>     <br>Contact: Anjali Rohatgi <br>Phone: 314-273-6621 <br>Email: <a href=""mailto:a.rohatgi@wustl.edu"">a.rohatgi@wustl.edu</a>   </span> </div>                                   <h4>Missouri</h4>                           <h5 class=""locationCity"">Saint Louis</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">Siteman Cancer Center at Washington University</strong>     <br>Contact: Anjali Rohatgi <br>Phone: 314-273-6621 <br>Email: <a href=""mailto:a.rohatgi@wustl.edu"">a.rohatgi@wustl.edu</a>   </span> </div>                           			</div> 		</div> 			<div class=""trialContainer""> 			<h2 class=""hangingIndent"">30. A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer</h2> 						<a class=""hangingIndent print-check-for-updates"" href=""/research/participate/clinical-trials-search/v?d=C1967&d=C2167&d=C93259&d=C199379&d=C172809&d=C82379&d=C116377&d=C1855&d=C65530&d=C124993&d=C148147&d=C66940&d=C2693&d=C97273&loc=0&pn=7&rl=2&st=C162158&st=C153201&st=C176727&st=C147924&st=C202131&st=C3512&st=C155908&st=C156093&st=C156094&st=C157364&st=C128798&st=C9133&st=C133254&st=C135017&st=C174510&st=C155901&st=C171612&st=C162642&t=C2926&id=NCI-2024-06705""><span>Check for Updates</span></a> 			<table class=""trialDataTable""> 				<tr class=""trialDataHeaderRow""> 					<td>Phase</td> 					<td>Type</td> 					<td>Status</td> 					<td>Age</td> 					<td>Trial IDs</td> 				</tr> 				<tr> 					<td>Phase I/II</td> 					<td>Treatment</td> 					<td>Active</td> 					<td>18 													and over 						 						</td> 					<td class=""trialIDCell""> 						<span class = ""dataTableIDLabel"">Primary ID</span> CR109323<br> 						<span class = ""dataTableIDLabel"">Secondary IDs</span> NCI-2024-06705, 2022-501452-29-00, 61186372PANSC2002<br> 						<span class = ""dataTableIDLabel"">Clinicaltrials.gov ID</span> <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT05908734"" target=""_blank"">NCT05908734</a><br> 					</td> 			</table>  			<h3>Description</h3> 			<div>The purpose of this study is to identify the recommended Phase 2 (combination) dose (RP2CD) of the amivantamab and cetrelimab combination therapy in participants with non-small cell lung cancer (NSCLC) in Phase 1 (combination dose selection); and to evaluate the antitumor effect of the combination at the selected RP2CD in participants with NSCLC characterized on the basis of epidermal growth factor receptor (EGFR) and Programmed-cell death Ligand (PD-L)1 status, in the Phase 2 (expansion).</div>  			<h3 class=""printHeading"">Eligibility Criteria</h3>  																																																																																																																																																																																																															<h4>Inclusion Criteria</h4> 										<div> 							<ul> 															<li>Participant must have histologically or cytologically confirmed non-small cell lung cancer (NSCLC) (any histology), and must have metastatic NSCLC at the time of enrollment: Phase 1 (Combination Dose Selection) Cohort; Metastatic NSCLC progressed on or after standard of care systemic anti-cancer therapy and participant is declining other systemic treatment options, if any;1. Participants without known mutations must have had disease progression on, or have intolerance to, prior platinum-based chemotherapy and PD-(L)1-targeted immunotherapy given concurrently or sequentially, OR 2. Participants with NSCLC characterized by known driver mutations must have had disease progression on, or have intolerance to, appropriate targeted therapies as per local standard of care. Participants may have received prior therapy with amivantamab as long as discontinuation was not due to toxicity. Participants with EGFR mutation must not have had an anti-PD-1/PD-L1 therapy, Phase 2 Expansion Cohorts; Cohort A: Participant&#39;s tumor must have an EGFR exon19del or L858R mutation, as determined by local molecular testing, Cohort B: Participants must have tumors lacking known primary driver mutations and must have PD-L1 expression of greater than or equal to (&gt;=)50 percentage (%), per local testing, and are treatment-na&#239;ve in the metastatic setting</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Participant must have at least 1 measurable lesion, according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, that has not been previously irradiated</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1</li> 												</ul> 						</div> 														<h4>Exclusion Criteria</h4> 										<div> 							<ul> 																<li>Participant has an uncontrolled illness, including but not limited to: a. Uncontrolled diabetes, b. Ongoing or active infection (includes infection requiring treatment with antimicrobial therapy [participants will be required to complete antibiotics 1 week prior to starting study treatment] or diagnosed or suspected viral infection), c. Active bleeding diathesis, d. Impaired oxygenation requiring continuous oxygen supplementation, e. Psychiatric illness or any other circumstances (including social circumstances) that would limit compliance with study requirements</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Medical history of (non-infectious) interstitial lung disease (ILD)/pneumonitis, or has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Has an active autoimmune disease or a documented history of autoimmune disease that requires systemic steroids or immunosuppressive agents</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Participant has received radiotherapy for palliative purposes less than 14 days prior to the first dose of study treatment</li> 												</ul> 						</div> 										<div> 							<ul> 																<li>Participant has a. (or has a history of) leptomeningeal disease (carcinomatous meningitis), b. spinal cord compression not definitively treated with surgery or radiation</li> 												</ul> 						</div> 							 			 							<h3 class=""printHeading"">Lead Organization</h3> 									<div>Janssen Pharmaceuticals</div> 														<h3 class=""printHeading"">Locations & Contacts</h3> 			<div class=""locationNoteBlock""> 				<span>Note:</span> Information about participating sites on pharmaceutical industry trials may be incomplete, so please look up the <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT05908734"" target=""_blank"">NCT number</a> on ClinicalTrials.gov 			</div> 			<div> 								           <h3 class=""locationCountryLabel"">U.S.A.</h3>               <h4>California</h4>                           <h5 class=""locationCity"">Duarte</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">City of Hope Comprehensive Cancer Center</strong>     <br>Name Not Available   </span> </div>                                   <h4>Texas</h4>                           <h5 class=""locationCity"">Houston</h5>                                         <div itemprop=""location"" itemscope="""" itemtype=""http://schema.org/Place"" class=""locationBlock"">   <strong itemprop=""name"">M D Anderson Cancer Center</strong>     <br>Name Not Available   </span> </div>                           			</div> 		</div> 			<div class=""trialContainer""> 			<h2 class=""hangingIndent"">31. Amivantamab in Combination with Tyrosine Kinase Inhibitors for the Treatment of Patients with Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Carcinoma Harboring ALK, ROS1, and RET Gene Fusions</h2> 						<a class=""hangingIndent print-check-for-updates"" href=""/research/participate/clinical-trials-search/v?d=C1967&d=C2167&d=C93259&d=C199379&d=C172809&d=C82379&d=C116377&d=C1855&d=C65530&d=C124993&d=C148147&d=C66940&d=C2693&d=C97273&loc=0&pn=7&rl=2&st=C162158&st=C153201&st=C176727&st=C147924&st=C202131&st=C3512&st=C155908&st=C156093&st=C156094&st=C157364&st=C128798&st=C9133&st=C133254&st=C135017&st=C174510&st=C155901&st=C171612&st=C162642&t=C2926&id=NCI-2023-04100""><span>Check for Updates</span></a> 			<table class=""trialDataTable""> 				<tr class=""trialDataHeaderRow""> 					<td>Phase</td> 					<td>Type</td> 					<td>Status</td> 					<td>Age</td> 					<td>Trial IDs</td> 				</tr> 				<tr> 					<td>Phase I/II</td> 					<td>Treatment</td> 					<td>Active</td> 					<td>18 													and over 						 						</td> 					<td class=""trialIDCell""> 						<span class = ""dataTableIDLabel"">Primary ID</span> 22-1450<br> 						<span class = ""dataTableIDLabel"">Secondary IDs</span> NCI-2023-04100<br> 						<span class = ""dataTableIDLabel"">Clinicaltrials.gov ID</span> <a class=""nctIdLink"" href=""http://clinicaltrials.gov/show/NCT05845671"" target=""_blank"">NCT05845671</a><br> 					</td> 			</table>  			<h3>Description</h3> 			<div>This phase Ib/II trial studies the side effects and best dose of amivantamab when given together with tyrosine kinase inhibitors (TKI) and to see how well it works in treating patients with non-small cell lung cancer that has spread to nearby tissue or lymph nodes (locally advanced), that cannot be removed by surgery (unresectable) or has spread from where it first started (primary site) to other places in the body (metastatic). The treatment of ALK, ROS1, and RET positive non-small cell lung cancer (NSCLC) has evolved over the last decade and patients harboring these gene fusions demonstrate dramatic and sustained responses to TKI therapy. Despite these important advances, acquired drug resistance remains inevitable and there is currently no approved treatment regimens for resistance. In many of these cases, increased activation of the ERBB or cMet pathways appears to be a bypass signaling mechanism that allows these cancer cells to circumvent the selective pressure from TKIs. Recent data have suggested that these pathways compensate for each other in situations where one pathway is inhibited, leading to “kinase switch” drug resistance. Amivantamab, a bispecific EGFR-MET antibody, has shown synergistic (acting together) inhibition of tumor growth when combined with EGFR TKIs. An antibody is a protein made by the immune system to help fight infections and other harmful processes, cells, or molecules. Giving amivantamab with TKIs may improve overall effectiveness by limiting the compensatory pathway activation and kill more cancer cells in patients with locally advanced, unresectable or metastatic non-small cell lung cancer.</div>  			<h3 class=""printHeading"">Eligibility Criteria</h3>  																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																															<h4>Inclusion Criteria</h4> 										<div> 							<ul> 															<li>Provision to sign and date the informed consent form</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Stated willingness to comply with all study procedures and be available for the duration of the study</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Participant is &gt;= 18 years of age</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Participant has histologic or cytologic confirmation of locally advanced (unresectable) or metastatic NSCLC with a known (and documented) ALK, ROS1, or RET fusion based on approved diagnostic testing methods specified below. Note that next generation sequencing NGS testing (using either archival or pre-treatment tissue biopsy) is required for all participants, but screening if any of tests below are positive  * Immunohistochemistry (IHC): For ALK NSCLC only using the ALK D5F3 antibody * Fluorescence in situ hybridization (FISH) with &gt;= 15% of 100 cells sampled constituting positivity * NGS using a Clinical Laboratory Improvement Act (CLIA)-certified test</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Participants must have clinical progression on at least one prior Food and Drug Administration (FDA)-approved TKI. They must be on a TKI at the same dose for at least 8 weeks without radiographic progression or clinical intolerance of the TKI prior to enrolling on this study. TKIs that will be considered include (but not limited to): * ALK fusions – alectinib, brigatinib, lorlatinib * ROS1 fusions – entrectinib, lorlatinib * RET fusions – selpercatinib, pralsetinib</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Participants must have at least 1 measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 criteria using computed tomography (CT) scan or magnetic resonance imaging (MRI) * Measurable Central Nervous System (CNS) lesions &gt;= 10mm must be captured as overall and intracranial RECIST target lesions. CNS lesions 5-9mm may be included in the intra-cranial data set alone but must be listed as non-target lesions * Measurable, treated brain metastases (&gt;= 10mm) growing after whole-brain radiotherapy (WBRT) or resection are allowed as target lesions, but lesions growing after stereotactic radiosurgery (SRS) are allowed as target lesions only if radiation necrosis or pseudoprogression is ruled out</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Participant has an Eastern Cooperative Oncology Group (ECOG) score of 0-2</li> 												</ul> 						</div> 										<div> 							<ul> 															<li>Par